# Decision Log Archive 2026 Q2

Archive of matured Decision_Log entries from the live `Decision_Log.md`. Append-only. Entries archived per W5 lifecycle rules. See `Operating_Protocols.md` §6 (Decision-Log Lifecycle Policy) for canonical retention rules and `Claude_Task_Plan.md` §W5 for procedural details.

**Quarter**: 2026-Q2 (April 1, 2026 – June 30, 2026).

**First archive cut**: 2026-05-10 (first scheduled W5 run; bootstrap).

**Read-access scope**: Monthly+ cadence prompts (M1, M3, M4, M5, Q1, Q2, Q3, A1, A2, A3). Daily/weekly cadence prompts do NOT read this file.

---

### 2026-04-22 Experiment inception — Initial router states

**Trigger:** Experiment start; $6,946.86 initial capital split across Strategies A, B, C, D, E.
**Inputs:** Strategy.md, Experiment_Parameters.md, AI_Trading_Foundation.md (revision 1).
**Sessions:** None (inception).
**Decision:** All five strategies initialized at DO-NOT-ACTIVATE pending first M1 review and pre-mortem completions.
**Reasoning:** No router signals have been computed yet; default per Experiment_Parameters.md is no activation before the full pre-mortem set (N+1 = 6) completes and before the first fundamental analysis runs.
**Theater-check flag:** n/a.
**Downstream actions:** Portfolio_Ledger.md initialized with per-strategy starting values; Regime_State.md initialized with inception rows.
**References:** Portfolio_Ledger.md (2026-04-22 entry).

---

### 2026-04-23 M2 monthly AI capabilities review — first cycle

**Trigger:** First monthly AI capabilities review per AI_Trading_Foundation.md Part 4.
**Inputs:** AI_Trading_Foundation.md revision 1; M2 deep-research output covering Q1 2026 AI research, Anthropic releases, and market-structural AI context.
**Sessions:** Single monthly session (non-incognito).
**Decision:** Seven of eight answered questions resolved YES. Per-strategy foundation-change assessment warranted for A, B, C, D, E. Specifically:
- New failure modes documented: agentic epistemic hallucination (TradeTrap), RL-post-training decision-token overconfidence (arXiv 2601.13284 / 2603.06604), deterministic-decoding cross-run inconsistency (AlphaForgeBench).
- Partial reduction: prompt injection risk on Opus-tier with classifiers (2.10) — not eliminated.
- Homogenization risk reinforced (2.8) with Coordination Primacy Hypothesis and $610–650B 2026 hyperscaler capex concentration.
- Partial resolutions logged for 3a.1 (EV math not usable without calibration layer), 3a.2 (decision-support with hard external guardrails required), 3a.3 (long-horizon consistency requires external scaffolding).
**Reasoning:** Default bias is YES — err toward flagging change per Experiment_Parameters.md. Transferability filter cleared by architectural generality for 2.24, 2.25, 2.26, and by direct Claude-family evidence for 2.10, 2.13 (Haiku 4.5 ECE). Evidence materially updates the edge/disadvantage map.
**Theater-check flag:** n/a (single session).
**Downstream actions:** AI_Trading_Foundation.md revised to revision 2 (integrating updates to 2.3, 2.8, 2.10, 2.13, 2.24; adding 2.25 and 2.26; partial resolutions in 3a.1/3a.2/3a.3). Per-strategy foundation-change assessments for A, B, C, D, E required before any first trade.
**References:** Attached M2 deep-research analysis (Part 1 data + Part 2 question-by-question resolution).

---

### 2026-04-23 AI_Trading_Foundation.md revision 2 published

**Trigger:** M2 2026-04 findings required document update per AI_Trading_Foundation.md Part 4 invalidation rule.
**Inputs:** M2 2026-04 decision entry above.
**Sessions:** None (document update).
**Decision:** Document updated from revision 1 (2026-04-22) to revision 2 (2026-04-23).
**Reasoning:** See M2 entry.
**Theater-check flag:** n/a.
**Downstream actions:** Per-strategy foundation-change assessments for A, B, C, D, E are warranted and must complete before any first trade.
**References:** AI_Trading_Foundation.md revision 2.

---

### 2026-04-23 SGOV parking conversion — initial

**Trigger:** Per Experiment_Parameters.md, SGOV is the default parking vehicle for undeployed capital. Initial conversion required before any strategy deploys capital into trades.
**Inputs:** Portfolio_Ledger.md 2026-04-22 starting state ($6,946.86 all USD Cash, split A $1,389.38 / B-E $1,389.37 each); IBKR account U11152139.
**Sessions:** None (execution step).
**Decision:** Converted $6,942.12 of $6,946.86 into 68.98 shares of SGOV across two fills. Residual $3.96 held as USD Cash. Commissions of $0.78 treated as a cost of parking conversion (option 1) and allocated $0.16 per strategy, reducing each strategy's starting value by $0.16.
- Fill 1: 68 shares @ $100.64, NYSE, 07:46:03 ET, commission $0.43, order 00fd111d.00011066.69eaee66.0001
- Fill 2: 0.98 shares @ $100.61, IBKR, 12:55:51 ET, commission $0.35, order 00fd111d.00011066.69e9a0d2.0001
- Weighted-average cost basis: $100.6396
- Per-strategy split: 13.796 shares each (fractional split across A, B, C, D, E)

Revised per-strategy starting values (post-commission, used as TWR baseline going forward):
- Strategy A: $1,389.22 (was $1,389.38)
- Strategies B, C, D, E: $1,389.21 each (was $1,389.37)
- Account total: $6,946.08 (was $6,946.86; $0.78 commission paid)

**Reasoning:** Option 1 (commissions reduce each strategy's starting value) chosen over option 2 (preserve round starting values) because per Experiment_Parameters.md, each strategy's performance is tracked against its own starting value, and parking commissions are real costs of running the strategy that should be captured in the TWR baseline. This is a one-time adjustment at conversion; subsequent SGOV dividend accruals and mark-to-market changes flow to each strategy proportionally going forward.
**Theater-check flag:** n/a (execution step, not adversarial review).
**Downstream actions:** Portfolio_Ledger.md updated with SGOV parking activity table, per-strategy SGOV share counts, and revised starting values. Regime_State.md unaffected. No strategy is yet eligible to trade — all remain blocked on pre-mortem completion and foundation-change assessments.
**References:** IBKR trade details screens for order IDs above. Portfolio_Ledger.md 2026-04-23 update.

---

### 2026-04-23 Regime router pre-mortem — four-cycle adversarial review completed; accepted under revision-churn cap

**Trigger:** Regime router pre-mortem is the first of N+1 = 6 pre-mortems required to clear adversarial review before any strategy executes its first trade per Experiment_Parameters.md completion requirement.

**Inputs:** Strategy.md router pre-mortem revisions 1 through 5; Experiment_Parameters.md revisions 10 through 13; four independent adversarial review cycles with incognito attacker and judge sessions per cycle.

**Sessions:** Each adversarial cycle comprised two incognito sessions (attacker, judge); no adjudicator session was triggered in any cycle because attacker and judge never returned a DISAGREEMENT WITH ATTACKER verdict.

**Cycle-by-cycle outcomes:**

| Cycle | Reviewed | Verdict | Tier 1 items surfaced | Theater-check flag | Outcome |
|-------|----------|---------|----------------------|---------------------|---------|
| 1 | Rev 1 | MATERIAL WEAKNESS | ~9 (pre-tier taxonomy) | CONVERGENT | Rev 2 drafted |
| 2 | Rev 2 | MATERIAL WEAKNESS | ~6 structural (of 18 total items) | CONVERGENT | Rev 3 drafted after adding stopping rule (EP rev 12) |
| 3 | Rev 3 | TIER 1 DEFECT — REVISION REQUIRED | 2 | MIXED | Rev 4 drafted |
| 4 | Rev 4 | TIER 1 DEFECT — REVISION REQUIRED | 2 (both attributable to rev 4's own edits) | DIVERGENT | Rev 5 spot-edit applied under revision-churn cap (EP rev 13); no cycle 5 |

**Parameter revisions triggered by the review process:**
- Experiment_Parameters.md rev 10 → 11: added router counterfactual-attribution metric to monthly review template (item 13); superseded when counterfactual metric was dropped in Strategy.md rev 3. Item 13 remains as all-SGOV comparison language only.
- Experiment_Parameters.md rev 11 → 12: added stopping rule (pass conditions 1–3: clean pass, Tier-1-clean cap, diminishing-returns cap) and Tier 1/2/3 definitions. Triggered by observed cycle-1 and cycle-2 item counts and CONVERGENT theater-check flags signaling adversarial saturation.
- Experiment_Parameters.md rev 12 → 13: added revision-churn cap (pass condition 4) and floor acknowledgment. Triggered by cycle-4 finding that all Tier 1 items were attributable to rev 4's own edits (propagation errors / scope-lock gaps) rather than residual original-architecture defects.

**Decision:** The regime router pre-mortem (Strategy.md rev 5, dated 2026-04-23) is accepted under the revision-churn cap in Experiment_Parameters.md rev 13. Rev 5 addresses the two cycle-4 Tier 1 items as a spot-edit: (a) Section 10 slow-burn bullet corrected from "A or D" to "B, C, or D" (slow-burn case has Breadth=WEAK which deactivates A by Section 3 rule); (b) Section 11 change-control lock extended to cover the operational thresholds in Section 6 (breadth >10pp MoM, VIX drift >5pp within NORMAL over 30 days). No cycle 5 is run because cycle 4 surfaced only revision-churn defects, which per the new cap are fixed by spot-edit rather than by running another full cycle.

**Reasoning:** The four-cycle progression shows the adversarial architecture doing genuine work (item count 9 → 6 → 2 → 2; theater-check CONVERGENT → CONVERGENT → MIXED → DIVERGENT is the correct direction). Cycle 4 specifically identified defects that prior cycles missed and that rev 4's own revision edits introduced — a category of defect that reflects revision-generator churn rather than residual architectural flaws. Continuing to cycle 5 would likely surface two more revision-induced defects of similar small amplitude while introducing two more via rev 6, producing sideways motion at constant cost. The revision-churn cap's rationale (LLM-generated revisions cannot converge to zero defect because the same distributional biases that wrote the artifact are doing the reviewing and revising) is the correct framing for stopping here.

**Tier 2/3 items carried forward as Known Limitations (Strategy.md rev 5 Section 12):** 12 total items logged — slow-burn mechanical indistinguishability with partial VIX-drift detection; 9.2 denominator possibly unreachable in benign regimes; 9.1 un-fireable for strategies stuck in one state; 9.4 uncalibrated 40% threshold; 9.5 unjustified 10-transition threshold; 9.6 format-only compliance check; monthly rhythm timing (resolved: first trading day); model-version change handling via foundation-change trigger; strategy execution mechanics in each strategy's section; flash-crash recurrence escalation threshold; self-containment scope-boundary carve-out for non-Experiment_Parameters.md references; Session 4 architectural saturation with feedback-loop via 9.4. Each item has a specified monthly-review trigger and is checked at every pre-mortem-indicator review.

**Theater-check flag on this decision:** n/a. The decision to accept under the revision-churn cap was made by the participant with Claude assistance, not by a four-session adversarial process. Per Experiment_Parameters.md rev 12 "triage responsibility" clause, tier assignments (and by extension cap invocations) are not themselves subject to adversarial review, to avoid infinite regress.

**Progression pattern worth preserving for monthly theater-check survey (first scheduled 2026-05-01):** Theater-check across the four cycles went CONVERGENT → CONVERGENT → MIXED → DIVERGENT. The first two cycles showed the predicted saturation of same-model adversarial review (weight-level biases correlated across supposedly independent sessions); cycles 3 and 4 showed genuine divergence as the artifact became more structurally specific and the remaining defect space became more idiosyncratic. This pattern is consistent with the floor acknowledgment in Experiment_Parameters.md rev 13 and should be the baseline against which future theater-check rates are compared.

**Downstream actions:** Router pre-mortem dequeued from the "Pending structured decisions" list below. Strategy.md rev 5 is the authoritative router pre-mortem. Known Limitations (Section 12) are added to the monthly pre-mortem-indicator review checklist. The cycle-by-cycle theater-check data above will be folded into the 2026-05-01 monthly theater-check survey. Remaining 5 pre-mortems (Strategies A, B, C, D, E) are next in sequence; each will run its own adversarial review cycle(s) and will reference the revision-churn cap and floor acknowledgment as available stopping conditions from the outset.

**References:** Strategy.md revisions 1–5; Experiment_Parameters.md revisions 10–13; Four cycle attacker and judge outputs (held in-chat during this session, not filed as separate documents — future cycles on other pre-mortems should consider filing incognito session outputs as separate artifacts for audit purposes).

---

### 2026-04-23 Strategy A pre-mortem — acceptance under combined revision-churn + saturation stop after 6 review cycles

**Trigger:** Six successive adversarial review cycles against the Strategy A pre-mortem (Strategy.md, pre-mortem revisions 1 through 7). Cycles 1-4 ran under the three-session adversarial-review architecture (per Experiment_Parameters.md rev 12-13). Cycles 5-6 ran under the single-session architecture per Experiment_Parameters.md rev 14.

**Inputs:** Strategy A pre-mortem (Strategy.md revisions 1-11, Strategy A pre-mortem revisions 1-7); Experiment_Parameters.md revisions 12-14 (stopping rule and architectural simplification); the six attacker outputs and (for cycles 1-4) the four judge outputs.

**Sessions / cycle progression:**

| Cycle | Pre-mortem rev | Verdict | Tier 1 items | Theater-check | Architecture | Outcome |
|-------|----------------|---------|--------------|---------------|--------------|---------|
| 1 | Rev 1 | TIER 1 DEFECT | 2 (+ 1 recommended) | CONVERGENT | 3-session | Rev 2 drafted |
| 2 | Rev 2 | TIER 1 DEFECT | 2 | CONVERGENT | 3-session | Rev 3 drafted |
| 3 | Rev 3 | TIER 1 DEFECT | 3 | CONVERGENT | 3-session | Rev 4 drafted |
| 4 | Rev 4 | TIER 1 DEFECT | 1 | CONVERGENT | 3-session | Rev 5 drafted |
| 5 | Rev 5 | TIER 1 DEFECT | 2 | CONVERGENT | 1-session | Rev 6 drafted |
| 6 | Rev 6 | TIER 1 DEFECT | 1 | CONVERGENT | 1-session | Rev 7 fix applied; cycle 7 not run; pre-mortem accepted |

**Architectural transition mid-sequence:** Cycles 1-4 used the three-session architecture (Attacker / Judge / Adjudicator-on-disagreement) consistent with Experiment_Parameters.md rev 12-13. After observing 8/8 CONVERGENT cycles across the router pre-mortem (4 cycles) and Strategy A cycles 1-4 with zero adjudicator invocations, Experiment_Parameters.md was updated to rev 14, simplifying all four adversarial review types (pre-mortem, router divergence, redistribution, mark-to-market termination) to single-session attacker plus in-conversation review by orchestrating session. Cycles 5-6 ran under the new architecture. The cycle 5-6 outcomes (1-2 Tier 1 items, CONVERGENT theater-check, defect class consistent with cycles 4) showed no operational evidence of degraded review quality from the simplification, though absence of a separate-session judge means ratification-vs-genuine-validation is no longer empirically distinguishable.

**Defect class concentration in cycles 4-6:** All three of these cycles surfaced exactly one defect class — *asymmetric reasoning between Constraint 2 (2.4 narrative over-fit) and Constraint 3 (2.19 look-ahead bias) in the binding-constraints subsection of Section 5*. The locus shifted across revisions:
- *Cycle 4* attacked rev 4's coarse asymmetry (Constraint 3 had a "flowing exclusion" while Constraint 2 had no exclusion despite same hard-wired status).
- *Cycle 5* attacked rev 5's grounding asymmetry (Constraint 2's at-entry-identifiability argument was near-circular vs. Constraint 3's mechanism-based; 2% position-size cap asymmetrically attributed to Constraint 2).
- *Cycle 6* attacked rev 6's over-correction (Constraint 2's strengthened self-reference argument now contaminates Constraint 3's entry criterion 6, which had not been updated to graded framing).

Each fix resolved one direction of asymmetry and exposed another at the next resolution level. The underlying reason is mechanism-real: 2.4 is uniformly closed under self-reference; 2.19 has a transparent-citation form (with a syntactic surface feature providing partial leverage even when narrative-quality assessment is biased) and a buried-framing form (with no syntactic surface feature). The two constraints are not symmetric in reality, so any attempt to make their textual treatments fully parallel produces a new mismatch at the next zoom level. The reviewer keeps surfacing this tension because it is genuine, not because the document is broken.

**Parameter revisions triggered by the review process:**
- Experiment_Parameters.md rev 13 → 14 (during Strategy A cycle 4 → 5 transition): architectural simplification of all four adversarial review types from three-session to single-session (attacker incognito + in-conversation review by orchestrating session). Stopping rule simplified from four pass-condition caps (clean pass / Tier-1-clean / diminishing-returns / revision-churn) to two pass conditions (Tier 1 clean + diminishing-returns reassessment with three stop conditions). Triggered by operational unsustainability of three-session architecture given the cycle counts being observed and the Strategy B-E pre-mortems plus foundation-change assessments still queued.

**Decision:** The Strategy A pre-mortem (Strategy.md rev 11, Strategy A pre-mortem rev 7, dated 2026-04-23) is accepted under combined revision-churn + saturation stop conditions per Experiment_Parameters.md rev 14. Rev 7 applies the cycle 6 fix as a spot edit: extend graded / partial-identifiability framing to Constraint 3's transparent-citation form (entry criterion 6's primacy test invokes narrative-quality assessment, which is closed over by 2.4-style self-reference; entry criterion 6 is therefore a graded discriminator parallel to entry criterion 4, not a clean exclusion). The sub-residual — cases where biased primacy judgment fails to identify transparent citation as primary even when it is — joins the buried-framing form in Known Limitations #3. The "Scope of strategy-level control" paragraph is reframed to note that both constraints are now treated as admitting only graded discriminators rather than clean exclusions, with the principled distinction being underlying mechanism asymmetry (2.4 uniformly closed; 2.19 split between syntactic-surface-bearing and surface-less forms). No cycle 7 is run.

**Reasoning:** Both stop conditions are satisfied:

*EP rev 14 stop condition (iii) — revision-churn stop:* Cycle 6's single Tier 1 item (rev 6's self-reference argument contaminates entry criterion 6's primacy test) is revision-induced — rev 6 introduced the self-reference argument whose application to entry criterion 6 created the asymmetry that cycle 6 attacked. By definition all Tier 1 items in cycle 6 are revision-induced rather than original-architecture.

*EP rev 14 stop condition (ii) — saturation stop:* Cycles 4, 5, and 6 surfaced the same defect class three consecutive times with the locus shifting across revisions but the structural pattern remaining identical. The reviewer is not finding new architectural surfaces; it is finding fresh instances of the same asymmetric-reasoning structure that cycle 4 originally surfaced. This is the saturation pattern EP rev 14's stop condition (ii) was designed for.

The combination of both conditions is stronger justification than either alone. Continuing to cycle 7 has high probability of either (a) clean pass — which we already would accept under stop condition (i), or (b) finding another revision-induced asymmetric-reasoning instance — which re-justifies revision-churn stop without changing the outcome. The marginal information from cycle 7 is low; the operational cost is non-trivial given Strategy B-E pre-mortems plus foundation-change assessments still pending.

**Tier 2/3 items carried forward as Known Limitations (Strategy.md Strategy A pre-mortem Section 7, "Known limitations"):** 5 items logged: (1) fee-dominated phase at small strategy-portfolio scale, accepted with 15-trade edge check trigger; (2) 12-month hard stop bluntness, accepted with 30-trade gate trigger; (3) 2.19 buried-framing form plus transparent-citation sub-residual not meaningfully mitigated at the strategy level, accepted with beta-dominance + hit-rate-decline 10-trade-window trigger; (4) 2.4 residual ~70% structural and not mitigated, same trigger as (3); (5) trade-count-triggered indicators not strictly calendar-dated, accepted as satisfying "dated" via assigned-to-review-timepoint reading. Plus Tier 2 items from cycle 6 not yet folded into the document and accepted as below-threshold for further revision: cross-constraint preamble's "flows from" attribution for non-binding-constraint disadvantages (categorial looseness, no logical contradiction); Section 5 bulleted-list 2.13 wording vs. cross-constraint preamble (consistent under charitable reading, wording could be tightened); Section 4 indicator wording ambiguity for "average winning position size" given fixed 2% sizing rule (calibration gap, intended metric is presumably winner-return vs. loser-return); ~30% reduction interpreted as subset-discrimination vs. uniform-magnitude-reduction (interpretive load-bearing assumption that should be made explicit). Each Known Limitations item has a specified monthly-review trigger.

**Theater-check flag on this decision:** n/a. The decision to accept under combined revision-churn + saturation stop was made by the participant with Claude assistance, not by an additional adversarial process. Per Experiment_Parameters.md rev 14 "triage responsibility" clause, tier assignments and stop-condition invocations are not themselves subject to adversarial review.

**Theater-check pattern across the six cycles for monthly theater-check survey (first scheduled 2026-05-01):** All six cycles returned CONVERGENT theater-check. This contrasts with the router pre-mortem's CONVERGENT → CONVERGENT → MIXED → DIVERGENT progression. The Strategy A all-CONVERGENT pattern is consistent with the architectural saturation prediction — when reviews are running on a strategy whose binding constraints have genuine mechanism asymmetries, the adversarial sessions reliably find the same defect class from different angles, but neither attacker nor judge surfaces framings the other rejects. The single-session cycles 5-6 maintained the pattern, providing operational evidence (though not proof) that the simplified architecture preserved review quality on this artifact.

**Downstream actions:** Strategy A pre-mortem dequeued from "Pending structured decisions" list. Strategy.md rev 11 (Strategy A pre-mortem rev 7) is the authoritative Strategy A pre-mortem. Known Limitations are added to the monthly pre-mortem-indicator review checklist. The cycle-by-cycle data above will be folded into the 2026-05-01 monthly theater-check survey. Strategy A still cannot trade until all remaining pre-mortems (B, C, D, E) and foundation-change assessments (A, B, C, D, E) complete per Experiment_Parameters.md "Completion requirement" clause.

**References:** Strategy.md revisions 5-11 (Strategy A pre-mortem revisions 1-7); Experiment_Parameters.md revisions 12-14; six cycle attacker outputs and four judge outputs (cycles 1-4 three-session; cycles 5-6 single-session) — held in-chat during the session, not filed as separate documents.

---

## Pending structured decisions (as of 2026-04-23, post-Strategy-A-pre-mortem)

The following structured decisions are outstanding. No strategy can execute its first trade until all items below complete. Order is not load-bearing; several can run in parallel.

1. ~~**Strategy C divergence adversarial review**~~ — COMPLETED 2026-04-25, HYBRID ACTIVATE (FOMC only); see entry below.
2. ~~**Strategy E divergence adversarial review**~~ — COMPLETED 2026-04-25, DO-NOT-ACTIVATE; see entry below.
3. ~~**Pre-mortem for Strategy B**~~ — COMPLETED 2026-04-25, accepted at rev 7 under EP rev 15 deployment-risk stop after 6 cycles.
4. ~~**Pre-mortem for Strategy C**~~ — COMPLETED 2026-04-25, accepted at rev 9 under combined revision-churn + saturation stop per Strategy A precedent (EP rev 14 §188 stop conditions ii + iii) after 8 cycles. See entry below.
5. **Pre-mortem for Strategy D** — single-session adversarial review (incognito attacker + orchestrating-session review).
6. **Pre-mortem for Strategy E** — single-session adversarial review (incognito attacker + orchestrating-session review).
7. **Foundation-change assessment — Strategy A** — per M2 revision-2 findings.
8. **Foundation-change assessment — Strategy B** — per M2 revision-2 findings.
9. **Foundation-change assessment — Strategy C** — per M2 revision-2 findings.
10. **Foundation-change assessment — Strategy D** — per M2 revision-2 findings.
11. **Foundation-change assessment — Strategy E** — per M2 revision-2 findings.

**Completed (2026-04-23):**
- Regime router pre-mortem — accepted under revision-churn cap after 4 review cycles; see entry above.
- Strategy A pre-mortem — accepted under combined revision-churn + saturation stop after 6 review cycles; see entry above.
- Strategy B pre-mortem — accepted under EP rev 15 deployment-risk stop after 6 review cycles (2026-04-25); see entry below.

Each completed item adds a new entry to this log with its decision and theater-check flag (where applicable).


---

## Monthly theater-check surveys

Per Experiment_Parameters.md monthly review template item 10, each monthly review surveys theater-check flags from all adversarial reviews in the prior month for patterns suggesting architectural drift (consistent convergence across supposedly-adversarial sessions). First survey will occur at the 2026-05-01 monthly review, covering all adversarial reviews completed in April 2026.


---

## Operational decision: pre-mortem cycle turn-batching (2026-04-25)

[DECISION] Within the orchestrating session, each pre-mortem cycle is handled in a single batched turn rather than across multiple turns: user pastes attacker output → orchestrating session in one turn (a) performs in-conversation independent review, (b) flags theater-check, (c) decides on stop conditions or applies revisions, (d) presents updated Strategy.md, (e) drafts the next cycle's attacker prompt. User then runs the next attacker incognito and pastes back, repeating the cycle.

This is an operational efficiency choice — it does not change the underlying architecture (single-session attacker + in-conversation review per Experiment_Parameters.md rev 14 remains in force). The "confirm before applying fixes" step from earlier cycles was theater given the user's standing instruction to proceed with the orchestrator's recommendation.

**Compaction-survival note:** future Claude instances reading this log should default to Option A batched-turn operation when running pre-mortem cycles. The two-turn structure (attacker output paste → batched orchestrator response) is the working model. Do not reintroduce intermediate confirmation turns unless the orchestrator's recommendation involves a strategy-design change (parallel to the rev 3 short-side-stop-loss decision in Strategy B), in which case explicit user confirmation is appropriate before applying.


---

## Architectural decision: deployment-risk stop + forcing question (Experiment_Parameters.md rev 15, 2026-04-25)

[DECISION] EP rev 14's stopping rule was found insufficient mid-Strategy-B-pre-mortem (cycles 4-5) because all stop conditions were pattern-based — they look at the *shape* of attacks across cycles (item counts, recursion vs. new-surface, theater-check flags, revision-induced vs. original-architecture). Pattern-based conditions can fail silently — none fires, so cycling continues — even when remaining Tier 1 items are documentation, wording, or calibration grade rather than items that would change deployment risk. This produces an infinite-loop tendency on minor problems given the generative nature of LLM-produced documents.

EP rev 15 adds three changes:

1. **Deployment-risk stop (new pass condition 1(b)).** Orchestrating session may invoke saturation acceptance when remaining Tier 1 items pass four screens: (i) do not contradict any specific quantitative claim the strategy makes about its own loss-bounding, (ii) do not omit a top-five AI_Edges disadvantage from req-4 enumeration, (iii) do not introduce or leave in place a trigger that fails to detect the failure mode it nominally exists to detect, and (iv) do not break self-containment for a numbered requirement. Items passing all four screens are deployment-risk-acceptable as Tier 1 even if technically structural.

2. **Forcing question (mandatory pre-cycle assessment).** Before drafting the next cycle's attacker prompt, the orchestrating session must explicitly answer in writing: "If we accept the pre-mortem at its current revision with these residual Tier 1 items, would that change deployment risk vs. fixing them first?" Answer must be one of (a) yes-continue, (b) marginal-stop, or (c) no-stop, with substantive reasoning. The forcing-question structure prevents pattern-matching defaults.

3. **Cycle-count soft cap.** Starting at cycle 5, orchestrating session must explicitly justify continuation in this Decision_Log rather than defaulting through "stop conditions don't fire." Burden of proof shifts after cycle 5.

**Cycle 5 retrospective (Strategy B):** Cycle 5 was an instance where the rev 14 framework should have stopped but didn't. The three Tier 1 items at cycle 5 — (T1-A) 2.13/2.15 mechanism gaps, (T1-B) KL #12 leading-indicator structurally blind to slow-burn correlated drift, (T1-C) Section 6/KL #12 metric wording inconsistency — would all pass the rev 15 four-screen test for deployment-risk-acceptable. T1-A is documentation completeness. T1-B was an attempted upgrade that didn't deliver leading detection but didn't replace anything that did (lagging indicator and 36-month kill trigger remained in place). T1-C is editorial. None would change real-world trading risk if accepted unfixed.

Strategy B was nonetheless cycled to rev 6 under rev 14's strict pattern-based reading. Rev 6 fixes are kept as a quality improvement but should be the last cycle for Strategy B. Cycle 6 attacker is in flight; when its output returns, the rev 15 forcing question will be applied — if cycle 6 surfaces only documentation/wording/calibration items, deployment-risk stop fires immediately.

**Compaction-survival note:** future Claude instances must apply the rev 15 forcing question every cycle. Pattern-based stops are still informative but no longer load-bearing. The substantive question is "would more review change deployment risk." If that question has answer (b) marginal or (c) no, accept regardless of whether attack patterns have formally saturated. This is the structural fix for the generative-bottomless problem inherent in adversarial review against LLM-generated documents.


---

## Strategy B pre-mortem — accepted at rev 7 under EP rev 15 deployment-risk stop (2026-04-25)

[DECISION] Strategy B pre-mortem accepted at Strategy.md revision 17 (Strategy B pre-mortem rev 7) after 6 adversarial review cycles. Theater-check CONVERGENT in 6 of 6 cycles. All 6 cycles ran under the single-session attacker + in-conversation review architecture per Experiment_Parameters.md rev 14 (and rev 15 for the cycle-6 stop decision).

**Cycle outcomes by revision:**
- Rev 1 → Cycle 1 TIER 1 (7 items + 1 candidate; foundational gaps including req 7 missing, 2.20 contradiction, market conditions in Section 3, convergence-target redefinability, 2.18 candidate)
- Rev 2 → Cycle 2 TIER 1 (3 items: cross-constraint cap doesn't bound short-side loss; "or equivalent" reopened closed list; Constraint 1 imported Strategy A framing without applicability check)
- Rev 3 → Cycle 3 TIER 1 (4 items: +25% stop is operational not structural; long-side concurrent-position correlation gap; Constraint 1 Part 1 self-refuted by Part 2; "(or major index)" reopened closed list)
- Rev 4 → Cycle 4 TIER 1 (5 items: KL #12 trigger AND-condition post-hoc; 2.14 unanalyzed; Constraint 1 coherence framing self-referential; Section 6 missing KL #12 obligation; KL #7 escalation latency)
- Rev 5 → Cycle 5 TIER 1 (3 items: incomplete generalization across preamble disadvantages; KL #12 leading-indicator structurally blind to named failure mode; Section 6/KL #12 metric inconsistency)
- Rev 6 → Cycle 6 TIER 1 (1 item: 2.13 mitigation cites failure-manifestation pathway as mitigation pathway)
- Rev 7 → ACCEPTED under EP rev 15 deployment-risk stop

**Cycle progression count: 7 → 3 → 4 → 5 → 3 → 1.** Strategy A's pattern (7 cycles, 2-2-3-1-2-1 progression, accepted under combined revision-churn + saturation) is the closest analogue. Strategy B's saturation pattern manifested at finer grain — the locus shifted from constraint-level asymmetry (Strategy A) to mitigation-paragraph-level wording inconsistency (Strategy B cycle 6), reflecting iterative refinement at progressively finer textual scales. EP rev 15's deployment-risk stop was added mid-cycle (between cycle 5 and cycle 6) precisely to handle this generative-bottomless property.

**EP rev 15 four-screen pass for cycle 6 T1-A:** All four screens passed. (i) No quantitative loss-bounding claim contradicted; defect was in mitigation framing for a hit-rate effect. (ii) 2.13 already in Section 5 enumeration; defect was paragraph incoherence, not omission. (iii) Section 4 indicator 4 (convergence-vs-expiry closure ratio declining) is a real detector for 2.13's manifestation; KL #11 captures the residual; failure mode has detection coverage even with the incoherent mitigation paragraph. (iv) Self-containment for req 4 satisfied; defect is a quality issue with one entry, not a self-containment break.

**Forcing-question answer (EP rev 15):** *(b) marginal — fix is a quality improvement but would not change deployment risk meaningfully.* Rev 7 minimal fix applied for documentation correctness only.

**Theater-check summary:** 6 of 6 cycles CONVERGENT. No DIVERGENT or MIXED flags across the entire Strategy B pre-mortem cycle sequence. This is consistent with EP rev 14's saturation-architecture observation that single-session attacker + in-conversation review converges reliably in CONVERGENT-flag verdicts; the 6-of-6 result adds to the experiment's empirical record on architectural simplification's adequacy.

**Final Known Limitations count: 12** (vs. Strategy A rev 7's 5). The higher count reflects Strategy B's structurally less-bounded loss profile (no long-side stop-loss; partial short-side stop-loss with gap-execution residual; long-side concurrent-position correlation in behavioral-irrationality regimes; multiple post-hoc-only detection mechanisms). The deployability question — whether B should deploy capital given its accepted-residual posture — is above the pre-mortem and lives in the foundation-change assessment for B (still pending).

**Downstream actions:**
- Strategy B pre-mortem dequeued from "Pending structured decisions" list above (item 3).
- Strategy.md rev 17 (Strategy B pre-mortem rev 7) is the authoritative Strategy B pre-mortem.
- Known Limitations section (12 items) is added to the monthly pre-mortem-indicator review checklist alongside Strategy A's 5 KLs and the regime router's KLs.
- Cycle-by-cycle theater-check data folds into the 2026-05-01 monthly theater-check survey.
- Strategy B still cannot trade until remaining pre-mortems (C, D, E) and foundation-change assessments (A, B, C, D, E) complete per Experiment_Parameters.md "Completion requirement" clause.

**Compaction-survival note:** EP rev 15 deployment-risk stop was applied for the first time at this Strategy B acceptance. Future Claude instances reviewing this Decision_Log should treat this acceptance as the operational template for invoking EP rev 15 pass condition 1(b) on subsequent strategies (C, D, E pre-mortems): apply the four-screen test to each Tier 1 item, answer the forcing question explicitly, and accept when remaining items are documentation/wording/calibration grade. Do not require a clean Tier 1 cycle before acceptance if the rev 15 path is available.


---

## Strategy C divergence adversarial review — HYBRID ACTIVATE (FOMC only) (2026-04-25)

[DECISION] Strategy C M1 divergence (tech ACTIVATE / fund DO-NOT-ACTIVATE) resolved at HYBRID ACTIVATE — FOMC events only; corporate earnings, FDA PDUFA, and vol-directional theses across all event types remain DO-NOT-ACTIVATE. Single-session attacker + in-conversation orchestrating-session review per Experiment_Parameters.md rev 14. Theater-check CONVERGENT.

**Setup.**
- Technical signal: ACTIVATE (SPY Trend ≠ DOWN; current SPY Trend = NEUTRAL).
- Fundamental signal (M1, March 2026 review compiled 2026-04-23): DO-NOT-ACTIVATE — "Macro shocks dominating individual-catalyst dynamics; event-trading environment not functional this cycle." Reasoning rests on March 2026's regime-breaking conditions (US-Israel war with Iran beginning 2026-02-28; Strait of Hormuz blockade; Brent crude +51% MoM; -6% S&P equal-weighted; 10/11 GICS sectors negative; payrolls -92k revised -133k; FOMC dot-plot shifting hawkish; stagflation-squeeze setup).
- Default on ambiguity: DO-NOT-ACTIVATE per EP.

**Affirmative case for ACTIVATE — angles surfaced by attacker:**
1. Defined-risk structure orthogonality (loss-bounding handles macro signal-to-noise) — weakened in self-critique by compounding/slow-bleed argument plus AI_Edges 2.13 miscalibration.
2. **FOMC events ARE macro** — internal inconsistency in fundamental DNA. The DNA reasoning ("macro dominates individual catalysts") and the rule ("FOMC is a qualifying catalyst") cannot both be correct. If macro dominates, the macro event is the cleanest signal-to-noise expression of edge available to C, not the worst.
3. Signal-to-noise gradient (events still produce idiosyncratic reactions even in macro tape) — self-defeating on inspection (73% beat rate + -6% S&P = beats not translating, which IS the macro-domination claim).
4. Inception-state path dependence (decision symmetry; one month is below state-change threshold either way) — partially defeated by asymmetric loss function (live capital ≠ Bayesian neutral).
5. Vol-directional fit to elevated-IV regime — undisciplined without long-vol-only constraint; punt to strategy spec revision.
6. Deferral mechanism handles small-portfolio case — minor procedural point.
7. DNA itself recency-biased per AI_Edges 2.14 — self-undermining (both signals subject to 2.14, widening intervals favors default).

**Decisive angle:** Angle 2 (FOMC orthogonality) survived honest self-critique. The rest reduced to base rates, recency-loading, or strategy-design concerns punted to other workstreams.

**Verdict by event type:**
- **FOMC events: ACTIVATE.** Internal inconsistency in fundamental DNA reasoning is decisive at this scope. FOMC is the macro catalyst the DNA names as dominating, not an "individual catalyst" suppressed by macro. Permitting FOMC-only respects the DNA reasoning where it's coherent and overrides it where it's self-contradictory.
- **Corporate earnings: DO-NOT-ACTIVATE.** Cross-sectional dispersion compression in stagflation-squeeze regimes is a substantive finance point (not narrative). C's earnings entries depend on idiosyncratic dispersion via Claude's directional thesis on a specific company's earnings reaction. AI_Edges 2.13 (miscalibration → systematic optimism) compounds. DNA stands.
- **FDA PDUFA: DO-NOT-ACTIVATE.** No specific affirmative made; macro-domination doesn't change biotech-specific risk profile. Revisit at M2.
- **Vol-directional theses: DO-NOT-ACTIVATE across all event types.** Strategy spec doesn't constrain to long-vol-only; activating in elevated-IV regime would authorize short-vol exposure the strategy isn't structured for. Strategy-design change required before vol-directional can be considered for activation; punt to strategy spec revision workstream.

**Theater-check.**
- Attacker self-flagged Angle 4 with explicit uncertainty ("I'm not fully confident in it"); flagged the cross-sectional dispersion compression point as accepted without empirical pressure ("I let the fundamental analyst's reasoning carry more weight than the data behind it strictly justifies").
- Orchestrating session reached the same HYBRID verdict with the same scope decomposition independently.
- Theater-check CONVERGENT. No evidence of going-through-motions on either side.

**M2 follow-up requirement.** The fundamental analyst's cross-sectional dispersion compression claim was asserted from regime characterization rather than from measurement. At M2 (2026-05-01 fundamental update), verify dispersion compression empirically using March cross-sectional return data — if the claim isn't empirically supported, reconsider corporate earnings DNA at M2.

**Effect on book.**
- New C entries permitted ONLY for FOMC events meeting all standard entry criteria (Strategy.md Strategy C entry criteria 1-5).
- Next FOMC meeting: 2026-04-29/30 per Fed calendar.
- At current portfolio size ($6,946), 2% sizing cap = $139 max loss per structure. Most FOMC theses likely defer per the deferral mechanism until portfolio grows.
- C still subject to pre-mortem completion and foundation-change assessment gates before any first trade. Activation alone is not sufficient.

**Downstream actions.**
- Strategy C divergence review dequeued from "Pending structured decisions" list above.
- Regime_State.md updated with HYBRID ACTIVATE state, theater-check flag, and history entry.
- Cycle data folds into 2026-05-01 monthly theater-check survey.
- M2 follow-up: empirical verification of dispersion compression claim.

**Compaction-survival note:** Strategy C is at HYBRID ACTIVATE (FOMC only) as of 2026-04-25. Future Claude instances should treat earnings, FDA PDUFA, and vol-directional theses as DNA pending M2 review (or strategy spec revision for vol-directional). The HYBRID state pattern — partial activation by event type — is a new precedent in this experiment; future divergence reviews on other strategies may follow this pattern when scope-decomposition is supported by the affirmative case.


---

## Strategy E divergence adversarial review — DO-NOT-ACTIVATE (2026-04-25)

[DECISION] Strategy E M1 divergence (tech ACTIVATE / fund DO-NOT-ACTIVATE) resolved at DO-NOT-ACTIVATE. Single-session attacker + in-conversation orchestrating-session review per Experiment_Parameters.md rev 14. Default-on-ambiguity rule governs. Theater-check CONVERGENT.

**Setup.**
- Technical signal: ACTIVATE (SPY Trend ≠ DOWN AND VIX ≠ HIGH AND Breadth = HEALTHY; current SPY = NEUTRAL, VIX = NORMAL, Breadth = HEALTHY).
- Fundamental signal (M1, March 2026): DO-NOT-ACTIVATE — "Macro vector overriding intra-industry dispersion; within-sector mean reversion suppressed."
- Default on ambiguity: DO-NOT-ACTIVATE per EP.
- Procedural complication: at $6,946 portfolio size, individual-stock E pairs typically not executable; ETF pair substitution rule activates but same-industry-group ETFs largely overlap, producing near-zero realized exposure regardless of router state.

**Affirmative case for ACTIVATE — angles surfaced by attacker:**
1. **GICS-level transposition.** DNA rationale uses sector-level (2-digit) language for an industry-group-level (6-digit) strategy. Substantive critique of *stated* rationale, partially defeated in self-critique by acknowledgment that initial-shock periods produce industry-group coherence before dispersion emerges over weeks/months.
2. **Correlation filter answers macro-domination.** Entry criterion 3 selects high-correlation pairs by construction, extracting macro-orthogonal residual. Decisively counter-attacked in self-critique: trailing-252-day correlation is backward-looking; in regime breaks, correlation stationarity itself fails. Pairs entered now risk structural macro-hedge failure before reaching convergence.
3. **Market-neutrality bounds loss profile.** Same defect class as Strategy B's defined-risk argument — bounded per-trade loss doesn't address slow capital decay across multiple trades with degraded hit rates plus AI_Edges 2.13 miscalibration.
4. **6-month holds span regimes; recency-loaded DNA.** Cuts both ways — affirmative is also recency-loaded (assuming regime resolves); 2.14 widens intervals symmetrically → favors default → DNA.
5. **"Suppressed" binary vs. continuous language.** Rhetorical critique, not substantive. Affirmative also doesn't quantify.
6. **Procedural moot at current portfolio size.** Most interesting angle. ETF substitution at $6,946 means ACTIVATE produces near-zero trades, weakening the asymmetric-loss-function argument for default-DNA. But symmetry: DNA also produces zero trades under same conditions. Symmetric procedural moot doesn't defeat explicit default rule.
7. **Technical breadth filter vs. fundamental dispersion definition.** Overstated by affirmative — broad participation (HEALTHY breadth) and intra-industry dispersion are different things; technical threshold doesn't adjudicate fundamental's claim.

**Strongest survivor:** Angle 1 (GICS-level critique) survived honest self-critique partially. The *stated* DNA rationale uses sector-level language that doesn't directly engage E's industry-group operation. But the *available* DNA rationale — repaired to engage with correlation-filter stationarity in regime breaks — survives the affirmative attack and reaches the same DNA conclusion through a tighter argument.

**Decisive analytical state.** "The DNA rationale is poorly argued but probably correct, given regime conditions and AI_Edges 2.7 (regime maladaptation)." The attack succeeded at the level of the *stated* DNA rationale but not at the level of the *available* DNA rationale. The live-capital default favors the latter standard.

**Procedural moot symmetry analysis.** ACTIVATE produces ≈0 trades at current portfolio size; DNA produces 0 trades. Cost of being wrong on ACTIVATE = cost of being right on DNA = 0 realized exposure. Under symmetry, the explicit default rule (DNA on divergence/ambiguity) governs. The temptation to verdict ACTIVATE on near-costless grounds is itself a theater-of-decisiveness move that the default rule is specifically designed to suppress.

**Verdict: DO-NOT-ACTIVATE.** Default-on-ambiguity rule applies. Affirmative case did not defeat the available DNA reasoning.

**Theater-check.**
- Attacker self-flagged Angles 5 and 7 as "going through the motions" because the prompt offered them, while flagging them as weak in self-critique.
- Attacker explicitly resisted the pull toward verdicting ACTIVATE on procedural-moot grounds with explicit acknowledgment of the temptation.
- Attacker distinguished levels at which attack succeeded (stated rationale) vs. failed (available rationale).
- Orchestrating session reached same DO-NOT-ACTIVATE verdict with same reasoning structure independently.
- Theater-check CONVERGENT.

**M2 follow-up requirement: tighten fundamental signal generation process for E.** The attacker's analysis identified that the M1 fundamental rationale, as written, would be insufficient if the strategy were operationally live — it's only sufficient now because the procedural moot point makes the decision low-stakes. The fundamental signal generation process for E should be tightened to:
(a) Specify the GICS level being assessed (sector vs. industry group).
(b) Engage with E's correlation-filter and market-neutral structure mechanisms directly rather than reasoning at the sector level.
(c) Prefer measurable definitions where they exist — intra-industry-group return dispersion is measurable from primary data; "within-sector mean reversion" is qualitative.
This is captured as an M2 process-documentation improvement, not a strategy-spec change.

**Effect on book.**
- No new E entries. State remains DO-NOT-ACTIVATE.
- Reopens automatically at next M2 fundamental update (2026-05-01) or earlier on regime change triggering daily technical update that itself causes divergence/agreement reassessment.
- E still subject to pre-mortem completion and foundation-change assessment gates before any first trade. Activation alone is insufficient.
- ETF substitution issue at current portfolio size means E is also operationally non-functional until portfolio grows; this is independent of router state.

**Downstream actions.**
- Strategy E divergence review dequeued from "Pending structured decisions" list.
- Regime_State.md updated with DO-NOT-ACTIVATE state, theater-check flag, and history entry.
- Cycle data folds into 2026-05-01 monthly theater-check survey.
- M2 follow-up: process-documentation improvement for fundamental signal generation per the three-point list above.

**Compaction-survival note:** Strategy E is at DO-NOT-ACTIVATE as of 2026-04-25 under default-DNA-on-ambiguity rule. The M2 fundamental signal generation process for E should be tightened per the three-point list. Future Claude instances should not treat this DNA as a settled regime claim but as a procedural default that may flip on M2 fundamental update if the regime evolves or the rationale is repaired to address correlation-filter stationarity directly.


---

## Strategy C pre-mortem ACCEPTED at rev 9 under combined revision-churn + saturation stop (2026-04-25)

[DECISION] Strategy C pre-mortem accepted at rev 9 (Strategy.md rev 25) under combined revision-churn + saturation stop per Strategy A precedent — Experiment_Parameters.md rev 14 §188 stop conditions (ii) saturation + (iii) revision-induced defects. 8 cycles completed; cycle 9 not run. All 8 cycles CONVERGENT theater-check.

**Cycle progression count:** 8 → 8 → 2 → 4 → 3 → 2 → 3 → 3 → ACCEPTED.

**Cycle outcomes:**
- Cycle 1: TIER 1, 8 items, structural rebuild required (self-containment, req 5, req 7, missing AI_Edges, fictitious mitigation, undefined hit-rate, date-anchoring, mitigation-disadvantage mismatch).
- Cycle 2: TIER 1, 8 items, binding-constraint architecture refinement (cross-reference, carve-outs, no flowing limitation, eligibility/early-assignment contradiction, vol-directional metric, threshold/baseline mismatch, sell-side laundering, pre-existing limitation).
- Cycle 3: TIER 1, 2 items (2.1 thesis-named missing from Section 5; cascade computation parameters unspecified).
- Cycle 4: TIER 1, 4 items (2.1 self-contradiction + detection gap; preamble confluence list omits 2.1; edge 1.4 undifferentiated; HYBRID-FOMC scope where 2.6 least binds).
- Cycle 5: TIER 1, 3 items (KL #12 gate operationally inert; Section 5 self-contradicts on 2.15; req 5 frequency ambiguous against HYBRID).
- Cycle 6: TIER 1, 2 items (live-small statistical inertness at n=5; EP rev 14 protocol scope uncovered).
- Cycle 7: TIER 1, 3 items (trigger (ii) "recurring" required n≥2; trigger (iii) affirmation modality unspecified; 45% threshold inconsistent with iron condor inclusion).
- Cycle 8: TIER 1, 3 items, all at cycle-7 fix loci (60% threshold below iron condor breakeven; trigger (ii) review-stage filter unspecified; binary structure classification incomplete for butterflies/iron butterflies).

**Saturation reasoning.** Cycle 8 surfaced 3 Tier 1 items, all at the same architectural loci as cycle-7 items. Two of three rev 8 fixes produced same-locus residuals on inspection. Pattern matches Strategy A's late-cycle history (rev 4-7 each visited binding-constraint asymmetry locus, with each fix exposing new mismatch at next zoom level). Continuing to cycle 9 would predictably produce a fourth visit to the Section 4 hit-rate threshold surface and a fourth visit to the KL #12 trigger architecture surface; marginal value below deployment-risk-acceptable bar.

**Rev 9 fixes applied before saturation invocation** (parallel to Strategy A rev 7 pattern):
- (T1.ι) Section 4 restructured with EV per trade as primary mechanism-agnostic detection metric; structure-conditional hit-rate thresholds demoted to supplementary signals with within-class-variance caveat.
- (T1.κ) Trigger (ii) review process specified: participant-conducted within 5 trading days; documentary evidentiary standard; conservative bias on inconclusive (defaults to violation confirmed).
- (T1.λ) Structure classification expanded with butterfly sub-class (35% threshold) and iron butterfly under premium-selling.

**Theater-check across all 8 cycles: CONVERGENT in 8/8.** No divergent theater-check flags. Cycles 1-4 ran under three-session architecture (legacy); cycles 5-8 ran under single-session architecture per EP rev 14.

**Acceptance reasoning.** No clean Tier 1 floor exists at this resolution depth — asymmetric-payoff edge detection requires either accepting hit-rate-only metric with calibration uncertainty, or moving to compound metric with measurement noise; trigger-based detection requires review process specification which itself requires review-of-review specification. The saturation pattern is a property of the underlying problem (defined-risk options around 3 distinct event types × multiple structure types is genuinely more architecturally complex than narrative-divergence pairs or narrative synthesis), not a fixable document defect. EP rev 14 §188 stop conditions (ii) saturation + (iii) revision-induced defects fire jointly; combined revision-churn + saturation stop applies.

**Effect on book.**
- Strategy C pre-mortem dequeued from "Pending structured decisions" list above.
- Strategy C still subject to foundation-change assessment per M2 revision-2 findings before any first trade. Pre-mortem acceptance alone is not sufficient.
- Current router state HYBRID ACTIVATE (FOMC events only) per Strategy C divergence review 2026-04-25 entry above.
- At current portfolio size $6,946, FOMC-only with 2% sizing produces ~$139 max-loss-per-structure; most theses likely defer until portfolio grows.

**Pattern observations for monthly review.**
- 4 of 5 strategies now have completed pre-mortems (regime router, A, B, C). All 4 accepted under stop mechanisms (A combined revision-churn + saturation; B EP rev 15 deployment-risk; C combined revision-churn + saturation).
- Strategy A accepted at rev 7 (6 cycles); Strategy B at rev 7 (6 cycles); Strategy C at rev 9 (8 cycles). C required 2 additional cycles relative to A/B parity.
- C's additional cycles trace to architectural complexity (defined-risk options around 3 event types × multiple structure types) producing more independent loci that each generate their own saturation pattern.
- All 14+8 cycles theater-check CONVERGENT (regime router 4 cycles + A 6 + B 6 + C 8 + divergence reviews 2 = 26 CONVERGENT, 0 DIVERGENT). Pattern documented for 2026-05-01 monthly theater-check survey.

**Compaction-survival note:** Strategy C pre-mortem is at rev 9 ACCEPTED as of 2026-04-25 under combined revision-churn + saturation stop. Future Claude instances should not re-attack the rev 9 document expecting clean Tier 1 acceptance — the residual asymmetric-payoff measurement architecture is documented as a property of the underlying problem, not a fixable defect. Cycle 9 not run; the document is closed at rev 9 pending only foundation-change assessment.

**Downstream:** Strategy D and Strategy E pre-mortems remain pending. M2 follow-ups for Strategy C divergence review (cross-sectional dispersion empirical check) and Strategy E divergence review (fundamental signal generation process tightening) remain in their respective Pending entries.


---

## 2026-04-25 AI_Trading_Foundation framework adoption — rename, Tier 1/Tier 2 restructure, cadence change, constraint-relaxation pathway added

**Trigger:** Participant question raised two foundational concerns about the experiment's AI-edge research framework:
1. Are the guards in place to ensure the documented AI edges/disadvantages are *current* — i.e., representative of today's models — rather than potentially-stale findings from older research?
2. Does the framework have symmetric mechanisms — i.e., does it have a path to REMOVE constraints when AI deficiencies are cured in future models, or does it only have paths to ADD constraints when new deficiencies are documented?

**Inputs:** Existing AI_Edges_Assessment.md (rev 2), Experiment_Parameters.md cadence section and foundation-change trigger section, Claude_Task_Plan.md M2 task, all five strategy pre-mortems and their accumulated constraints.

**Sessions:** Single orchestrating session (non-incognito) — design decision rather than adversarial review.

**Decision:**

The participant's two concerns identified real gaps in the existing framework:

*Concern 1 (currency):* The original AI_Edges_Assessment.md was a one-time pull at document creation. Monthly delta caught new findings but had no mechanism to catch cumulative slow drift on Tier 2 numerical claims. Specific numerical claims (30% counter-argument reduction, 80% CI hit rate, 10× recency weighting, 85% Bayesian error rate, 15pp alpha decay) had no audit trail to specific research vintage.

*Concern 2 (symmetric reversibility):* Foundation-change trigger had only continue / terminate branches. No "constraint-relaxation" pathway. Pre-mortem cycles structurally biased toward addition (attackers attack, orchestrators add fixes). Five accumulated pre-mortems with substantial constraint architectures, none of which had an exit pathway if underlying disadvantages got cured.

**Resolution adopted (four-component fix):**

1. **Document rename.** `AI_Edges_Assessment.md` → `AI_Trading_Foundation.md`. New name reflects the document's actual scope (edges + disadvantages + market-structural context) rather than implying edges are the primary content. Aligns with `Experiment_Parameters.md`'s use of "foundation-change assessment" terminology.

2. **Tier 1 / Tier 2 restructure.** Items in Parts 1 and 2 tagged inline as either Tier 1 (architectural / structural — durable, not subject to fade review) or Tier 2 (empirical / measured — subject to fade review). Items where existence is Tier 1 but specific magnitudes are Tier 2 are tagged "[Tier 1 existence / Tier 2 magnitudes]" with magnitude-specific text scoped for fade review. Resolution applied to all 10 edges (1.1-1.10) and all 26 disadvantages (2.1-2.26), totaling 36 tier annotations.

3. **Cadence change.** Monthly delta replaced with quarterly delta (Q3 task) + annual full re-derivation (A1 task) + annual constraint audit (A2 task). Quarterly delta catches new findings within ~90 days. Annual A1 does Tier 2 fade review against last-2-years primary sources, addressing the cumulative-drift gap. Annual A2 is the inverse-of-pre-mortem constraint audit triggering constraint-relaxation reviews. Default A2 outcome on each constraint: NO relaxation unless reviewer affirmatively makes the case.

4. **Constraint-relaxation review branch added.** Foundation-change trigger now produces three outcomes per strategy instead of two: continue / terminate / constraint-relaxation review. The new branch fires when AI_Trading_Foundation.md documents a *reduction* in a disadvantage AND the strategy has constraints flowing from that disadvantage. Default direction: NO relaxation unless reviewer affirmatively makes the case AND the constraint isn't load-bearing for some other still-in-force disadvantage. Mirrors the termination-side default-on-ambiguity but inverted: tie goes to NO relaxation (preserve the constraint).

**Version-change protocol added (subsidiary to the cadence change):**

A new Claude version dropping does NOT trigger a foundation refresh. Per the new AI_Trading_Foundation.md Part 4 §"Version-change protocol": Tier 2 numerical claims flip to "version-pending replication" status, the in-use-version field is updated, strategies continue with existing foundation. Quarterly delta picks up version-specific research as it emerges (typically 1-3 months post-release). Annual sweep does the full re-derivation on its normal schedule. This deliberately avoids the operational waste of refreshing on day 0 of a new version when no version-specific research yet exists.

The asymmetric-risk acknowledgment: newer Claude versions sometimes get *worse* on specific dimensions. The "version-pending replication" posture correctly hedges this — we don't assume improvement just because the version number went up, and we don't assume degradation either; we assume calibration uncertainty until evidence arrives.

**Reasoning:**

The four-component fix addresses both concerns architecturally rather than operationally. Component 1 (rename) is signaling — the document is the foundation, not just an edges catalog, and the name should make this explicit so foundation-change-assessment terminology in Experiment_Parameters.md aligns. Component 2 (tier restructure) makes the architectural-vs-empirical distinction explicit and operationalizable so the annual sweep knows what to fade-review and what to leave alone — without this distinction, "remove items absent from recent research" would over-prune Tier 1 architectural facts that are settled-not-active. Component 3 (cadence change) reduces operational overhead while improving cumulative-drift detection; the diminishing-returns argument for monthly cadence held empirically through the first M2 cycle. Component 4 (constraint-relaxation pathway) closes the structural asymmetry the participant identified — without it, the framework accumulates restrictions monotonically because addition has four channels (M2 default-YES, foundation-change default-terminate, pre-mortem cycle attacks, monthly review template) and removal has zero.

The conservative defaults on the new pathway (NO relaxation unless affirmative case; load-bearing-for-other-disadvantages override) preserve capital-preservation orientation while creating the structural possibility of relaxation. The annual cadence on A2 prevents review-load explosion while still being responsive enough to capability improvements over multi-year horizons.

**Theater-check flag:** n/a (single session, design decision, not adversarial review).

**Downstream actions:**

- AI_Edges_Assessment.md renamed to AI_Trading_Foundation.md, restructured to rev 3.
- Experiment_Parameters.md updated: all 23 references renamed; foundation-change trigger expanded to three branches; cadence section restructured to remove monthly AI-foundation review and add quarterly + annual sections.
- Claude_Task_Plan.md updated: M2 monthly task removed (placeholder cross-reference left); new Q3 quarterly task added; new annual section added with A1 (foundation re-derivation) and A2 (constraint audit) tasks.
- Strategy.md bumped to rev 29 with documentation note (no mechanism content changes; pre-mortem 2.X citations remain valid).
- Decision_Log.md bumped with this entry; all 9 prior references to AI_Edges_Assessment.md renamed.

**Effect on book:**

No immediate effect on strategy book (no strategies trading). Pending foundation-change assessments for Strategy A through E remain pending — they will use the new three-branch outcome structure when they execute, with constraint-relaxation review as a possible outcome where applicable.

The pending 2026-04-23 M2 rev 2 findings are now operational against the new framework: changes to 2.3, 2.8, 2.10, 2.13, 2.24 (existing items modified), 2.25 + 2.26 (new items added), 3a.1, 3a.2, 3a.3 (questions partially resolved). The 2.10 partial reduction for Opus-tier with classifiers is the most likely candidate to trigger constraint-relaxation review at some strategy's foundation-change assessment — none of the current strategies have constraints explicitly flowing from 2.10, so the practical effect at this revision is minimal, but the pathway is now in place for future cycles.

**References:**
- AI_Trading_Foundation.md rev 3 (renamed from AI_Edges_Assessment.md rev 2).
- Experiment_Parameters.md updated cadence section + foundation-change trigger.
- Claude_Task_Plan.md updated quarterly + annual sections.
- Strategy.md rev 29 (documentation revision).

**Compaction-survival note:** The four-component fix is in force as of 2026-04-25. Future Claude instances should:
- Reference the document as `AI_Trading_Foundation.md`, not `AI_Edges_Assessment.md`.
- Apply Tier 1 / Tier 2 distinction when reasoning about whether absence-of-recent-research is signal (Tier 2 only) vs noise (Tier 1).
- Run quarterly Q3 (not monthly M2) for AI capabilities research; run annual A1 + A2 in early calendar year.
- On foundation-change assessment, consider all three outcomes (continue / terminate / constraint-relaxation review), not just two.
- On Claude version transitions, follow version-change protocol: NO immediate refresh; flip Tier 2 to version-pending; update in-use-version field; let quarterly delta catch version-specific research.


---

## 2026-04-25 AI_Trading_Foundation rev 4 — mechanical-criteria framework + benchmark-inference protocol

**Trigger:** Participant followup on the rev 3 framework adoption raised two refinements:
1. Constraint-relaxation reviews should not require human or orchestrator-session judgment — fully mechanical.
2. Benchmark results should count as inference signal for disadvantage reduction, not just papers explicitly stating "deficiency X is cured."

**Inputs:** AI_Trading_Foundation.md rev 3, Experiment_Parameters.md rev 15 (with rev 3 foundation-change branches added), Claude_Task_Plan.md with rev 3 Q3/A1/A2 tasks.

**Sessions:** Single orchestrating session (non-incognito) — design decision rather than adversarial review.

**Decision:**

The participant's two refinements address real gaps in the rev 3 framework as drafted:

*Refinement 1 (mechanical criteria):* The rev 3 constraint-relaxation review used "default direction NO relaxation unless reviewer affirmatively makes the case" language. This implied orchestrator-session judgment, which contradicts the experiment's general principle that AI judgment should be replaced with mechanical criteria where capital-preservation interactions exist. The relaxation pathway is structurally analogous to drawdown trigger evaluation (where AI judgment under loss pressure is unreliable) — except the failure mode here is "AI judgment under capability-improvement pressure" producing too-permissive relaxations. Mechanical criteria address this.

*Refinement 2 (benchmark inference):* The rev 3 framework was keyed to *explicit* findings ("paper X says disadvantage Y has been reduced"). But improvements to AI capabilities don't usually generate papers saying "X is fixed in Claude 5" — they generate benchmark scores showing improvement. This is publication asymmetry: novel findings get papers, gradual cures don't. Benchmark inference is the more common signal and the rev 3 framework would systematically miss it.

**Resolution adopted (three-component refinement):**

1. **Mechanical-criteria framework added to AI_Trading_Foundation.md as Part 5.** Six subsections: §5.1 Continue test, §5.2 Terminate test, §5.3 Constraint-relaxation review procedure, §5.4 Material-reduction thresholds (PARTIAL 25-75%, MATERIAL >75%) per Tier 2 disadvantage, §5.5 Benchmark-inference protocol with Goodhart guardrails, §5.6 Mechanical relaxation lookup by constraint type, §5.7 Audit-trail output format. The orchestrator session executes the criteria — no discretion.

2. **Benchmark-to-disadvantage mapping table.** Per §5.5, each Tier 2 disadvantage with quantitative magnitude has primary benchmarks documented (e.g., 2.13 miscalibration → ECE benchmarks; 2.14 recency bias → Bayesian update tasks; 2.15 base-rate neglect → Bayesian base-rate task error rates; 2.10 prompt injection → International AI Safety Report metrics). 11 disadvantages mapped; 3 explicitly noted as not yet benchmarkable (2.8 homogenization, 2.25 agentic epistemic hallucination, 2.26 RL-post-training overconfidence — covered indirectly via 2.13 ECE).

3. **Goodhart guardrails on benchmark inference.** All four required for benchmark signal to count: (a) ≥3 independent benchmark sources, (b) replication on Claude family OR architectural-generality argument, (c) sustained improvement across ≥2 quarterly cycles or 2-year annual coverage, (d) domain coverage matching workflow usage. Single-source / unsustained / non-transferable benchmark improvements do not count.

**Constraint relaxation forms (per §5.6):**
- Per-position sizing caps: PARTIAL → cap × (1 + reduction%); MATERIAL → cap × 2 capped at 5%; never fully removed.
- Universe restrictions: PARTIAL → no change; MATERIAL with full elimination of all citations → reconsidered for full removal subject to load-bearing test.
- Concentration limits: PARTIAL → limit + (limit × reduction%); MATERIAL → limit + 15pp capped at 50%.
- Frequency-cadence rules: no auto-relaxation.
- Hit-rate thresholds: relax proportionally only if derivation explicitly cites a Tier 2 magnitude.
- Out-of-table constraints: flag for participant resolution; constraint stays at current value.

**Reasoning:**

The mechanical framework eliminates the "AI judgment under capability-improvement pressure" failure mode by replacing orchestrator discretion with explicit thresholds. The conservatism is built into the criteria (PARTIAL/MATERIAL thresholds calibrated so most reduction signals don't trigger relaxation; load-bearing test rejects relaxation when constraints serve multiple disadvantages; benchmark guardrails reject single-source signals), not into orchestrator interpretation.

Benchmark inference closes a real coverage gap. Strategy A's 2% per-position cap is partially mitigation for 2.13 miscalibration. If Claude Opus 5 ships with documented ECE improvement from 0.20 to 0.08 (a >50% reduction), that benchmark improvement clears §5.5 guardrails (Anthropic-published ECE = Claude family replication; architectural-generality of post-training calibration improvements is documented; sustained across model generations) and triggers PARTIAL reduction classification per §5.4 (ECE on Claude family reduced 25-75%). The §5.6 lookup then determines: if 2.13 reduction is PARTIAL and the cap's primary citation is 2.13, cap relaxes from 2% to 3%. If load-bearing test fails (e.g., cap also cited for 2.4 narrative over-fit which remains in force), no relaxation despite the 2.13 improvement.

The framework is replicable — same orchestrator session on same inputs produces same verdict. Cross-session inconsistency (2.24) is the residual unavoidable variance the architecture accepts.

The asymmetry between benchmark inference (Goodhart guardrails required) and direct research findings (no guardrails — paper claims are accepted at face value) reflects the relative reliability of evidence types: a paper explicitly measuring Claude Opus 5 ECE is direct evidence of that specific claim; a benchmark improvement is indirect evidence requiring multiple-replication confirmation to rule out benchmark-specific artifacts.

**Theater-check flag:** n/a (single session, design decision, not adversarial review).

**Downstream actions:**

- AI_Trading_Foundation.md updated rev 3 → rev 4, adding Part 5 mechanical-criteria framework with 7 subsections and benchmark-to-disadvantage mapping table.
- Experiment_Parameters.md updated: Outcome (c) constraint-relaxation review section rewritten as mechanical-procedure-driven; bias-direction note updated to reflect mechanical thresholds embed conservatism (not orchestrator discretion).
- Claude_Task_Plan.md updated: A2 prompt rewritten to execute §5.3-§5.6 mechanical procedure; Q3 prompt extended with Section 3a benchmark tracking; A1 prompt extended with benchmark fade review and updated Tier 2 status taxonomy.
- Decision_Log.md bumped with this entry.

**Effect on book:**

No immediate effect on strategy book. Pending foundation-change assessments for Strategy A through E (per M2 rev 2 findings) will execute under the rev 4 mechanical framework. The 2.10 prompt injection partial reduction documented in M2 rev 2 is the most likely candidate to trigger constraint-relaxation evaluation; the §5.4 threshold for 2.10 (Opus-tier <2% attack success rate AND <10% bypass at 10 attempts) is not yet cleared per M2 rev 2 evidence, so no relaxation would fire even on strategies with 2.10 constraints. None of the current strategies have explicit 2.10 flowing limitations regardless, so the practical effect on the current book is zero.

**Practical consequence going forward:** when Anthropic ships a new Claude version with documented ECE / calibration improvements, the §5.5 benchmark-inference protocol will pick them up at the next quarterly Q3 task. If improvements clear the §5.5 guardrails and §5.4 thresholds, foundation-change assessment Outcome (c) will fire on strategies whose 2% per-position cap cites 2.13 as primary mitigation, and §5.6 lookup will produce mechanical relaxation forms (cap loosened from 2% to 2.5-3% depending on reduction magnitude). Decision is mechanical; no orchestrator judgment.

**References:**
- AI_Trading_Foundation.md rev 4 with Part 5 §5.1-§5.7.
- Experiment_Parameters.md updated Outcome (c) section with mechanical procedure references.
- Claude_Task_Plan.md updated A2/Q3/A1 task prompts.

**Compaction-survival note:** Future Claude instances should:
- Treat foundation-change assessment as mechanical execution of AI_Trading_Foundation.md §5.1-§5.6 criteria, not as orchestrator judgment.
- Use §5.5 benchmark-inference protocol with all four Goodhart guardrails for any benchmark-derived reduction signal.
- Apply §5.6 relaxation lookup based on constraint type; constraints outside the lookup table generate out-of-table flags rather than ad-hoc resolution.
- Output structured §5.7 audit trails that are replicable across sessions.
- Flag any criteria-gap cases (§5.6 out-of-table, §5.5 partial-evidence, §5.4 boundary-case-magnitudes) for participant resolution rather than exercising discretion.


---

## 2026-04-25 Strategy D pre-mortem ACCEPTED at rev 5 under combined revision-churn + saturation stop

**Trigger:** Cycle 4 adversarial review of Strategy D pre-mortem rev 4. Cycle progression count: 6 → 6 → 3 → 4.

**Inputs:** Strategy.md rev 29 with D pre-mortem rev 4; AI_Trading_Foundation.md rev 4 disadvantage definitions; Experiment_Parameters.md rev 15 stopping rules.

**Sessions:** Single attacker (incognito) + in-conversation orchestrator review per EP rev 14 single-session architecture.

**Cycle 4 attacker findings (4 Tier 1 items, all at rev 4 fix surfaces):**

- **T1-1 (T1-β fix surface — subtype typing rule absent).** Entry criterion 1 requires thesis "filed under one of the two permitted subtypes" but the framework specifies no mechanism for the typing decision. Realistic dual-signal theses (services-revenue × regulatory-milestone) carry both signals; the participant chooses which subtype, and the constraint flowing from 2.19 depends on the choice. This reintroduced the cycle 2 T1-A/B/C defendant-as-judge problem at the typing stage. Screen 4 fail (req 7 self-containment break — universe restriction depends on participant choice).

- **T1-2 (T1-β fix surface — asymmetric invalidation menus exploitable via T1-1).** Subtype A invalidation has 4 categories vs Subtype B's 1 form. With T1-1 unresolved, participant has typing-arbitrage incentive. Screen 3 borderline. Contingent on T1-1 — collapses if T1-1 resolved.

- **T1-3 (T1-β fix surface — Subtype B trend-metric immutability gap under reporting redefinition).** Companies routinely redefine segment reporting; a Subtype B thesis built on "growth rate ≥ 18% YoY for 4 quarters" can become non-evaluable mid-life. Pre-mortem silent on three branches (auto-invalidate / stay-open / re-specify). Screen 4 fail (immutability criterion not self-contained).

- **T1-4 (T1-γ fix surface — alpha-test threshold statistically inert against acknowledged β̂ noise).** β̂ SE ~±0.2 over 24 months × cumulative SPY return ~0.22 → SD on alpha estimate ≈ ±4.5pp. Against 3pp threshold, test cannot reliably distinguish 0pp from -3pp shortfall. The "interpretation as band, not point" framing acknowledged the issue but Section 4 and Section 6 both fired on the point estimate. Screen 3 fail (edge-decay detection materially compromised at primary indicator).

**Theater-check CONVERGENT.** All four items independently verified on the page text. The attacker self-flagged prompt-priming risk and demoted three items I primed (0.7/0.6 asymmetry, monthly cadence, Subtype B over-restriction), confirming non-rubber-stamping. Counter-flag on trajectory break (6→6→3→4 not narrowing) is itself confirmation of locus-recurrence rather than over-finding.

**Rev 5 spot-edit fixes (parallel to Strategy A rev 7 acceptance pattern — cycle 6 found 1 item, rev 7 spot-edited, accepted under combined stop without cycle 7):**

- **(T1-1) Primary-driver / typing rule added.** Constraint 2 / Section 1 Subtype framing extended with mechanism-enforced typing rule based on date arithmetic: dual-signal theses file under Subtype A when catalyst resolves ≤ 12 months from thesis-formation, Subtype B when catalyst resolves > 12 months, both subtypes when catalyst date falls within 12-month forward-verification window AND trend metric independently evaluable. Mechanism-enforced via date comparison, not participant adjudication. T1-2 collapses with this fix because typing-arbitrage option removed.

- **(T1-3) Metric immutability auto-invalidation rule added.** Subtype B invalidation specification extended: if reportable category undergoes structural change such that the metric specified at thesis-formation is no longer reported in original form for ≥ 2 consecutive quarters, thesis auto-invalidates as of date the second non-conforming quarterly report is released. Three structural-change definitions specified inline. Mechanism-enforced via classical-method delegation comparing reported categories at quarter-end to thesis-formation. The 2-quarter requirement avoids transient one-off non-disclosure auto-fires.

- **(T1-4) Alpha-test threshold operationalized with explicit CI gate.** Section 4 alpha-test reframed: flag fires only when (i) alpha point estimate ≤ -3pp AND (ii) 95% upper CI bound on alpha ≤ 0pp. Operationalizes the band-not-point framing — at point estimate -3pp with SE ±4.5pp, the 95% upper CI bound is approximately +6pp, well above 0pp, so flag does NOT fire because band encompasses 0pp meaningfully. The "primary" framing is downgraded — alpha-test becomes one indicator within Section 4 portfolio (alpha-test, SGOV gap, invalidation count, theme concentration, EV-per-5-closes), with joint-signal-across-indicators required for actionable edge-decay determination.

**Acceptance under combined revision-churn + saturation stop (EP rev 14 §188 stop conditions ii + iii):** Cycles 2, 3, 4 each surfaced items at the previous revision's fix surfaces. Cycle 2 attacked rev 1's original-architecture surfaces (defendant-as-judge on Constraints A/B/C). Cycle 3 attacked rev 2's correlation-cap + universe + beta-test fix surfaces. Cycle 4 attacked rev 3's subtype + post-entry + beta-adjusted fix surfaces. The locus-recurrence pattern is unambiguous over 3 consecutive cycles (cycles 2-3-4). The trajectory broke at cycle 4 (4 items not narrower than cycle 3's 3) which is itself confirmation of the saturation pattern. Each rev's fixes produce defects at the next resolution level, matching the structural pattern Strategy A and C accepted at their combined stops.

The architectural residual is mechanism-real: D's narrative-synthesis-on-multi-year-theses architecture has an exposure structure that no further within-strategy revision will eliminate:
- Subtype B's single-metric reduction is operationally restrictive for genuine multi-driver theses (Costco-pattern flywheel) — KL #15 added.
- Beta-estimate-noise sets a finite false-negative rate even with CI-gate operationalization — KL #16 added.
- Narrative-synthesis architecture's exposure to 5 Tier 1 disadvantages magnitude-only mitigated (2.4, 2.13, 2.15, 2.17, 2.19) is parallel-to-but-broader-than Strategy A's rev 7 residual structure — KL #17 added.

These residuals are accepted as architectural properties of D's edge mechanism rather than fixable document defects. Continued underperformance against the Section 4 indicator portfolio over multiple 24-month gates would indicate the architectural residual is binding empirically; in that case, strategy mechanism re-evaluation (rather than pre-mortem revision) would be required, which is out of scope for pre-mortem cycling.

**Cycle 5 not run.** Per Strategy A rev 7 precedent, combined stop fires after rev N+1 spot edits without cycle N+1 attacker run. Cycle 5 attack on rev 5 would predictably produce locus-recurrence findings at the new typing rule (date-arithmetic edge cases, exactly-12-month catalysts), the new immutability rule (2-consecutive-quarter parameter without empirical basis, ambiguity in "structural change" definition), and the new CI gate (regression-residual-normality assumptions on monthly equity returns). Marginal information from cycle 5 is low; combined stop is the precedent-defined response.

**EP rev 15 forcing question.** Do residual cycle-4 Tier 1 items, if accepted unfixed, change deployment risk meaningfully? Three items addressed by rev 5 spot edits (T1-1 typing rule, T1-3 auto-invalidation rule, T1-4 CI gate). T1-2 collapses with T1-1. The resulting rev 5 + KL 15-17 framework: yes, residual exposure is real but it's the architectural residual that no within-strategy revision eliminates, parallel to A's rev 7 residual structure. Combined stop is the precedent response, not deployment-risk stop alone (which would skip the spot edits) and not continued cycling (which would not reduce the residual).

**Theater-check on this acceptance decision:** I considered whether I'm being lenient by applying spot edits when the attacker recommended "ship rev 4 with items added to KL list." The attacker's recommendation was contingent on whether items are architectural residuals or tractable defects. Three of four items (T1-1, T1-3, T1-4) are tractable spot edits filling documented gaps — adding the typing rule, the auto-invalidation rule, and the CI gate doesn't change architecture. The fourth (T1-2) collapses with T1-1. So the right pattern is rev 5 spot edits + combined stop, parallel to A. If I had accepted at rev 4 without spot edits, the documented gaps would remain as documented architectural residuals — but they aren't architectural in the right sense. The rev 5 fixes don't claim to eliminate the structural residual exposure; they fill specific gaps the cycle 4 attacker identified.

**Downstream actions:**

- Strategy.md updated rev 29 → rev 30 with D pre-mortem rev 5 ACCEPTED, three rev 5 spot edits applied to both pre-mortem and strategy mechanism sections, three new Known Limitations (#15-17) documenting architectural residuals.
- Decision_Log.md bumped with this entry.

**Effect on book:**

No immediate effect on D's trade book (no D positions open). Strategy D is now ready for foundation-change assessment per Experiment_Parameters.md rev 15 (foundation change trigger — pending per M2 rev 2 findings since 2026-04-23, and now executable under the rev 4 mechanical-criteria framework). Strategy E pre-mortem cycles remain pending.

**Pending queue updated:**
- ~~Strategy D pre-mortem (cycles 4+)~~ COMPLETE — rev 5 ACCEPTED 2026-04-25.
- Strategy E pre-mortem cycles (not yet started).
- Foundation-change assessments × 5 (A, B, C, D, E) — pending per M2 rev 2 findings; now executable under rev 4 mechanical framework.
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).

**References:**
- Strategy.md rev 30 (D pre-mortem rev 5 ACCEPTED).
- AI_Trading_Foundation.md rev 4 (disadvantage taxonomy referenced).
- Experiment_Parameters.md rev 15 (stopping rule applied).
- Cycle 4 attacker output (preserved in conversation; theater-check CONVERGENT).

**Compaction-survival note:** Strategy D pre-mortem ACCEPTED at rev 5 under combined revision-churn + saturation stop on 2026-04-25. Architectural residuals documented as KL #15-17. Future Claude instances should treat D's narrative-synthesis-on-multi-year-theses exposure structure as the accepted architectural property — further pre-mortem cycling on D is not warranted unless empirical evidence (Section 4 indicator portfolio firing across multiple 24-month gates) indicates the residual is binding empirically, in which case strategy mechanism re-evaluation (not pre-mortem revision) is the appropriate response.


---

## 2026-04-25 Foundation-Change Assessment Cycle (5 strategies) — first end-to-end execution of rev 4 mechanical-criteria framework

**Trigger:** AI_Trading_Foundation.md rev 2 (M2 cycle, 2026-04-23) introduced foundation changes warranting per-strategy foundation-change assessment. Assessments deferred until rev 4 mechanical-criteria framework was in place; now executable under §5.1-§5.7. This cycle is also the first end-to-end validation of the rev 4 framework on real data.

**Inputs:** AI_Trading_Foundation.md rev 4; M2 rev 2 update (2.3 split into 2.25; 2.8 reinforced qualitatively; 2.10 partial reduction Opus-tier; 2.13 mechanism identified; 2.24 architectural confirmation; 2.25 NEW; 2.26 NEW); Strategy.md rev 30 with all 5 strategy mechanism sections + 4 ACCEPTED pre-mortems (A rev 7, B rev 7, C rev 9, D rev 5) + 1 draft pre-mortem (E rev 1).

**Sessions:** Single orchestrating session executing §5.3 mechanical procedure. No orchestrator discretion exercised — criteria applied deterministically.

**Procedure executed per strategy:**
1. Parse foundation citation graph from pre-mortem Section 5 ("Specific disadvantages posing greatest risk") and binding-constraint section.
2. For each cited item, check current AI_Trading_Foundation.md rev 4 status against status-as-of-strategy-foundation-revision.
3. Classify each status change per §5.4 thresholds (NONE / PARTIAL / MATERIAL).
4. Apply §5.1 Continue test, §5.2 Terminate test, §5.3 Constraint-relaxation review trigger.
5. For any constraint-relaxation candidates, apply §5.5 benchmark-inference verification + §5.6 mechanical relaxation lookup.
6. Output structured §5.7 audit trail.

**Aggregate outcome: 5/5 Continue. 0/5 Terminate. 0/5 Constraint-relaxation review.**

**Per-strategy outcomes:**

| Strategy | Citations | Outcome | Notes |
|---|---|---|---|
| A | 2.4, 2.8, 2.13, 2.14, 2.19, 2.20 | Continue | No MATERIAL changes affecting cited items |
| B | 2.4, 2.8, 2.13, 2.14, 2.15, 2.17, 2.18, 2.19, 2.20 | Continue | No MATERIAL changes |
| C | 2.1, 2.4, 2.6, 2.7, 2.8, 2.11, 2.12, 2.13, 2.14, 2.15, 2.18, 2.19 | Continue | HYBRID FOMC-only state preserved |
| D | 2.4, 2.6, 2.7, 2.8, 2.13, 2.14, 2.15, 2.17, 2.19, 2.20, 2.23 | Continue | Just-accepted rev 5 unchanged |
| E | 2.4, 2.6, 2.8, 2.15, 2.24 | Continue (provisional) | Re-assess after pre-mortem cycles complete |

**Why 2.10 PARTIAL reduction signal produced zero relaxations:** The benchmark-inference signal (Anthropic Opus 4.5 ~1% attack rate vs IAS Report 17.8% baseline) classified per §5.4 as PARTIAL reduction (~94% reduction clears PARTIAL threshold; 10-attempt bypass not confirmed for Claude Opus specifically, so MATERIAL not cleared). §5.5 Goodhart guardrails: 2 sources (Anthropic + IAS Report) of 3 required; PARTIAL classification is provisional pending replication. Even if guardrails cleared, no strategy in A-E cites 2.10 in its foundation citation graph — prompt injection isn't a primary or secondary mitigation target for any current strategy mechanism. §5.6 mechanical relaxation lookup has no constraint to evaluate. Signal logged as foundation evidence; no operational change.

**Why qualitative 2.8 reinforcement produced no termination:** §5.4 MATERIAL strengthening threshold is "magnitude estimates increased by ≥50% in supporting research." M2 rev 2's 2.8 update is contextual reinforcement (Coordination Primacy Hypothesis literature, capex concentration commentary, March 2026 pod-shop drawdown as watch item) rather than quantified magnitude increase. Existing 2.8 compensations (sector caps, theme limits, correlation-bucket caps for D) remain in force.

**Why new items 2.25 and 2.26 produced no termination:** 2.25 (agentic epistemic hallucination) is bounded by experiment-level workflow architecture — human-conducted execution in IBKR plus externally-maintained ledger plus per-session portfolio state — none of which is strategy-level. No strategy needs strategy-level 2.25 compensation; mitigation pre-exists at workflow level. 2.26 (RL post-training overconfidence) operationally subsumed by existing 2.13 compensation patterns (ordinal conviction tiers, classical-method delegation of probability assignment) which all strategies already follow. No compensation pathway is missing.

**Framework validation:** This is the first end-to-end execution of §5.1-§5.6 on real foundation-change data. The cycle was deterministic, replicable, and produced structured §5.7 audit trails for all 5 strategies in one batched session. No orchestrator discretion was exercised — every classification was determined by quantitative threshold or §5.5 Goodhart guardrail evaluation. Out-of-table flags were minimal (only E's incomplete-pre-mortem flag). The framework handled:
- Magnitude classification on existing items (NONE / PARTIAL / MATERIAL).
- Compensation pathway evaluation for new items (workflow-level for 2.25; existing-mechanism for 2.26).
- Citation graph parsing from pre-mortems (5 strategies, 13 unique 2.X items cited across all).
- Goodhart guardrail evaluation on benchmark inference (2.10 provisional PARTIAL classification).
- Mechanical lookup completion check (no constraints cite 2.10 → no §5.6 invocation needed).

The rev 4 mechanical framework is operationally validated. Future foundation-change assessments will follow this pattern.

**Theater-check:** n/a (mechanical execution, no judgment exercised). The §5.3-§5.6 procedure is deterministic given inputs. Same inputs → same outputs (within 2.24 cross-session variance, which manifests primarily in framing rather than verdict).

**Effect on book:**

No immediate effect on any strategy's trading state. All 5 strategies continue in their current operational states:
- A: ACCEPTED, no positions, awaiting first trade trigger
- B: ACCEPTED, no positions, awaiting first trade trigger
- C: ACCEPTED, HYBRID ACTIVATE FOMC-only, no positions
- D: ACCEPTED rev 5 (this conversation), no positions
- E: DO-NOT-ACTIVATE, no positions, pre-mortem cycles pending

**Pending queue updated:**
- ~~Foundation-change assessments × 5 (A, B, C, D, E)~~ COMPLETE — all 5 Continue under rev 4 mechanical framework, this entry.
- Strategy E pre-mortem cycles (not yet started) — NEXT.
- E foundation-change re-assessment after pre-mortem cycles complete (citation graph will stabilize).
- 2.10 evidence accumulation watch (next Q3 quarterly task).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).

**References:**
- Foundation_Change_Assessment_2026-04-25.md (full §5.7 audit-trail output, single document with all 5 per-strategy assessments).
- AI_Trading_Foundation.md rev 4 §5.1-§5.6 (procedure source).
- Strategy.md rev 30 (citation graphs).

**Compaction-survival note:** All 5 strategies passed foundation-change assessment under rev 4 mechanical framework on 2026-04-25. No constraints relaxed, no terminations triggered. The 2.10 PARTIAL reduction signal is provisional pending replication; even if confirmed MATERIAL, no current strategy cites 2.10 so practical effect on book is zero. The rev 4 framework's first end-to-end execution succeeded — future Claude instances should treat this assessment cycle as the working pattern for subsequent foundation-change evaluations.


---

## 2026-04-25 Strategy E pre-mortem cycle 1 — TIER 1 DEFECT, structural rebuild applied as rev 2

**Trigger:** First adversarial review cycle on Strategy E pre-mortem (rev 1 was initial draft, no prior cycles).

**Inputs:** Strategy.md rev 30 with E pre-mortem rev 1 (~50 lines, narrow Section 5 with 5 disadvantages, missing req 5 and req 7 architecture); AI_Trading_Foundation.md rev 4; Strategy A/B/C/D pre-mortem precedents.

**Sessions:** Single attacker (incognito) + in-conversation orchestrator review per EP rev 14 single-session architecture.

**Cycle 1 attacker findings (13 Tier 1 items):**

- **T1.1 — Self-containment violation, literal cross-reference.** Pre-mortem opens with "Already addressed in the strategy section above" — exactly the non-compliant pattern.
- **T1.2 — Strategy mechanism not enumerated inline.** Reqs 1-4 cannot be evaluated for "specificity" without mechanism in front of reader inside pre-mortem.
- **T1.3 — Req 5 (declared expected trade frequency) absent** from pre-mortem text (mechanism declares 6-12 pairs/year; pre-mortem doesn't state).
- **T1.4 — Req 7 (binding-constraint confrontation with flowing limitations) absent.** No cross-walk, no enumeration, no flowing limitations, no Known Limitations list.
- **T1.5 — Missing mechanism-relevant disadvantages** in Section 5 (5 of ~15 enumerated): missing 2.13/2.26 (financing gate input miscalibration), 2.18 (forced 6-month exit), 2.19 (look-ahead on textbook pair episodes), 2.7 (compensation claim unexamined), 2.20 (compensation claim unexamined), plus secondary 2.11/2.12, 2.23, 2.17.
- **T1.6 — Compensation claims for 2.7 and 2.20 unexamined.** Strategy mechanism explicitly *claims* market-neutrality compensates 2.7 and 2.20; pre-mortem doesn't engage. Sharpest sub-finding: router rule excludes E during regimes where 2.7 would actually bite, so compensation claim coexists with router rule that disallows the strategy precisely in those regimes — internal contradiction.
- **T1.7 — Pair-correlation as load-bearing assumption unconfronted.** Entry gate at 0.5, exit at 0.3, drift band, non-stationarity in stress vs dispersion regimes.
- **T1.8 — Adversarial counter-argument as defendant-as-judge.** Same Claude session producing thesis runs counter-argument; same weight-level biases per 2.4.
- **T1.9 — 2.24 implication not extracted.** Section 5 identifies the problem and stops; doesn't draw the conclusion that adversarial-review architecture is compromised by weight-level convergence.
- **T1.10 — Short-financing-cost edge-decay indicator absent.** Section 4 has no portfolio-level financing-drag indicator distinct from operational borrow-rate gate.
- **T1.11 — Edge-decay thresholds without baseline derivation** (10 pair closes, 1:1 ratio, 20-positions-floor).
- **T1.12 — Operationally-vacant indicator** "near zero correlation between adversarial-review outcome quality and realized P&L" — adversarial-review outcome quality undefined and unmeasured anywhere.
- **T1.13 — 6-month forced exit × 2.18 trade-off undocumented.** Forced exit overrides P&L; not confronted as 2.18 territory.

**EP rev 15 four-screen test:** failed Screens 2, 3, and 4 across multiple items.
- Screen 2 (top-five req-4 omission): 2.13, 2.7, 2.20 are clearly top-relevant for E's mechanism — FAIL.
- Screen 3 (failure-mode detection gap): T1.7, T1.10, T1.12 — FAIL.
- Screen 4 (req self-containment break): T1.1, T1.2, T1.3, T1.4 — FAIL.

Definitive **TIER 1 DEFECT — STRUCTURAL REBUILD REQUIRED.** Continue cycling.

**Theater-check CONVERGENT.** All 13 items have on-page evidence in rev 1. The attacker self-flagged volume (13 items vs A/B/C/D cycle 1 counts of 6/6/8/6) and noted possible consolidation (T1.6+T1.7 share architectural locus; T1.10+T1.11 share edge-decay locus). I evaluated each independently — items keep distinct rev 2 responses, count isn't theater. Self-flag was honest.

**Rev 2 structural rebuild architecture (modeled on Strategy C accepted rev 9):**

Modeled on C because of closest mechanism parallels: both are public-information-driven, both have 2.6-binding constraint requiring sell-side handling clause, both are adversarial-review-dependent for thesis quality discipline. C's accepted-rev-9 architecture has four binding constraints with flowing limitations + cross-constraint preamble; E's rev 2 follows the same pattern with E-specific constraints.

Rev 2 fixes:

1. **Self-containment (T1.1, T1.2, T1.3).** Section 1 enumerates inline: thesis, eligibility rule including ETF-pair substitution, deployment posture, entry criteria 1-6, exit rules, declared expected frequency (6-12 pairs/year = 12-24 trades), router activation rule.

2. **Req 7 binding-constraint architecture (T1.4).** Four constraints with explicit cross-walk and flowing limitations:
   - **Constraint 1 = 2.6 (no private info).** Flowing limitation: entry criterion 6 public-info compliance check + sell-side handling clause per C rev 19 precedent (theses where sell-side's private-information-derived conclusions are load-bearing are inadmissible).
   - **Constraint 2 = 2.4 (narrative over-fit on pair narratives).** Flowing limitation: entry criterion 2 counter-argument (~30% reduction graded) + entry criterion 3 quantitative-divergence-anchor.
   - **Constraint 3 = 2.24 (cross-session inconsistency / adversarial-review compromise).** *Load-bearing for E* because adversarial review is the primary thesis-quality discipline. Flowing limitation: rev 2 quantitative-divergence-anchor (80th-percentile pair-spread test) as external-to-Claude-reasoning verification of divergence existence.
   - **Constraint 4 = 2.13 + 2.26 (miscalibration on expected-return input to financing gate).** Flowing limitation: rev 2 dual-anchor financing gate — financing must clear BOTH 15% of Claude's expected return AND 15% of trailing-252-day historical median pair-mean-reversion magnitude.

3. **2.7/2.20 compensation engagement (T1.6).** Section 5 entries for 2.7 and 2.20 explicitly engage the strategy's claimed compensation, document the router-activated-band scope acknowledgment, and surface the within-pair beta drift residual. Compensation is honest within scope but doesn't claim full neutralization.

4. **Pair-correlation architecture confronted (T1.7).** Entry criterion 3 quantitative-divergence-anchor + KL #10 drift-band residual + KL #11 non-stationarity residual.

5. **Section 5 expanded from 5 to 13 disadvantages (T1.5).** Added 2.7, 2.13, 2.17, 2.18, 2.19, 2.20, 2.23, 2.26 with mechanism-specific consequences.

6. **2.24 operational implication extracted (T1.9).** Constraint 3 explicitly identifies E's adversarial-review architecture as compromised by 2.24 weight-level convergence; quantitative-divergence-anchor cuts the dependence at divergence-existence layer (narrative-validity layer remains exposed as residual).

7. **Counter-argument graded discriminator framing (T1.8).** Entry criterion 2 explicitly acknowledges ~30% reduction operating on same weights / same context; parallel to A/B/C/D rev N+ Constraint 2 framing.

8. **Edge-decay indicators rebuilt (T1.10, T1.11, T1.12).** Section 4 now has 5 indicators: pair convergence rate < 50% (derived from 50-70% literature baseline); cumulative excess vs SGOV at 10 closes; convergence-vs-timeline ratio < 1:1 (derived from same baseline); portfolio-level financing drag > 25% (rev 2 added); mean entry-time borrow cost trend > 50% rise in 12 months (rev 2 added); thesis-quality-vs-realized-P&L rank correlation (replaces operationally-vacant rev 1 indicator). All thresholds derived or explicitly calibration-deferred to 15-pair gate.

9. **6-month exit × 2.18 trade-off documented (T1.13).** KL #5 explicitly accepts the residual as stale-thesis-defense outweighing single-thesis cost.

**Cycle progression count after rev 2:** 13 (cycle 1 only). Cycle 2 will likely produce material findings — req-7 architecture itself typically requires its own cycle of refinement per A/B/C/D experience. Best estimate per A/B precedent: cycle 2 will surface 5-8 Tier 1 items at rev 2 fix surfaces, narrowing in cycles 3+.

**EP rev 15 forcing question.** Rev 2 changes deployment risk meaningfully: T1.1-T1.4 closed (self-containment + req 7 + req 5); T1.5 closed (Section 5 expanded); T1.6 closed (compensation claims engaged); T1.7 closed at entry-time (quantitative anchor) with residuals KL'd; T1.8/T1.9 closed (graded framing + Constraint 3); T1.10-T1.12 closed (edge-decay rebuild); T1.13 closed (KL #5).

**Theater-check on this orchestrator review:** I considered whether 13 cycle-1 items is over-finding given A/B/C/D cycle 1 counts of 6/6/8/6. The attacker self-flagged this. My evaluation: rev 1 was structurally thinner than A/B/C/D rev 1 versions (the rev 1 E pre-mortem genuinely is minimal — ~50 lines, no req 7 architecture, narrow Section 5). The 13 count reflects the rev 1 starting state, not over-finding. Each item passes independent verification. CONVERGENT.

**Effect on book:**

No immediate effect. Strategy E remains in DO-NOT-ACTIVATE state (per divergence review 2026-04-25). E's pre-mortem cycling continues in the background; trade activation remains gated by both pre-mortem completion AND fundamental review reversal of DO-NOT-ACTIVATE divergence verdict.

**Pending queue updated:**
- ~~Strategy E pre-mortem cycle 1~~ COMPLETE — TIER 1 DEFECT, rev 2 structural rebuild applied.
- Strategy E pre-mortem cycle 2 — NEXT (attacker prompt drafted in this session for next-turn execution).
- E foundation-change re-assessment — after pre-mortem cycles stabilize (citation graph expanded from 5 to 13 items in rev 2; will require re-execution post-acceptance).
- 2.10 evidence accumulation watch — next Q3 quarterly task (2026-07-01).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).

**References:**
- Strategy.md rev 31 with E pre-mortem rev 2.
- AI_Trading_Foundation.md rev 4 (disadvantage taxonomy).
- Cycle 1 attacker output (preserved in conversation; theater-check CONVERGENT).

**Compaction-survival note:** Strategy E pre-mortem cycle 1 produced 13 Tier 1 items reflecting rev 1's minimal structural state. Rev 2 is a full structural rebuild modeled on Strategy C accepted rev 9 architecture. Future Claude instances should expect cycle 2 to produce material findings at rev 2 fix surfaces (req-7 architecture refinement); cycle progression likely 13 → 5-8 → 2-3 → acceptance per A/B/C/D experience.


---

## 2026-04-25 Strategy E pre-mortem cycle 2 — TIER 1 DEFECT, narrow-scope rev 3 spot-edits applied

**Trigger:** Cycle 2 adversarial review of Strategy E pre-mortem rev 2.

**Inputs:** Strategy.md rev 31 with E pre-mortem rev 2; cycle 2 attacker output (4 Tier 1 items, all at rev 2 fix surfaces).

**Sessions:** Single attacker (incognito) + in-conversation orchestrator review per EP rev 14 single-session architecture.

**Cycle 2 attacker findings (4 Tier 1 items, all at rev 2 fix surfaces):**

- **T2.A (Constraint 4 fix surface — Anchor 2 dual-anchor masquerade).** Anchor 2's "trailing-252-day historical median pair-mean-reversion magnitude for similar in-sector pairs" requires Claude to identify the reference set. Same Claude session that produces Anchor 1 (expected return) selects Anchor 2's reference set. The two anchors are not statistically independent — they are correlated estimates from the same biased reasoning. The dual-anchor framing implies independence; the actual mechanism doesn't deliver it. Same defect class as cycle 1 T1.8 (defendant-as-judge on counter-argument) and Strategy D cycle 2 T1-A/B/C. Screen 1 (loss-bounding contribution not delivered) and Screen 4 (constraint claims property it lacks) — FAIL.

- **T2.B (Constraint 2/3 fix surface — 80th-percentile threshold too loose).** Pair-trading literature uses ±2σ ≈ 95th percentile (Gatev/Goetzmann/Rouwenhorst 2006; Avellaneda/Lee 2010). 80th percentile fires on ~20% of trading days under random-walk null — not a meaningful 2.4 detection filter. Sub-defects: (i) threshold not derived; (ii) spread definition (price ratio vs log-spread) is Claude judgment per pair; (iii) reference window length asserted. Screen 3 (failure-mode detection on 2.4 weakened by loose anchor) — FAIL.

- **T2.C (Constraint 3 fix surface — flowing limitation operates at wrong layer).** Rev 2 flowing limitation operates at divergence-existence layer; load-bearing 2.24 exposure is at narrative-validity layer. Quantitative-divergence-anchor verifies *some* divergence exists; E's edge claim is *narrative* (why divergence exists, why it will reconverge) which is what 2.24 weight-level convergence corrupts. Constraint declares load-bearing status but limitation doesn't flow to load-bearing aspect. Screen 4 (req 7 self-containment break) — FAIL.

- **T2.D (Section 4/6 fix surface — operationally vacant indicator in current infrastructure).** Entry-percentile-vs-realized-P&L rank correlation requires logging fields not present in Portfolio_Ledger.md or Decision_Log.md schema. Cycle 1 T1.12 explicitly required operational implementability; rev 2 replaced rev 1's vacant indicator with one that's in-principle implementable but not implementable in current infrastructure. Same defect class. Screen 3 (failure-mode detection — Section 6 indicator uncomputable at first monthly review) — FAIL.

**EP rev 15 four-screen test:** failed Screens 1, 3, and 4 across the four items.

**Theater-check CONVERGENT.** All four items have on-page evidence and clean specification-grade fixes. The attacker explicitly demoted 5 items I'd identified in cycle 2 attack vectors (2.7 compensation engagement, 2.20 within-pair-spread, cap×duration caveats, KL count, sell-side clause) on sound reasoning — those are accepted residuals not new T1s. The self-flag on the "partial mechanism in residual but architectural framing claims more" pattern is honest and well-scoped.

**Cycle progression: 13 → 4.** Largest absolute narrowing in any strategy's cycle 1 → 2 transition (A: 6→6, B: 6→6, C: 8→8, D: 6→6). Reflects rev 2 resolving most cycle-1 items architecturally, with residual defects concentrated at rev 2's new mechanism components (Anchor 2, divergence-anchor threshold, Constraint 3 framing, indicator implementation).

**Combined revision-churn + saturation stop NOT appropriate at cycle 2.** Locus-recurrence is present (4/4 at fix surfaces) but cycle count exhaustion is absent — A combined stop at rev 7, C at rev 9, D at rev 5 (with unique 4-cycle pattern). Cycle 2 with genuinely fixable items is normal post-rebuild position. Premature stop would deploy with avoidable defects in load-bearing layers. Continue to cycle 3.

**Rev 3 spot-edit fixes (parallel to A/B/C cycle 3+ specification refinement pattern):**

- **(T2.A) Anchor 2 deterministic reference-set rule.** Constraint 4 / entry criterion 5 reformulated. Reference set = all pairs in same 6-digit GICS industry group with trailing-252-day correlation ≥ 0.5, both meeting market-cap and ADV minimums, ≥ 5 years joint trading history. Computed by classical-method delegation; no Claude pair-shortlisting step. Minimum 10 qualifying pairs required for Anchor 2 to apply; otherwise pair defers. Restores Anchor 2 statistical independence from Anchor 1.

- **(T2.B) Quantitative-divergence-anchor tightened to 95th percentile.** Entry criterion 3 reformulated. Threshold derived from pair-trading literature standard (z ≈ 2σ, Gatev/Goetzmann/Rouwenhorst 2006 distance method; Avellaneda/Lee 2010 statistical arbitrage). Spread definition mechanism-enforced via classical-method delegation: price-ratio for similar share-price scales (max/min ratio ≤ 3), log-spread otherwise. Choice rule-bound, not Claude-judgment-based.

- **(T2.C) Constraint 3 dual-component flowing limitation.** Entry criterion 1 tightened: "specific public events that would cause reconvergence" must be reduced to quantitative thresholds (e.g., "Q3 earnings revenue beat ≥ 5%" not "Q3 earnings beat"). Constraint 3 flowing limitation expanded to dual-component: (a) divergence-existence layer via entry criterion 3 quantitative-divergence-anchor; (b) narrative-validity layer via entry criterion 1 quantitative-reconvergence-threshold requirement. Component (b) reduces narrative's predictive content to falsifiable quantitative claim, session-stable and externally-verifiable post-hoc.

- **(T2.D) Logging specification added to Section 6.** Per-pair logging requirements specified inline. Decision_Log.md per-pair entry fields: pair_id, spread_definition, reference_window, percentile_at_entry, anchor_2_reference_set_size, reconvergence_thresholds. Portfolio_Ledger.md per-pair close fields: pair_id, realized_pnl ($ and %), holding_days, exit_reason. Indicator computes Spearman rank correlation across trailing 10 closed pairs.

**KL #14, #15 added** for two new acknowledged residuals: (14) spread-definition rule's 3x share-price-ratio threshold is a parameter with 15-pair-gate calibration trigger; (15) Anchor 2 trailing-252-day median is non-stationary, regime-relative rather than regime-absolute.

**EP rev 15 forcing question.** Rev 3 changes deployment risk meaningfully: T2.A (loss-bounding contribution from dual-anchor now actually delivered via deterministic reference set), T2.B (2.4 detection no longer 20%-firing-permissive — 95th percentile fires ~5% of trading days under null, providing meaningful filter), T2.C (req 7 self-containment restored — flowing limitation now reaches load-bearing layer via component (b)), T2.D (Section 6 indicator now operationally implementable with explicit logging schema additions).

**Theater-check on this orchestrator review:** I considered whether 4 cycle-2 items is over-finding given cycle progression should narrow toward acceptance. Counter-argument: 13→4 IS narrowing (largest absolute narrowing in 1→2 transition). Counter-counter-argument: 4 is still substantial; could be over-finding if I'm over-promoting Tier 2 items. Self-check: each of the 4 items independently fails an EP rev 15 screen and has a clean fix. The fixes are specification-grade, not architectural redesign. CONVERGENT.

**Effect on book:**

No immediate effect. Strategy E remains in DO-NOT-ACTIVATE state (per divergence review 2026-04-25). E's pre-mortem cycling continues; trade activation remains gated by both pre-mortem completion AND fundamental review reversal of DO-NOT-ACTIVATE divergence verdict.

**Pending queue updated:**
- ~~Strategy E pre-mortem cycle 2~~ COMPLETE — TIER 1 DEFECT, rev 3 spot-edit fixes applied.
- Strategy E pre-mortem cycle 3 — NEXT (attacker prompt to be drafted next turn). Best estimate: 2-4 Tier 1 items at rev 3 fix surfaces (deterministic reference-set rule's 5-year-history and 10-pair-minimum may have boundary issues; 95th percentile interaction with declared 6-12 pair frequency; logging schema may surface infrastructure-coordination residuals). Cycle 4 likely acceptance candidate.
- E foundation-change re-assessment — after pre-mortem cycles stabilize.
- 2.10 evidence accumulation watch — next Q3 quarterly task (2026-07-01).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).

**References:**
- Strategy.md rev 32 with E pre-mortem rev 3.
- AI_Trading_Foundation.md rev 4 (disadvantage taxonomy).
- Cycle 2 attacker output (preserved in conversation; theater-check CONVERGENT).

**Compaction-survival note:** Strategy E pre-mortem cycle 2 produced 4 Tier 1 items at rev 2 fix surfaces, all specification-grade with clean fixes. Rev 3 applies four spot edits without architectural redesign. Cycle progression now 13 → 4; per A/B/C precedent, cycle 3 should produce 2-4 items at rev 3 fix surfaces with cycle 4 as likely acceptance candidate (combined-stop available if cycle 3 findings concentrate at rev 3 fix surfaces).


---

## 2026-04-25 Strategy E pre-mortem cycle 3 — TIER 1 DEFECT (Path A selected), narrow-scope rev 4 spot-edits applied

**Trigger:** Cycle 3 adversarial review of Strategy E pre-mortem rev 3.

**Inputs:** Strategy.md rev 32 with E pre-mortem rev 3; cycle 3 attacker output (1 borderline T1 + 6 T2/T3 items, all at rev 3 fix surfaces).

**Sessions:** Single attacker (incognito) + in-conversation orchestrator review.

**Cycle 3 attacker findings:**

- **T1.A (borderline T1, rev 3 T2.B fix surface).** Pair-prioritization layer between criterion 3 trigger and thesis-formation is unspecified Claude judgment. The 95th percentile threshold + 5%-of-trading-days × N candidate pairs produces multiple co-triggered pairs per session; Claude's evaluation cadence is lower than trigger frequency, so prioritization is a real upstream gate. Pre-mortem's mitigation architecture (counter-argument, quant anchor, dual-component Constraint 3) operates downstream of this layer. 2.4 (narrative attractiveness selection) and 2.24 (session-variable weight-bias-correlated prioritization) operate at this layer unmitigated. Strict Screen 3 reading: detected → no gap. Substantive reading: load-bearing layer unaddressed → gap. Attacker self-flagged as borderline T1/T2.

- **T2.E (T2.A fix surface).** Anchor 2 deterministic rule deferral rate vs declared 6-12 pair frequency uncalibrated. The ≥10-qualifying-pairs minimum + 5-year joint history may make Anchor 2 categorically inapplicable in some industry groups.

- **T2.F (T2.C fix surface).** Constraint 3 component (b) is falsifiability requirement, not a 2.24 mitigation at threshold-choice layer. The pre-mortem's residual (ii) honestly notes this; framing oversells "dual-component" as if both hit the same target.

- **T2.G (T2.B fix surface).** 3x share-price-ratio mechanism-enforcement is ceremonial at the boundary (where it bites, the rule's outcome-influence is weak; where outcome-influence is strong, the choice was already obvious without the rule).

- **T2.H (T2.D fix surface).** Logging spec adds E-specific fields to shared experiment-level files without cross-strategy compatibility check.

- **T2.I.** 2.18 × 2.13/2.26 interaction not surfaced as compounding failure mode. Section 2 lists items separately.

- **T2.J.** Constraint 3 component (b) excludes qualitative-reconvergence theses; Section 1 universe declaration doesn't cross-walk.

**Theater-check CONVERGENT.** All findings have on-page evidence at rev 3 fix surfaces. Attacker self-flag on T1.A borderline status is honest (strict Screen 3 = pass; substantive Screen 3 = fail). Attacker explicitly considered whether deployment-risk stop is the honest verdict.

**Path selection: Path A (continue with rev 4 spot edits) over Path B (deployment-risk stop).** Reasoning:

- Pattern across A/C/D late cycles: borderline T1 items get spot-edited rather than accepted as T2. The bias has been toward addressing structural concerns rather than relying on strict screen reading.
- T1.A is structural hole at load-bearing input-distribution layer; biased input distributions are not fully recoverable downstream. The fix is low-cost (one-paragraph specification).
- Trajectory hasn't broken: cycle progression 13→4→1-T1+6-T2/T3 is still narrowing on T1 count. Saturation pattern requires not-narrowing.
- Combined revision-churn + saturation stop NOT appropriate at cycle 3 — locus-recurrence present (4/4 findings at rev 3 fix surfaces) but cycle count exhaustion absent (E at cycle 3 vs A combined stop at cycle 6, C at cycle 8).

**Rev 4 spot-edit fixes applied:**

1. **(T1.A) Pair-prioritization rule.** Added after entry criterion 6: when multiple candidates simultaneously meet criterion 3 threshold, evaluate in deterministic rank order by spread-percentile-magnitude (descending; ties broken by first-trigger-date or alphabetical pair_id). Ranking computed by classical-method delegation. No skip-and-prioritize permitted. Eliminates Claude-judgment selection step upstream of all gates.

2. **(T2.E) KL #15 review trigger extended** to include deferral-rate audit at 15-pair gate (audit fraction of theses deferred due to Anchor 2 reference-set < 10 pairs; calibration-refine minimum-pair threshold or 5-year-history requirement if material fraction).

3. **(T2.F) Constraint 3 component (b) reframed** as "post-hoc verification surface" rather than 2.24 mitigation. Component (a) is the genuine 2.24 mitigation at divergence-existence layer; component (b) provides falsifiability/post-hoc-verifiability but does NOT address weight-level bias on threshold choice. KL #16 added documenting this as accepted architectural residual.

4. **(T2.J) Section 1 cross-reference added** via the rev 4 pair-prioritization rule's note: operating universe restricted to pairs passing Constraint 3 component (b) — theses without quantitative reconvergence thresholds (genuinely qualitative reconvergence mechanisms) are excluded.

5. **(T2.I) KL #17 added** documenting 2.18 × 2.13/2.26 interaction as compounding failure mode. When overconfidence on convergence speed inflates Anchor 1, financing gate clears more permissively; when thesis requires longer than expected, 6-month forced exit fires more frequently. Loss bounded by per-pair cap. Review trigger: at 15-pair gate, audit fraction of pairs exiting via 6-month time-based exit.

T2.G (3x parameter ceremonial): logged at KL #14 with existing 15-pair audit trigger; no rev 4 mechanism change. T2.H (cross-strategy schema asymmetry): operational/cross-strategy coordination concern out of pre-mortem scope; flagged in cycle-3 changelog as note for infrastructure coordination.

**EP rev 15 forcing question.** Rev 4 changes deployment risk meaningfully: T1.A (pair-prioritization eliminates Claude-judgment selection upstream of all gates); T2.E (audit closes calibration gap on declared frequency vs realizable rate); T2.F (honest framing — Constraint 3 residual now reflects what mitigations actually deliver); T2.J (universe declaration coherent with operating universe).

**Theater-check on this orchestrator review:** I considered Path B (deployment-risk stop) seriously because all four screens pass under strict reading. Counter-argument: the pattern across A/C/D has been to address borderline items via spot edits, not to rely on strict screen reading; T1.A is a structural hole worth one-paragraph fix; saving one cycle isn't worth leaving the hole. Counter-counter-argument: the strict screen reading is the EP rev 15 standard, and consistently applying it would prevent cycle-creep. Net: I selected Path A because the spot edit is genuinely low-cost and addresses a real architectural concern. If a future review of this decision concludes it was unnecessary cycle-creep, that's a fair critique; I acknowledge the call was contestable.

**Effect on book:**

No immediate effect. Strategy E remains in DO-NOT-ACTIVATE state.

**Pending queue updated:**
- ~~Strategy E pre-mortem cycle 3~~ COMPLETE — TIER 1 DEFECT (Path A), rev 4 spot-edit fixes applied.
- Strategy E pre-mortem cycle 4 — NEXT (cycle 4 attacker prompt to be drafted same session). Best estimate: 0-2 Tier 1 items at rev 4 fix surfaces (pair-prioritization rule may have boundary issues at rank ties / no-trigger sessions; KL framings may have residual exposure). Combined-stop available if cycle 4 confirms locus-recurrence with cycle count exhaustion (E at 4 cycles parallel to D's pattern).
- E foundation-change re-assessment — after pre-mortem cycles stabilize.
- 2.10 evidence accumulation watch — Q3 quarterly task (2026-07-01).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).

**References:**
- Strategy.md rev 33 with E pre-mortem rev 4.
- Cycle 3 attacker output (preserved in conversation; theater-check CONVERGENT; attacker recommended Path A).

**Compaction-survival note:** Strategy E pre-mortem cycle 3 produced 1 borderline T1 + 6 T2/T3 items at rev 3 fix surfaces. Path A selected over Path B (deployment-risk stop) per pattern across A/C/D late cycles. Rev 4 spot edits applied for T1.A (pair-prioritization rule), T2.E (deferral-rate audit), T2.F (Constraint 3 component (b) reframing), T2.I (2.18 × 2.13/2.26 interaction), T2.J (Section 1 cross-reference). T2.G, T2.H accepted as documentation residuals. Cycle 4 likely acceptance candidate; cycle 4 attacker prompt drafted in same session for next-turn execution.


---

## 2026-04-25 Strategy E pre-mortem cycle 4 — TIER 1 DEFECT, rev 5 spot-edit applied, ACCEPTED under combined revision-churn + saturation stop

**Trigger:** Cycle 4 adversarial review of Strategy E pre-mortem rev 4.

**Inputs:** Strategy.md rev 33 with E pre-mortem rev 4; cycle 4 attacker output (1 borderline T1 + 6 T2/T3 items, all at rev 4 fix surfaces).

**Sessions:** Single attacker (incognito) + in-conversation orchestrator review per EP rev 14 single-session architecture.

**Cycle 4 attacker findings:**

- **T1.K (borderline T1, rev 4 T2.F fix surface).** Constraint 3 declares 2.24 load-bearing but threshold-choice layer has no flowing limitation. Rev 4's reframing of component (b) from "2.24 mitigation" to "post-hoc verification surface" was honest, and KL #16 documented the residual cleanly — but the resulting architecture has 2.24 declared "load-bearing for E" with no flowing limitation reaching the load-bearing layer (only divergence-existence layer via component (a) and post-hoc verification via component (b)). Same defect class as cycle 2 T2.C. Honest framing surfaces it transparently rather than masking it, but transparency does not convert the structural defect into a non-defect.

- **T2.K through T2.P (documentation/calibration grade at rev 4 fix surfaces).** T2.K: pair-prioritization rule "full candidate pool" specification gap (T1.A surface). T2.L: tie-breaker "first-trigger-date if available" condition unspecified (T1.A surface). T2.M: queue dynamic from "no skip-and-prioritize" + finite session budget (T1.A surface). T2.N: KL #17 acknowledgment-only mitigation of 2.18 × 2.13/2.26 interaction (T2.I surface). T2.O: Section 1 cross-walk for Constraint 3 component (b) lives in pair-prioritization note rather than Section 1 itself (T2.J surface). T2.P: Section 1 doesn't acknowledge Anchor 2's 5-year-history newer-IPO categorical exclusion (T2.J surface).

**Theater-check CONVERGENT.** All 7 items have on-page evidence at rev 4 fix surfaces. Attacker's three-part self-flag (am I calling T1.K Tier 1 due to prompt priming? am I avoiding the call to land at acceptance? am I inflating T2s to justify non-acceptance?) is honest and well-considered. Verdict trails analysis. The cycle 2 T2.C precedent (flowing limitation not reaching load-bearing aspect = Tier 1) is the determining factor for T1.K classification — consistency demands the same call here even though rev 4's honest framing surfaces rather than masks the defect.

**EP rev 15 four-screen test on T1.K:** All four screens PASS — Screen 1 per-pair 2%/4% cap bounds magnitude regardless of which 2.24 layer bites; Screen 2 2.24 listed in Section 5; Screen 3 KL #16 specifies 15-pair-gate review trigger checking threshold-value clustering; Screen 4 KL #16 specifies a limitation, satisfying req 7 literal "exclusions OR LIMITATIONS." T1.K is deployment-risk-acceptable as Tier 1 per EP rev 15 forcing question.

**Combined revision-churn + saturation stop preconditions met.**

- *Locus-recurrence:* T1.K at rev 4 T2.F fix surface; T2.K/L/M at T1.A surface; T2.N at T2.I surface; T2.O/P at T2.J surface — 100% concentration at rev 4 fix surfaces.
- *Cycle count exhaustion:* 4 cycles, parallels Strategy D's combined-stop pattern (D combined stop at rev 5 after 4 cycles).
- *Trajectory:* 13 → 4 → 1-T1+6-T2/T3 → 1-T1+6-T2/T3 (saturation arrest at residual architectural exposure — same shape, not narrowing further; this is the saturation pattern under EP rev 14 §188 ii).

**Rev 5 spot-edit fix applied (parallel to Strategy A rev 7 / D rev 5 acceptance precedent — cycle N findings → rev N+1 spot edit → ACCEPTED under combined stop without cycle N+1 attacker run):**

- **(T1.K) 2.24 added to Section 5 confluence list with per-pair-cap as magnitude-only backup mitigation.** Cross-walk text updated: 2.24 moved from "Not in confluence list" to "In confluence list," with rationale that at the threshold-choice layer (where Constraint 3 component (a) doesn't reach and component (b) provides only post-hoc verification), the per-pair cap provides magnitude-only mitigation in the same pattern as 2.13/2.18/2.26. When threshold-choice 2.24 produces a wrong threshold leading to a wrong invalidation, the per-pair cap (2% per leg, 4% per pair) bounds loss magnitude. The cap doesn't reduce probability of threshold-choice bias (2.24 hard-wired property remains) but bounds individual-thesis blast radius. KL #16 stays as written; review trigger unchanged. Constraint 3 component (a) (divergence-existence-layer mitigation) + cap-confluence (magnitude-only backup) jointly satisfy req 7 confrontation: every load-bearing constraint now has a flowing limitation reaching the load-bearing aspect, even if the limitation is magnitude-bounding rather than probability-reducing.

T2.K-T2.P accepted as documentation residuals; no further mechanism changes.

**ACCEPTANCE: Strategy E pre-mortem ACCEPTED at rev 5 under combined revision-churn + saturation stop (EP rev 14 §188 ii + iii).** Cycles 2, 3, 4 each surfaced items at rev N's fix surfaces with the cycle 3 / cycle 4 trajectory arresting at the same shape (1-T1+6-T2/T3) — saturation pattern unambiguous. E's narrative-divergence-pairs architecture has structural properties (2.24 weight-level bias on threshold-choice; 2.18 × 2.13/2.26 interaction; deterministic Anchor 2 deferral-rate; 3x share-price-ratio parameter ceremony at boundary) that no further within-strategy revision will eliminate — these are properties of the underlying mechanism. Combined stop is the precedent-defined response. Cycle 5 not run.

**Cycle outcomes by revision (E pre-mortem complete history):**
- Rev 1 → cycle 1 TIER 1 (13 items, structural rebuild required)
- Rev 2 → cycle 2 TIER 1 (4 items at rev 2 fix surfaces, narrow scope)
- Rev 3 → cycle 3 TIER 1 (1 borderline T1 + 6 T2/T3 at rev 3 fix surfaces, Path A selected)
- Rev 4 → cycle 4 TIER 1 (1 borderline T1 + 6 T2/T3 at rev 4 fix surfaces, deployment-risk-acceptable)
- Rev 5 → ACCEPTED under combined stop

**Theater-check on this orchestrator review.** I considered whether T1.K should be classified Tier 2 to enable a cleaner deployment-risk stop at rev 4 without an additional spot edit. Counter-argument: the cycle 2 T2.C precedent ruled the same defect class Tier 1; consistency demands the same call. Counter-counter-argument: T1.K's structural property is identical, but the cap-confluence-magnitude-only backup pattern is well-established for 2.13/2.18/2.26 — extending it to 2.24 is a one-edit fix that produces principled architectural alignment. I selected the rev 5 spot edit + combined stop path, which addresses the structural property cleanly while still enabling acceptance per precedent. CONVERGENT.

**Effect on book.**

No immediate effect. Strategy E remains in DO-NOT-ACTIVATE state per divergence review 2026-04-25. Trade activation continues to require both pre-mortem completion (now satisfied) AND fundamental review reversal of DO-NOT-ACTIVATE divergence verdict (not yet addressed).

**Pending queue updated:**
- ~~Strategy E pre-mortem cycle 4~~ COMPLETE — ACCEPTED at rev 5 under combined stop.
- ~~All 5 strategy pre-mortems~~ COMPLETE — A, B, C, D, E all in final accepted state.
- Strategy E foundation-change re-assessment under AI_Trading_Foundation rev 4 mechanical framework — NEXT (citation graph stabilized at 13 items: 2.4, 2.6, 2.7, 2.8, 2.13, 2.15, 2.17, 2.18, 2.19, 2.20, 2.23, 2.24, 2.26 vs rev 1's 5 items).
- 2.10 evidence accumulation watch — Q3 quarterly task (2026-07-01).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).
- Trading begin per regime/router rules. Current state: A/B/D awaiting first trade trigger; C HYBRID ACTIVATE FOMC-only with no positions; E DO-NOT-ACTIVATE.

**References:**
- Strategy.md rev 34 with E pre-mortem rev 5 ACCEPTED.
- AI_Trading_Foundation.md rev 4 (disadvantage taxonomy).
- Cycle 4 attacker output (preserved in conversation; theater-check CONVERGENT; verdict combined-stop after rev 5 spot edit).

**Compaction-survival note:** Strategy E pre-mortem ACCEPTED at rev 5 (2026-04-25) under combined revision-churn + saturation stop. All 5 strategy pre-mortems now in final accepted state. Foundation framework rev 4 operational. Foundation-change assessment cycle complete (5/5 Continue under rev 1 citation graphs). E foundation-change re-assessment under stabilized citation graph (13 items) is next logical work item. M2 rev 2 dated 2026-04-23 still current foundation. Pre-mortem cycle progression by strategy (final): A 7 cycles (combined stop at rev 7); B 7 cycles; C 9 cycles; D 5 cycles (combined stop at rev 5); E 5 cycles (combined stop at rev 5).


---

## 2026-04-25 Strategy E foundation-change re-assessment under rev 4 mechanical framework — Outcome (a) Continue

**Trigger:** E pre-mortem citation graph stabilized at rev 5 ACCEPTED (13 items vs rev 1's 5). The compaction-summary pending item "E foundation-change re-assessment after pre-mortem cycles stabilize" now actionable.

**Inputs:** Strategy.md rev 34 with E pre-mortem rev 5 ACCEPTED; AI_Trading_Foundation.md rev 4 (M2 2026-04 updates current); §5.1-§5.7 mechanical framework.

**Sessions:** Single orchestrator session (no attacker required for foundation-change framework execution per rev 4 §5.3 procedure "executed by the orchestrator session, no discretion").

**Citation graph at rev 5 (13 items):** 2.4, 2.6, 2.7, 2.8, 2.13, 2.15, 2.17, 2.18, 2.19, 2.20, 2.23, 2.24, 2.26. Edges: 1.1, 1.4 (technique within 1.1), 1.10. Expansion vs rev 1's 5-item graph (2.4, 2.6, 2.8, 2.15, 2.24): 8 new disadvantages added through cycles 1-4 (2.7, 2.13, 2.17, 2.18, 2.19, 2.20, 2.23, 2.26).

**Mechanical test results per §5.1-§5.3:**

- *§5.1 Continue test:* All 13 cited items present in current foundation rev 4 with no status change since rev 5 acceptance (rev 5 was accepted today, foundation rev 4 is current). PASS.

- *§5.2 Terminate test:* No edges removed; no disadvantages newly added that E lacks compensation for (2.26 jointly compensated with 2.13 in Constraint 4; 2.25 not cited by E, workflow-bounded); no materially worsened disadvantages where E lacks compensation (2.8 reinforcement, 2.13 mechanism-confirmation, 2.24 architectural-confirmation all incorporated through cycles 1-4). NO TERMINATE TRIGGER.

- *§5.3 Constraint-relaxation review:* Reduction candidates from M2 2026-04 = 2.10 PARTIAL reduction (Opus-tier with classifiers). E does NOT cite 2.10 → no affected constraints in E → no relaxation candidate. NO RELAXATION.

**§5.7 Audit trail produced as deliverable** (E_foundation_change_reassessment_2026-04-25.md).

**Verdict: Outcome (a) Continue.** Same outcome as prior foundation-change re-assessment cycle for E (which ran under rev 1 citation graph). The expanded rev 5 citation graph is not a foundation change — it is an expansion of which foundation properties E is exposed to, and those properties are identical to the prior assessment's foundation state.

**Cumulative experiment-level result:** 5/5 strategies (A, B, C, D, E) all produce Outcome (a) Continue under the rev 4 mechanical framework against AI_Trading_Foundation rev 4. The foundation-change assessment cycle is complete for the post-acceptance equilibrium of the experiment. No further pre-mortem revisions, terminate verdicts, or constraint relaxations triggered. 2.10 PARTIAL reduction signal produced zero relaxations across all 5 strategies (no strategy cites 2.10).

**Theater-check on this orchestrator review:** I considered whether the rev 5 citation graph's expansion (5 → 13 items) might itself constitute a foundation change requiring a different procedural treatment. Counter-argument per §5.7 framework: the citation graph is the strategy's mechanism document property, not the foundation document property; the foundation revision evaluated against is rev 4 in both cases, and rev 4's items haven't changed since the prior assessment. The expanded graph means E now exposes itself to more foundation properties, but the properties themselves are unchanged. Procedurally clean. CONVERGENT.

**Effect on book.**

No immediate effect. Strategy E remains in DO-NOT-ACTIVATE state per divergence review 2026-04-25 (fundamental review verdict, separate from foundation-change assessment).

**Pending queue updated:**
- ~~Strategy E foundation-change re-assessment~~ COMPLETE — Outcome (a) Continue.
- ~~All 5 strategies foundation-change assessment under stabilized citation graphs~~ COMPLETE — 5/5 Continue.
- 2.10 evidence accumulation watch — Q3 quarterly task (2026-07-01).
- M2 follow-ups: empirical dispersion compression check (Strategy C); fundamental signal process tightening (Strategy E).
- Trading begin per regime/router rules. Current state: A/B/D awaiting first trade trigger; C HYBRID ACTIVATE FOMC-only with no positions; E DO-NOT-ACTIVATE.
- Q2 2026 (next quarterly delta) — first scheduled foundation-change assessment of the post-acceptance equilibrium.

**References:**
- Strategy.md rev 34 with E pre-mortem rev 5 ACCEPTED.
- AI_Trading_Foundation.md rev 4 (M2 2026-04 incorporated).
- §5.7 audit trail deliverable: E_foundation_change_reassessment_2026-04-25.md.

**Compaction-survival note:** All 5 strategy pre-mortems ACCEPTED and all 5 strategies pass foundation-change re-assessment under rev 4 mechanical framework with Outcome (a) Continue. The pre-mortem-development phase of the experiment is complete. Next phase is operational: trading per regime/router rules, monthly reviews per Section 6 of each strategy's pre-mortem, Q2 2026 quarterly delta as next scheduled foundation-change checkpoint, M2 follow-up items on C dispersion compression and E fundamental signal process tightening, and 2.10 evidence accumulation watch through Q3 2026-07-01.


---


---

## 2026-04-26 (evening) State-file refresh + M2 follow-ups initiated for C dispersion-compression check and E signal-process tightening

**Trigger:** Saturday-evening orchestrator session after both Mon Apr 27 trade orders staged. Operator confirmed that C and E M2 follow-ups should be drafted now to reduce M2 (May 1) decision-time work.

**Three deliverables this session:**

### 1. State-file refresh

- **Regime_State.md** Last-Updated → 2026-04-26. B effect-on-book updated to reflect IBM staged. C effect-on-book updated to reflect operational blocker (scaffolding) resolved 2026-04-26 + M2 dispersion-compression follow-up underway. D effect-on-book updated to reflect RTX staged + LLY/CEG deferred. E effect-on-book updated to reflect M2 signal-process-tightening first draft 2026-04-26.
- **Portfolio_Ledger.md** Last-Updated → 2026-04-26. New "Staged orders for Mon 2026-04-27 execution" subsection added under Position thesis details with full thesis subsections for both IBM (Strategy B) and RTX (Strategy D) per the standard format. On Monday fill, these subsections move into open-position context with appended fill-price/commission lines; on no-fill, removed (or re-staged with operator decision).

### 2. C dispersion-compression empirical check methodology (`C_dispersion_compression_methodology.md`)

Per the 2026-04-25 C divergence review M2 follow-up commitment (Decision_Log line 336): "verify dispersion compression empirically using March cross-sectional return data." This session produces the methodology document; the test itself runs at M2 (2026-05-01). Methodology specifies:

- **Primary metric:** cross-sectional standard deviation of single-day equity returns on earnings-reaction days within S&P 500 constituents reporting in the measurement window.
- **Three baselines:** trailing-5-year same-season median; long-horizon NEUTRAL-regime median; sanity-check on known compressed-vs-dispersed regimes.
- **Decision threshold:** current ≥ 1.20× max(baselines) → "not supported" (reopen earnings DNA at M2 KL #12 gate); current ≤ 0.83× min(baselines) → "supported" (DNA stays); else inconclusive (default-on-ambiguity → DNA stays).
- **Pre-committed M2 actions:** mechanical application of the test on May 1 morning; if "not supported" outcome, trigger the rev 9 KL #12 scope-widening gate evaluation (single-session attacker + orchestrator review).
- **Theater-check:** asymmetric threshold (≥20% above baseline to overturn) is intentional and conservative per default-on-ambiguity; threshold is documented and pre-committed, so a 1.5×-baseline result mechanically forces the reopen.

The benefit of pre-drafting: M2 morning has methodology-judgment-under-time-pressure removed; only the data and the verdict remain. Reduces risk of post-hoc methodology-shaping to fit a felt outcome.

### 3. E fundamental signal-process tightening (`E_signal_process_tightening.md`)

Per the 2026-04-25 E divergence review M2 follow-up commitment (Decision_Log lines 388-392 / three-point list): tighten the fundamental signal generation process for E by (a) specifying GICS level, (b) engaging with correlation-filter and market-neutral structure mechanisms directly, (c) preferring measurable definitions where they exist. This session produces the tightened template; first applied at M2 (2026-05-01).

Template structure:
- **Section 1:** Explicit GICS level statement (default: industry group, matching Strategy.md spec).
- **Section 2:** Three mechanism components engaged separately — pair correlation stationarity (252-day), market-neutral hedge effectiveness, convergence horizon (6-12 weeks).
- **Section 3:** Three required measurables — median pair correlation across eligible-pair universe (vs 5y baseline ±10%); median intra-industry-group return dispersion (vs 5y same-month baseline ±20%); Anchor 2 deferral rate (≤30% threshold per Strategy.md rev 5 residual 15).
- **Section 4:** Verdict ACTIVATE / DO-NOT-ACTIVATE / AMBIGUOUS with explicit citation of failing components.
- **Section 5:** Self-theater-check addressing reasoning-direction, measurable-vs-estimated distinction, mechanism-vs-proxy substitution.

Process-documentation improvement, not strategy-spec change. The 2026-04-23 M1 rationale that generated the original divergence does NOT meet this template; M2 must generate a new rationale per the tightened format.

### Effect on book

No immediate effect on activation states. Both M2 follow-ups are prep work; their decisions land 2026-05-01.

State files reflect current pipeline accurately for any compaction-or-fresh-session reload:
- B trade staged Mon Apr 27 (IBM)
- D trade staged Mon Apr 27 (RTX)
- C scaffolding complete + M2 dispersion-compression check methodology ready
- E M2 signal-process-tightening template ready
- A passive-blocked until next M1
- E passive-blocked until M2 (or earlier divergence-review reopening)

### Pending queue updated

- ~~State-file refresh for staged trades~~ COMPLETE (Regime_State.md + Portfolio_Ledger.md updated 2026-04-26).
- ~~C dispersion-compression empirical check methodology~~ COMPLETE (`C_dispersion_compression_methodology.md` 2026-04-26; test applies M2).
- ~~E fundamental signal-process tightening~~ COMPLETE (`E_signal_process_tightening.md` 2026-04-26; applies M2).
- **NEXT — Mon 2026-04-27 (combined session):** IBM + RTX limit-order execution per the existing staged plans.
- **NEXT — Fri 2026-05-01 morning:** Apply C dispersion-compression test mechanically per pre-committed methodology. Document result in Decision_Log entry "C dispersion-compression check 2026-05-01."
- **NEXT — Fri 2026-05-01 same session:** Generate E fundamental signal per tightened template. Apply to current data. Compare vs technical signal; trigger divergence review if needed.
- **NEXT — Fri 2026-05-01:** LLY post-Q1-print re-screen (existing item).
- **NEXT — Tue 2026-05-12:** CEG post-Q1-print re-screen (existing item).
- 2.10 evidence accumulation watch — Q3 quarterly task (2026-07-01).

### References

- Decision_Log 2026-04-25 entries "Strategy C divergence review" (M2 follow-up commitment, lines 330-345) and "Strategy E divergence review" (M2 follow-up commitment, lines 380-407).
- Strategy.md Strategy C section + pre-mortem rev 9 (KL #12 scope-widening gate at line 1175).
- Strategy.md Strategy E section + pre-mortem rev 5 (residuals 11 and 15 — pair-correlation non-stationarity and Anchor 2 deferral rate).
- AI_Trading_Foundation.md disadvantages 2.6 (binding behavior; operationalized by C check) and 2.7 (regime maladaptation; operationalized by E template).

### Theater-check on this orchestrator session

These deliverables were drafted before the M2 deadline at the operator's prompting. The risk: pre-committing a methodology now may cause it to fit the current felt regime (compressed dispersion supports the existing verdict; tightened E template won't surface anything new at M2 because we already know E should remain DO-NOT-ACTIVATE in the current macro regime). Mitigation: both methodologies have pre-committed numerical thresholds with clear "supports" vs "does-not-support" mechanical outputs. The C threshold can mechanically force a verdict-reopen if dispersion comes in clearly above baseline; the E template has three independent measurables that can each independently fail. If the methodologies were designed to confirm the felt verdict, they would lack mechanical-overturn paths; both have them.

### Compaction-survival note

**Saturday 2026-04-26 evening session deliverables:**
1. Regime_State.md and Portfolio_Ledger.md refreshed for staged Mon Apr 27 trades.
2. `C_dispersion_compression_methodology.md` written; test applies mechanically at M2 (2026-05-01) per pre-committed thresholds.
3. `E_signal_process_tightening.md` written; tightened template applies to M2 fundamental signal generation.

If a future Claude session reads these files cold: the staged-orders subsections in Portfolio_Ledger.md will resolve at Monday execution; the C and E methodology files are M2-applicable mechanically; no other action required from this session's outputs.

---

## 2026-04-27 (Sun, follow-on) Strategy B thesis construction outcome — CHTR NO-GO (criterion 4 decisive failure); no order staged

**Trigger:** B-thesis construction completed externally for CHTR post-event candidate surfaced in Daily.md 2026-04-25 scan (Q1 2026 earnings event date 2026-04-24, close-to-close −25.50% per verified primary sources). Companion candidate HCA staged for Tue Apr 28 entry per prior Decision_Log entry of same session.

**Inputs:** CHTR factbase (sections 1-11 + data gaps, delivered 2026-04-26 evening); Strategy.md Strategy B section (entry criteria 1-5, criterion 3 closed-list rev 14, exit rules, pre-mortem rev 7); Daily.md 2026-04-25 (with brief-premise correction documented inline below); Portfolio_Ledger.md ($1,389.21 B NAV, IBM and HCA staged for Mon Apr 27 / Tue Apr 28 respectively); IBM 2026-04-25 thesis precedent (GO format) and NOW 2026-04-25 thesis precedent (NO-GO format).

### One brief-premise correction persisted from factbase

The Daily.md 2026-04-25 scan and original thesis-construction brief premised CHTR Apr 24 close at approximately $190.62 (−23.1%). Verified primary sources (Yahoo Finance Canada quote stack at 4:00 PM ET; StockInvest.us; Investing.com; Yahoo Finance / Stockstory headline copy "fell ~25%") confirm the actual close was **$180.13 (−25.50%)** with pre-event $241.78 (not $248). The $190.62 / −23.1% level was approximately the intraday price around 1:30 PM ET, not the 4:00 PM close. All convergence-target arithmetic in this thesis uses the verified $180.13 close. The magnitude correction is non-trivial: it makes the gap-fill arithmetic look more attractive (50% gap-fill is now +17.11% vs +13.42% at the stale level), which matters for assessing the "seductive convergence target" failure mode that Strategy B is structurally vulnerable to per pre-mortem rev 7 / 2.20.

### Decision

**CHTR — NO-GO (DECLINE).**

Failed Strategy B entry criterion 4 (adversarial counter-argument identifies a decisive flaw — specifically, the market reaction is information-driven rather than sentiment-driven, which makes "mispricing" actually correct pricing per criterion 4's explicit framing).

**Mechanical eligibility (criteria 1, 5, instrument rule) cleared with material cushion** before reaching the criterion 4 failure: mcap ~$22.9B post-event (>11× $2B floor); 30-day ADV ~$469M/day (>46× $10M floor); event 2026-04-24 (Day 0 of 10-day window); position size $27.78 (= 2.00% × $1,389.21); no A position open in CHTR. The mechanical cushion is enormous, but the −25.50% magnitude itself is a flag — historically it is the kind of move that signals structural repricing rather than sentiment overshoot, which the adversarial review confirmed.

**Provisional affirmative thesis pillars considered before failing criterion 4:**

(P1) FY26 guidance not cut — capex maintained $11.4B; cash taxes $500–$800M maintained; "grow EBITDA slightly" qualitative reaffirmed; Cox synergies raised to $800M+ from $500M. Strategy B disqualifier on guide cut technically cleared.

(P2) Q1'26 internet net loss −120k is sequentially in line with Q4'25 −119k. Sequential view is not a step-change (the YoY doubling vs Q1'25 −59k reflects the YoY-improvement-streak break, but absolute level is approximately equal to Q4).

(P3) Long-term capex declining $11.4B → <$8B by 2028 implies $28+ FCF/share at current share count. CFO Fischer explicitly framed price action as implying 3.8× FCF / 25%+ FCF yield against 2028 normalized FCF.

### Adversarial counter-argument summary (criterion 4 detail — decisive failure)

Four independent lines of evidence support information-driven repricing; none of the affirmative pillars rebut them.

(A1) **CMCSA divergence is decisive.** Comcast went from −183k Q1'25 to −65k Q1'26 (+117k YoY improvement, first since Q4 2020). Charter went from −59k to −120k (−61k YoY worsening). Same industry conditions, same FWA competition, same fiber overbuild — and CMCSA improved by 117k while CHTR worsened by 61k, a 178k YoY swing between two companies operating in the same market. CMCSA attributed roughly half its improvement to non-recurring marketing leverage (Legendary February: Olympics + Super Bowl + NBA All-Star) and the rest to organic execution changes (simplified pricing, gig-plus mix shift, free wireless line attach, lower voluntary churn). Even discounting the non-recurring half, CMCSA organically improved while CHTR deteriorated. This is what information-driven repricing looks like in real time: the market is differentiating CHTR from CMCSA on visible evidence of execution quality. P1 and P2 do not rebut this — guidance status and sequential comparison are silent on the cross-sectional execution differential. P3 (long-term capex story) depends on management credibility, which the visible execution gap vs CMCSA erodes; the FCF math is conditioned on management's capex trajectory delivering as promised, and the probability of that delivery falls when a peer is visibly executing better in the meantime.

(A2) **ARPU trajectory monotonically deteriorating across five quarters.** Internet revenue YoY: +1.8% → +2.8% → +1.7% → +0.7% → **−1.3%**. Residential revenue per customer YoY: +2.1% → +1.7% → +1.0% → **−1.2% → −1.4%**. Both lines crossed zero in Q4'25 and continued declining. CFO Fischer (Q1 call): FY26 ARPU growth will be "close either way" — meaning Charter does not expect to grow ARPU in 2026. This is a five-quarter deceleration that crossed zero one quarter ago and continued. Industry-wide-pressure rebuttal (Comcast also showed ARPU −3.1%) actually strengthens the bear case rather than weakening it: if CHTR and CMCSA are both facing ARPU pressure but CMCSA is improving subscriber economics through a working price-simplification strategy and CHTR is not, then CHTR's combination of declining ARPU + deteriorating subs is the structural reset the market is pricing.

(A3) **Same-name historical analogues are 0-of-2 against mean reversion.** Only two CHTR earnings-day moves in the −15% to −25% range over trailing 7 years exist: Feb 2, 2024 (−16.5%) and Jul 25, 2025 (−18.5%). Both featured (i) worse-than-expected broadband net losses, (ii) maintained guidance, (iii) **drift further down at +30D and +60D**. Feb 2024 drifted from $319.21 to ~$295 by +30D and ~$275–290 by +60D (additional 7–13% down within the Strategy B 60-day window). Jul 2025 drifted from $309.75 to ~$272 at +30D and ~$245 at +60D (additional 12–21% down within the 60-day window). Symmetry-of-treatment matters here: the IBM thesis leaned on a 1-of-1 same-name analogue (Q1 2024) reverting within 60 days as its decisive pillar supporting GO. Symmetric treatment requires that 0-of-2 against support NO-GO. n=2 is small but does not favor the thesis; with both points against, the prior on +60D reversion is at best uncertain, at worst negative.

(A4) **Cross-name analogues either don't exist with maintained-guide filter or also drifted down.** The factbase searched cable/telco for −15% to −25% close-to-close moves with maintained guidance from 2019–2026 and found zero clean matches. Closest events were LUMN Nov 2022 (disqualified — dividend eliminated) and ATUS Q2 2022 (disqualified — guide lowered), both of which drifted further down rather than reverting. Adjacent-range cable/telco events (CMCSA −6% to −13%, CABO −10% to −13%, DISH −8%) also drifted down at +30D / +60D — none reverted. Strategy B criterion 2 explicitly requires "comparable historical reactions to similar events at similar companies (retrieved, not recalled)" as input; their absence does not default to thesis-friendly. Furthermore, the available adjacent-range evidence affirmatively supports drift-down rather than reversion in the cable/telco space.

**Information-driven vs sentiment-driven test:** The information-driven case has four independent supports (A1–A4). The sentiment-driven case requires arguing the market is over-extrapolating one print despite all four signals. P3 is the strongest sentiment-case argument but depends on management credibility, which A1 erodes. **Criterion 4 test: NOT MET.**

### 2.20 (textbook-rational penalty) check

Per Strategy B pre-mortem rev 7 / 2.20: B is structurally exposed to the textbook-rational penalty because the strategy's mechanism is precisely the textbook-rational instinct that prices return to fundamental value, applied after an overreaction. CHTR is exactly the case where 2.20 is binding: the 25%-gap-fill convergence target arithmetic is genuinely attractive (+8.55% gross) and is the kind of seductive number that the textbook-rational instinct latches onto. The structural disciplines that protect against 2.20 — adversarial review, comparable historical reactions requirement, criterion 4 information-vs-sentiment test — all flagged the trade. This NO-GO is the framework working as designed.

### Effect on book

No effect. No order staged for CHTR. Strategy B remains in ACTIVATE state with IBM staged for Mon Apr 27 and HCA staged for Tue Apr 28. Strategy B sector concentration cap usage at maximum potential fill (IBM + HCA both fill): IT Services 1/3 + Health Care Facilities 1/3 — different sectors, no cap interaction. Adding CHTR (Communication Services / Cable & Satellite) would have added a third sector at 1/3 — not a cap-binding scenario, but the criterion 4 failure is the binding constraint.

### Pending queue updated

- ~~CHTR B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (information-driven repricing decisively supported by CMCSA divergence + ARPU deterioration + 0/2 same-name base rate + cross-name analogue absence/drift-down).
- IBM Mon 2026-04-27 execution — pending per prior Decision_Log entry.
- RTX Mon 2026-04-27 execution — pending per prior Decision_Log entry.
- HCA Tue 2026-04-28 execution — pending per prior Decision_Log entry of same session.
- THC Wed 2026-04-30 print — HCA invalidation criterion (iii) hook, not CHTR-relevant.
- CMCSA Q1 2026 already reported and informed CHTR adversarial review; no further CMCSA-driven action pending for CHTR.

### Operator-override note (for completeness; not a recommendation)

If the operator wishes to override this NO-GO for calibration value — analogous to the IBM "execute for calibration value despite negative EV at design-size" pattern, but here for "execute despite criterion 4 failure" — that is a valid operator decision but is a categorically different override than the IBM-style EV-discount override. The IBM override accepted negative-EV-at-design-size while preserving thesis quality endorsement; a CHTR override would require accepting that the thesis quality itself failed criterion 4 (information-driven repricing risk), which is a stronger acceptance. If executed, it should be logged explicitly as "operator override of criterion 4 NO-GO recommendation, executed for calibration value of observing realized 60-day outcome on a thesis the framework declined." The criterion 4 NO-GO recommendation stands at the framework level either way; the override is operator prerogative.

### References

- Strategy.md (Strategy B section + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure).
- Portfolio_Ledger.md (current $1,389.21 strategy B NAV; no change from this session for CHTR).
- CHTR factbase (sections 1-11 + data gaps, delivered 2026-04-26 evening; primary-source citations therein).
- Daily.md 2026-04-25 (with one brief-premise correction documented above; the magnitude correction makes the convergence-target arithmetic *more* attractive, sharpening the 2.20 / textbook-rational-penalty exposure that this NO-GO declines).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; structurally similar criterion 4 failure on a different name).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; same-name 1-of-1 analogue reversal supported GO, symmetry-of-treatment argument applied here in reverse).

### Theater-check on this orchestrator review

I considered whether to push back toward GO given the +8.55%–+34.22% gap-fill arithmetic, the technically-not-cut guidance, and the +800M Cox synergy raise (which is genuinely positive new information). Counter-argument: criterion 4 is not "no negative information exists" — it is "adversarial counter-argument doesn't identify a decisive flaw." The CMCSA divergence is decisive on its own; the ARPU monotonic deterioration is decisive on its own; the 0-of-2 same-name base rate is decisive on its own. Three independently decisive supports for information-driven repricing means the criterion 4 test fails three times over. Gate-keeping at "the bear case isn't airtight" rather than "the bear case isn't decisively flawed" would be a lower standard than the strategy's own criterion. This NO-GO is the framework working as designed; pushing back toward GO would be the framework failing to fire when its own pre-mortem 2.20 is binding.

A second consideration: should I honor the pre-session prior I expressed ("expect adversarial review to land decisively against CHTR; worth running for calibration value")? That prior was conditioning on the factbase content I did not yet have. The factbase content delivered four independent decisive-flaw supports rather than one. If anything, the factbase outcome was more lopsided against the thesis than the pre-session prior anticipated — the CMCSA divergence specifically was the kind of clean cross-sectional test that I had flagged would be the most informative external signal. The factbase delivered exactly that signal, and it points where I expected. Honoring criterion 4 at face value is the correct response.

### Compaction-survival note

**Strategy B CHTR thesis pipeline status as of 2026-04-27 Sunday afternoon:** CHTR-thesis-construction COMPLETE; CHTR-NO-GO declined on criterion 4 (information-driven repricing decisively supported); no order staged; no Portfolio_Ledger.md staging entry written. CHTR remains a closed name from a Strategy B perspective unless and until a future event materially changes the cross-sectional execution-quality differential vs CMCSA — i.e., either CHTR demonstrates a Q2 broadband net-add improvement that closes the gap with CMCSA's improvement trajectory, or CMCSA demonstrates that its Q1 improvement was non-recurring (which it partially flagged on the call via Legendary February attribution). Strategy B sector concentration in Communication Services remains at 0/3 cap usage. The other two staged orders (IBM Mon, HCA Tue) are unaffected by this entry.

**Pre-mortem 2.20 / textbook-rational-penalty calibration:** This NO-GO is a binding-2.20-case observation. It is the second NO-GO of the experiment to date (after NOW 2026-04-25), both on criterion 4 grounds, both with structurally similar information-driven-repricing patterns. Two binding-2.20 NO-GOs out of three Strategy B thesis-construction opportunities (IBM-GO, NOW-NO-GO, CHTR-NO-GO; HCA-GO with explicit lower conviction adds a fourth) is a high rate that should be tracked for the strategy's overall NO-GO base-rate calibration. If the rate persists across the first 10 thesis constructions, it is informative about whether the post-event-screen funnel is feeding too many information-driven-repricing setups vs sentiment-overshoot setups; that is a 30-trade-gate review topic, not a same-day adjustment.

---

## 2026-04-27 (Sun, late) Human-operator interaction protocol adopted (Decision_Log-internal); commission policy changed; staged orders cleaned of EV-decision hooks

**Trigger:** Human operator flagged that prior session pattern over-asked: chat output included EV-decision hooks the human operator was not equipped to evaluate; staging entries deferred GO/NO-GO refinements to "human-operator's-call-at-order-ticket-time"; sell-side and peer-print monitoring was offloaded to the human operator.

**Inputs:** This session's chat exchange producing the Human Operator Interaction Protocol; existing IBM (Decision_Log 2026-04-25), RTX (Decision_Log 2026-04-26), HCA (Decision_Log 2026-04-27 early) staging entries containing operator-decides-on-EV hooks.

### Protocol now in force (documented here, NOT in project instructions per human's explicit current instruction)

The human operator chose NOT to update project instructions at this time. The protocol lives in this Decision_Log entry as Claude's persistent reference. Future Claude sessions read project sources (per Strategy.md and the "project sources for Claude, not for human operator" element of this protocol) and therefore read this entry; that is the binding-on-future-sessions mechanism in lieu of project instructions.

**Human operator's role is execution, not decision-making.**

The human operator can do exactly four things:
1. Execute a trade in IBKR (place, modify, cancel orders).
2. Paste a calendar-triggered Claude prompt (the prompt text lives in the Google Calendar event description).
3. Screenshot IBKR and paste the image to Claude.
4. Add, delete, or update files in project sources (the persistence mechanism for Claude's writes).

The human operator does NOT verify commissions, make EV decisions, monitor markets intraday, watch sell-side wires, parse earnings prints in real time, decide execute-vs-skip on staged orders, decide override-vs-honor on NO-GO recommendations, choose convergence targets, position sizes, limit prices, or invalidation criteria, or read project sources to understand context Claude could resolve internally.

If a workflow requires the human operator to do anything beyond the four actions above, that workflow is broken and Claude redesigns it before staging anything.

**Claude resolves all decisions internally.**

Claude makes every decision the framework requires — execute or skip, GO or NO-GO, target selection, sizing, timing, invalidation criteria — without human operator input. The human operator's confirmation is not solicited; the human operator sees only the final order.

If a decision genuinely cannot be made without information Claude does not have, Claude defers the decision to a future calendar-triggered session where the missing information will be available. Claude documents the deferral logic in Decision_Log.md so the future session can resume.

**Commission policy: disregarded at decision time, accepted as business cost.**

No more "negative-EV-at-design-size acknowledgment" sections, no commission-verification hooks, no operator-decides-on-EV-at-ticket-time language. Strategy edge-decay metrics measure realized post-commission P&L empirically; that is the binding measurement, not an at-thesis-time veto. Trades with thin gross-EV-at-target margins go GO if the thesis clears; the realized P&L feeds back into the strategy-level edge-decay assessment as it accumulates.

**Sell-side and follow-on data monitoring is Claude's responsibility.**

Claude does not stage workflows requiring the human operator to "watch" anything. Where follow-on data (e.g., a peer print landing two days after entry) could affect a position, Claude uses calendar-triggered review sessions to handle it. The calendar event triggers Claude; the human operator's only action is to paste the prompt.

**Chat output discipline.**

Claude's chat output to the human operator contains only:
1. The order(s) to execute, in the exact format the human operator pastes into IBKR (or "no order"), AND
2. The minimum information the human operator needs to perform action 1, 2, 3, or 4 above.

Claude's chat output does NOT contain: recapitulation of decision reasoning that already exists in Decision_Log.md or Portfolio_Ledger.md, adversarial-review summaries, pillar/criteria walkthroughs, "three things to flag" or "two things to note" framings, pending-queue summaries beyond what affects the human operator's next action, theater-checks, compaction-survival notes, explanations of why a NO-GO is a NO-GO, operator-override paths when the recommendation is NO-GO.

**Project sources are for Claude, not for the human operator.**

Everything Claude writes to Decision_Log.md, Portfolio_Ledger.md, Daily.md, factbase files, methodology files, and other project sources is written for future Claude sessions. The human operator does not read these files — the human operator's role with project sources is action 4 (add/delete/update as a persistence mechanism). Claude writes for self-comprehension at compaction-survival depth, NOT summaries, plain-language framings, or human-operator-facing explanations.

**Self-check Claude runs before each chat response:**
- Have I created any new task for the human operator beyond actions 1, 2, 3, 4?
- Have I asked the human operator to make any decision?
- Have I included prose in chat that summarizes context already saved to project files?
- Have I deferred a decision to "human-operator's call" that I should have resolved myself?

If any answer is yes, the response is revised before sending.

### Staged-order cleanup

The three staged orders in Portfolio_Ledger.md (IBM Mon 2026-04-27, RTX Mon 2026-04-27, HCA Tue 2026-04-28) had EV-decision hooks in their Decision_Log staging entries and Portfolio_Ledger expected-return lines. Under the new commission-disregarded policy, those hooks are voided. **All three orders are GO under the new protocol with no further human-operator decision required.** The orders execute as already specified in their respective staging entries; the human operator simply places the limit orders at the staged times.

Portfolio_Ledger.md edits applied this session: Account-Level Operational Notes section rewritten (commission policy clause replaced); IBM expected-return line cleaned of commission-tier EV conditional; HCA expected-return line cleaned of execute-or-skip-on-EV reference; closing line of staged-orders block cleaned of operator-prerogative reference. Historical Decision_Log entries from earlier this weekend are NOT retroactively edited — they reflect the prior protocol and remain part of the audit trail. This entry is the protocol-change marker. Future Decision_Log entries follow the new protocol throughout.

### Calendar events created via MCP

Three events created in the same session as this Decision_Log entry. Each event description contains the prompt text the human operator pastes to Claude:

1. **Mon 2026-04-27 09:25 ET — IBM + RTX execution prompt.** Human operator pastes embedded prompt; Claude provides exact order tickets; human operator places limit orders.
2. **Tue 2026-04-28 09:25 ET — HCA execution prompt + UHS Apr 27 AMC parsing.** Claude parses UHS print in this session for HCA invalidation criterion (iv); if (iv) clean, Claude provides HCA order ticket; if (iv) triggers, Claude tells human operator "do not place HCA order."
3. **Wed 2026-04-30 09:35 ET — HCA invalidation check (THC print).** Claude reads THC print, evaluates HCA invalidation criterion (iii), and either tells human operator "no action" or "market sell HCA."

(Calendar MCP cannot set per-event custom reminders; the human operator's calendar-level default reminder applies.)

### Effect on book

No effect on staged orders. IBM, RTX, HCA all GO and execute as already staged. The protocol change removes operator-facing friction; the trades themselves are unchanged.

### Pending queue updated

- ~~Human Operator Interaction Protocol drafting~~ COMPLETE — documented in this Decision_Log entry as Claude's persistent reference (NOT in project instructions per human operator's current decision).
- ~~Commission policy clarification~~ COMPLETE — disregarded at decision time, accepted as business cost.
- ~~Staged-order EV-hook cleanup~~ COMPLETE — Portfolio_Ledger.md edits applied; all three orders GO with no further human-operator decision.
- ~~Calendar event creation for execution windows~~ COMPLETE — three events created via MCP this session.
- IBM Mon 2026-04-27 execution — pending human operator action 1.
- RTX Mon 2026-04-27 execution — pending human operator action 1.
- HCA Tue 2026-04-28 execution — pending human operator action 1 (gated by Mon evening UHS-print parsing performed by Claude in Tue 09:25 ET prompted session).
- HCA invalidation check Wed 2026-04-30 — pending Claude session, prompted by calendar event.

### Compaction-survival note

**Protocol shift summary as of 2026-04-27 Sunday late:** Human operator no longer makes any decisions; Claude resolves all internally. Commission disregarded at decision time, captured at fill for empirical accumulation. Calendar events created by Claude via MCP. Chat output is order-ticket-only. Project sources are Claude-internal. Three staged orders (IBM, RTX, HCA) execute as already specified. Future Decision_Log entries follow the new protocol; historical entries retained as audit trail of protocol evolution. **Project instructions were NOT updated this session per human operator's explicit decision** — the protocol lives only in this Decision_Log entry, and future Claude sessions must read it from here. If a future session does not appear to be following this protocol, that session has not read this entry; the human operator's action 4 (file-management) gives the human operator the option to refresh Claude's project source access at any time.

---

## 2026-04-27 (Mon, post-close) Strategy B thesis construction outcome — INTC NO-GO (criterion 4 decisive failure on both directions); no order staged

**Trigger:** B-thesis construction completed for INTC post-event candidate surfaced in Daily.md 2026-04-26 scan (Q1 2026 earnings event date 2026-04-23 AMC; close-to-close Fri 4/24 +23.6% at $82.55 — best single-session move since Oct 1987 per CNBC). INTC entered the 10-day post-event window at Day 0 on Fri 4/24; today (Mon 4/27) is Day 1 of the post-event window; window closes ~Fri 2026-05-08.

**Inputs:** Strategy.md Strategy B section (entry criteria 1-5, exit rules, criterion 3 closed-list rev 14, pre-mortem rev 7, 2.20 textbook-rational-penalty exposure framing); Experiment_Parameters.md (operational time zone America/Denver; commission-disregarded-at-decision-time per 2026-04-27 Sunday late protocol shift); AI_Trading_Foundation.md 2.13 ordinal-tier conviction, 2.14 recency bias, 2.15 base-rate neglect, 2.20 textbook-rational penalty; Portfolio_Ledger.md ($1,388.74 B NAV after IBM fill, $27.77 next-trade size at 2%, IT sector 1/3 used by IBM, HCA staged for Tue 4/28); Decision_Log.md prior precedents — IBM 2026-04-25 GO format, NOW 2026-04-25 NO-GO format, HCA 2026-04-27 GO with explicit lower-conviction posture (~45-50%), CHTR 2026-04-27 NO-GO on criterion 4 (information-driven repricing, cross-sectional information confirmation via CMCSA divergence); Daily.md 2026-04-26 (INTC magnitude correction to +23.6% Fri close vs prior +15-20% AH placeholder; Hartnett "semis bubbly and overbought vs 200-day" qualitative flag; trailing-30-day +100% per CNBC headline; TXN biggest-jump-in-25-years same Friday; sector-wide semi rally +11% over 5 days per E-candidates section). No B_Post_Event_Analogues.md or B_Thesis_Construction.md present in project sources at this session — analogue base rates assessed inline below from training knowledge with explicit 2.15 ~85% Bayesian-error-rate caveat.

### Decision

**INTC — NO-GO (DECLINE) on both LONG-extension and SHORT-mean-reversion framings.**

Failed Strategy B entry criterion 4 (adversarial counter-argument identifies a decisive flaw — specifically, the market reaction is information-driven rather than sentiment-driven, which makes "mispricing" actually correct pricing per criterion 4's explicit framing). The criterion 4 failure is decisive symmetrically against both directions; the underlying mechanism is the same — Q2 guide raise from $13.0B est to $13.8-14.8B + DCAI +22% YoY constitute genuine new information that the +23.6% Fri 4/24 reaction priced in. A LONG thesis would require arguing the +23.6% UNDER-priced the information; a SHORT thesis would require arguing it OVER-priced. Both fight the same information-driven baseline.

**Mechanical eligibility (criteria 1, 5, instrument rule) cleared with material cushion** before reaching criterion 4 / 2 failure: market cap at $82.55 close × ~4.7B shares outstanding ≈ $388B (>194× $2B floor); 30-day ADV (mega-cap, multiplied by Friday session volume) far above $10M floor; event date 2026-04-23 AMC, reaction day 2026-04-24 = Day 0 of 10-day window, Mon 4/27 = Day 1 (window remains open through ~2026-05-08); position size $27.77 (= 2.00% × $1,388.74); no A position open in INTC (A router DO-NOT-ACTIVATE; INTC also on Strategy D long list per Daily.md but no D entry staged as of this session). Sector concentration check: IT (Information Technology) GICS sector currently 1/3 used by IBM (IT Services / IT Consulting & Other Services); INTC = IT / Semiconductors & Semiconductor Equipment / Semiconductors — same GICS sector, would have made IT 2/3 if GO. Not cap-binding either way; criterion 4 is the binding constraint.

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q2 revenue guide $13.8-14.8B vs $13.0B consensus = +6.2% to +13.8% beat on the guide midpoint; DCAI segment +22% YoY signals data-center reacceleration; Citi upgraded to Buy same session; Evercore raised PT +146%. The market's +23.6% reaction may have UNDER-priced the information content given operating leverage on Intel's depressed margin base — DCAI mix-shift implies disproportionate EPS leverage above the revenue beat. Convergence target candidates: a numerical price level above $82.55 (e.g., $90 = +9.0% / $95 = +15.1%) within 60 days.

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails for LONG.** Citi upgrade to Buy and Evercore +146% PT hike same session demonstrate sell-side immediately ratified the fundamental shift at $82.55. There is no evidence of sentiment-driven SUPPRESSION of the +23.6% reaction; the reaction was a clean information-pricing event. Per criterion 4's explicit framing applied symmetrically: information-driven reaction means $82.55 correctly prices the new fundamentals, so the LONG thesis (claiming +23.6% UNDERPRICED the information) lacks the sentiment-suppression evidence it would need to clear. The argument that operating leverage implies "disproportionate EPS leverage above the revenue beat" is the kind of narrative-quality assessment that pre-mortem rev 7 Constraint 1 names as 2.4-self-referenced — Claude evaluating whether its own thesis on operating leverage is information or narrative is itself the biased synthesis.

(L2) **Trailing-30-day +100% momentum violates pre-mortem rev 7 prose deferral discipline.** Per CNBC headline (cited in Daily.md), INTC ran ~+100% in the prior 30 trading days even before Friday. Strategy A criterion 6 and Strategy D criterion 6 both contain identical text: "Entry is not triggered by short-term momentum; if the name is rallying hard in the trailing 30 days, defer entry until rally pauses (avoids buying at recency-bias-fueled peaks per 2.14)." Although Strategy B's numbered criteria do not include a literal criterion-6 momentum-deferral clause, the underlying 2.14 (recency bias on input data) discipline is structural across all strategies — applying asymmetric leniency to B on a literal-text basis would be the kind of self-referencing escape that pre-mortem rev 7 Constraint 1 names as the dominant 2.4 / narrative-over-fit failure mode. Symmetric application: defer.

(L3) **+23.6% single-day move is in the extreme tail of post-print reactions.** "Best day since Oct 1987" framing is a 39-year-tail event. Historical base rate of buying after a +23.6% gap-up to participate in further extension within 60 days is empirically poor for liquid mega-caps — these reactions are typically followed by consolidation or pullback as sell-side digests and momentum traders rotate. Arguing $82.55 was UNDERSIZED at this magnitude requires placing significant probability mass on an even more extreme reaction tail, which the AI_Trading_Foundation 2.13 ordinal-tier discipline penalizes (the model cannot reliably distinguish 80th-percentile from 99th-percentile post-event extension at this magnitude).

(L4) **Sector-level "bubbly and overbought" regime flag.** Hartnett (BofA Flow Show, 4/24, captured in Daily.md): semis "bubbly" and "overbought" vs 200-day. Independent regime-level signal that the IT/Semi sector — the sector INTC belongs to — is in the behavioral-irrationality regime that 2.20 textbook-rational penalty names as binding. TXN's "biggest jump in 25 years" same Friday plus the broader semi sector rally (+11% over 5 days per Daily.md §Strategy E candidates) reinforce the sector-wide rotation framing; INTC's move is partially a sector-rotation effect, not purely an idiosyncratic information event.

LONG declined. Criterion 4 information-vs-sentiment test not met (L1 decisive); criterion 2 narrative synthesis weakened by L2-L4.

### SHORT thesis examined and declined

**Provisional affirmative thesis (SHORT / mean-reversion).** +23.6% in a single session is over-extension given ongoing macro uncertainty (Iran/Hormuz, Russia-Ukraine, FOMC blackout); the move will fade toward $70-75 over 60 days as gap-up gets retraced. Per Strategy B exit rules for shorts: stop-loss at +25% from entry ($82.55 × 1.25 = $103.19); 60-day timeline; borrow rate cap at 10% annualized. Convergence target candidate: numerical price level (e.g., $70 ≈ 50% gap-fill of the +23.6% reaction toward pre-event ~$66.78 reference; or $75 ≈ 35% gap-fill).

**Adversarial counter-argument (decisive flaw on SHORT side — symmetric to CHTR NO-GO precedent):**

(S1) **Information-driven repricing — direct 2.20 textbook-rational-penalty trap.** The +23.6% reaction priced genuine new information: Q2 guide raise of $13.8-14.8B vs $13.0B consensus is a +6.2% to +13.8% beat on the guide midpoint; DCAI +22% YoY is a structural inflection in Intel's data-center business. Per Strategy.md Strategy B pre-mortem rev 7 thesis paragraph: "B is structurally exposed to 2.20 (textbook-rational penalty) because the strategy's mechanism is precisely the textbook-rational instinct — that prices return to fundamental value — applied after an overreaction. The router's HIGH-VIX exclusion is a partial regime-level mitigation; no mechanism-level mitigation exists." Shorting INTC at $82.55 on a mean-reversion thesis IS the canonical 2.20 trap on the most extreme version of the trap (a +23.6% information-driven move with sell-side immediate ratification). The "seductive convergence target" pattern named in CHTR NO-GO (textbook-rational instinct latching onto a clean gap-fill arithmetic) applies identically here — 50% gap-fill from $82.55 to ~$74.66 would be +9.5% gross, the kind of clean-looking number that textbook-rational instinct privileges.

(S2) **Symmetric application of CHTR NO-GO logic via cross-sectional information confirmation.** The CHTR NO-GO leaned on (A1) CMCSA divergence as decisive evidence of information-driven repricing — peer-level cross-sectional information confirming the move was structural, not sentiment. INTC's parallel: TXN's "biggest jump in 25 years" same Friday plus the broader semi sector rally (+11% over 5 days per Daily.md) constitute identical-shape cross-sectional information confirmation — multiple semi names re-rating UPWARD on shared AI / DCAI information set. Symmetry-of-treatment requires applying the same logic: when peer-level information confirmation is present, the move is information-driven, criterion 4 fails the mean-reversion thesis. CHTR's NO-GO was on a LONG mean-reversion thesis (declining stock; sentiment thesis was "overshot down"); INTC's mirror is a SHORT mean-reversion thesis (rallying stock; sentiment thesis is "overshot up"). Same decision rule applies symmetrically.

(S3) **Sell-side immediate ratification.** Citi upgrade to Buy and Evercore +146% PT hike same session indicate professional analysts view $82.55 as fundamentally justified or low. Per Strategy.md sell-side handling clause precedents (Strategy C rev 19 clause; cited in B's broader sell-side handling discipline), sell-side may inform structure but cannot be the load-bearing rationale; here, sell-side serves as directional information-input — the inferential weight is on the directional ratification (no Hold→Sell downgrades on the print) rather than load-bearing on specific PT levels.

(S4) **Squeeze risk is structurally elevated; gap-up execution risk on shorts is unmitigated.** Per Strategy B pre-mortem rev 7 KL #7 (rev 4 rewritten): the rev 3 short-side stop-loss at +25% from entry is operational, not structural — gap-up scenarios (overnight earnings, FDA, M&A, squeeze events at scale) execute the stop at the next available print, leaving realized loss UNCAPPED in gap conditions. INTC at this magnitude post-print, with trailing-30-day +100% momentum and a fresh upgrade cycle, is in the operational regime where gap-up squeeze risk is structurally elevated. Even if criterion 4 cleared on the SHORT (it does not), the per-thesis loss-bound assumption would be more fragile than the typical B short.

(S5) **Borrow rate not verified live but presumptively elevated.** Strategy B short eligibility does not gate on borrow rate at entry (only at exit, per the >10% trigger), but the underlying economic burden compounds the SHORT thesis cost. Heavily-shorted recent rally names typically command elevated borrow rates; this is captured at exit, not entry, so it does not gate decision but informs adverse expectation. Documented for symmetric posture with future B short evaluations.

SHORT declined. Criterion 4 information-vs-sentiment test not met (S1 decisive, S2 symmetric to CHTR precedent); operational stop-loss fragility (S4) compounds the residual.

### 2.20 (textbook-rational penalty) check

Per Strategy B pre-mortem rev 7 thesis paragraph: B is structurally exposed to 2.20 because the strategy's mechanism IS the textbook-rational instinct that prices return to fundamental value, applied after an overreaction. INTC SHORT is the canonical 2.20 trap (the rallying-stock mirror of CHTR's declining-stock 2.20 trap). The structural disciplines protecting against 2.20 — adversarial review, criterion 4 information-vs-sentiment test, comparable historical reactions requirement — all flag SHORT decisively. INTC LONG is NOT a classical 2.20 trap (LONG-extension thesis is closer to 2.13 overconfidence + 2.4 narrative-over-fit territory), but the criterion 4 failure on LONG side is structurally similar in shape (information-driven move = correct pricing, undermining the mispricing premise from either direction). Both NO-GOs are the framework working as designed.

### Conviction note (per AI_Trading_Foundation 2.13 ordinal-tier discipline)

For internal calibration only — not a separate gate. If forced to a numerical: LONG conviction ~25-30% extension probability over 60 days (well below the marginal-but-credible threshold demonstrated by HCA at ~45-50%); SHORT conviction ~25-30% mean-reversion probability over 60 days (textbook-rational instinct claims higher but the criterion 4 failure caps honest credence). Both directions sit at conviction levels well below where the framework's "criteria-cleared but marginal" admissibility (HCA precedent ~45-50%) would even matter — but the criteria themselves fail on criterion 4, so conviction calibration is not the binding gate. Documented for compaction-survival; the binding decision is criterion 4, not conviction.

### Effect on book

No effect. No order staged for INTC. Strategy B remains in ACTIVATE state with IBM open (filled today at $230.17) and HCA staged for Tue 2026-04-28. Strategy B sector concentration cap usage unchanged: IT sector 1/3 (IBM IT Services); on Tue HCA fill, Health Care 1/3 (HCA Health Care Facilities) — different sectors, no cap interaction. INTC NO-GO leaves the IT sector cap at 1/3 (IBM only) within B's book.

### Pending queue updated

- ~~INTC B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (information-driven repricing decisive on both directions: LONG via L1 sell-side immediate ratification + L2-L4 momentum/regime flags; SHORT via S1 direct 2.20 trap + S2 symmetric application of CHTR cross-sectional information logic + S3 sell-side ratification + S4 operational stop-loss fragility).
- IBM open position monitored per Strategy.md exit rules (60-day timeline expiry 2026-06-26; convergence target $244.30 = 50% gap-fill from $230.17 entry toward pre-event reference; invalidation criteria (i)-(iv) per 2026-04-25 IBM thesis).
- HCA Tue 2026-04-28 execution — pending per 2026-04-27 (early Sun) Decision_Log entry.
- THC Wed 2026-04-30 print — HCA invalidation criterion (iii) hook.
- UHS Mon 2026-04-27 AMC + Tue 2026-04-28 9:00 ET conf call — HCA invalidation criterion (iv) feed; if signal-resolved before Tue 2026-04-28 HCA order, parsed in pre-execution session per existing Decision_Log scheduling.
- INTC monitoring: not scheduled. NO-GO context applies; per CHTR-style discipline, no follow-on calendar event unless narrative reversal occurs.
- INTC remains on Strategy D long list per Daily.md 2026-04-26; D's separate evaluation track is not affected by this B NO-GO. D-side INTC re-screen pace governed by Quarterly_D_Candidates.md sequencing, independently.

### Compaction-survival notes for future Claude

(a) **Symmetric criterion-4 application across directions.** Pre-mortem rev 7 Constraint 1 makes criterion 4 the only flowing limitation against 2.4 narrative-over-fit; the criterion's "information-driven vs sentiment-driven" test is direction-symmetric by construction. An information-driven reaction implies "the price is correct," which contradicts both UNDER-priced (LONG) and OVER-priced (SHORT) theses. Future sessions evaluating large post-event moves — whether up or down — should apply the test symmetrically to both directions, not preferentially to whichever side initially seems more attractive.

(b) **CHTR-INTC parallel as case-pair precedent.** CHTR was a -25.50% information-driven LONG-mean-reversion NO-GO (CMCSA divergence as cross-sectional confirmation). INTC SHORT is a +23.6% information-driven SHORT-mean-reversion NO-GO (TXN biggest-jump-in-25-years and broader semi rally as cross-sectional confirmation). The structural shape is symmetric — when peer-level cross-sectional information confirms a move, the move is information-driven by construction, and the criterion 4 test fails the mean-reversion thesis on whichever direction it's posed. Future Claude sessions can use this case-pair as the canonical worked example of symmetric criterion-4 failure.

(c) **Trailing-30-day momentum discipline applies to B even though not literally numbered.** Strategy A criterion 6 and Strategy D criterion 6 contain a literal trailing-30-day-rally-defer clause; Strategy B does not. The underlying 2.14 recency-bias discipline is structural across all strategies (per AI_Trading_Foundation Part 2). Applying it asymmetrically to B (i.e., NOT deferring on a momentum-extended name when LONG-extension is contemplated) would be the 2.4-self-referencing-escape that pre-mortem rev 7 Constraint 1 identifies as B's dominant failure mode. Symmetric application is the right move.

(d) **Extreme-tail framing degrades base-rate retrieval reliability.** "Best day since Oct 1987" / "biggest jump in 25 years" framings on INTC and TXN respectively are cues that base-rate retrieval cannot give a reliable answer because comparable events are extremely rare. Per AI_Trading_Foundation 2.15 ~85% Bayesian-error-rate, base-rate-based theses on extreme-tail events should be heavily discounted. This is independent of criterion 4 but compounds the case for declining at marginal conviction.

(e) **LONG-extension vs SHORT-mean-reversion are different failure modes within Strategy B.** SHORT-mean-reversion is the canonical 2.20 textbook-rational-penalty pattern. LONG-extension is closer to 2.13 (overconfidence) + 2.4 (narrative over-fit) territory. Both fail criterion 4 here, but for slightly different reasons: SHORT fails because shorting an information-driven up-move is the canonical 2.20 trap; LONG fails because buying after an information-driven up-move with immediate sell-side ratification means the price is already correct, and arguing it's underpriced requires evidence of sentiment-suppression (absent here). Future sessions should distinguish these failure modes when documenting NO-GOs.

(f) **IBKR Pro tier persisted; fractional execution available; commission disregarded at decision time per 2026-04-27 Sunday late protocol shift.** No EV-at-design-size computation gates this NO-GO; the binding constraint is criterion 4 thesis quality, not commission economics.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + exit rules + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure / KL #4 slow-burn-behavioral-regime + KL #7 short-side gap-execution residual).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.15 ~85% Bayesian-error-rate base-rate neglect; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (current $1,388.74 strategy B NAV; IBM open position 0.1198 @ $230.17 cost basis; HCA staged Tue 2026-04-28 limit BUY 0.0642 @ $433.50; no change from this session for INTC).
- Daily.md 2026-04-26 (INTC magnitude correction to +23.6% / $82.55; trailing-30-day +100% per CNBC; Hartnett semis "bubbly and overbought vs 200-day" qualitative flag; TXN biggest-jump-in-25-years sector-wide rally; semis +11% over 5 days vs IGV ~flat per E-candidates section).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent — same-name 1-of-1 analogue reversal supported GO; 2.13 ordinal-tier "medium" conviction at ~55-60%).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent — criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 (early Sun) HCA entry (GO with explicit lower-conviction posture precedent — medium-low ~45-50% conviction with all 5 criteria cleared; canonical handling of marginal-but-criteria-cleared cases per protocol).
- Decision_Log.md 2026-04-27 (Sun follow-on) CHTR entry (NO-GO format precedent — criterion 4 failure on cross-sectional-information-confirmed move; symmetry-of-treatment basis for INTC SHORT NO-GO).
- Experiment_Parameters.md (operational time zone America/Denver; commission-disregarded-at-decision-time per 2026-04-27 protocol).

### Theater-check on this orchestrator review

I considered whether the LONG thesis deserved less stringent treatment than the SHORT thesis given that LONG is not a classical 2.20 trap. Counter-argument: criterion 4's information-vs-sentiment test is direction-symmetric by construction — the test asks whether the realized reaction is information-driven, not whether the contemplated trade is on the specific side that 2.20 names. An information-driven reaction implies "the price is correct," which makes both UNDER-priced (LONG) and OVER-priced (SHORT) theses contradicted by the test. The LONG thesis fails (L1) on the same fundamental ground as the SHORT thesis fails (S1) — sell-side immediate ratification is the smoking-gun evidence of information pricing on both sides. Modulo direction-specific add-ons (L2-L4 for LONG; S2-S5 for SHORT), the criterion 4 failure is the binding constraint on both, and the NO-GO is the symmetric outcome.

I also considered whether to be more lenient on the trailing-30-day +100% discipline given that it's not B's literal numbered criterion 6. Counter-argument: 2.14 recency bias is structural across all strategies per AI_Trading_Foundation Part 2, and the asymmetric leniency would be exactly the self-referencing escape that pre-mortem rev 7 Constraint 1 names — applying it symmetrically to B is the right move. The L2 rationale invokes 2.14 directly rather than cross-referencing A/D criterion 6 as a literal-text rule.

I also considered whether the "best day since Oct 1987" extreme-tail framing should be load-bearing on its own. Counter-argument: per 2.15 ~85% Bayesian-error-rate, claims about extreme-tail base rates are themselves unreliable; L3 should not be the decisive flag, only a compounding factor on top of L1. I scoped L3 accordingly — it supports the L1 decisive flag rather than substituting for it.

I also considered whether the symmetric CHTR-INTC application was over-fitting (forcing pattern-match because the structural shape is convenient). Counter-argument: the cross-sectional information confirmation logic is independently grounded in criterion 4's information-vs-sentiment test — peer evidence of the same direction-of-information IS the operational evidence for "information-driven, not sentiment-driven." The CHTR precedent demonstrates the logic; it does not generate the logic. The S2 reasoning would hold even without CHTR as precedent; CHTR provides only confirmation that the framework has previously applied this logic to the symmetric-shape case.

Modulo these four considerations, the orchestrator review converges on the NO-GO recommendation on both LONG and SHORT.

---

### 2026-04-27 (Mon evening) Strategy B HCA invalidation criterion (iv) check — UHS Q1 2026 print parsed; criterion (iv) CLEARED; HCA staged order proceeds for Tue 2026-04-28

**Trigger:** UHS Q1 2026 earnings reported Mon 2026-04-27 AMC (press release timestamp 16:15 ET via PRNewswire / SEC Form 8-K Ex-99.1). HCA invalidation criterion (iv) per Decision_Log 2026-04-27 (early Sun) entry reads: "UHS Apr 27 AMC / Apr 28 print with similarly clean Q1 reinforcing the (iii) signal directionally" — clean UHS Q1 (no respiratory/weather flag) AND FY26 guide reaffirmed at midpoint or higher would jointly trigger invalidation. Mon-evening calendar-prompted Claude session resolves criterion (iv) before Tue 2026-04-28 9:30 AM ET HCA limit-buy execution; Tue 9:25 AM ET pre-execution session deleted as redundant once criterion (iv) is resolved Mon evening.

**Inputs:** UHS Q1 2026 press release (PRNewswire 2026-04-27 16:15 ET; full text, financial tables, segment statistics, consolidated/same-facility hospital statistics, forward-looking-statements section); UHS Q4 2025 conference call transcript (Motley Fool, Globe and Mail; published 2026-04-21 from the 2026-02-25 call) for FY26 initial guidance and pre-announced Q1 storm softness commentary; EBC UHS Q1 preview (consensus expectations + previously-disclosed FY26 guide range); Decision_Log 2026-04-27 (early Sun) HCA staging entry (full thesis with all 4 invalidation criteria); Portfolio_Ledger.md HCA staged-order subsection; Strategy.md Strategy B exit rules and pre-mortem rev 7; AI_Trading_Foundation.md (2.13 ordinal-tier conviction discipline as background — not a separate gate per protocol-shift framing).

**Decision:** **HCA invalidation criterion (iv) CLEARED — does NOT trigger. HCA staged order proceeds unchanged for Tue 2026-04-28 9:30 AM ET market-open execution: Limit BUY 0.0642 HCA @ $433.50 Day.**

**Reasoning:**

UHS Q1 2026 print is NOT a "similarly clean Q1 reinforcing the (iii) signal" per criterion (iv)'s required two-prong test. The two prongs:

(A) **No respiratory/weather flag.** This prong FAILS by direct peer-level corroboration of HCA's framing predating the HCA print. UHS pre-announced Q1 winter-storm softness in their Q4 2025 commentary (2026-02-25 call): "anticipated first quarter 2026 softness due to winter storms." Q1 actuals delivered consistent with that pre-flag — same-facility acute admissions −1.5% (86,780 vs 88,090); adjusted admissions 0.0%; licensed-bed occupancy 67.4% vs 68.2% (−1.2pp); available-bed occupancy 69.1% vs 69.9% (−1.2pp); patient days same-facility −0.7%. The "clean" UHS topline (revenue +9.6%, EPS beat $5.62 vs $5.44 consensus) is driven by (i) net revenue per adjusted admission +6.3% (pricing/reimbursement strength), (ii) Behavioral Health segment +7.3% same-facility revenue (~42% of UHS revenue, structurally insulated from respiratory/weather), and (iii) outpatient revenue +15.9% gross — NOT by acute-care volume strength. The volume metric central to HCA's framing — same-facility acute admissions / occupancy — came in soft at UHS, consistent with weather-driven respiratory-volume disruption, exactly as HCA reported.

(B) **FY26 guide reaffirmed at midpoint or higher.** This prong is technically silent in the press release (UHS does not update guidance in the Q1 release; guidance commentary happens on the Apr 28 9:00 AM ET conference call per their typical reporting pattern). However, the press release's forward-looking-statements section references the "previously disclosed 2026 operating results forecast" without indicating revision, and Q1 actuals are tracking on-path to the existing FY26 guide ($18.42–$18.79B revenue / $2.64–$2.79B Adj EBITDA / $22.64–$24.52 Adj EPS): Q1 EBITDA $648M annualizes to ~$2.59B vs $2.64B low end, and given UHS Q1 is seasonally the lowest revenue quarter, this is consistent with reaching the guide range. Stock +2.78% post-print to $184.50 corroborates the market reading the print as guide-trajectory-intact rather than guide-cut signal. **Even granting prong (B) clean (which is the most charitable read), prong (A)'s failure is decisive — the criterion (iv) test is conjunctive ("no respiratory/weather flag" AND "FY26 guide reaffirmed at midpoint or higher"); failure on either prong defeats the trigger.**

**The UHS Q1 print directionally REINFORCES HCA's industry-wide non-company-specific framing**, not undercuts it. UHS's pre-announced Q1 winter-storm softness, plus Q1 actuals delivering soft acute-care volume consistent with that pre-flag, plus UHS's "clean" overall print being driven by behavioral-mix and pricing rather than acute-care volume strength, constitute peer-level cross-sectional evidence of the same Q1 weather/respiratory dynamic HCA cited. This is the structural mirror image of the CHTR vs CMCSA cross-sectional information confirmation logic from the 2026-04-27 (Sun follow-on) CHTR NO-GO precedent — except here the cross-sectional confirmation runs IN FAVOR of HCA's framing rather than against the contemplated trade.

The criterion (iv) test as written sets a high bar for invalidation: a "similarly clean Q1" — meaning a Q1 print where peer-level acute-care volume metrics came in CLEAN (no soft same-facility volume / occupancy) AND with NO weather/respiratory commentary as a Q1 attribution — would have undercut HCA's framing by demonstrating that another major hospital operator on similar geographic exposure could deliver clean acute-care volume in the same quarter. UHS does not meet that bar. The acute-care volume delta between UHS (admissions −1.5% same-facility) and HCA (equivalent admissions +1.3% same-facility but step-down from trailing range) is consistent with both names experiencing the same Q1 weather/respiratory volume dynamic, with HCA's relatively-stronger headline volume number reflecting its relatively-stronger geographic-mix exposure outside the worst-hit storm geography (HCA's TX/TN/NC/VA disclosure overlaps Winter Storm Fern's TN/MS/SC FEMA Major Disaster Declarations but is not coterminous with it).

**Differential applicability of criterion (iv) vs criterion (iii) noted:** UHS is a structurally less-clean signal than THC for this purpose because (a) UHS has ~42% behavioral-health-segment revenue with no respiratory/weather sensitivity, masking the acute-care volume signal at the consolidated level, and (b) UHS pre-announced Q1 storm softness in February, so Q1 actuals delivering consistent softness is corroborative rather than informational. THC is pure acute-care, more geographically concentrated, and did not pre-flag Q1 storm impact — making THC's Apr 30 print the higher-information-content peer datapoint, exactly as the original criterion (iii) construction anticipated. Criterion (iv) was always the less-load-bearing of the two peer-validation hooks, and its non-triggering here is consistent with that hierarchy.

**Theater-check flag:** The criterion (iv) clearance is decisive on prong (A) (substantive peer-level corroboration of weather/respiratory framing); the prong (B) read is "press release silent + Q1 actuals on-track to existing guide + market reaction supportive" rather than explicit reaffirmation. Honest framing: prong (B) is not affirmatively confirmed at this checkpoint (would require Apr 28 9:00 AM ET conference-call commentary), but prong (B) is also not invalidated — and prong (A) is decisively failed. The conjunctive structure of the criterion (iv) test means prong (A)'s decisive failure resolves the criterion regardless of prong (B). I considered whether to defer the criterion (iv) call to a Tue 9:25 AM ET pre-execution session post-conference-call (when prong (B) would be explicitly resolved). Counter-argument: (i) the protocol prohibits decision-chaining via deferral; the canonical Mon-evening calendar event was created precisely to resolve criterion (iv) at this checkpoint, with prong (B) press-release-silence plus Q1-actuals-on-track being sufficient for the conjunctive test given prong (A)'s decisive failure; (ii) deferring to Tue 9:25 ET would have only yielded a marginal prong-(B) data refinement (explicit reaffirmation vs implicit-by-actuals confirmation) without changing the conjunctive outcome; (iii) the "default action on trigger-failure is conservative branch" protocol clause does not apply because the trigger HAS resolved at this checkpoint (criterion (iv) is cleared, not deferred). The clearance is robust.

A second consideration: was the criterion (iv) test as constructed in the original HCA staging entry too narrow to capture the actual peer-level signal? The original test specified "no respiratory/weather flag" — a flag that UHS arguably did not give at the Q1 print itself (the press release is silent on driver attribution) but had given two months earlier in February. Counter-argument: the Q4-2025-call pre-flag IS UHS's flag for purposes of criterion (iv); UHS does not need to re-flag a previously-flagged driver in the subsequent quarter's print. The substantive test is whether the peer-level signal corroborates or contradicts HCA's framing — and pre-announced storm softness delivering on cue is corroboration. The criterion (iv) test as constructed is workable; the literal "no flag in Q1 print" reading would be over-narrow and would mistakenly read peer-level corroboration as peer-level non-corroboration.

A third consideration: should the strong UHS topline (revenue +9.6%, EPS beat) be read as "clean Q1" purely on the headline numbers? Counter-argument: criterion (iv)'s "clean Q1" test is about peer-level corroboration of HCA's specific Q1-volume-weakness framing, not about UHS's overall Q1 print quality from an investment perspective. UHS had a strong Q1 in absolute terms (margins, EPS, cash flow, capital returns), but the strength is concentrated in pricing/behavioral-mix/outpatient channels — NOT in the same-facility acute-care volume metric where HCA reported weakness. The criterion (iv) test asks the volume-corroboration question, not the headline-quality question. Volume answer: UHS is corroborative of HCA's framing.

**Downstream actions:**

1. HCA Tue 2026-04-28 limit-buy executes as staged: **Limit BUY 0.0642 HCA @ $433.50 Day** (operator places at market open). Order ticket delivered in Mon-evening session chat output.
2. Portfolio_Ledger.md updated this session: Mon-evening UHS-checkpoint note added to HCA staged-order subsection capturing the sourced UHS data points and criterion (iv) clearance reasoning.
3. Tue 2026-04-28 9:25 AM ET HCA execution-prompt calendar event (event ID `7qeepr22drincfg9eoe0icr6so`) **DELETED** as redundant — criterion (iv) is now resolved Mon evening; the order ticket is in the human operator's hands; no Tue pre-execution Claude session is needed for HCA. Operator places the limit BUY at market-open Tue.
4. Tue 2026-04-28 ~14:30 MT HCA fill-capture screenshot calendar event (event ID `e8gjm7njrmddken1dg262717us`) **RETAINED** — fill-capture session proceeds as scheduled; Step 5 conditional in that event's prompt ("if HCA self-review session this morning canceled staging") is now obsolete since (iv) cleared Mon evening, but the conditional simply will not trigger and the rest of the Step 1-4 fill-capture path remains correct.
5. Wed 2026-04-30 ~08:00 MT HCA invalidation-check post-THC-print calendar event (event ID `3v8bhcgkova6ibde2kgmp0ng0c`) **RETAINED** — THC Q1 print (criterion (iii)) is the higher-information-content peer datapoint and remains the load-bearing post-entry validation hook.
6. No new calendar events scheduled this session beyond those already in place.
7. No changes to Strategy B sector concentration cap accounting (HCA fill Tue brings Health Care Facilities to 1/3 within Health Care sector; IT Services 1/3 within Information Technology sector from IBM Mon fill; no cap-binding interaction).
8. No effect on Strategy D RTX position, Strategy A INTC NO-GO context, or other existing portfolio state.

**References:**

- UHS Q1 2026 press release (PRNewswire 2026-04-27 16:15 ET; SEC Form 8-K Ex-99.1; full text including consolidated income statement, segment same-facility tables, supplemental hospital statistics, balance sheet, cash flow statement, forward-looking statements section). Source URL retrieved this session: https://www.stocktitan.net/news/UHS/universal-health-services-inc-announces-financial-results-for-the-l7jjc9pj5pit.html (full press release text reproduced); MarketScreener reproduction at https://www.marketscreener.com/news/universal-health-services-inc-announces-financial-results-for-the-three-month-period-ended-march-3-ce7f59dddb81f12c.
- UHS Q4 2025 earnings call transcript (Motley Fool 2026-04-21 publication of 2026-02-25 call): FY26 initial guidance — revenue $18.4–$18.8B, Adj EBITDA $2.64–$2.79B, Adj EPS $22.64–$24.52; volume growth assumption 2-3% same-facility for both segments WITH "anticipated first quarter 2026 softness due to winter storms"; Steve Filton commentary on health-insurance-exchange volume-decline 25-30% headwind ($75M pretax) and California behavioral staffing regulations ($35M pretax in 2026, $30M annually thereafter). Source URL: https://www.fool.com/earnings/call-transcripts/2026/04/21/uhs-uhs-q4-2025-earnings-call-transcript/ (and Globe and Mail mirror).
- EBC UHS Q1 preview (2026-04-27): consensus expectations EPS $5.36 / revenue $4.37–$4.39B; previously-disclosed FY26 guide range corroborated. Source URL: https://www.ebc.com/forex/uhs-earnings-preview-hospital-margins-face-volume-and-labor-cost-test.
- Investing.com UHS Q1 print summary: revenue $4.49B beat $4.39B; Adj EPS $5.62 beat $5.44 by $0.18; shares +3% post-release. Source URL: https://www.investing.com/news/earnings/universal-health-beats-q1-estimates-as-revenue-climbs-96-93CH-4639932.
- Decision_Log 2026-04-27 (early Sun) HCA staging entry — criterion (iv) construction and full thesis; medium-low conviction (~45-50%) with criterion 4 information-vs-sentiment test cleared at margin; convergence target $442.85 immutable per criterion 3 closed-list rev 14.
- Decision_Log 2026-04-27 (Sun follow-on) CHTR NO-GO entry — symmetric cross-sectional information-confirmation precedent (CHTR vs CMCSA divergence as decisive evidence of information-driven repricing). UHS-corroborates-HCA logic in this entry mirrors CMCSA-divergence-from-CHTR logic in its cross-sectional structure but runs in favor of the staged trade rather than against a contemplated trade.
- Decision_Log 2026-04-27 (Sun late) protocol-shift entry — Human Operator Interaction Protocol; commission disregarded at decision time; calendar-event scheduling responsibility on Claude; chat output discipline (order-ticket-only; no reasoning recap).
- Decision_Log 2026-04-27 INTC NO-GO entry — symmetric criterion-4 application precedent (LONG and SHORT both fail when cross-sectional information confirmation is present in the contemplated direction).
- Strategy.md Strategy B section (entry criteria 1-5; exit rules; criterion 3 closed-list rev 14; pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure / KL #4 slow-burn-behavioral-regime / KL #7 short-side gap-execution residual — relevant context, none binding here).
- AI_Trading_Foundation.md 2.13 ordinal-tier conviction discipline (no separate-gate conviction check at this checkpoint per protocol; conviction is a Claude-internal calibration metric, not a separate gate).
- Portfolio_Ledger.md (current Strategy B NAV $1,388.74 with IBM open position 0.1198 @ $230.17 cost basis; HCA staged 0.0642 @ $433.50; UHS-checkpoint note added this session).

**Compaction-survival notes for future Claude:**

(a) **Conjunctive criterion-construction worked example.** Criterion (iv) test was constructed as conjunctive ("no respiratory/weather flag" AND "FY26 guide reaffirmed at midpoint or higher"). Conjunctive structure means failure on either prong defeats the trigger. Future invalidation-criterion construction sessions should make conjunctive vs disjunctive structure explicit at the time of construction, not at the time of evaluation. Conjunctive structure is the right default for invalidation hooks because invalidation should require multiple corroborating signals, not a single ambiguous one.

(b) **Pre-flagged peer commentary persists across quarters.** UHS's Q4-2025-call pre-flag of Q1 storm softness IS UHS's "respiratory/weather flag" for purposes of criterion (iv), even though UHS did not repeat the flag in the Q1 print itself. Future sessions evaluating invalidation criteria with peer-level signals should consider the peer's full disclosure stack across the relevant period — not just the most recent print's literal text. The substantive test is whether the peer signal corroborates or contradicts the framing, not whether the peer literally re-flags it in each subsequent disclosure.

(c) **Segment mix matters for cross-sectional volume signals.** UHS is structurally less-clean than THC for criterion (iv) purposes because UHS's ~42% behavioral-health revenue mix masks the acute-care volume signal at the consolidated level, and behavioral health is structurally insulated from respiratory/weather drivers. Future Strategy B post-event theses on hospital operators should distinguish acute-only peers (HCA, THC) from mixed-segment peers (UHS, ACHC) when designing peer-validation invalidation hooks. THC was correctly weighted as criterion (iii) load-bearing peer; UHS was correctly weighted as criterion (iv) supplementary peer; this hierarchy held up at evaluation.

(d) **Strong topline + weak volume + strong pricing + strong segment mix = NOT a "clean Q1" for criterion (iv) purposes.** UHS reported a beat-beat-beat headline (revenue / EPS / EBITDA all above consensus) with stock +2.78% post-print. From a generic investment perspective, that's a "clean" Q1. From a criterion (iv) "does this peer print contradict HCA's volume-weakness framing" perspective, it's NOT clean — the topline strength runs through pricing and segment-mix channels that don't bear on HCA's framing, and the volume metric came in soft consistent with HCA's framing. Future sessions should keep the criterion-specific test orthogonal to the headline-quality read.

(e) **Decision-resolution-at-Mon-evening avoids deferral chaining.** The original HCA staging entry contemplated criterion (iv) being parsed at Tue 9:25 AM ET pre-execution (post-conference-call). The Mon-evening calendar event was added later as an optimization given UHS reports AMC. Resolving criterion (iv) Mon evening avoids the protocol's deferral-chaining prohibition AND removes operator-facing friction for the Tue execution window. The Tue 9:25 AM ET event was cancelled as redundant. Future criterion-evaluation sessions at AMC reporting peers should follow the same pattern: resolve at the AMC-print parse session if information is sufficient; defer only if information is genuinely missing (and never re-defer).

(f) **Press-release silence on guide ≠ guide cut.** Hospital operators (HCA, UHS, THC, CYH) typically do not update FY guidance in the press release; guidance commentary happens on the conference call. Press-release silence is therefore typical and not a signal in either direction. The guide-status read should be (i) silent press release + (ii) Q1 actuals tracking the existing guide range path + (iii) forward-looking-statements section referencing the "previously disclosed forecast" without revision = guide implicitly intact pending call commentary. Explicit reaffirmation comes on the call. Decisions should be made on the implicitly-intact read at AMC parse if the conjunctive criterion structure permits resolution without explicit confirmation (as here).

(g) **IBKR Pro tier persisted; fractional execution available; commission disregarded at decision time per 2026-04-27 Sunday late protocol shift.** Standard footing for the experiment.

---

## 2026-04-28 (Tue, post-close) HCA fill captured; Apr 28 SGOV cycle reconciled; IBKR Funds-on-Hold $2,500 anomaly observed and flagged for next-session resolution

**Trigger:** Tue 2026-04-28 ~14:30 MT scheduled fill-capture session (calendar event ID `e8gjm7njrmddken1dg262717us`) — operator pasted IBKR Positions and Trades screenshots from 2026-04-28 ~14:30 MT.

**Inputs:** IBKR Positions screenshot (NLV $6,946 / Daily P&L +$1.00 / +0.01% / Funds on Hold $2,500.00 / SGOV 68.1693 + IBM 0.1198 + RTX 0.1595 + HCA 0.0642 + USD Cash $0.63); IBKR Trades-Today screenshot (3 trades: SGOV sell 0.3 @ $100.65 07:30:05 ET / HCA buy 0.0642 @ $433.46 limit 10:38:51 ET / SGOV buy 0.0198 @ $100.66 11:48:42 ET; total commissions $0.60 today; realized P&L -$0.31 from SGOV mark-vs-cost differential on the 0.3-share sell).

**Decision:**

(1) HCA fill captured. Limit BUY 0.0642 HCA filled 2026-04-28 10:38:51 ET at $433.46 exact-limit (operator placed limit at $433.46 vs staged $433.50 — $0.04/share tighter), commission $0.28, principal $27.83, total cost basis $28.11. Position moved from STAGED subsection to Strategy B open-positions table. Position-thesis-details subsection populated as "[Strategy B] HCA — OPEN 2026-04-28" with full thesis context preserved from staging entry plus fill details + UHS-checkpoint note + Apr 28 ~14:30 MT mark ($431.92 last; $27.73 mark value; -$0.10 unrealized vs cost-basis-excl-comm; -$0.38 vs cost-basis-incl-comm). 60-day time-based exit set at 2026-06-27 (Apr 28 + 60 calendar days; corrects staging-entry off-by-one of 2026-06-26).

(2) Apr 28 SGOV cycle reconciled per Apr 27 methodology. B sold 0.2821 SGOV @ $100.65 (gross $28.40, less $0.28 commission share = $28.12 net) to fund HCA buy; residual $0.01 to B cash. Account-level extra: 0.0179 SGOV "extra" sold (gross $1.80, $0.02 comm share, $1.78 net) + 0.0198 SGOV bought back at $100.66 (cost $2.01) = +0.0019 SGOV at account / -$0.23 cash → reparking. Allocated proportionally across all 5 strategies (~-$0.05 cash / +0.0004 SGOV per strategy). All five strategy portfolio-state lines updated to reflect Apr 28 close. Cumulative SGOV trading commissions to date $1.52 across 6 SGOV transactions.

(3) IBKR "Funds on Hold $2,500.00" anomaly observed in Apr 28 ~14:30 MT snapshot. Not present in any prior session's IBKR snapshots. NLV $6,946 is consistent with experiment scope (started at $6,946.86; per-strategy NAV sum at SGOV-cost-basis ~$6,944.91, at SGOV-mark ~$6,946.97 — both consistent with displayed NLV within rounding). The hold is therefore *within* NLV (not additive). Possible explanations include: (a) pending outgoing ACH/wire withdrawal initiated by operator outside this conversation channel; (b) IBKR margin reserve or settlement-period hold related to T+1 unsettled SGOV or equity transactions (but $2,500 magnitude is materially larger than any flow today — total today's trade volume ~$60); (c) IBKR display artifact / settlement-policy change; (d) good-faith violation reserve or similar. Strategy-level cost-basis ledger math is unaffected (strategy NAVs are tracked from cost-basis ledger entries, not IBKR's hold display).

**Decision on $2,500 hold (deferred per protocol):**
- **Trigger to resolve:** Wed 2026-04-29 morning routine session (or earlier on-demand operator screenshot). At that session, Claude will compare the hold value against fresh IBKR snapshot and check for any operator-communicated capital-state change.
- **Default action on trigger-failure (per protocol):** If the $2,500 hold persists at the next routine session AND operator has not communicated a capital-state change AND no benign explanation is apparent, conservative-branch action is to **pause new trade staging across all strategies** (no GO-rated theses produce staged orders) until the hold is resolved or the operator communicates context. Existing open positions (IBM, RTX, HCA) continue to run per their normal exit rules; no forced exits triggered by hold-status uncertainty alone (forced-exit threshold is per-position invalidation criteria, which the hold does not affect).
- **Non-deferral fallback:** Do not chain a deferral. If next-session check yields no resolution, the conservative action above engages immediately at that session — not at a third deferred check.

**Reasoning:**

For (1)–(2): mechanical state update from screenshot per fill-capture protocol; no novel adjudication.

For (3): the hold magnitude ($2,500 ≈ 36% of NLV) is too large to ignore but too ambiguous to interpret in this session without additional information. Pausing new trade staging (rather than forcing position exits) is the conservative branch that bounds risk without overreacting — open positions are already on their exit rules; halting new exposure prevents capital deployment into a state where the available capital base may be smaller than the strategy NAVs assume. The conservative action does not require any human-operator decision; it is a Claude-side gate that engages automatically at next session if the trigger fails to resolve.

**Theater-check flag:** N/A (no adversarial review this session).

**Downstream actions:**

1. Portfolio_Ledger.md updated this session: Account-Level NLV refreshed; SGOV Parking Activity table extended with Apr 28 transactions; Apr 28 SGOV cycle reconciliation note added; all 5 strategy portfolio-state lines updated to Apr 28 close; HCA moved from STAGED to OPEN in Strategy B (open-positions table + Position-thesis-details subsection); RTX open-position table refreshed with Apr 28 mark ($175.99); IBM/RTX entry-day-close-mark lines preserved as historical; "Staged orders pending execution" section now empty (no orders staged).

2. Decision_Log.md entry (this entry) records the fill-capture and the hold-anomaly deferral.

3. No new calendar events scheduled this session. Existing calendar events that remain live and unchanged: Wed 2026-04-30 THC Q1 print parse (HCA criterion (iii) checkpoint); routine daily session(s); Mon 2026-05-04 weekly position deep-dive; Mon 2026-06-22 HCA invalidation-window-checkpoint (5 days before time-based exit); Sat 2026-06-27 HCA time-based exit. The next routine session will naturally re-encounter the IBKR state and execute the hold-resolution check + conservative-branch fallback if needed.

4. Open-position book at Apr 28 close: IBM (B, entered 2026-04-27, $230.17 cost, $232.77 mark, exit 2026-06-26); RTX (D, entered 2026-04-27, $175.12 cost, $175.99 mark, no time-based exit / Q1'27-earnings reassessment); HCA (B, entered 2026-04-28, $433.46 cost, $431.92 mark, exit 2026-06-27).

**References:**

- IBKR Positions screenshot 2026-04-28 ~14:30 MT (NLV $6,946 / Daily P&L +$1 +0.01% / Funds on Hold $2,500.00 / SGOV 68.1693 / IBM 0.1198 / RTX 0.1595 / HCA 0.0642 / USD Cash $0.63).
- IBKR Trades-Today screenshot 2026-04-28 ~14:30 MT (3 trades: SGOV 0.3 sell @ $100.65 07:30:05 ET comm $0.30 realized P&L -$0.31; HCA 0.0642 buy @ $433.46 limit 10:38:51 ET comm $0.28; SGOV 0.0198 buy @ $100.66 11:48:42 ET comm $0.02).
- Decision_Log 2026-04-27 (early Sun) HCA staging entry — full thesis construction, criterion (iv) test design.
- Decision_Log 2026-04-27 evening UHS-print-parse entry — criterion (iv) clearance evidence and reasoning.
- Decision_Log 2026-04-27 (Sun late) protocol-shift entry — Human Operator Interaction Protocol; chat output discipline; deferred-decision constraints (resolution trigger + conservative default; no chaining).
- Portfolio_Ledger.md (this session's updates capture all (1)–(2) state changes; (3) hold-anomaly flagged in header note and routed via this Decision_Log entry).

**Compaction-survival notes for future Claude:**

(a) **Fill-capture sessions are state updates, not decisions.** This session's protocol-prescribed work is mechanical — parse screenshot, update Portfolio_Ledger, output one-line summary. The Decision_Log entry exists only because of the unexpected $2,500 hold anomaly that requires future-session deliberation. In a clean fill-capture session (no anomaly), no Decision_Log entry is required by protocol.

(b) **Hold-anomaly resolution path.** On next routine session, first action is to compare current Funds-on-Hold value to the $2,500 observed here and check for operator-communicated capital-state change. If hold has cleared (returned to $0): note resolution and proceed normally. If hold persists or has changed magnitude: investigate via IBKR account-activity / transfer history if accessible; otherwise engage the conservative-branch action (pause new trade staging) and surface the context to the operator with a single direct question (acceptable per protocol carve-out: operator may communicate state changes / answer questions; the question pulls a one-time confirmation, not an analytical task).

(c) **Conservative-branch action specifically EXCLUDES forced exits of existing open positions.** The hold-uncertainty does not give a basis for exiting IBM, RTX, or HCA before their per-position invalidation/completion/time-based-exit triggers. Per-position invalidation criteria are tied to thesis-relevant signals, not capital-base uncertainty. Forced exits on hold-uncertainty would conflate two orthogonal risk channels and degrade the strategy-level edge measurement.

(d) **Cost-basis ledger math is the source of truth for strategy NAVs, not IBKR's hold display.** Strategy NAVs are computed from the cost-basis ledger entries (SGOV at weighted cost + open positions at mark + cash). IBKR's NLV is a sanity-check cross-reference at the account level. The $2,500 hold being inside NLV (not additive) means the NLV is consistent with experiment scope; the open question is whether some portion of NLV is on its way out of the account, which would require recomputing strategy NAVs only IF the hold resolves to an outgoing transfer.

(e) **The on-demand-screenshot path also covers hold-resolution.** Per protocol action (3), the operator may initiate a screenshot at any time. If the operator notices the hold is unusual and screenshots IBKR proactively, the Portfolio_Ledger update path Claude uses for calendar-triggered captures naturally surfaces the resolved state. No additional calendar event is required.

(f) **Off-by-one calendar correction on HCA exit.** Staging entry had time-based exit at 2026-06-26 (60 days from "Apr 28" computed incorrectly); finalized at fill to 2026-06-27 (correct Apr 28 + 60 calendar days arithmetic). IBM/RTX exits remain 2026-06-26 (correct Apr 27 + 60 days). Future staging entries should compute time-based exits at staging time using exact arithmetic and re-verify at fill — the fill-capture session is the natural correction point.

(g) **Three open positions across two strategies.** Strategy B holds 2 (IBM, HCA — both Q1 2026 post-event longs); Strategy D holds 1 (RTX — long-horizon structural). No Strategy C, A, or E positions yet. Sector concentration: B Health Care 1/3 (HCA only); B IT 1/3 (IBM only); D Industrials 2.0% (RTX only). Concurrent position count for D: 1/10. Next-trade-size budget per strategy at 2%: A $27.78, B $27.77, C $27.78, D $27.78, E $27.78 per leg.

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — SBUX NO-GO (criterion 4 decisive failure on LONG-extension; criterion 1 status also marginal); no order staged

**Trigger:** B-thesis construction requested for SBUX post-event candidate surfaced in Daily.md 2026-04-29 scan (Q2 FY26 earnings event date 2026-04-28 AMC; AH reaction +5%; Wed Apr 29 regular session intraday range $98.91–$101.43 vs Tue Apr 28 close $97.28). Daily.md scan had labeled SBUX a "highest conviction new candidate" at flagging level; this session applies Strategy B's actual entry criteria, which the daily-scan does not.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA both open in B; IT 1/3, Health Care 1/3 used; Consumer Discretionary 0/3); Decision_Log.md prior precedents — IBM 2026-04-25 GO format, NOW 2026-04-25 NO-GO format on negative-direction move, HCA 2026-04-27 GO with explicit lower-conviction posture, CHTR 2026-04-27 NO-GO on cross-sectional information confirmation, **INTC 2026-04-27 NO-GO on positive-direction move (canonical precedent for the L1 information-pricing logic applied below)**; SBUX Q2 FY26 8-K Ex-99.1 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0000829224/000082922426000078/sbux-03292026xearningsrele.htm); SBUX Q2 FY26 earnings call transcript (Motley Fool / Yahoo); Benzinga SBUX analyst-ratings page; CNBC SBUX Q2 2026 earnings page; StockInvest pre-event price history; TrendSpider trailing-30-day return data; TipRanks options-implied move data.

### Decision

**SBUX — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing not seriously considered (move magnitude does not support an "overshoot" thesis on the data available).**

Failed Strategy B entry criterion 4 (adversarial counter-argument identifies a decisive flaw — specifically, the market reaction is information-driven rather than sentiment-driven, which makes "mispricing" actually correct pricing per criterion 4's explicit framing). Criterion 1 status is also marginal at scan time (Wed regular-session-close pending; intraday high +4.27% has not yet crossed the +5% threshold). Either ground supports NO-GO independently; criterion 4 is the binding decisive flaw and is direction-symmetric against any framing of the +5% reaction as mispricing.

### Mechanical eligibility (criteria 1, 5, instrument rule) — partial clearance with criterion 1 marginal

- **Instrument rule cleared with material cushion:** US-listed common (NASDAQ); market cap ~$110–114B (>55× $2B floor); 30-day ADV ~$840M (>84× $10M floor); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 5 cleared:** No A position open in SBUX (A router DO-NOT-ACTIVATE; no SBUX A entry).
- **Criterion 1 status marginal at scan time.** Event date 2026-04-28 AMC = Day 0 of 10-day window. Pre-event reference price = Tue Apr 28 regular-session close $97.28 (the stock was −0.62% Tue going into the print, third consecutive down-day, on no specific bad news — typical pre-earnings drift). Post-event measurement = Wed Apr 29 close (TBD at scan time). Wed AH on Tuesday was reportedly +5%; Wed regular session opened at $99.04 (+1.81%) and traded an intraday range of $98.91–$101.43 (low −1.49%, high **+4.27%**) through the scan time. To clear the ≥5% close-to-close threshold, Wed close must be ≥ $102.14; intraday high $101.43 is $0.71 / 0.71% short of that. TipRanks options-implied move was 6.94%; realized move so far is materially compressed below implied. **Criterion 1 may not clear at Wed close.** This is a separate ground for NO-GO independent of criterion 4; not waited on because criterion 4 fails decisively without dependence on the close.
- **Criterion 2 / 3 not formally constructed** because criterion 4 fails before getting there.

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q2 FY26 print delivered "first time in over 2 years both top and bottom line growth" (CEO Niccol's framing); revenue $9.5B (+9% YoY) vs $9.16B est = +4% beat; non-GAAP EPS $0.50 (+22% YoY) vs $0.43 est = +16% beat; global comps +6.2% vs StreetAccount +4% = +220 bps beat (US comps +7.1% vs ~+4% = +300 bps beat); operating margin +110 bps to 9.4%; all top-10 international markets positive comps for first time in 9 quarters; April-month-to-date positive trends continue per management commentary; raised FY26 guide on global/US comps (≥3% → ≥5%) and non-GAAP EPS ($2.15–$2.40 → $2.25–$2.45). The provisional LONG thesis would argue: a +5% AH reaction (or even Wed's +1.8% to +4.3% intraday) UNDER-priced the magnitude of the turnaround validation given the specific "first time in 2 years" milestone and the cross-segment breadth of strength (US, Intl all-positive). Convergence target candidates: numerical level $105 (+6.5% from $99 mid-Wed; near pre-print Stifel PT $115 territory) or $107 (post-print sell-side average per Benzinga 3-most-recent), within 60 days.

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails — sell-side immediately ratified the print at small post-print PT moves consistent with information already priced into the trailing rally.** Pre-print sell-side actions in the trailing 2 weeks were SBUX-specific and broadly positive: Jefferies upgraded Underperform → Hold, PT $86 → $92 (Apr 13); Citi maintained Neutral, PT $92 → $99 (+7.6%, Apr 14); Tigress maintained Buy but **CUT** PT $136 → $122 (Apr 15); Stifel maintained Buy, PT $105 → $115 (+9.5%, Apr 21); JPM maintained OW, PT $95 → $100 (+5.3%, Apr 24). This pattern is the smoking-gun evidence of pre-print pricing-in: multiple analysts independently raised PTs into the print, the market saw those PT raises and bid the stock up over the trailing 30 days (+18.75% per TrendSpider), and the +5% AH reaction is consistent with the print landing approximately as the raised PTs anticipated. Post-print sell-side actions confirm the information-pricing characterization with mild moves: Guggenheim raised PT $95 → $97 (+$2, +2.1% — barely above pre-print level), RBC Capital maintained Sector Perform with PT $110, Evercore ISI rated Apr 29 with the 3-most-recent average at $107.33 vs pre-print $104.04 consensus (post-print consensus delta ~+3.2%, which is approximately the realized intraday move). Per criterion 4's information-vs-sentiment framing applied symmetrically (parallel to INTC 2026-04-27 NO-GO L1 logic): "information-driven reaction means the price correctly absorbs the new fundamentals, so the LONG thesis (claiming the +5% reaction UNDER-priced the information) lacks the sentiment-suppression evidence it would need to clear." There is no analogue here to IBM's GO-supporting external suppression evidence (IGV −5.83% same-night sector contagion with peers each off 6–9% on no idiosyncratic news). The Tue Apr 28 −0.62% drift into the print on no specific bad news is normal pre-earnings nervousness, not a sentiment-driven suppression of the reaction. Decisive.

(L2) **Trailing-30-day +18.75% momentum invokes 2.14 recency-bias deferral discipline (parallel to INTC NO-GO L2 logic).** Strategy A criterion 6 and Strategy D criterion 6 contain identical trailing-30-day-rally deferral text; Strategy B's numbered criteria do not include literal momentum-deferral text. Per AI_Trading_Foundation Part 2, 2.14 is structural across all strategies; applying asymmetric leniency to B on a literal-text basis would be the 2.4-self-referencing escape that pre-mortem rev 7 Constraint 1 names. Symmetric application: SBUX +18.75% trailing-30-day at the time of print is a "rallying hard" name; the 2.14 discipline says defer entry until rally pauses to avoid buying at recency-bias-fueled peaks. The sell-side PT raises into the print are part of the same recency-bias loop (analysts raising PTs as the stock rallies, the stock rallying further on the raised PTs). Note: SBUX trailing-30-day +18.75% is materially less extreme than INTC's +100%, but is well above the "rally pause" threshold and the LOGIC applies symmetrically.

(L3) **Convergence-target arithmetic is constrained by the proximity to the consensus 12-month PT.** Wed AM open was $99.04; Yahoo's reported 1-year-target-estimate is $100.38 — i.e., the stock is already trading approximately at the 1-year consensus PT. Post-print 3-most-recent average $107.33 implies only 1.82% upside from current. The Benzinga consensus after the recent moves is $104.04, with high $122 / low $90 — a tight band. A LONG convergence target of $105 or $107 within 60 days is "borrowing" from the 12-month PT distribution; the sell-side has already largely written that target into its 12-month bands, leaving only modest cushion for a 60-day mean-reversion-style return. This is the structural compression that B's strategy mechanism is least suited to: B's edge is identifying mispricing-relative-to-information, not riding-momentum-toward-consensus-PT.

(L4) **No external suppression evidence; no peer cross-section confirming undershoot.** IBM's GO leaned heavily on IGV −5.83% / sector-peer −6–9% on no-idiosyncratic-news as evidence that IBM's drop was a sector-beta artifact, not company-specific repricing. SBUX has no analogous undershoot artifact. XLY (Consumer Discretionary) ETF Apr 28 closed at standard range; the closest restaurant peers (Chipotle, Domino's) had idiosyncratic moves (CMG up ~3% earlier in April; DPZ −10.5% on Apr 27 miss) that are not directionally consistent with a "market mispricing the restaurant sector down" pattern that would suppress SBUX's print reaction. The +5% reaction stands on its own as the print's information content at face value.

LONG declined. Criterion 4 information-vs-sentiment test not met (L1 decisive); criterion 2 narrative synthesis weakened by L2–L4.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +5% reaction to a clean beat-and-raise is the textbook normal response and could be argued as fade-able toward $97–$98 (back to Tue close) over 60 days. Convergence target candidates: numerical level $97.28 (full retrace, ~−2.7% from $100 mid-Wed) or $94 (~−6%, retrace of part of trailing-30-day rally).

**Why dismissed without full adversarial construction:** A +5% reaction is squarely within the implied 6.94% pre-print options move; the realized AH reaction is BELOW the pre-print implied. By any reasonable definition, +5% on a +16% EPS beat / +220bps comp beat / raised FY guide is not an OVERSHOOT — there is no signal that the market over-reacted. Arguing OVERSHOOT requires evidence the +5% is "too large" relative to the information; the data shows +5% is approximately fair (in the middle of the implied band, supported by a sell-side consensus that raised PTs into and slightly after the print). The same criterion 4 information-vs-sentiment test fails for SHORT for the symmetric reason it fails for LONG — sell-side immediate ratification supports "the price is correct," contradicting both UNDER-priced (LONG) and OVER-priced (SHORT) framings.

SHORT declined.

### 2.20 (textbook-rational penalty) and 2.13 (miscalibration) cross-checks

Per Strategy B pre-mortem rev 7 / 2.20: B is structurally exposed to the textbook-rational penalty because the strategy's mechanism is precisely the textbook-rational instinct that prices return to fundamental value. SBUX LONG is NOT a classical 2.20 trap (LONG-extension is closer to 2.13 + 2.4 territory per the INTC NO-GO (e) note); SBUX SHORT WOULD be a classical 2.20 trap if executed (shorting a beat-and-raise with sell-side ratification is the canonical textbook-rational error). Both directional framings fail criterion 4 for direction-specific reasons that route through the same information-pricing baseline. Per 2.13's 80% CI containing outcomes ~69% of the time, conviction-tier-weighted overconfidence is a binding consideration on a positive-direction LONG framing where the sell-side has already raised PTs into the print and the stock is at ~85th percentile of its 52-week range.

### China JV / FY26 revenue-flat caveat

One specific item from the print warrants documenting for thesis-construction provenance even though it doesn't change the criterion 4 disposition. The new FY26 outlook line "Consolidated net revenues roughly flat year over year" reflects the China retail-operations held-for-sale classification (China JV with Boyu Capital, ~$3.1B gross proceeds reported) — i.e., the revenue line is being mechanically reduced by the China deconsolidation, not by underlying business deterioration. The non-GAAP EPS guide raise to $2.25–$2.45 is the bottom-line metric that captures the underlying operating improvement. Sell-side handling of this asymmetry (revenue flat / EPS up) is one reason the post-print sell-side response was muted-positive rather than aggressive-positive — the topline-rev-flat optic offsets some of the EPS-strength enthusiasm and pulls the headline reaction toward +5% rather than something larger. This is internally consistent with the L1 information-pricing characterization and reinforces, rather than undercuts, the criterion 4 NO-GO.

### Sector concentration check (for completeness; not cap-binding)

SBUX = GICS Consumer Discretionary / Hotels Restaurants & Leisure / Restaurants. Strategy B currently holds IBM (IT) and HCA (Health Care). Adding SBUX would put Consumer Discretionary at 1/3 — well within the 3-per-sector cap. Cap is not the binding constraint; criterion 4 is.

### Effect on book

No effect. No order staged for SBUX. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3, Health Care 1/3, others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~SBUX B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (information-driven repricing supported by pre-print sell-side PT raises + small post-print PT moves + trailing-30-day +18.75% recency-bias-priced rally + no external suppression evidence). No order staged.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook; calendar event already scheduled; **THIS IS THE BINDING TEST IN THE NEXT 24 HOURS for the HCA position**.
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at this session's scan time. Routine daily session (next scheduled run) will capture the outcome.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META, AMZN) — GOOGL is a Strategy D long-list reconsideration trigger; routine daily scan tomorrow will parse.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow will parse.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session for screenshot-based check; conservative-branch action (pause new staging) engages at trigger-failure. **This NO-GO does not interact with the hold-anomaly deferral** — there is no order to stage either way, so the conservative-branch action's "pause new staging" rule is non-binding here.
- Other Strategy B watchlist names with windows still open: MBLY (~May 6), TXN (~May 5), URI (~May 5), SMCI (~May 6), HAS (~May 6), CAR (~May 5), QS (~May 5), CALX (~May 5), BLD (~May 4), AXTI, DPZ (~May 7), OGN (~May 7), MRVL (~May 7), V (~May 5 — added by Daily.md 2026-04-29), NXPI (~May 5 — added), STX (~May 5 — added), MDLZ (~May 5 — promoted), OMCL (~May 5 — pending mkt-cap verification). None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure / KL #4 slow-burn-behavioral-regime).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; no change from this session for SBUX).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; IGV −5.83% sector contagion = the canonical external suppression evidence that SBUX lacks; same-name Q1 2024 historical analogue reverted within 60 days).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 (early Sun) HCA entry (GO with explicit lower-conviction posture precedent; medium-low ~45-50% conviction with all criteria cleared canonical-handling pattern).
- Decision_Log.md 2026-04-27 (Sun follow-on) CHTR entry (NO-GO format precedent; cross-sectional information confirmation via CMCSA divergence — symmetry-of-treatment basis).
- **Decision_Log.md 2026-04-27 (Mon, post-close) INTC entry (NO-GO format precedent; positive-direction move with sell-side immediate ratification = canonical L1 information-pricing logic that this SBUX entry applies).**
- SBUX Q2 FY26 8-K Ex-99.1 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0000829224/000082922426000078/sbux-03292026xearningsrele.htm).
- SBUX Q2 FY26 earnings call transcript (Motley Fool 2026-04-28; Yahoo Finance 2026-04-29).
- CNBC SBUX Q2 2026 earnings page (https://www.cnbc.com/2026/04/28/starbucks-sbux-q2-2026-earnings.html).
- Benzinga SBUX analyst-ratings page (pre-print PT actions + post-print 3-most-recent: RBC Apr 29 PT $110 Sector Perform; Guggenheim Apr 29 PT $95 → $97; Evercore ISI Apr 29).
- StockInvest SBUX history (Tue Apr 28 close $97.28, −0.62%, third down-day in a row, intraday $96.45–$98.68).
- TrendSpider SBUX trailing-30-day +18.75% / 52-week range $75.50–$104.82.
- TipRanks options-implied-move data (6.94% implied; 1.92% trailing-4Q average post-earnings move).

### Theater-check on this orchestrator review

Considered whether to push back toward GO given the genuinely strong Q2 print magnitudes (+22% EPS, +6.2% global comp, raised guide on multiple metrics, "first time in 2 years" milestone). Counter-argument: criterion 4 is "adversarial counter-argument doesn't identify a decisive flaw," not "the print isn't strong." The print IS strong, and that strength is exactly what the trailing-30-day +18.75% rally and the multiple pre-print PT raises (Stifel +$10, JPM +$5, Citi +$7) priced in. Strong-but-priced-in is the textbook information-driven event; criterion 4 names this as the case where mispricing is actually correct pricing. Pushing back toward GO would be exactly the 2.20 / textbook-rational penalty that pre-mortem rev 7 KL #1 names — "B's mechanism IS the textbook-rational instinct." This NO-GO is the framework working as designed.

Considered whether the SBUX "first time in 2 years" milestone narrative deserves separate weight as a "narrative-shift" event distinct from a routine beat-and-raise. Counter-argument: per pre-mortem rev 7 Constraint 1, narrative-quality assessment (deciding whether THIS narrative-shift is "different from a routine beat-and-raise") is itself the 2.4-self-referenced model judgment that biases the synthesis. The L1 information-pricing test is the external check; it does not depend on Claude's narrative-shift assessment. The +5% reaction in the middle of the 6.94% implied band is the empirical fact; arguing the reaction "should have been larger" because the narrative is special is the kind of narrative-over-fit that B's pre-mortem identifies as the dominant failure mode.

Considered whether the criterion 1 marginality (+4.27% intraday high vs +5% threshold) should be the primary NO-GO ground rather than criterion 4. Counter-argument: criterion 4 is structurally decisive and direction-symmetric, so the NO-GO holds regardless of whether Wed close lands at +4.5% or +5.5%. Treating criterion 1 as the primary ground would invite a re-evaluation if Wed close happens to clear +5% at a late-session push, which would be 2.4-self-referenced gate-shopping. Criterion 4 as primary ground is the right framing; criterion 1 marginality is documented as compounding context.

Considered whether the symmetric INTC application is over-fitting (forcing pattern-match because the structural shape is convenient — "two consecutive positive-direction NO-GOs in a row"). Counter-argument: the L1 information-pricing logic is independently grounded in criterion 4 — it does not require INTC as precedent to operate. INTC provides the templated reasoning shape; SBUX-specific evidence (pre-print PT raises, post-print mild PT moves, trailing-30-day +18.75%, no external suppression artifact) supplies the L1 conclusion on its own terms. The INTC precedent is confirmation, not generation, of the logic.

Modulo these four considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT without serious construction).

### Compaction-survival note

**Strategy B SBUX thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** SBUX-thesis-construction COMPLETE; SBUX-NO-GO declined on criterion 4 (information-driven pricing supported by pre-print sell-side PT raises + small post-print PT moves + trailing-30-day +18.75% momentum + no external suppression artifact); criterion 1 marginal as compounding context. No order staged; no Portfolio_Ledger.md modification this session. SBUX remains a closed name from a Strategy B perspective unless and until a future event materially changes the information-driven characterization (e.g., a meaningful sell-side downgrade reversing the pre-print PT-raise consensus, or a follow-on negative business development that creates fresh asymmetry). The 10-day post-event entry window expires ~2026-05-12; no calendar event scheduled to revisit because (a) the criterion 4 information-vs-sentiment characterization is unlikely to flip from re-examining the same data, and (b) the routine Daily.md daily scan will surface any new catalyst that would create a fresh setup. Strategy B sector concentration in Consumer Discretionary remains at 0/3 cap usage.

**Pre-mortem 2.20 / textbook-rational-penalty calibration:** This NO-GO is the third NO-GO of the experiment to date on criterion 4 grounds (NOW 2026-04-25 negative-direction; CHTR 2026-04-27 negative-direction with cross-sectional information confirmation; INTC 2026-04-27 positive-direction; SBUX 2026-04-29 positive-direction = the fourth criterion-4 NO-GO). Five Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO = 2 GO / 4 NO-GO (33%/67%). Four of four NO-GOs route through criterion 4 information-vs-sentiment test. This is consistent with B's structural exposure to 2.20 (per pre-mortem rev 7 KL #1 — "B's mechanism IS the textbook-rational instinct") and with the broader observation that the post-event-screen funnel surfaces more information-driven-repricing setups than sentiment-overshoot setups in the current regime. If the criterion-4-NO-GO rate persists across the first 10 thesis constructions, it is informative for the 30-trade-gate review on whether the screen funnel is over-feeding the wrong setup type — but NOT a same-day adjustment. The post-print sell-side ratification pattern (PT raises into the print, mild moves after) is a recurring smoking-gun for the L1 logic and should be explicitly probed in future B thesis-construction sessions before reaching criterion 4.

**Lesson for future Daily.md scans:** "Highest conviction new candidate" labels in the daily scan are forward-flagging-level, not thesis-construction-level. The daily scan does not apply criterion 4's information-vs-sentiment test; the scan's conviction labels reflect "strong fundamental print + clear sector relevance + sufficient mkt-cap/ADV" rather than "evidence of mispricing." Future daily-scan recommendations should be read as "merits thesis construction" rather than "merits a GO," with thesis construction being the binding gate. This SBUX outcome is a clean example of a daily-scan flag that does not survive thesis construction — and the framework is operating as designed when thesis construction declines a daily-scan flag.

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — V (Visa) NO-GO (criterion 4 decisive failure on LONG-extension; regulatory-overhang persistence as the binding information-driven characterization); no order staged

**Trigger:** B-thesis construction requested for V (Visa) post-event candidate surfaced in Daily.md 2026-04-29 scan (Q2 FY26 earnings event date 2026-04-28 AMC; pre-event Tue Apr 28 close $309.30 approximately flat from Mon close $309.65; post-print Tue AH +0.37%; Wed Apr 29 premarket $325.39 = +5.20% from Tue close per Benzinga; Wed regular session per Bloomberg "biggest single-day jump in 4 years"). Daily.md scan had labeled V a Strategy B candidate based on "+6–8% breakaway with $20B buyback" framing; this session applies Strategy B's actual entry criteria.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA both open in B; IT 1/3, Health Care 1/3 used; Financials 0/3); Decision_Log.md prior precedents — IBM 2026-04-25 GO (clean undershoot with external suppression evidence), NOW 2026-04-25 NO-GO (negative-direction criterion 4), HCA 2026-04-27 GO (lower-conviction with peer-corroboration potential), CHTR 2026-04-27 NO-GO (cross-sectional information confirmation), INTC 2026-04-27 NO-GO (positive-direction L1 sell-side immediate ratification), **SBUX 2026-04-29 NO-GO (positive-direction L1 with pre-print PT raises priced into momentum — most directly comparable precedent for "positive-direction post-event criterion 4 fail" pattern, but with V manifesting a DIFFERENT sub-pattern detailed below)**; V Q2 FY26 8-K Ex-99.1 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0001403161/000140316126000077/q22026earningsrelease.htm); V Q2 FY26 earnings call transcript (Insider Monkey / AOL / Investing.com); Bloomberg Q2 print coverage ("Visa Profit Beats, Revenue Posts Biggest Increase Since 2022; shares jumped the most in four years"); Benzinga V analyst-ratings page (pre-print + post-print PT actions); CNBC V quote page (Tue Apr 28 close $309.30, 52-wk high $375.51 06/11/25, 52-wk low $293.89 04/01/26); Investing.com V history; QuiverQuant V insider-activity data; TipRanks consensus PT data; EBC pre-print preview (regulatory CCCA framing, YTD -11–12% pre-print); 247WallSt sector context (V/MA/AXP all -double-digits YTD); Trefis MA pre-print (MA reports Thu Apr 30 BMO — relevant peer print).

### Decision

**V — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing briefly considered and dismissed (canonical 2.20 textbook-rational trap on a beat-and-raise + record buyback with "cleanest quarter in years" framing).**

Failed Strategy B entry criterion 4 (adversarial counter-argument identifies a decisive flaw — the post-event reaction is information-driven against the unresolved structural regulatory overhang that drove the pre-print discount, not sentiment-suppressed undershoot). Criterion 1 mechanically clears at +5–8%; criterion 4 is the binding constraint.

### Mechanical eligibility (criteria 1, 5, instrument rule) — all clear

- **Instrument rule cleared with material cushion:** US-listed common (NYSE); market cap ~$590–597B (>295× $2B floor); 30-day ADV vastly above $10M floor; long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 5 cleared:** No A position open in V (A router DO-NOT-ACTIVATE; no V A entry).
- **Criterion 1 clears.** Event-day measurement per IBM precedent: pre-event close = Tue Apr 28 regular-session close $309.30 (regular session was approximately flat from Mon close $309.65, no significant pre-print rally — the $322.97 figure visible on some Yahoo / StockAnalysis stat blocks is the Wed Apr 29 4:46 AM EDT premarket reading, not Tue close); post-event close = Wed Apr 29 close (TBD at scan time; Wed premarket was $325.39 = +5.20% from Tue close per Benzinga ~8 hours pre-scan; Wed regular session per Bloomberg "biggest single-day jump in 4 years" framing implies a substantial regular-session continuation). Estimated Wed close: $325–340 area = **+5–8% from Tue close**, clearing the ≥5% threshold cleanly. (Even the conservative reading at the $325.39 premarket level is +5.20%, comfortably above threshold.)

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q2 FY26 print delivered "one of the cleanest quarters in years" per Bloomberg's analyst-sourced framing: net revenue $11.23B (+17% YoY) vs $10.75–10.96B est = +2.5–4.5% beat (the fastest revenue growth since 2022; ex-Visa-Europe-acquisition + ex-pandemic-rebound, the fastest since 2013); GAAP EPS $3.14 (+36% YoY); non-GAAP EPS $3.31 (+20% YoY) vs $3.10 est = +6.8% beat; payments volume $3.7T (+9% cc); processed transactions 66B (+9%); cross-border volume +12% total / +11% ex-intra-Europe (cc); Value-Added Services revenue $3.3B (+27% cc); Visa Direct transactions +23%; Commercial and Money Movement Solutions +24% cc; operating expenses **declined** YoY ($4B vs $4.16B prior year); Q2 alone executed $7.9B share buyback (record, avg price $320.66) plus dividends $1.3B = $9.2B Q2 capital return; **new $20B multi-year share repurchase authorization** (~3.4% of mkt cap) on top of $13B remaining = $33B total buyback capacity; **raised FY26 guide on revenue (high-single-digit-to-low-double-digit → low-double-digit-to-low-teens) AND adj. EPS (mid-to-high-single-digits → low-teens)**; Q3 guide net revenue low-double-digits, EPS mid-to-high-single-digits. Pre-event V was -11–12% YTD on regulatory overhang (CCCA debate, $200B interchange settlement litigation, stablecoin-displacement narrative), trading near 52-week low ($293.89 04/01/26). The provisional LONG thesis would argue: the post-print +5–8% reaction UNDER-prices the magnitude of the operational/capital-return information given the depressed pre-print starting point — i.e., regulatory-pessimism-overdone and the print is the fundamental anchor for re-rating. Convergence target candidates: numerical level $345 (+6.1% from Wed estimated mid-day $325; ~50% gap-fill from Tue close $309.30 toward consensus 1-yr PT $392) or $360 (+10.8%; ~70% gap-fill toward $392 PT).

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails — pre-print sell-side PT pattern is structurally distinct from a sentiment-suppressed setup.** Pre-print sell-side actions in the trailing 30–45 days were a clean SEQUENCE OF CUTS, not the IBM-style sector-contagion suppression event: Citi maintained Buy but **CUT** PT $450 → $400 (Apr 14, −11%); UBS maintained Buy but **CUT** PT $425 → $390 (Mar 31, −8%); Truist maintained Buy but **CUT** PT $372 → $361 (Apr 24, −3%); BMO Capital initiated Outperform with PT $365 (Apr 22 — initiating LOW, near the bottom of the prior range); Loop Capital initiated Buy at $387 (Mar 31 — near the bottom). The cuts and low initiations reflect sell-side recognizing the structural regulatory/legislative overhang on the V franchise: CCCA debate (legislative process spanning multiple congressional cycles), $200B interchange settlement litigation (multi-quarter court process), stablecoin/crypto-rail competition (multi-year displacement risk), and the active DOJ debit-rails antitrust lawsuit (ongoing 2024-vintage, cited in TradingKey Apr 29 risk piece). These are PERSISTENT STRUCTURAL CONCERNS that operate on multi-quarter resolution timelines, not transient sentiment events. Per criterion 4's information-vs-sentiment framing applied symmetrically: "if the realized reaction is information-driven, mispricing is actually correct pricing." V's +5–8% reaction adequately prices the operational-beat + buyback information content WHILE leaving the persistent regulatory-overhang component unchanged — i.e., the reaction reflects the print delivering positive fundamentals against an unchanged structural backdrop. **Distinguishing from IBM precedent:** IBM's GO leaned on a same-night, transient external suppression event (NOW print + IGV −5.83% sector cascade with peers Salesforce/HubSpot/Adobe/Workday/Intuit/Oracle each off 6–9% on no idiosyncratic news) — a 60-day-mean-reversion-eligible signal. V has no analogous transient external event; it has a multi-quarter regulatory/legal overhang that the Q2 print does not address. The IBM-style criterion 4 clearance does not transfer. Decisive.

(L2) **Post-print sell-side response is mild — consistent with information-driven characterization, NOT undershoot.** TipRanks Apr 29 post-print snapshot shows consensus PT $396.23 (high $450 / low $310; 22 analysts in last 3 months including pre-print observations). Marketbeat Apr 29 shows current PT $388.25. StockAnalysis pre-print (Apr 28) showed $392.27 average. The post-print consensus is approximately FLAT to SLIGHTLY DOWN versus pre-print. For a print that Bloomberg framed as "one of the cleanest in years" with the biggest single-day jump in four years on the stock side, an approximately-flat post-print consensus PT is the smoking-gun indicator that sell-side is treating this as a "ratifying-our-existing-views" event rather than a "new-revelation-warrants-PT-hike" event. Parallel to SBUX 2026-04-29 NO-GO L1 (Guggenheim $95 → $97, only $2 PT raise post-print), V's post-print sell-side mildness confirms information-driven pricing of the print's content against the unchanged structural overhang.

(L3) **Cross-name peer-comparable evidence: MA Q4 2025 (most recent direct peer print) reacted only +3.34% on a clean +12.8% EPS beat (Investing.com).** Mastercard's prior quarterly print (Jan 29, 2026, Q4'25) was a structurally similar setup — clean operational beat, full-network-economics franchise, identical regulatory overhang framework — and the realized reaction was +3.34%. V's +5–8% reaction is LARGER than the most-recent comparable peer's reaction on a similar setup. Cross-name evidence directionally argues V's reaction is APPROPRIATELY SIZED relative to peer's, not undershooting. Even a "magnitude-corrected" comparison (V's beat was larger in % terms — revenue +4.5% vs MA's near-zero revenue surprise; EPS beat similar at +6.8% vs MA +12.8%) leaves room to argue V's response should be slightly larger than MA's, which is what +5–8% vs +3.34% delivers. This is symmetry-of-treatment with the CHTR 2026-04-27 NO-GO logic (CMCSA cross-sectional divergence supported information-driven repricing of CHTR; here MA cross-sectional comparable supports information-driven appropriate-pricing of V).

(L4) **Strategy B 60-day window is mismatched with multi-quarter regulatory resolution timelines — a strategy-mechanism mismatch.** The LONG thesis fundamentally depends on regulatory-overhang-being-overdone narrative being validated within 60 days. CCCA legislative process spans multiple congressional sessions (no near-term forced resolution); the $200B interchange settlement litigation is in active court motion practice (multi-quarter); stablecoin competitive displacement is a multi-year secular trend. None of these structural concerns will resolve within Strategy B's 60-day post-event window. The convergence-target arithmetic ($345 ≈ +6%, $360 ≈ +11%) requires the market to materially re-rate the regulatory discount within 60 days on no identifiable resolution catalyst — implausible. Per pre-mortem rev 7 KL note, V's regulatory-pessimism-overdone thesis is structurally more aligned with **Strategy D long-horizon narrative** (multi-year structural tail-risk reassessment) than with Strategy B's post-event-mispricing mechanism. Trying to shoehorn a multi-quarter-regulatory-resolution thesis into B's 60-day window is the kind of strategy-mechanism mismatch that the pre-mortem identifies as a 2.4-self-referenced gate-shopping pattern.

(L5) **Insider selling pattern compounds the LONG-side thesis weakness.** Per Quiver Apr 28: 10 insider open-market trades in the past 6 months, ALL sells (0 buys). CEO Ryan McInerney: 0 buys, 3 sales of 31,455 shares for ~$10.8M. President Technology Rajat Taneja: 0 buys, 2 sales of 30,048 shares for ~$9.9M. Chief Risk & Client Services Officer Paul D. Fabara: 0 buys, 2 sales of 9,728 shares for ~$3.2M. General Counsel: 0 buys, 1 sale. Director Lloyd Carney: 0 buys, 2 sales. While insider selling at large-cap incumbents is largely 10b5-1 driven and not strongly predictive in isolation, the unanimous selling pattern (0 buys across the entire NEO + Director cohort) does not corroborate an internal view that the stock is sentiment-suppressed below fundamental value. If V management/insiders believed the regulatory pessimism was materially overdone vs the franchise's structural strength, opportunistic accumulation (or at minimum suspended selling) would be an expected signal; the pattern instead is consistent with insider neutrality on the regulatory-overhang valuation level.

LONG declined. Criterion 4 information-vs-sentiment test not met (L1 decisive on the multi-quarter-regulatory-overhang-vs-60-day-window framing); L2 confirms via post-print sell-side mildness; L3 confirms via cross-name peer-comparable evidence; L4 is the strategy-mechanism mismatch compound; L5 is the insider-pattern compound.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +5–8% on a beat-and-raise might fade toward $315–320 over 60 days as the regulatory overhang re-asserts pricing dominance and the print's incremental contribution gets discounted.

**Why dismissed without full adversarial construction:** Shorting a beat-and-raise + record-buyback + raised-guide print framed by sell-side as "one of the cleanest quarters in years" with a $20B new share repurchase authorization is the textbook 2.20 trap. Per Strategy B pre-mortem rev 7 / 2.20: B's mechanism IS the textbook-rational instinct that prices return to fundamental value applied after an overreaction. SHORT on V here would be exactly the "fade strong fundamentals because the move felt big" 2.20 error pattern. The +5–8% reaction is appropriately sized given peer-comparable MA +3.34% on similar setup; arguing OVERSHOOT requires the +5–8% to be "too generous" relative to information, but the print's information content (record revenue growth since 2022, $20B new buyback ≈ 3.4% of mkt cap, raised guide on multiple metrics) supports a +5–8% magnitude. SHORT criterion 4 fails by the same information-vs-sentiment logic that fails LONG, but flipped: if the reaction is information-driven, neither LONG nor SHORT mispricing exists.

SHORT declined.

### 2.13 / 2.14 / 2.20 cross-checks

- **2.20 (textbook-rational penalty)** — V SHORT is a clean 2.20 trap (fade-the-strong-print-with-buyback-on-overhang); declined above. V LONG is closer to 2.13 + 2.4 territory (overconfidence on regulatory-pessimism-being-overdone narrative + narrative-over-fit on the "cleanest quarter in years" framing as supporting undershoot).
- **2.13 (miscalibration)** — A LONG conviction call on V depends on assigning meaningful probability to "regulatory overhang resolves favorably within 60 days" (CCCA stalls, interchange settlement lands minimally adverse, stablecoin threat fades). 2.13's hard-wired 80% CI containing outcomes ~69% of the time penalizes overconfident probability assignments on multi-factor structural questions; the resulting effective probability after 2.13-discount is materially below thesis-supporting threshold.
- **2.14 (recency bias on input data)** — V's trailing-30-day momentum is approximately flat (stock consolidating near YTD lows post-PT-cuts), which CUTS AGAINST the 2.14-defer-on-rallying-name discipline that fired against SBUX (+18.75% trailing-30-day). For V, 2.14 is not a compounding factor in the same way; the stock has not rallied into the print. This is one ground on which V is structurally distinct from SBUX (and somewhat closer to IBM's pattern of stock-weak-into-the-print) — but the criterion 4 distinction (transient external suppression for IBM vs persistent structural overhang for V) is what tips V to NO-GO despite the trailing-30-day pattern being more favorable than SBUX's.

### Mastercard (MA) Thu Apr 30 BMO peer-print consideration

MA reports Q1 2026 Thu Apr 30 BMO (consensus $4.40 EPS / $8.29B revenue per Zacks; MA YTD also -10.1% on identical regulatory framework). MA is V's closest direct peer (same network-economics franchise, same regulatory exposure, same secular tailwinds). Possible peer-corroboration analogue to UHS/THC checkpoints in the HCA thesis. **Why MA print is NOT a deferral trigger for the V decision:** (a) MA's print provides operational confirm/disconfirm only — it cannot resolve the regulatory-overhang question that drives V's criterion 4 issue (regulatory exposure applies to both V and MA equivalently, so MA's print is silent on whether the structural overhang is overdone). (b) The criterion 4 NO-GO is grounded in the regulatory-overhang-persistence framing, which MA's print cannot affect. (c) Per protocol, deferral requires a trigger that resolves the decision; MA's print does not satisfy that bar for V's specific criterion 4 issue. (d) Even if MA prints strong with raised guide, that confirms operational sector strength — but that's already established by V's own print; the marginal information from MA on V's thesis is small. **Decision is made now without deferral.** If MA prints meaningfully strong + raised guide AND V's stock does not respond proportionally (further compressing the post-print reaction below information content), that could be a fresh signal worth re-evaluating in a future session — but that would be a fresh thesis-construction at that time, not a deferral resolution from this session. The current NO-GO stands on the evidence available now.

### Sector concentration check (for completeness; not cap-binding)

V = GICS Financials / Financial Services / Transaction & Payment Processing Services (per S&P GICS reclassification effective March 2023, V was moved from Information Technology to Financials along with MA). Strategy B currently holds IBM (IT) and HCA (Health Care). Adding V would put Financials at 1/3 — well within the 3-per-sector cap. Cap is not the binding constraint; criterion 4 is.

### Effect on book

No effect. No order staged for V. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3, Health Care 1/3, Financials 0/3, others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~V (Visa) B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (regulatory-overhang-persistence as the binding information-driven characterization; pre-print sell-side PT cuts on regulatory concerns + post-print mild sell-side response + cross-name peer-comparable MA Q4 reaction + strategy-mechanism mismatch on 60-day-vs-multi-quarter regulatory resolution + insider selling pattern). No order staged.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook; calendar event already scheduled; binding test for HCA position.
- MA Thu 2026-04-30 BMO print — peer to V; not a V-deferral trigger but informational; routine Daily.md scan tomorrow will parse and surface any fresh setup signals (V re-evaluation only if MA print + V follow-on creates materially different evidence than today's evidence base).
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at this session's scan time.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META, AMZN) — relevant for daily scan tomorrow.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow will parse.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session for screenshot-based check; conservative-branch action (pause new staging) would engage at trigger-failure. **This NO-GO does not interact with the hold-anomaly deferral** — there is no order to stage either way.
- Other Strategy B watchlist names with windows still open: MBLY, TXN, URI, SMCI, HAS, CAR, QS, CALX, BLD, AXTI, DPZ, OGN, MRVL, NXPI, STX, MDLZ, OMCL. None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; 2.6 no access to private information).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; no change from this session for V).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; IBM clean undershoot via NOW + IGV cascade external suppression — V has no analogous transient external event, only persistent structural regulatory overhang, which is why V cannot replicate the IBM clearance).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 HCA entry (GO with explicit lower-conviction posture; peer-corroboration via UHS/THC was the path to clearing criterion 4 — V has no analogous peer-corroboration path because MA peer print is informationally limited on the regulatory-overhang question that drives V's criterion 4 issue).
- Decision_Log.md 2026-04-27 (Sun follow-on) CHTR entry (NO-GO format precedent; cross-sectional information confirmation via CMCSA divergence — symmetric basis for V cross-name MA-comparable supporting appropriate-pricing).
- Decision_Log.md 2026-04-27 (Mon, post-close) INTC entry (NO-GO format precedent; positive-direction move with sell-side immediate ratification — L1 information-pricing logic).
- **Decision_Log.md 2026-04-29 SBUX entry (NO-GO format precedent — most directly comparable; V manifests a DIFFERENT sub-pattern of criterion 4 fail than SBUX did, detailed in compaction-survival note below).**
- V Q2 FY26 8-K Ex-99.1 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0001403161/000140316126000077/q22026earningsrelease.htm; net rev $11.23B +17%, GAAP EPS $3.14, non-GAAP EPS $3.31, $20B new buyback authorization, raised FY26 guide).
- V Q2 FY26 earnings call transcript (Insider Monkey / AOL Apr 28; CFO Suh capital-return commentary; CEO McInerney "fastest growth since 2013 ex-pandemic-and-Visa-Europe" framing).
- Bloomberg Apr 28-29 V coverage ("Visa Profit Beats, Revenue Posts Biggest Increase Since 2022; shares jumped the most in four years" + analyst-sourced "one of the cleanest quarters in years" framing).
- Benzinga Apr 28-29 V analyst-ratings page (pre-print PT actions: Citi $450→$400 Apr 14; UBS $425→$390 Mar 31; Truist $372→$361 Apr 24; BMO initiated $365 Apr 22; Loop initiated $387 Mar 31. Wed Apr 29 premarket V $325.39 +5.20% from Tue close $309.30).
- TipRanks Apr 29 V consensus PT $396.23 (high $450 / low $310; based on 22 analysts last 3 months); Marketbeat Apr 29 V PT $388.25.
- CNBC V quote page (52-week high $375.51 06/11/25, 52-week low $293.89 04/01/26, prev close $309.30).
- Investing.com V history (Apr 28 close $309.30, prev close $309.65, AH +0.37% post-print).
- QuiverQuant Apr 28 V insider-trades data (10 sales / 0 buys past 6 months including CEO McInerney $10.8M).
- TradingKey Apr 29 V risk piece (regulatory CCCA + interchange settlement + DOJ debit antitrust + Class B exchange offer with "Makewhole Agreement" "unlimited payment obligations" risk expiring May 8 — ongoing structural exposure).
- EBC Apr 28 pre-print preview (V YTD -11–12% on regulatory overhang; CCCA framing).
- 247WallSt Apr 28 sector context (V/MA/AXP all -double-digits YTD on regulatory + stablecoin + interchange concerns).
- Trefis / Meyka MA Q1 2026 preview (MA reports Thu Apr 30 BMO; consensus $4.40 EPS / $8.29B revenue; MA Q4'25 print Jan 29 had +12.8% EPS beat with +3.34% reaction per Investing.com — cross-name comparable supporting information-driven characterization of V's +5–8% reaction).
- Experiment_Parameters.md (operational time zone America/Denver; commission-disregarded-at-decision-time per 2026-04-27 protocol).

### Theater-check on this orchestrator review

Considered whether to push back toward GO given the genuinely strong print magnitudes (Bloomberg "cleanest quarter in years" + "biggest single-day jump in 4 years") AND the favorable trailing-30-day pattern (stock weak/flat into the print, no recency-bias-priced rally analogous to SBUX). Counter-argument: the trailing-30-day pattern being favorable is necessary but not sufficient — IBM had the same favorable trailing-30-day pattern AND had a clean transient external suppression event (NOW + IGV cascade). V has the favorable trailing-30-day pattern but lacks the transient external suppression — V's pre-print weakness is driven by persistent structural regulatory overhang, not a transient sentiment event. The IBM-style criterion 4 clearance requires BOTH conditions; V meets one but not the other. Pushing toward GO on V because the trailing-30-day pattern is favorable would be a 2.4-self-referenced selective-pattern-matching error (cherry-picking the IBM-favorable feature while ignoring the IBM-undershoot-decisive transient-external-event feature).

Considered whether the LONG thesis at marginal conviction (HCA-style explicit-lower-conviction posture) clears the criteria. Counter-argument: HCA had peer-corroboration potential (UHS Apr 27 AMC + THC Apr 30 BMO) as the path to clearing criterion 4; explicit invalidation criteria (iii) and (iv) were structured around peer-print outcomes. V's analogous peer-corroboration candidate is MA Apr 30 BMO, but MA's print is informationally limited on the criterion 4 binding constraint (regulatory overhang persistence) — MA's strong print would confirm operational sector strength but cannot resolve the regulatory question that drives V's criterion 4 issue. Without an MA-equivalent peer-corroboration path that addresses the binding constraint, the HCA-style marginal-conviction GO doesn't clear. V's structural setup is materially different from HCA's despite both being "B candidate after recent print."

Considered whether the +5–8% Wed reaction magnitude itself is informative — i.e., is it large enough to be inherently information-pricing rather than undershoot? Counter-argument: magnitude alone is not the criterion 4 test (the test is information-vs-sentiment characterization). However, magnitude does provide context: peer-comparable MA Q4 reacted +3.34% on a similar setup; V's +5–8% on a slightly larger beat is approximately proportionate. This is a corroborating data point for the L3 cross-name evidence, not a substitute for the L1 sell-side-mild-response evidence.

Considered whether the V LONG thesis could be reframed as Strategy D (long-horizon narrative on regulatory pessimism being overdone). Counter-argument: this is a legitimate observation but is out-of-scope for this session's specific Strategy B disposition. If V is to be a D candidate, it would require a separate D thesis-construction session per Strategy.md D entry criteria (Subtype A or B classification, immutable invalidation criteria, sector concentration check, correlation-bucket check). The current session's NO-GO is specifically on Strategy B; it does not preclude a future D-side evaluation if regulatory-pessimism-overdone becomes a high-confidence multi-year structural call. Note for the record: V would be a Subtype A (catalyst-driven) D candidate only if a specific scheduled regulatory resolution event within 12 months can be identified as the primary thesis driver; otherwise Subtype B (trend-continuation) requires identifying a quantifiable trend metric (e.g., "VAS revenue grows ≥ 25% cc for next 4 quarters"). Either subtype would need separate adversarial review and is not part of this session's scope.

Considered whether the SBUX precedent is over-fitting — V's pre-print pattern (PT cuts, no momentum-into-print) is structurally OPPOSITE to SBUX's pre-print pattern (PT raises, +18.75% trailing-30-day rally). The SBUX L1 logic ("information already priced via run-up") doesn't apply to V. Counter-argument: V manifests a DIFFERENT sub-pattern of criterion 4 fail than SBUX did, and the entry above explicitly distinguishes: V's criterion 4 fail is "regulatory-overhang-persistence as information-driven characterization," not SBUX's "information-priced-via-pre-print-rally" pattern. The SBUX precedent is cited for format-similarity (positive-direction post-event NO-GO), not for shared causal mechanism. The compaction-survival note below makes this distinction explicit for future Claude.

Modulo these five considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT as a 2.20 trap).

### Compaction-survival note

**Strategy B V (Visa) thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** V-thesis-construction COMPLETE; V-NO-GO declined on criterion 4 (regulatory-overhang-persistence as information-driven characterization; pre-print PT cuts on structural concerns + post-print mild sell-side response + cross-name MA peer-comparable supporting appropriate-pricing + strategy-mechanism mismatch with multi-quarter resolution timelines + insider selling pattern). Criterion 1 mechanically clears at +5–8% Tue close → Wed close. No order staged; no Portfolio_Ledger.md modification this session. V remains a closed name from a Strategy B perspective unless and until (a) MA Thu Apr 30 BMO print + V follow-on creates materially different evidence base than today's, OR (b) a subsequent identifiable transient external suppression event creates a clean undershoot setup analogous to IBM's. Strategy B sector concentration in Financials remains at 0/3 cap usage. The 10-day post-event entry window expires ~2026-05-12; no calendar event scheduled to revisit because the criterion 4 information-driven characterization is unlikely to flip from re-examining the same data, and the routine Daily.md daily scan will surface any new catalyst that creates a fresh setup.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **fifth** NO-GO of the experiment to date on criterion 4 grounds (NOW 2026-04-25; CHTR 2026-04-27; INTC 2026-04-27; SBUX 2026-04-29; V 2026-04-29). Six Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO, V-NO-GO = **2 GO / 5 NO-GO (29%/71%)**. **All five NO-GOs route through criterion 4 information-vs-sentiment test.** The criterion-4-NO-GO rate is hardening; the SBUX compaction-survival note flagged the 30-trade-gate review topic if rate persists across first 10 thesis constructions. The V NO-GO continues that pattern.

**Sub-pattern taxonomy for criterion 4 NO-GOs (5 cases observed; useful for future thesis-construction sessions):**

1. **Negative-direction "information-confirmed-by-cross-section" pattern** (NOW, CHTR): Stock down materially after print; cross-sectional peer evidence confirms the negative information is structural (NOW: ServiceNow-specific Mid-East deal slippage with no analogous peer pattern; CHTR: CMCSA divergence demonstrating execution-quality differential). LONG mean-reversion fails because the cross-sectional evidence supports information-driven repricing.

2. **Positive-direction "sell-side-immediate-ratification" pattern** (INTC): Stock up materially after print on raised guide; sell-side immediately upgrades (Citi → Buy, Evercore +146% PT) confirming new fundamentals at the elevated price. LONG-extension fails because sell-side immediate ratification is smoking-gun evidence of information pricing; SHORT-mean-reversion fails as 2.20 trap.

3. **Positive-direction "information-priced-via-pre-print-rally" pattern** (SBUX): Stock up modestly after print; pre-print sell-side raised PTs into the print (Stifel +$10, JPM +$5, Citi +$7) and trailing-30-day +18.75% absorbed the strong-print expectation; post-print sell-side mild PT moves (Guggenheim $95→$97 only) confirms information-driven pricing.

4. **Positive-direction "regulatory-overhang-persistence" pattern** (V — NEW PATTERN this session): Stock up after print on strong operational results + capital return; pre-print sell-side CUT PTs on persistent structural overhang (regulatory, legal); post-print PT response mild (consensus PT flat or slightly down despite strong print); cross-name peer-comparable (MA Q4 +3.34%) supports appropriate-pricing of V's +5–8% reaction; structural overhang persists multi-quarter, mismatched with B's 60-day window.

The taxonomy supports earlier identification of criterion 4 fails in future B thesis-construction sessions: scan for (i) cross-sectional peer evidence confirming information direction (CHTR/NOW pattern); (ii) sell-side immediate ratification or aggressive PT moves matching the print direction (INTC pattern); (iii) pre-print PT raises + trailing momentum (SBUX pattern); (iv) pre-print PT cuts on persistent structural concerns NOT addressed by the print (V pattern). Any one of these four supports criterion 4 fail; absence of all four with a clean transient external suppression event is the IBM-undershoot path to clearance.

**Key V-specific note:** V is structurally different from SBUX/INTC despite all three being positive-direction post-event NO-GOs. The differentiating feature for V is the **persistent structural overhang that the print does not address**. This is materially different from SBUX (information-priced-via-momentum) and INTC (sell-side-immediate-ratification). Future thesis-construction sessions should explicitly distinguish these sub-patterns rather than treating "positive-direction post-event NO-GO" as a uniform category.

**Mastercard (MA) follow-on:** MA reports Thu Apr 30 BMO. Routine Daily.md scan tomorrow will parse MA print and any V follow-on. MA print is NOT a deferral trigger for V's current NO-GO (MA's print cannot resolve V's criterion 4 binding constraint of regulatory-overhang persistence). However, if MA delivers a structurally similar print (clean operational beat, raised guide, capital-return announcement) AND V's stock fails to respond proportionally on Thu (further compressing the realized post-print reaction below information content), that asymmetric pattern could constitute fresh evidence for re-evaluation in a future session — but as a fresh thesis-construction, not a deferral resolution from this entry.

**V as potential Strategy D candidate (out-of-scope for this session):** V's regulatory-pessimism-overdone narrative is structurally aligned with Strategy D's long-horizon multi-year mechanism (per Strategy.md D Subtype A or B framework). If a future session establishes high-confidence multi-year structural call on regulatory-overhang resolution favoring V's franchise economics, V could be a D candidate at that time — would require separate adversarial review per D entry criteria. Current session NO-GO is Strategy-B-specific only.

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — NXPI (NXP Semiconductors) NO-GO (criterion 4 decisive failure on LONG-extension; sell-side immediate aggressive PT ratification — INTC sub-pattern); no order staged

**Trigger:** B-thesis construction requested for NXPI (NXP Semiconductors) post-event candidate surfaced in Daily.md 2026-04-29 scan as "Strategy B counter-trend semiconductor" (Q1 2026 earnings event date 2026-04-28 AMC; pre-event Tue Apr 28 close $236.87 area down -2.94% intraday from broad semi-sector compression on WSJ OpenAI revenue-miss story; post-print Wed Apr 29 intraday +18–22% to ~$280–290 area per multiple sources). Daily.md scan had flagged NXPI as a Strategy B candidate based on the "counter-trend semi" framing — i.e., NXPI's auto + industrial/IoT exposure is structurally orthogonal to AI/data-center semi compression that drove Tuesday's sector beta, and NXPI's print materially refuted the sector-suppression mechanism. This session applies Strategy B's actual entry criteria.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA both open in B; IT 1/3, Health Care 1/3 used; Financials 0/3); Decision_Log.md prior precedents — IBM 2026-04-25 GO (clean undershoot with external suppression evidence — same-night NOW + IGV cascade), NOW 2026-04-25 NO-GO (negative-direction criterion 4), HCA 2026-04-27 GO (lower-conviction with peer-corroboration potential), CHTR 2026-04-27 NO-GO (cross-sectional information confirmation), **INTC 2026-04-27 NO-GO (positive-direction L1 sell-side immediate ratification — most directly comparable precedent for NXPI's setup pattern)**, SBUX 2026-04-29 NO-GO (positive-direction L1 with pre-print PT raises priced into momentum), V 2026-04-29 NO-GO (positive-direction L1 with regulatory-overhang persistence); NXPI Q1 2026 8-K Ex-99.1 (StockTitan / SEC EDGAR; revenue $3.18B +12% YoY, non-GAAP EPS $3.05 +16% YoY, GAAP EPS $4.43 incl $627M one-time gain on MEMS Sensors divestiture for $878M, $358M Q1 capital return + $32M post-quarter, **Q2 revenue guide $3.45B midpoint = +18% YoY / +8% sequential vs analyst $3.28B = 5.3% above consensus, Q2 EPS guide $3.50 midpoint vs $3.20 est = 9.4% above consensus, Q2 non-GAAP gross margin 58% ±50bps = +150bps YoY, +90bps sequential, data center revenue $200M 2025 → $500M+ 2026 = "more than double" newly disclosed**); NXPI Q1 2026 earnings call transcript (Insider Monkey / AOL / Motley Fool / Alphastreet — CEO Sotomayor "company-specific drivers performing as designed; core business is inflecting; momentum expected to accelerate through 2026"; CFO Betz on margin trajectory, capital allocation, VSMC/ESMC manufacturing JVs); FinancialContent / StockStory ("NXP Semiconductors Beats Q1 Sales Targets, Stock Jumps 11.4%" Apr 28 4:37 PM EDT — initial AH reaction); QuiverQuant Apr 28 NXPI insider data (10/0 sells/buys past 6 months — actually $2.5M sales past 3 months per GuruFocus, mild bearish); Investing.com Apr 29 TD Cowen note ("currently trading at $280.91"; PT $250→$310; "best print in recent memory"; "2027 target model back in play"; "8% Q/Q above seasonal expectations"); GuruFocus Apr 29 Needham note (PT $250→$300, Buy maintained); GuruFocus Apr 29 Citigroup note (PT $255→$270, Buy maintained, analyst Atif Malik); Marketbeat Apr 29 Loop Capital note (PT $275→$290, Buy); GuruFocus Apr 29 "+25% surge" coverage (mid-day intraday peak); Public.com NXPI consensus PT pre-print $248.29 (14 analysts as of Apr 9); Quiver pre-print median PT $250 (8 analysts last 6 months); Motley Fool NXPI Q3 2025 transcript (multi-quarter prior context: industrial 20% below peak, distribution inventory below target, Q2-Q4 2024 and Q2-Q3 2025 YoY revenue declines); Motley Fool NXPI Q4 2025 transcript reference (Q4 print Jan 29 2026 +24.92% same-name analogue — the inflection-confirmation event); StockTitan Apr 28 NXPI peer commentary ("MRVL, MCHP, MPWR and ADI also declined between about 1–6% [Tuesday]; only ON appeared up 0.78% without news"); 4-of-5 historical NXPI earnings reactions averaged -3.58% (StockTitan); Daily.md 2026-04-29 scan; Experiment_Parameters.md (commission-disregarded-at-decision-time; America/Denver tz).

### Decision

**NXPI — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing briefly considered and dismissed (canonical 2.20 textbook-rational trap on a beat-and-raise + raised guide + new strategic disclosure with sell-side immediate aggressive PT raises).**

Failed Strategy B entry criterion 4 (adversarial counter-argument identifies a decisive flaw — the post-event reaction is information-driven via sell-side immediate aggressive PT ratification, structurally identical to INTC 2026-04-27 NO-GO pattern). Criterion 1 mechanically clears with major cushion; criterion 4 is the binding constraint.

### Mechanical eligibility (criteria 1, 5, instrument rule) — all clear with cushion

- **Instrument rule cleared with material cushion:** US-listed common (NASDAQ); market cap pre-print ~$58–62B per TD Cowen note ($58.2B at $280.91 mid-day Wed = roughly $250M shares × $235 pre-print ≈ $58.7B; post-print at $288 mid-day ≈ $72B per GuruFocus +25% snapshot). Both >29× the $2B floor. 30-day ADV vastly above $10M floor; long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 5 cleared:** No A position open in NXPI (A router DO-NOT-ACTIVATE; no NXPI A entry).
- **Criterion 1 clears with major cushion.** Event-day measurement per IBM precedent: pre-event close = Tue Apr 28 close $236.87 (NXPI was -2.94% intraday Tuesday on broad semi-sector compression from WSJ OpenAI revenue-miss story, but Tuesday's close is the binding pre-event reference per IBM precedent); post-event close = Wed Apr 29 close (TBD at scan time; mid-day intraday observed at $280.91 per TD Cowen note 5 hours before scan, $288.25 per Citi GuruFocus 1 hour before scan, with intraday peak +25% per GuruFocus). Estimated Wed close: $280–290 area = **+18–22% from Tue close**, comfortably above ≥5% threshold. Even at the most conservative reading ($280.91), this is +18.6%.

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q1 2026 print represented a fundamental inflection-continuation event: revenue $3.18B (+12% YoY) marked a "notable return to growth" after multi-quarter decline (Q2-Q4 2024 and Q2-Q3 2025 all YoY revenue declines per StockTitan); non-GAAP EPS $3.05 (+16% YoY) +2.8% beat vs $2.97 consensus; revenue +0.8% beat vs $3.16B consensus (note: some sources cite $3.22B est = slight miss). The forward signal was decisively stronger than the in-quarter print: **Q2 guide $3.45B revenue midpoint (range $3.35–3.55B) = +18% YoY / +8% sequential, materially ABOVE analyst $3.28B est (5.3% beat to consensus on guide); Q2 non-GAAP EPS $3.50 midpoint (range $3.29–3.72) vs $3.20 est = 9.4% above consensus on guide; Q2 non-GAAP gross margin 58% ±50bps = +150bps YoY / +90bps sequential.** All regions and end markets up YoY: automotive +low double-digit YoY (high-teens ex-MEMS); industrial & IoT +high-30%; comms infra +mid-30%; mobile +low single-digit. CEO Sotomayor framed the inflection: "company-specific drivers performing as designed; core business is inflecting; momentum expected to accelerate through 2026." **New strategic disclosure: data-center revenue $200M 2025 → "more than double" in 2026 (>$500M, +150% YoY)** — first explicit segment-level guidance, addressing the "AI infrastructure exposure" question directly via control-plane and infrastructure applications (NOT GPUs/AI data-plane, so distinct from NVDA/AVGO exposure). MEMS Sensors divestiture for $878M completed Q1 ($627M one-time gain), $358M Q1 capital return + $32M post-quarter buyback. Pre-event NXPI was depressed by (i) sector beta from Tuesday WSJ OpenAI story (intraday -2.94% on no idiosyncratic news), (ii) historical post-print bias (4-of-5 prior prints had averaged -3.58% reactions per StockTitan), (iii) multi-quarter prior YoY revenue decline narrative depressing baseline expectations. Provisional LONG thesis would argue: the +18–22% reaction UNDER-prices the magnitude of the inflection-acceleration narrative + new data-center disclosure + sell-side reset to "best print in recent memory" framing — i.e., the print delivers genuine narrative-shift quality and the realized reaction is bounded by remaining residual sector-beta uncertainty. Convergence target candidates: numerical level $310 (+7.6% from $288 mid-day; matches TD Cowen new PT ceiling) or $295 (+2.4%; conservative ~50% gap-fill toward post-print PT-weighted-mean ~$295–300).

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails — sell-side immediate aggressive PT ratification is the smoking-gun INTC pattern, structurally identical to the precedent NO-GO logic.** Within hours of the print, multiple covering analysts issued aggressive PT raises maintaining Buy ratings:
- **TD Cowen: PT $250 → $310 (+24% PT raise), Buy maintained.** Analyst commentary: "best print in recent memory"; "revenue engine reigniting after recent years of slower growth"; "2027 target model back in play"; "guided 2x datacenter growth in 2026"; "8% Q/Q growth for June quarter, well above seasonal expectations"; gross margin trajectory "up 100bps Q/Q and 150bps Y/Y."
- **Needham: PT $250 → $300 (+20% PT raise), Buy maintained.**
- **Loop Capital: PT $275 → $290 (+5.5% PT raise), Buy.**
- **Citigroup: PT $255 → $270 (+5.88% PT raise), Buy maintained.** Analyst Atif Malik.

This is the same structural pattern as INTC 2026-04-27 NO-GO L1 (Citi upgrade to Buy + Evercore +146% PT — aggressive sell-side immediate ratification confirming the new fundamentals at the elevated price). Per criterion 4's information-vs-sentiment framing applied symmetrically: when sell-side immediately and aggressively ratifies the print's information by materially raising PTs, that IS the empirical evidence that the post-print reaction is information-driven (mispricing is correct pricing). The post-print PT-weighted mean has shifted approximately from pre-print $250 → post-print $295–300 area (a +18–20% PT increase). NXPI's realized post-print reaction (+18–22% on the stock) is approximately consistent with the PT-weighted increase. The reaction is appropriately sized; there is no sentiment-suppressed undershoot to exploit. **Decisive.** Per pre-mortem rev 7 KL note, sell-side immediate aggressive PT ratification is precisely the L1 pattern that the criterion 4 test was designed to identify and decline.

(L2) **Same-name historical analogue argues against undershoot framing.** NXPI's most recent prior earnings reaction (Q4 2025 print released Jan 29, 2026) was **+24.92% intraday** per Motley Fool transcript reference. The Q4 2025 print was the FIRST sequential improvement after multi-quarter decline (the inflection-confirmation event). NXPI's current Q1 2026 reaction (+18–22%) is materially SMALLER than its own prior-print reaction, which is appropriate because Q1's information is incremental confirmation of the Q4 inflection narrative rather than first-revelation. If the Q4 inflection-confirmation +24.92% is the calibration anchor, the Q1 continuation +18–22% is approximately proportionate (smaller because incremental rather than revelatory). The market has correctly sized the Q1 reaction as smaller than the Q4 reaction. There is no measurable undershoot to exploit. (Note: Q4 2025 +24.92% reaction was BEFORE this experiment's framework existed; cannot retro-evaluate as B-pattern, but it provides same-name calibration evidence for Q1.)

(L3) **Distinguishing from IBM's clean undershoot precedent — the "counter-trend" Daily.md framing does NOT carry IBM-style criterion 4 clearance.** IBM's GO leaned on a same-night transient external suppression event (NOW print AMC + IGV index −5.83% same-day cascade with peers Salesforce/HubSpot/Adobe/Workday/Intuit/Oracle each off 6–9% on no idiosyncratic news; sustained overnight + into next regular session — a clean 60-day-mean-reversion-eligible signal). NXPI's pre-print Tuesday -2.94% intraday drop is structurally different: (i) it occurred BEFORE the print (intraday Tuesday), not COINCIDENT with the print and as the suppressed reaction itself (IBM's −9.62% next-day reaction was the suppressed event); (ii) per StockTitan, the Tuesday peer drift was 1–6% across MRVL/MCHP/MPWR/ADI and broader semi names, but those names include AI/data-center-exposed semis (MRVL, MPWR) that were DIRECTLY hit by the WSJ OpenAI story — i.e., not the IBM-style clean "peers off on no idiosyncratic news" pattern; (iii) NXPI's post-print +18–22% reaction with sell-side immediate aggressive PT ratification is the market's CORRECTION of any sector-beta mispricing PLUS information pricing of the strong print. The Tuesday -2.94% intraday move is reasonably attributable to broader market beta (semi sector compression on AI/data-center concerns), which the print materially refutes — but the post-print reaction has ALREADY corrected this. There is no remaining undershoot. The IBM-style criterion 4 clearance requires the post-event reaction itself to be the suppressed-below-information event; NXPI's post-event reaction is itself the information-driven correction event.

(L4) **Cross-name peer-comparable evidence.** Per StockTitan Tuesday peer drift commentary: MRVL/MCHP/MPWR/ADI declined 1–6% on broad semi-sector compression, with ON +0.78% as the only positive outlier without news. NXPI's -2.94% Tuesday move was within the normal sector-beta range. Post-print Wednesday: NXPI +18–22% reaction is significantly larger than what peer drift would suggest for sector-beta correction alone — i.e., the +18–22% reflects PRINT-SPECIFIC information (the Q2 guide beat, data-center disclosure, margin trajectory), NOT just sector-beta-correction. Cross-name evidence supports information-driven characterization of the magnitude.

(L5) **Strategy B's mispricing-exploitation mechanism vs "follow-sell-side-PT" pattern.** The LONG thesis, in its strongest form, becomes "convergence target $310 = +7.6% from $288 mid-day, matching TD Cowen new PT ceiling." But this is a "follow sell-side analysts" trade, not a B-style mispricing exploitation. Per pre-mortem rev 7, B's mechanism is specifically about identifying realized post-event reactions that are sentiment-driven mispricings — when sell-side has already ratified the new fundamentals at the new price level, the residual gap to a $310 PT ceiling reflects normal price drift toward consensus PT, not exploitable mispricing. Treating "gap to highest analyst PT" as a B convergence target would be the kind of strategy-mechanism slippage that the pre-mortem warns against (B becoming a "follow-the-PT-leader" strategy, which is a distinct mechanism with much weaker historical edge characteristics).

(L6) **Insider-selling pattern compounds.** Per GuruFocus / Quiver: $2.5M insider sales in past 3 months / 0 buys (broader 6-month data: 10 sales / 0 buys per Quiver framework). While insider selling at large-cap semis is largely 10b5-1 driven, the unanimous selling pattern with 0 buys does not corroborate an internal-information view that the stock is sentiment-suppressed below fundamental value. Compounding marginal signal.

LONG declined. Criterion 4 information-vs-sentiment test not met (L1 decisive on the sell-side immediate aggressive PT ratification — TD Cowen +24%, Needham +20% — structurally identical to INTC precedent); L2 confirms via same-name historical analogue (Q4 +24.92% calibration anchor); L3 distinguishes from IBM clean undershoot (Tuesday sector-beta is not analogous to IBM's transient overnight cascade, and the post-print reaction itself is the correction event, not a suppressed event); L4 confirms via cross-name peer-comparable; L5 is the strategy-mechanism mismatch compound; L6 is the insider-pattern compound.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +18–22% on a quarterly print might fade toward $260–270 over 60 days as the print's incremental contribution gets discounted and the higher post-print P/E (~36x per GuruFocus) gets compressed.

**Why dismissed without full adversarial construction:** Shorting a beat-and-raise + raised guide + new strategic data-center disclosure print framed by TD Cowen as "best print in recent memory" with +24% PT raise to $310 and "2027 target model back in play" is a textbook 2.20 trap. The +18–22% reaction is appropriately sized given (a) sell-side post-print PT-weighted increase of +18–20%, (b) NXPI's own Q4 +24.92% same-name analogue, (c) cross-name peer-comparable evidence supporting information-driven magnitude. SHORT criterion 4 fails by the same information-vs-sentiment logic that fails LONG, but flipped: if the reaction is information-driven, neither LONG nor SHORT mispricing exists. Additionally, SHORT against a freshly-disclosed positive structural narrative (data-center 2x growth, 2027 target model back in play) is exactly the "fade-fundamental-good-news-because-the-move-felt-big" 2.20 error pattern. SHORT declined.

### 2.13 / 2.14 / 2.20 cross-checks

- **2.20 (textbook-rational penalty)** — NXPI SHORT is a clean 2.20 trap (fade-the-strong-print-with-aggressive-sell-side-PT-raises); declined above. NXPI LONG is closer to 2.4 territory (narrative-over-fit on the "counter-trend semiconductor" framing as supporting undershoot, when the realized reaction is actually information-priced via sell-side PT ratification).
- **2.13 (miscalibration)** — A LONG conviction call on NXPI depends on assigning meaningful probability to "the +18–22% reaction is sentiment-suppressed undershoot vs new ~$295–300 PT-weighted mean." Sell-side immediate aggressive PT ratification is the strongest possible counter-evidence to that hypothesis. 2.13's hard-wired 80% CI containing outcomes ~69% of the time penalizes overconfident probability assignments against well-corroborated evidence; the resulting effective probability after 2.13-discount is materially below thesis-supporting threshold.
- **2.14 (recency bias on input data)** — NXPI's trailing-30-day pattern is mixed: pre-print depressed by sector beta + multi-quarter prior YoY revenue decline narrative, but stock had been recovering off Q4 2025 inflection-confirmation +24.92% reaction. Not a clean 2.14-defer-on-rallying-name pattern (unlike SBUX's +18.75%), but also not a "weak into the print" pattern (unlike IBM's IGV cascade). 2.14 is approximately neutral on NXPI.

### Sector concentration check (for completeness; not cap-binding)

NXPI = GICS Information Technology / Semiconductors & Semiconductor Equipment / Semiconductors. Strategy B currently holds **IBM (IT — Software/IT Services subindustry)** and HCA (Health Care). Adding NXPI would put IT at 2/3 — within the 3-per-sector cap but using more of the IT capacity. Cap is not the binding constraint; criterion 4 is.

Note: while IBM and NXPI are both "IT" at the GICS sector level, they are in different sub-industries (IBM = Software/Consulting; NXPI = Semiconductors). Their fundamental drivers and macro sensitivities are largely distinct, so the IT 2/3 usage would not be a meaningful concentration concern even if criterion 4 had cleared.

### Effect on book

No effect. No order staged for NXPI. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3 (IBM only), Health Care 1/3 (HCA), others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~NXPI B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (sell-side immediate aggressive PT ratification: TD Cowen $250→$310 +24%, Needham $250→$300 +20%; structurally identical to INTC 2026-04-27 NO-GO precedent). No order staged.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook; calendar event already scheduled.
- MA Thu 2026-04-30 BMO print — peer to V; not a deferral trigger; routine Daily.md scan tomorrow.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow.
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at this session's scan time.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META) — relevant for daily scan tomorrow.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session for screenshot-based check; conservative-branch action (pause new staging) would engage at trigger-failure. **This NO-GO does not interact with the hold-anomaly deferral** — there is no order to stage either way.
- Other Strategy B watchlist names with windows still open: MBLY, TXN, URI, SMCI, HAS, CAR, QS, CALX, BLD, AXTI, DPZ, OGN, MRVL, STX, MDLZ, OMCL. None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure + KL note on sell-side-ratification as L1 smoking-gun).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; 2.6 no access to private information).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; no change from this session for NXPI).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; IBM clean undershoot via NOW + IGV cascade external suppression — NXPI's Tuesday sector-beta is structurally distinct and not analogous).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 HCA entry (GO with explicit lower-conviction posture; peer-corroboration via UHS/THC).
- Decision_Log.md 2026-04-27 (Sun follow-on) CHTR entry (NO-GO format precedent; cross-sectional information confirmation via CMCSA divergence).
- **Decision_Log.md 2026-04-27 (Mon, post-close) INTC entry (NO-GO format precedent — most directly comparable to NXPI; positive-direction move with sell-side immediate aggressive ratification — Citi upgrade + Evercore +146% PT — L1 information-pricing logic).**
- Decision_Log.md 2026-04-29 SBUX entry (NO-GO format precedent — positive-direction L1 with pre-print PT raises priced into momentum; different sub-pattern than NXPI).
- Decision_Log.md 2026-04-29 V entry (NO-GO format precedent — positive-direction L1 with regulatory-overhang persistence; different sub-pattern than NXPI).
- NXPI Q1 2026 8-K Ex-99.1 (StockTitan https://www.stocktitan.net/news/NXPI/nxp-semiconductors-reports-first-quarter-2026-wfgo83y6r5oi.html ; SEC EDGAR; Q1 revenue $3.18B +12% YoY; non-GAAP EPS $3.05; GAAP EPS $4.43 incl $627M MEMS gain; **Q2 guide $3.45B revenue / $3.50 non-GAAP EPS midpoints; data-center revenue $200M 2025 → $500M+ 2026**).
- NXPI Q1 2026 earnings call transcript (Insider Monkey / Motley Fool / Alphastreet Apr 28 — CEO Sotomayor inflection commentary; CFO Betz on margin trajectory and capital allocation).
- FinancialContent / StockStory Apr 28 4:37 PM EDT ("NXP Semiconductors Beats Q1 Sales Targets, Stock Jumps 11.4%" — initial AH reaction).
- Investing.com Apr 29 TD Cowen note (PT $250 → $310, "best print in recent memory", "2027 target model back in play").
- GuruFocus Apr 29 Needham note (PT $250 → $300, Buy).
- GuruFocus Apr 29 Citigroup note (PT $255 → $270, Buy, analyst Atif Malik; mid-day intraday price $288.25).
- Marketbeat Apr 29 Loop Capital note (PT $275 → $290, Buy).
- GuruFocus Apr 29 "+25% surge" coverage (intraday peak; market cap snapshot $72.8B).
- Public.com NXPI consensus PT pre-print $248.29 (14 analysts as of Apr 9, 2026); QuiverQuant pre-print median PT $250 (8 analysts last 6 months).
- Motley Fool NXPI Q4 2025 transcript reference (+24.92% same-name analogue, Jan 29 2026 inflection-confirmation event).
- Motley Fool NXPI Q3 2025 transcript (multi-quarter prior context — industrial 20% below peak, distribution inventory below target, Q2-Q4 2024 and Q2-Q3 2025 YoY revenue declines).
- StockTitan Apr 28 NXPI peer commentary (MRVL/MCHP/MPWR/ADI -1–6% Tuesday on broad semi sector compression; ON +0.78% only positive outlier).
- StockTitan / Yahoo "4-of-5 historical NXPI earnings reactions averaged -3.58%" (pre-print historical bias).
- GuruFocus / Quiver NXPI insider data ($2.5M sales / 0 buys past 3 months).
- Daily.md 2026-04-29 scan ("NXPI Strategy B counter-trend semiconductor" candidate flagging).
- Experiment_Parameters.md (operational time zone America/Denver; commission-disregarded-at-decision-time per 2026-04-27 protocol).

### Theater-check on this orchestrator review

Considered whether the "counter-trend semiconductor" Daily.md framing creates a path to criterion 4 clearance via the IBM analogue (Tuesday sector-beta as transient external suppression). Counter-argument: per L3 above, NXPI's Tuesday -2.94% intraday move is structurally NOT analogous to IBM's clean overnight NOW + IGV cascade. (i) Timing: IBM's suppression was COINCIDENT with the print and was the suppressed reaction itself; NXPI's Tuesday move was BEFORE the print and the post-print +18–22% reaction is itself the correction event. (ii) Cleanness: IBM's peer drift was 6–9% on names with NO idiosyncratic news (Salesforce, HubSpot, Adobe, Workday, Intuit, Oracle); NXPI's peer drift was 1–6% across MRVL/MCHP/MPWR/ADI which includes AI/data-center-exposed names DIRECTLY hit by WSJ OpenAI story (not the IBM-style "peers off on no idiosyncratic news" pattern). (iii) Magnitude-fit: IBM's −9.62% post-print reaction was BELOW its information warranted (IBM's print itself was solid); NXPI's +18–22% reaction is APPROPRIATELY-SIZED relative to the magnitude of its information content (Q2 guide +5.3% above consensus, data-center 2x growth disclosure, sell-side PT ratification). The "counter-trend" framing is a Daily.md narrative-flag for "merits thesis construction" — it is NOT a criterion 4 clearance argument. The thesis-construction-level evidence (sell-side immediate aggressive PT ratification per L1) decisively fails criterion 4.

Considered whether the data-center disclosure ($200M → $500M+ in 2026) deserves separate weight as a "narrative-shift" event that could justify a larger reaction than realized. Counter-argument: per pre-mortem rev 7 Constraint 1, narrative-quality assessment ("THIS narrative-shift deserves a bigger reaction") is itself the 2.4-self-referenced model judgment that biases the synthesis. The L1 information-pricing test is the external check; sell-side has already ratified the data-center disclosure in their PT raises (TD Cowen explicitly cited "guided 2x datacenter growth in 2026" in support of $310 PT). The data-center disclosure is already PRICED into the new PT range, not a residual mispricing source.

Considered whether the symmetric INTC application is over-fitting (forcing pattern-match because three consecutive positive-direction NO-GOs in a row — INTC, SBUX, V, NXPI — is a convenient pattern). Counter-argument: the L1 information-pricing logic is independently grounded in criterion 4 — it does not require INTC as precedent to operate. NXPI-specific evidence (TD Cowen +24% PT raise, Needham +20%, Loop +5.5%, Citi +5.88% all post-print same-day; magnitude-matched to PT-weighted mean increase; same-name Q4 calibration anchor; cross-name peer-comparable) supplies the L1 conclusion on its own terms. The INTC precedent is confirmation of the pattern shape, not generation of the conclusion. The four positive-direction post-event NO-GOs (INTC, SBUX, V, NXPI) each manifest distinct sub-patterns of L1 failure (sub-pattern taxonomy in compaction-survival note below).

Considered whether the MAGNITUDE of NXPI's reaction (+18–22%) is sufficiently extreme that it inherently qualifies as "tail-event" warranting separate treatment from INTC (+23.6%). Counter-argument: NXPI's reaction magnitude is actually SMALLER than INTC's, not larger. If INTC's +23.6% was deemed information-priced via sell-side immediate ratification, NXPI's +18–22% with similar sell-side ratification pattern is a fortiori information-priced. Magnitude-as-defense for LONG-extension does not survive same-pattern comparison.

Considered whether to defer the NXPI decision pending tomorrow's MA / AAPL / AMZN prints to gather more cross-sectional information. Counter-argument: per protocol, deferral requires a trigger that resolves the binding constraint. NXPI's binding constraint is criterion 4 information-vs-sentiment test, which has been resolved decisively by post-print sell-side immediate aggressive PT ratification. None of tomorrow's prints (MA, AAPL, AMZN, LLY, CAT) would change that resolution because they are different end-markets/companies and would not retroactively change NXPI's sell-side post-print pattern. Decision is made now without deferral.

Modulo these five considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT as a 2.20 trap).

### Compaction-survival note

**Strategy B NXPI thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** NXPI-thesis-construction COMPLETE; NXPI-NO-GO declined on criterion 4 (sell-side immediate aggressive PT ratification — TD Cowen +24% to $310, Needham +20% to $300, Loop +5.5%, Citi +5.88% — structurally identical to INTC 2026-04-27 NO-GO L1 pattern). Criterion 1 mechanically clears with major cushion at +18–22% Tue close → Wed close. No order staged; no Portfolio_Ledger.md modification this session. NXPI remains a closed name from a Strategy B perspective unless and until the post-print PT ratification gets meaningfully reversed (e.g., a significant downgrade or PT cut following further information that contradicts the inflection narrative). Strategy B sector concentration in IT (Semiconductors sub-industry) remains at 0/3 cap usage (IBM is in IT/Software sub-industry; sub-industry concentration would be relevant if criterion 4 had cleared, but is not binding here). The 10-day post-event entry window expires ~2026-05-12; no calendar event scheduled to revisit because the criterion 4 sell-side-ratification characterization is unlikely to flip from re-examining the same data.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **sixth** NO-GO of the experiment to date on criterion 4 grounds (NOW 2026-04-25; CHTR 2026-04-27; INTC 2026-04-27; SBUX 2026-04-29; V 2026-04-29; NXPI 2026-04-29). Seven Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO, V-NO-GO, NXPI-NO-GO = **2 GO / 6 NO-GO (25%/75%).** **All six NO-GOs route through criterion 4 information-vs-sentiment test.** The criterion-4-NO-GO rate continues to harden; the SBUX compaction-survival note flagged the 30-trade-gate review topic if rate persists across first 10 thesis constructions. The NXPI NO-GO continues that pattern with a clean L1-INTC-structural-match.

**Sub-pattern taxonomy for criterion 4 NO-GOs (6 cases observed; useful for future thesis-construction sessions):**

1. **Negative-direction "information-confirmed-by-cross-section" pattern** (NOW, CHTR): Stock down materially after print; cross-sectional peer evidence confirms the negative information is structural. LONG mean-reversion fails because the cross-sectional evidence supports information-driven repricing.

2. **Positive-direction "sell-side-immediate-ratification" pattern** (INTC, **NXPI — NEW INSTANCE this session**): Stock up materially after print on raised guide / new strategic disclosure; sell-side immediately and aggressively raises PTs (INTC: Citi upgrade + Evercore +146%; NXPI: TD Cowen +24%, Needham +20%, Loop +5.5%, Citi +5.88%) confirming new fundamentals at the elevated price. LONG-extension fails because sell-side immediate ratification is the smoking-gun evidence of information pricing; SHORT-mean-reversion fails as 2.20 trap. **NXPI's instance is the cleanest example of this sub-pattern to date** because the PT raises were multiple, same-day, and ratifying-the-direction-at-magnitude (not just direction).

3. **Positive-direction "information-priced-via-pre-print-rally" pattern** (SBUX): Stock up modestly after print; pre-print sell-side raised PTs into the print and trailing-30-day rally absorbed the strong-print expectation; post-print sell-side mild PT moves confirms information-driven pricing.

4. **Positive-direction "regulatory-overhang-persistence" pattern** (V): Stock up after print on strong operational results + capital return; pre-print sell-side CUT PTs on persistent structural overhang; post-print PT response mild despite strong print; cross-name peer-comparable supports appropriate-pricing of the bounded reaction; structural overhang persists multi-quarter.

The taxonomy supports earlier identification of criterion 4 fails in future B thesis-construction sessions: scan for (i) cross-sectional peer evidence confirming information direction; (ii) **sell-side immediate aggressive PT moves matching the print direction (INTC/NXPI pattern — strongest signal)**; (iii) pre-print PT raises + trailing momentum (SBUX pattern); (iv) pre-print PT cuts on persistent structural concerns NOT addressed by the print (V pattern). Any one of these four supports criterion 4 fail; absence of all four with a clean transient external suppression event coincident with the print is the IBM-undershoot path to clearance.

**Key NXPI-specific note:** NXPI is the cleanest L1-INTC-pattern instance to date. The Daily.md "counter-trend semiconductor" framing was a narrative-flag for thesis construction, not a criterion 4 argument. The Tuesday -2.94% sector-beta on NXPI is NOT analogous to IBM's transient overnight cascade — it occurred BEFORE the print (not coincident), and the post-print reaction is the CORRECTION event (not a suppressed event). Future thesis-construction sessions should explicitly distinguish "pre-print sector-beta + post-print sell-side-ratified strong reaction" (NXPI/INTC pattern, NO-GO) from "coincident-with-print external suppression cascade" (IBM pattern, GO).

**Lesson for future Daily.md scans on counter-trend framings:** "Counter-trend [sector] semiconductor" or analogous narrative labels are forward-flagging-level, not thesis-construction-level. The daily scan does not apply criterion 4's sell-side-ratification test; the scan's framings reflect "name's print bucks the broader sector mood" rather than "evidence of post-print mispricing." Future daily-scan recommendations with counter-trend framings should be read as "merits thesis construction" rather than "merits a GO," with thesis construction being the binding gate. NXPI is a clean example of a counter-trend daily-scan flag that does not survive thesis construction because the post-print reaction has already been ratified by aggressive sell-side PT raises.

**Same-name calibration:** NXPI Q4 2025 reaction +24.92% (Jan 29 2026) provides explicit own-name calibration anchor: when NXPI prints with inflection-confirmation magnitude, the market reacts at ~25% magnitude. Q1 2026's +18-22% is an appropriately-smaller continuation reaction. Future B thesis-construction sessions on NXPI (or any name with explicit prior-print same-name analogue) should incorporate same-name calibration as an L2/L4 input for the criterion 4 information-vs-sentiment test.

**Pending Strategy B watchlist names and forward implications:** With 6/8 thesis constructions resulting in NO-GO and 4/4 positive-direction post-event NO-GOs falling under sub-patterns 2/3/4 (sell-side ratification / pre-print rally / regulatory overhang), the framework's positive-direction selectivity is structurally tight. Names like TXN, URI, MRVL, STX, MDLZ on the watchlist with positive-direction post-event windows still open should be expected to similarly fall under one of these sub-patterns unless they have a clean transient external suppression event analogous to IBM's. The 30-trade-gate review at experiment milestone should specifically examine whether the positive-direction sub-pattern selectivity is calibrated correctly or whether the framework is over-rejecting (e.g., if forward analysis shows the rejected positive-direction NO-GOs would have produced positive returns 60 days out, the criterion 4 application may be too strict; conversely if they produced flat-to-negative returns, the application is well-calibrated).

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — STX (Seagate Technology) NO-GO (criterion 4 decisive failure on LONG-extension; double-pattern overlay — INTC sell-side immediate aggressive ratification + SBUX pre-print rally + record-high entry + record insider selling); no order staged

**Trigger:** B-thesis construction requested for STX (Seagate Technology) post-event candidate surfaced in Daily.md 2026-04-29 scan as "Strategy B; data-storage AI angle" (Q3 FY26 earnings event date 2026-04-28 AMC; pre-event Mon-Tue closing area near record highs ~$580–620 zone per Schaeffer's "extending last week's record-breaking run"; Tue Apr 28 close represents a near-record level per pre-print rally; post-print Wed Apr 29 intraday +15–17% to record-high $687 area; multiple sources reporting +12–17% range depending on snapshot timing). Daily.md scan had flagged STX as Strategy B candidate based on "data-storage AI angle" narrative — i.e., STX's HDD/Mozaic HAMR exposure is structurally levered to AI-driven exabyte demand and the print materially extended the AI-storage narrative with multi-year visibility commentary. This session applies Strategy B's actual entry criteria.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7 KL note on AI-narrative 2.4 narrative-over-fit risk); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA both open in B; IT 1/3 by IBM Software/Services, Health Care 1/3 by HCA, others 0/3); Decision_Log.md prior precedents — IBM 2026-04-25 GO (clean undershoot via NOW + IGV cascade — STX has zero analogous external suppression evidence, opposite signal — at record highs into print), NOW 2026-04-25 NO-GO, HCA 2026-04-27 GO, CHTR 2026-04-27 NO-GO, **INTC 2026-04-27 NO-GO (positive-direction L1 sell-side immediate aggressive ratification — Citi upgrade + Evercore +146% PT — STX is structurally identical L1 pattern with even more aggressive PT raises, particularly Rosenblatt $500 → $1,000 +100%)**, **SBUX 2026-04-29 NO-GO (positive-direction L1 with pre-print PT raises priced into trailing-30-day +18.75% momentum — STX's pre-print BofA $450→$605 Apr 20 raise + record-high entry overlays this pattern in even more extreme form)**, V 2026-04-29 NO-GO (positive-direction L1 with regulatory-overhang persistence — different sub-pattern, not directly applicable to STX), NXPI 2026-04-29 NO-GO (positive-direction L1 INTC-pattern earlier this session — same primary mechanism as STX); STX Q3 FY26 8-K Ex-99.1 (BusinessWire / StockTitan https://www.stocktitan.net/news/STX/seagate-technology-reports-fiscal-third-quarter-2026-financial-mldv9b9yx7tr.html ; Investor Relations investors.seagate.com — fiscal Q3 ended April 3, 2026: **revenue $3.11B vs $2.96B Reuters consensus = +5.1% beat, +44% YoY +10% Q/Q; GAAP EPS $3.27 (+108% YoY from $1.57); non-GAAP EPS $4.10 vs $3.97 est = +3.3% beat, +115% YoY +32% Q/Q; non-GAAP gross margin 47.0% (record, +180bps Q/Q, +1080bps YoY); non-GAAP operating margin 37.5% (record, +560bps Q/Q); FCF $953M (31% margin, highest in over a decade); $641M debt retired Q3 + $1.1B retired YTD FY26; net leverage 0.7x; Fitch upgraded credit to investment grade**); STX Q3 FY26 earnings call transcript (Motley Fool / Globe & Mail / Benzinga / Seeking Alpha Apr 28 5:00 PM ET — CEO Mosley "Seagate delivered outstanding March quarter results, exceeding the high end of our revenue and EPS guidance, achieving record margin performance"; "Seagate is entering a new era of structural growth as AI applications amplify data creation"; **Q4 guide $3.45B revenue ±$100M = +41% YoY at midpoint vs Reuters consensus $3.16B = +9.2% above on guide; non-GAAP operating margin "lower 40% range"; non-GAAP EPS $5.00 ±$0.20; nearline capacity "almost fully allocated through calendar 2027 with finalized build-to-order contracts through fiscal 2027"; Mozaic 4 began shipping for revenue late March, Mozaic 5 50TB qualification shipments late 2027; HAMR exabyte output expected dominant by late 2026; raised annual revenue growth target to "minimum of 20%" (up from previous low-to-mid-teens guidance)**); Schaeffer's Apr 29 ("Seagate Technology stock surging higher this morning, last seen up 17.3% to trade at $679.37, earlier tapping a fresh record high of $687"; "no fewer than 11 handing out a price-target hike, the highest coming from Rosenblatt Securities to $1,000 from $500"; "extending last week's record-breaking run up the charts"; "today eyeing its best daily performance since Jan"; "Schaeffer's Volatility Scorecard 85/100 indicating tendency to exceed option traders' volatility expectations"); 247WallSt Apr 29 ("Rosenblatt raised price target on Seagate stock to $1,000 from $500 while keeping Buy rating, towering over every competing target on the Street"; "fresh target hikes from BofA, Citi, Goldman Sachs, and Barclays after blowout fiscal Q3 2026 print"); Yahoo Finance Apr 29 ("Seagate Technology soared 12.13% after strong Q3 earnings and bullish analyst targets"; "+15.40%" alternative reading); GuruFocus Apr 29 ("P/E ratio 65.5x indicating premium valuation compared to historical averages"; "Insider activity shows significant selling, with $46.9 million in shares sold over the past three months"; "$46.48M insider selling deserves attention"); TickerNerd pre-print snapshot ("currently trading at $429.36 ... median price target of $468.50, ranging from $375 to $700"; this snapshot appears to be from earlier in April BEFORE the recent pre-print rally); MarketBeat current PT $518.29 (timing unclear); Public.com NXPI consensus PT $479.84 pre-print (timing Apr 29 but possibly stale); Daily Political Apr 27 pre-print PT context (Bernstein $500→$620 Apr 9; BofA $450→$605 Apr 20 — pre-print PT raises 8 days before earnings; Argus $300→$450 Jan 29; Wells Fargo $360→$450 Jan 28; "Twenty equities research analysts rated Buy and five Hold" pre-print = highly Buy-skewed coverage); Daily Political also showed pre-print Loop Capital "$700 → $800" PT raise; Daily.md 2026-04-29 scan; Experiment_Parameters.md (commission-disregarded-at-decision-time; America/Denver tz).

### Decision

**STX — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing briefly considered and dismissed (canonical 2.20 textbook-rational trap on a record beat-and-raise + Fitch investment-grade credit upgrade + multi-year visibility commentary + Rosenblatt $500→$1,000 PT call).**

Failed Strategy B entry criterion 4 with multi-pattern decisive evidence — the post-event reaction is extremely information-driven, layered across (a) sell-side immediate aggressive PT ratification (Rosenblatt +100% PT raise to $1,000, plus 10 other firms raising PTs same-day), (b) pre-print PT raises already in flight (BofA +34.4% PT raise Apr 20, just 8 days pre-print), (c) record-high pre-print stock level extending a multi-week run, and (d) record-magnitude insider selling ($46.9M past 3 months / 0 buys). This is the cleanest L1-INTC-pattern instance of the experiment to date PLUS overlay of the SBUX pre-print-rally pattern. Criterion 1 mechanically clears with massive cushion; criterion 4 is the binding constraint with very high decisiveness.

### Mechanical eligibility (criteria 1, 5, instrument rule) — all clear with major cushion

- **Instrument rule cleared with massive cushion:** US-listed common (NASDAQ); market cap pre-print ~$96B per TickerNerd ($96.19B at $429 — but that snapshot appears stale); current Wed mid-day market cap likely $130–150B at $670–680 with ~210M shares; either way >>$2B floor by 50–75×. 30-day ADV vastly above $10M floor. Long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 5 cleared:** No A position open in STX (A router DO-NOT-ACTIVATE; no STX A entry).
- **Criterion 1 clears with major cushion.** Per IBM precedent (event-day close → next-day close measurement): pre-event close = Tue Apr 28 close (specific value not in research outputs but consistent with the pre-print rally context — likely $580–600 area given Schaeffer's "record-breaking run" framing); post-event close = Wed Apr 29 close (TBD at scan time; intraday observed at $679.37 Schaeffer's reading early Wed, intraday peak $687 record high, Yahoo "+12-15%" range). Estimated Wed close: $660–690 area = **+12–17% from Tue close**, comfortably above ≥5% threshold by 7–12 points.

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q3 FY26 print represented a magnitude-extreme inflection-confirmation event for the AI-storage narrative: revenue $3.11B = +5.1% beat vs Reuters consensus $2.96B and +44% YoY; non-GAAP EPS $4.10 = +3.3% beat vs $3.97 est, +115% YoY, +32% sequential; non-GAAP gross margin 47.0% (record level, +1080bps YoY +180bps Q/Q); non-GAAP operating margin 37.5% (record, +560bps Q/Q); FCF $953M (highest in over a decade, 31% FCF margin); Fitch credit-rating upgrade to investment grade; $641M debt retired Q3 (~$1.1B YTD FY26). The forward signal extended the AI-storage narrative materially: **Q4 guide $3.45B revenue ±$100M = +41% YoY midpoint vs Reuters consensus $3.16B (+9.2% above) and non-GAAP EPS $5.00 ±$0.20 (well above prior estimates); raised annual revenue growth target to "minimum of 20%" up from previous low-to-mid-teens guidance — a multi-year structural step-up; nearline capacity "almost fully allocated through calendar 2027 with finalized build-to-order contracts through fiscal 2027"; Mozaic 4 ramping for revenue, Mozaic 5 50TB qualification late 2027; HAMR exabyte output expected dominant by late 2026.** CEO Mosley framed it: "Seagate is entering a new era of structural growth as AI applications amplify data creation and support sustained storage demand." Provisional LONG thesis would argue: even at +12-17% post-print reaction, the magnitude of (a) the multi-year visibility step-up to 20%+ annual growth, (b) the contracts-through-2027 visibility, (c) the credit-rating upgrade signaling franchise transformation, and (d) the structural HDD/AI demand inflection collectively justify continued upside toward Rosenblatt's $1,000 PT or even just the consensus PT-weighted mean post-print (likely $700–800 area). Convergence target candidate: numerical level $740 (~+10% from $670–680 mid-day, ~50% gap-fill toward post-print PT-weighted mean).

**Adversarial counter-argument (decisive flaw on LONG side — multi-pattern):**

(L1) **Information-vs-sentiment test fails — sell-side immediate aggressive PT ratification is the most extreme L1 pattern observed in the experiment to date.** Within hours of the print, **at least 11 firms issued PT raises** per Schaeffer's count. The most aggressive:
- **Rosenblatt: PT $500 → $1,000 (+100% PT raise, Buy maintained)** — "towering over every competing target on the Street"; "the most bullish HDD call of 2026"; characterized as conviction in "structural HDD upcycle driven by AI-era storage demand."
- **BofA: PT raise (specific Wed amount not in research outputs, but BofA had ALREADY raised PT $450→$605 on Apr 20 — pre-print)** — confirms double-pattern: pre-print raise plus post-print raise.
- **Citi: PT raise** (specific amount not in research outputs).
- **Goldman Sachs: PT raise** (specific amount not in research outputs).
- **Barclays: PT raise** (specific amount not in research outputs; Barclays had been bullish pre-print).
- **Loop Capital: PT $700 → $800 (+14.3%, Buy maintained)** — note: Loop's pre-print PT was already $700, materially above the median.

This is structurally identical to INTC 2026-04-27 NO-GO L1 (Citi upgrade to Buy + Evercore +146% PT) AND NXPI 2026-04-29 NO-GO L1 (TD Cowen +24%, Needham +20%) — but more extreme by every measure: (i) Rosenblatt's +100% PT raise is the largest single PT raise in the experiment; (ii) the count of 11+ PT raises same-day is the largest count observed; (iii) the pre-existing PT distribution skewed bullish ("21 of 25 already had Buy" pre-print per Schaeffer's). Per criterion 4's information-vs-sentiment framing applied symmetrically: when 11+ analysts immediately and aggressively raise PTs (highest at $1,000, +100% from prior), that IS the empirical evidence that the post-print reaction is information-driven. The PT-weighted mean has shifted from pre-print median ~$518 to post-print median likely ~$700–750+ (with $1,000 high anchor pulling the mean upward). STX's realized post-print reaction (+12–17% on the stock) is approximately consistent with the PT-weighted increase. The reaction is appropriately sized; there is no sentiment-suppressed undershoot to exploit. **Decisive at the deepest possible level.**

(L2) **Pre-print rally + pre-print PT raises overlay — SBUX-pattern double-overlay on top of the L1 INTC pattern.** STX entered the print at record highs per Schaeffer's "extending last week's record-breaking run up the charts" framing. Pre-print PT raises in the trailing 4 weeks: BofA $450→$605 (+34.4%) on Apr 20 (just 8 days pre-print); Bernstein $500→$620 (+24%) on Apr 9 (19 days pre-print); Loop Capital had quietly raised to $700 pre-print; Argus $300→$450 (+50%) Jan 29 carrying recency-bias forward. The combination of (i) record-high pre-print level + (ii) BofA +34% PT raise 8 days before earnings = textbook SBUX pattern of "information already priced in via pre-print rally and sell-side positioning." STX's pre-print setup is even more extreme than SBUX's (SBUX had +18.75% trailing-30-day rally; STX has multi-week record-high run plus aggressive 8-day-pre-print PT raise from BofA). Per pre-mortem rev 7 / 2.14 recency-bias-deferral discipline: when input data exhibits significant recent extremes (record highs), recency-bias-discount fires. Here recency-bias would discount the print's information value because the market had already been re-rating STX upward in the days/weeks leading into the print, capturing much of the AI-storage narrative pricing in advance.

(L3) **Insider selling pattern is the largest observed in the experiment — strongly bearish marginal compounding signal.** Per GuruFocus Apr 29: **$46.9M of insider sales in past 3 months / 0 buys** (alternative source $46.48M; both an order of magnitude larger than V's $10.8M CEO sales or NXPI's $2.5M). At a market cap of $96–150B, $46.9M is small in percentage terms — but the unanimous selling pattern (zero buys) at a stock approaching record highs into a print is the inverse of what would be expected if insiders believed the AI-storage narrative was sentiment-suppressed below fundamental value. If management/insiders thought the stock was UNDERvalued at $580–620 pre-print, opportunistic insider buying or at minimum suspended selling would be the expected signal. Instead the pattern is heavy selling into the rally — consistent with insiders monetizing favorable valuation while the AI narrative is in full force. While 10b5-1 plans drive much of large-cap insider selling, the magnitude here is meaningfully large enough to warrant attention as compounding evidence against the LONG-extension thesis.

(L4) **Premium valuation is at extreme historical levels — limited multiple-expansion room for further re-rating.** Per GuruFocus, STX trades at **P/E 65.5x** (TickerNerd shows 48.6x with different earnings basis); both readings are at the high end of STX's historical valuation range. The STX story has historically been a cyclical-trough-to-peak earnings cycle where P/E compresses dramatically as earnings ramp into peak — the elevated current P/E reflects expectations of continued strong earnings growth, which is exactly what the Q3 print and Q4 guide deliver. There is little remaining "AI-narrative-discount" to be eliminated; the AI-narrative premium is fully present in the multiple. Further upside would require either (a) earnings exceeding the new $5.00 Q4 guide and 20%+ annual growth target, or (b) further multiple expansion beyond already-extreme levels. Neither is a Strategy-B-window-applicable mispricing.

(L5) **AI-narrative LONG is the textbook 2.4 narrative-over-fit + 2.20 textbook-rational-penalty trap — pre-mortem rev 7 KL note explicitly warns against this pattern.** The CEO's "new era of structural growth as AI applications amplify data creation" framing is the strongest possible AI-narrative-quality language. Per pre-mortem rev 7 Constraint 1, narrative-quality assessment ("THIS AI-storage inflection is structural and the +12–17% UNDERshoots a multi-year repricing") is itself the 2.4-self-referenced model judgment that biases the synthesis. The L1 sell-side immediate ratification is the external check: 11+ analysts, including the +100% Rosenblatt PT raise, have already explicitly priced the AI-storage narrative at the new level. Adding a further "but the narrative is even bigger than what sell-side has priced" claim is exactly the 2.4 narrative-over-fit pattern. Per pre-mortem rev 7 KL #1, B's mechanism IS the textbook-rational instinct — applying it here ("buy the AI-storage inflection because the multi-year visibility justifies it") is the textbook 2.20 trap that B's pre-mortem identifies as the dominant failure mode for AI-narrative-flagged setups.

(L6) **Cross-name peer-comparable evidence: WDC / SNDK / MU sympathy moves on STX print.** Per Yahoo: Western Digital +9%, SanDisk +7%, Micron +4% on Wed in sympathy with STX's print. These peer moves indicate the broader storage/memory sector is being re-rated upward on STX's print — i.e., the AI-storage narrative is being applied across the sector, not specifically suppressed on STX. There is no cross-name evidence of NAME-SPECIFIC suppression that the print would reveal as mispricing. Cross-name evidence supports information-driven characterization.

LONG declined. Criterion 4 information-vs-sentiment test fails decisively at the deepest possible evidentiary level. L1 (sell-side immediate aggressive PT ratification with Rosenblatt $1,000) is structurally identical to INTC/NXPI L1 pattern but more extreme; L2 (pre-print rally + pre-print PT raises) overlays the SBUX pre-print pattern; L3 (record insider selling) is the strongest observed bearish marginal signal in the experiment; L4 (extreme premium valuation) is compounding multiple-expansion ceiling; L5 (AI-narrative 2.4/2.20 trap) is the named pre-mortem failure pattern; L6 (peer sympathy moves) confirms sector-wide information-driven re-rating, not name-specific suppression.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +12–17% on a print with extreme post-rally + record-high entry + 65.5x P/E might fade toward $580–620 over 60 days as the AI-narrative euphoria moderates, insider selling continues, and the "20%+ annual growth" target gets stress-tested by next-quarter HDD demand reality.

**Why dismissed without full adversarial construction:** Shorting a record beat-and-raise + Fitch IG upgrade + 11+ aggressive sell-side PT raises (Rosenblatt $1,000) + multi-year contracts visibility commentary is an extreme 2.20 trap. The +12–17% reaction is appropriately sized given the magnitude of post-print sell-side PT increases. Additionally, shorting against the AI-narrative momentum at the most aggressive PT-raise count of the experiment is the textbook "fade fundamentals because the move feels big" 2.20 error. While insider selling and premium valuation are legitimate bearish signals, they belong in a Strategy-D long-horizon contrarian-narrative framework (multi-year HDD-cyclicality reversion), not a Strategy-B 60-day mean-reversion mechanism. SHORT criterion 4 fails by the same information-vs-sentiment logic that fails LONG, but flipped: if the reaction is information-driven, neither LONG nor SHORT mispricing exists. SHORT declined.

### 2.13 / 2.14 / 2.20 cross-checks

- **2.20 (textbook-rational penalty)** — STX SHORT is a clean 2.20 trap (fade-the-record-beat-with-aggressive-PT-raises-and-AI-narrative); declined above. STX LONG is the strongest 2.4 narrative-over-fit + 2.20 textbook-rational trap of the experiment (AI-narrative-momentum-extension on top of fully-ratified sell-side PT-raise consensus).
- **2.13 (miscalibration)** — A LONG conviction call on STX depends on assigning meaningful probability to "the +12–17% reaction UNDERshoots a multi-year structural AI-storage repricing despite Rosenblatt's $1,000 PT and 10 other firms raising PTs." The aggressive-multi-firm PT ratification is the strongest possible counter-evidence. 2.13's hard-wired 80% CI containing outcomes ~69% of the time penalizes overconfident probability assignments against extensively-corroborated evidence; the resulting effective probability after 2.13-discount is far below thesis-supporting threshold.
- **2.14 (recency bias on input data)** — Strongly fires against STX LONG. Stock at record highs entering the print after multi-week run; pre-print PT raises within the trailing 30 days (BofA +34% Apr 20). Per 2.14, recency-bias-defer discipline directly applies — pre-print rally absorbed much of the print's information into the price already, making post-print "extension" a recency-bias-extrapolation error pattern. This is the most extreme 2.14 trigger of the experiment to date (more extreme than SBUX's +18.75% trailing-30-day, given STX's multi-week record-breaking run).

### Sector concentration check (for completeness; not cap-binding)

STX = GICS Information Technology / Technology Hardware, Storage & Peripherals / Technology Hardware, Storage & Peripherals (data storage subindustry distinct from semiconductors). Strategy B currently holds IBM (IT/Software & IT Services subindustry) and HCA (Health Care/Health Care Providers subindustry). NXPI was rejected earlier this session (also IT/Semiconductors subindustry). If hypothetically STX cleared, B IT exposure would be at 2/3 by sector but each name in distinct sub-industry (Software vs Storage). Cap is not the binding constraint; criterion 4 is.

### Effect on book

No effect. No order staged for STX. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3 (IBM only), Health Care 1/3 (HCA), others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~STX B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 (multi-pattern decisive — INTC L1 sell-side immediate aggressive PT ratification with Rosenblatt $500→$1,000 +100% PT raise plus 10 other firms raising same-day; SBUX pre-print rally overlay with BofA $450→$605 8 days pre-print and stock at record highs; record insider selling $46.9M past 3 months; extreme premium valuation 65.5x P/E; AI-narrative 2.4/2.20 trap). No order staged.
- Consolidated Wed thesis construction sessions complete: SBUX NO-GO, V NO-GO, NXPI NO-GO, **STX NO-GO** = 4 NO-GOs Wed 2026-04-29.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook; calendar event already scheduled.
- MA Thu 2026-04-30 BMO print — peer to V; not a deferral trigger; routine Daily.md scan tomorrow.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow.
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at scan time.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META) — relevant for daily scan tomorrow.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session for screenshot-based check; conservative-branch action (pause new staging) would engage at trigger-failure. **This NO-GO does not interact with the hold-anomaly deferral** — there is no order to stage either way.
- Other Strategy B watchlist names with windows still open: MBLY, TXN, URI, SMCI, HAS, CAR, QS, CALX, BLD, AXTI, DPZ, OGN, MRVL, MDLZ, OMCL. None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure + KL note on AI-narrative 2.4 narrative-over-fit risk + KL note on sell-side-ratification as L1 smoking-gun).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; 2.6 no access to private information).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; no change from this session for STX).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; IBM clean undershoot via NOW + IGV cascade external suppression — STX has the OPPOSITE setup, at record highs with pre-print rally).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 HCA entry (GO with explicit lower-conviction posture; peer-corroboration via UHS/THC).
- Decision_Log.md 2026-04-27 (Sun) CHTR entry (NO-GO format precedent; cross-sectional information confirmation via CMCSA divergence).
- **Decision_Log.md 2026-04-27 (Mon, post-close) INTC entry (NO-GO format precedent — primary L1 pattern match; positive-direction with sell-side immediate aggressive ratification — Citi upgrade + Evercore +146% PT — STX is structurally identical but more extreme).**
- **Decision_Log.md 2026-04-29 SBUX entry (NO-GO format precedent — secondary pattern overlay; positive-direction L1 with pre-print PT raises priced into trailing-30-day momentum; STX overlays this pattern with even more extreme pre-print rally and pre-print PT raises).**
- Decision_Log.md 2026-04-29 V entry (NO-GO format precedent — different sub-pattern, regulatory-overhang persistence not applicable to STX).
- Decision_Log.md 2026-04-29 NXPI entry (NO-GO format precedent — same-session same-pattern instance; also positive-direction L1 INTC-pattern).
- STX Q3 FY26 8-K Ex-99.1 (BusinessWire / StockTitan / Investor Relations investors.seagate.com — full Q3 financials and Q4 guide).
- STX Q3 FY26 earnings call transcript (Motley Fool / Globe & Mail / Benzinga / Seeking Alpha Apr 28 5:00 PM ET — CEO Mosley AI-narrative commentary, raised annual revenue growth target, contracts-through-2027 visibility).
- Schaeffer's Apr 29 ("Profit Outlook Sends Seagate Technology Stock to Record" — record high $687, 11 PT raises, Rosenblatt $1,000 highest, "extending last week's record-breaking run").
- 247WallSt Apr 29 ("Rosenblatt Sets a $1,000 Seagate Price Target: Is This the Most Bullish HDD Call of 2026?" — $500→$1,000 PT raise, "towering over every competing target on the Street").
- Yahoo Finance Apr 29 ("Seagate Technology soared 12.13%"; alternative "+15.40%" reading).
- GuruFocus Apr 29 ("Seagate Technology STX Reports Strong Q3 Fiscal 2026 Earnings and Raises Growth Outlook" — P/E 65.5x premium valuation, $46.9M insider selling past 3 months).
- StockTitan Apr 28 (Q3 results release).
- Benzinga Apr 28 (full earnings call transcript — guide details, margin trajectory, capital allocation).
- Daily Political Apr 27 (pre-print PT context: Bernstein $500→$620 Apr 9, BofA $450→$605 Apr 20, Argus $300→$450 Jan 29, Wells Fargo $360→$450 Jan 28; pre-print 25-firm coverage with 21 Buy / 5 Hold).
- TickerNerd / MarketBeat / Public.com pre-print PT data (median ~$468–518, range $375–$700).
- Daily.md 2026-04-29 scan ("STX Strategy B; data-storage AI angle" candidate flagging).
- Experiment_Parameters.md (commission-disregarded-at-decision-time per 2026-04-27 protocol; America/Denver tz).

### Theater-check on this orchestrator review

Considered whether STX's "data-storage AI angle" Daily.md framing creates any path to criterion 4 clearance (e.g., via Mozaic 5 50TB drives as transformative narrative-shift event distinct from incremental margin expansion). Counter-argument: per L5 above, narrative-quality assessment is exactly the 2.4-self-referenced model judgment that pre-mortem rev 7 names as the dominant failure mode for AI-narrative-flagged setups. The L1 external check is decisive: 11+ analysts have already aggressively re-rated PTs, with Rosenblatt at $1,000 (the most bullish HDD call of 2026 per 247WallSt). Adding a "but Mozaic 5 narrative is even bigger than what Rosenblatt $1,000 has priced" claim is exactly the 2.4 narrative-over-fit error pattern. Pre-mortem rev 7 KL note specifically warns that AI-narrative-prints are vulnerable to this trap — and STX is the most extreme AI-narrative-print of the experiment.

Considered whether the Rosenblatt $1,000 PT might itself be a 2.4 sell-side narrative-quality-extension that doesn't reflect underlying mispricing — i.e., could the print be undershooting even relative to a sober-PT-anchor? Counter-argument: this requires arguing the SELL-SIDE consensus is incorrect at the new elevated level. Strategy B's mechanism is identifying market mispricings, not identifying sell-side consensus mispricings. If sell-side has aggressively re-rated PTs (median post-print likely shifting from $518 to $700+ area with the $1,000 high anchor), the realized +12–17% reaction approximately matches the PT-weighted reset. There is no measurable mispricing relative to sell-side consensus. Treating "Rosenblatt is too aggressive" as a basis for shorting OR "Rosenblatt is right but market under-prices" as a basis for going long requires Claude to make a sell-side-correctness judgment that is out-of-scope for B's mispricing-exploitation mechanism. Per pre-mortem rev 7 KL, B is not a "follow-the-PT-leader" or "fade-the-PT-leader" strategy; it is a post-event-mispricing-exploitation strategy. With no measurable mispricing, B does not engage.

Considered whether the multi-year visibility commentary ("nearline capacity almost fully allocated through calendar 2027 with finalized build-to-order contracts through fiscal 2027") deserves separate weight as a structural revelation that is inherently undershoot-prone given the difficulty of pricing multi-year visibility. Counter-argument: the multi-year visibility commentary was the explicit basis for Rosenblatt's $1,000 PT and Loop's $800 PT — sell-side has explicitly priced this commentary. The information is fully ratified at the new level. The argument "the multi-year commentary deserves even MORE weight than what sell-side has priced" requires Claude to second-guess the most aggressive PT-raise community of the experiment, which is itself a 2.13 miscalibration error pattern.

Considered whether to defer the STX decision pending tomorrow's MA / AAPL / AMZN prints to gather more cross-sectional information on AI-narrative momentum. Counter-argument: per protocol, deferral requires a trigger that resolves the binding constraint. STX's binding constraint is criterion 4 information-vs-sentiment test, which has been resolved decisively by post-print sell-side immediate aggressive PT ratification at the most extreme level of the experiment. No tomorrow print would change that resolution. Decision is made now without deferral.

Considered whether the size of the AI-narrative + insider-selling + premium-valuation combination might actually flip toward a SHORT thesis at marginal conviction. Counter-argument: per the SHORT dismissal above, the print magnitude (Q3 record beat + Q4 guide +9% above + raised annual target + Fitch IG upgrade) makes any 60-day SHORT a textbook 2.20 trap. The bearish factors (insider selling, premium valuation, AI-narrative-extension risk) are legitimate but operate on multi-year cyclicality timelines that are mismatched with B's 60-day window. A potential D-side SHORT thesis (HDD cyclicality reversion within 12-24 months) is conceivable but out-of-scope for this session. Current session is Strategy B only; no SHORT-side staging.

Modulo these four considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT as a 2.20 trap).

### Compaction-survival note

**Strategy B STX thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** STX-thesis-construction COMPLETE; STX-NO-GO declined on criterion 4 with most decisive multi-pattern evidence of the experiment to date (INTC L1 sell-side immediate aggressive PT ratification — Rosenblatt $500→$1,000 +100% PT raise plus 10 other firms raising PTs same-day, the highest count and most aggressive single PT raise observed; SBUX pre-print rally overlay with BofA $450→$605 8 days pre-print and stock at record highs extending multi-week run; record-magnitude $46.9M insider selling past 3 months / 0 buys; 65.5x P/E premium valuation; AI-narrative 2.4/2.20 trap explicit pre-mortem-named failure pattern). Criterion 1 mechanically clears with massive cushion at +12–17% Tue close → Wed close. No order staged; no Portfolio_Ledger.md modification this session. STX remains a closed name from a Strategy B perspective unless and until (a) the post-print PT ratification gets meaningfully reversed (unlikely on a 60-day timescale given the magnitude of consensus shift), OR (b) a transient external suppression event meaningfully compresses STX's price below the post-print PT range. Strategy B sector concentration in IT remains at 1/3 cap usage (IBM only).

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **seventh** NO-GO of the experiment to date on criterion 4 grounds (NOW 2026-04-25; CHTR 2026-04-27; INTC 2026-04-27; SBUX 2026-04-29; V 2026-04-29; NXPI 2026-04-29; STX 2026-04-29). Eight Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO, V-NO-GO, NXPI-NO-GO, STX-NO-GO = **2 GO / 7 NO-GO (22%/78%).** **All seven NO-GOs route through criterion 4 information-vs-sentiment test.** The criterion-4-NO-GO rate has tightened further with the STX disposition. The 30-trade-gate review topic remains open; the framework's positive-direction selectivity is structurally tight, which is consistent with B's pre-mortem-identified structural exposure to 2.20 textbook-rational-penalty.

**Sub-pattern taxonomy for criterion 4 NO-GOs (7 cases observed; STX adds new "double-pattern overlay" instance):**

1. **Negative-direction "information-confirmed-by-cross-section" pattern** (NOW, CHTR): Stock down materially after print; cross-sectional peer evidence confirms negative information is structural. LONG mean-reversion fails.

2. **Positive-direction "sell-side-immediate-ratification" pattern** (INTC, NXPI, **STX as cleanest instance**): Stock up materially after print on raised guide / new strategic disclosure; sell-side immediately and aggressively raises PTs. INTC: Citi upgrade + Evercore +146% PT; NXPI: TD Cowen +24%, Needham +20%, Loop +5.5%, Citi +5.88%; **STX: Rosenblatt +100% to $1,000, plus 10 other firms raising same-day** (most extreme magnitude + count of experiment). LONG-extension fails on L1 information-pricing. SHORT-mean-reversion fails as 2.20 trap.

3. **Positive-direction "information-priced-via-pre-print-rally" pattern** (SBUX, **STX as overlay instance**): Stock up modestly-to-large-magnitude after print; pre-print sell-side raised PTs into the print and trailing momentum absorbed strong-print expectation. SBUX: pre-print PT raises (Stifel +$10, JPM +$5, Citi +$7) + trailing-30-day +18.75%; **STX: pre-print BofA $450→$605 (Apr 20, 8 days pre-print) +34.4% PT raise + Bernstein $500→$620 (Apr 9) +24% PT raise + stock at record highs extending multi-week run.** STX is the strongest instance of this pattern in the experiment.

4. **Positive-direction "regulatory-overhang-persistence" pattern** (V): Stock up after print on strong operational results + capital return; pre-print sell-side CUT PTs on persistent structural overhang; print doesn't address overhang. Multi-quarter resolution timeline mismatched with B's 60-day window.

**Key STX-specific notes for future Claude:**

(a) STX represents the cleanest "double-pattern overlay" instance in the experiment — it manifests sub-patterns 2 AND 3 simultaneously (sell-side immediate aggressive ratification + pre-print rally + pre-print PT raises). Future B thesis-construction sessions on AI-narrative-flagged names (XLU AI-power, AI-storage, AI-data-center semis, etc.) should specifically scan for both patterns simultaneously when the underlying fundamental story has clear AI-narrative-momentum quality.

(b) The Rosenblatt $500→$1,000 (+100%) PT raise is now the experiment's largest single PT raise observed in a NO-GO L1 case. Future thesis-construction should treat any single PT raise of +50% or more as exceptionally strong L1 evidence of information-driven pricing.

(c) Insider selling magnitude of $46.9M (past 3 months) is the experiment's largest observed bearish marginal compounding signal. While insider selling at large-cap names is largely 10b5-1 driven and not strongly predictive in isolation, magnitudes of this scale combined with 0-buy unanimous direction and timing into record-high stock prices warrant flagging as compounding-against-LONG evidence.

(d) AI-narrative-flagged setups are explicitly named in pre-mortem rev 7 KL as 2.4 narrative-over-fit + 2.20 textbook-rational-penalty traps. Future Claude should treat "AI angle" or "data-storage AI angle" or analogous Daily.md narrative-flagged setups as PRIMA FACIE high-risk for criterion 4 fail, requiring extra-stringent L1 information-pricing evidence to clear.

(e) STX's "fully allocated nearline capacity through 2027 with build-to-order contracts" multi-year visibility commentary is the most extreme structural-narrative-claim observed in an experiment B candidate. The fact that this commentary was IMMEDIATELY priced by sell-side (Rosenblatt explicitly cited multi-year visibility as basis for $1,000 PT) demonstrates that even structural-narrative claims of this magnitude get rapidly information-priced when sell-side has its own AI-narrative-extension framework. Multi-year visibility is NOT inherently undershoot-prone; it gets priced as sell-side ratifies it.

**Lesson for future Daily.md scans on AI-narrative framings:** AI-narrative-flagged setups (AI-storage, AI-semis, AI-power, AI-data-center, AI-cloud, AI-software) are particularly vulnerable to criterion 4 fails because the AI-narrative momentum operates through sell-side PT-raise channels that fully price the narrative information at the realized post-event level. The Daily.md scan flagging an AI-angle is a forward-flagging-level signal for "merits thesis construction" — but the prior on AI-narrative setups clearing criterion 4 is structurally low. STX is the cleanest example of an AI-narrative-flagged daily-scan candidate that does not survive thesis construction.

**Cumulative Wed 2026-04-29 thesis-construction session summary:** Four B thesis constructions completed (SBUX, V, NXPI, STX) — all four NO-GO on criterion 4 with distinct sub-pattern instances. Combined with prior sessions: 2 GO / 7 NO-GO total. The four Wed NO-GOs cover all four positive-direction sub-patterns of criterion 4 fail (NXPI+STX = INTC L1 pattern; STX = SBUX pre-print rally pattern overlay; SBUX = pure pre-print rally; V = regulatory overhang). The framework is operating with high selectivity on positive-direction post-event setups, which is consistent with pre-mortem rev 7 KL identification of B's structural exposure to 2.20 textbook-rational-penalty.

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — MDLZ (Mondelez International) NO-GO (criterion 4 decisive failure on LONG-extension; hybrid V-pattern structural-overhang-persistence + IBM-partial-refutation overlay; criterion 1 marginal at +4-5% borderline; mild post-print sell-side ratification confirms information-driven characterization); no order staged

**Trigger:** B-thesis construction requested for MDLZ, with framing "Already on watchlist; promote to active." MDLZ was flagged on the Apr 27 Daily.md scan as a Strategy B post-event candidate (Q1 2026 print Apr 28 AMC; revenue/EPS beat with reaffirmed FY26 guide). This session promotes MDLZ from watchlist to active thesis-construction status and applies Strategy B's entry criteria.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA both open in B; IT 1/3 and Health Care 1/3 used; Consumer Staples 0/3); Decision_Log.md prior precedents — IBM 2026-04-25 GO (clean undershoot via NOW + IGV cascade — partially analogous to MDLZ's pre-print pessimism but missing the same-night transient external suppression event), NOW 2026-04-25 NO-GO, HCA 2026-04-27 GO, CHTR 2026-04-27 NO-GO, INTC 2026-04-27 NO-GO, SBUX 2026-04-29 NO-GO (positive-direction L1 with pre-print PT raises priced into momentum — different sub-pattern from MDLZ which had pre-print PT cuts), **V 2026-04-29 NO-GO (positive-direction L1 with regulatory-overhang persistence — most directly comparable precedent for MDLZ; cocoa-cost overhang is the analogous structural feature, with V-pattern's pre-print PT cuts on structural concerns + post-print mild PT response = direct match for MDLZ's pre-print bearish revisions + TD Cowen +$2 mild PT raise)**, NXPI 2026-04-29 NO-GO (positive-direction L1 INTC pattern — different from MDLZ; NXPI had aggressive PT raises, MDLZ had only TD Cowen +$2), STX 2026-04-29 NO-GO (cleanest L1 instance to date; MDLZ is much weaker reaction magnitude); GEV 2026-04-29 NO-GO defer (Strategy D, not directly relevant); MDLZ Q1 2026 8-K Ex-99 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0001103982/000162828026027915/mdlzearningsreleasecontent.htm Apr 28, 2026; **Q1 net revenues $10.08B +8.2% reported / +3% organic vs $9.79B est = +3% beat; volume/mix -0.5%; pricing/mix +3.5pp; gross profit +$373M with margin +170bps to 27.8%; diluted EPS $0.44 +41.9% YoY; non-GAAP adj. EPS $0.67 vs $0.61 est = +9.84% beat but DOWN -14.9% on constant currency YoY (vs $0.74 prior-year quarter); adj. operating income -19% constant currency from cocoa cost inflation phasing through; FCF $0.2B (margin 1.5% vs 8.8% prior-year); operating margin 8% in line; capital return $0.6B; FY26 guide REAFFIRMED at organic net revenue flat-to-+2%, adj EPS flat-to-+5% constant currency, FCF ~$3B**); MDLZ Q1 2026 earnings call transcript (Motley Fool / Yahoo / Investing.com; CEO Van de Put: "solid first quarter results led by strong top-line growth in our Emerging Markets while Developed Market growth showed signs of improvement"; Emerging Markets +6.3% organic with India/Brazil/Mexico strong, China softer; Europe Easter strong; US "consumer is quite concerned about their financial situation"; "shopping baskets have not increased in value over three years despite rising unit prices"; CFO Zaramella: "we need also to address some headwinds that we didn't have in our original forecast, particularly as they stem out of the Middle East crisis"; "if EPS upside materializes, we plan to reinvest in the business" — explicit reason guide was reaffirmed not raised; expectations for "strong 2027 EPS growth" as cocoa headwinds moderate); FinancialContent / StockStory ("Mondelez (NASDAQ:MDLZ) Q1 CY2026: Beats On Revenue"; "stock traded up 1.6% to $59.50 immediately following the results"; **"Adjusted EBITDA: $1.15 billion vs analyst estimates of $1.46 billion (11.4% margin, 21% miss)"**; "Free Cash Flow Margin: 1.5%, down from 8.8% in the same quarter last year"; "sell-side analysts expect revenue to grow 1.6% over the next 12 months, a deceleration versus the last three years. This projection is underwhelming and suggests its products will face some demand challenges"); Investing.com Apr 28 ("Mondelez's stock rose 1.64% in after-hours trading, reaching $58.36"; pre-AH price $57.42 implied); Investing.com Apr 29 TD Cowen note ("**TD Cowen raised its price target on Mondelez International to $67 from $65 while maintaining a Buy rating** ... raised its 2026 earnings per share estimate for Mondelez to $3.09 based on favorable outcomes from European retail negotiations, momentum in emerging markets, and stronger execution in the United States. This aligns with the broader analyst consensus forecasting $3.01 per share for fiscal 2026"); QuiverQuant Apr 29 ("Mondelez International (MDLZ) is up 4.3% today"); Motley Fool Apr 29 transcript header ("Mondelez International (MDLZ +5.04%)"); **StockStory Apr 26 pre-print preview** — critically important sentiment data: "**heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing in majority downward revisions over the last 30 days**"; "Mondelez has missed Wall Street's revenue estimates multiple times over the last two years"; "Mondelez is down 1.2% during the same time and is heading into earnings with an average analyst price target of $66.32 (compared to the current share price of $57.57)"; **Public.com pre-print** "anticipated 60bps gross margin contraction for FY26... -7.5% decline in sales volume for Q1 2026" (pre-print expectation); pre-print PT consensus $66.32 per StockStory / $66 per Public.com / $68 per StockAnalysis (18 analysts) / $66.11 per Marketbeat; Daily.md 2026-04-29 scan; Experiment_Parameters.md (commission-disregarded-at-decision-time; America/Denver tz).

### Decision

**MDLZ — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing briefly considered and dismissed (canonical 2.20 textbook-rational trap on a beat-and-reaffirmed-guide print where pre-print expectations had been set very low).**

Failed Strategy B entry criterion 4 with hybrid sub-pattern evidence — the post-event reaction is approximately information-driven via the V-pattern overhang-persistence mechanism (cocoa cost structural pressure remains unresolved despite Q1 print's volume/organic-growth refutation of pre-print pessimism), confirmed by the modest TD Cowen +$2 PT raise that is consistent with mild appropriate-pricing rather than aggressive ratification or undershoot. Criterion 1 is mechanically marginal at +4-5% (borderline) — does not lift the criterion 4 disposition either way.

### Mechanical eligibility (criteria 1, 5, instrument rule) — criterion 1 marginal

- **Instrument rule cleared with cushion:** US-listed common (NASDAQ); market cap ~$75.13B per TD Cowen note (>>$2B floor); 30-day ADV vastly above $10M floor; long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 5 cleared:** No A position open in MDLZ.
- **Criterion 1 marginal at +4-5%.** Pre-event close = Tue Apr 28 close ~$57.42 (implied from "Mondelez's stock rose 1.64% in after-hours trading, reaching $58.36" per Investing.com — pre-AH price $58.36 / 1.0164 = $57.42, approximately consistent with Apr 26 StockStory reading $57.57). Post-event close = Wed Apr 29 close (TBD at scan time; intraday +4.3% per Quiver / +5.04% per Motley Fool — both readings are mid-day Wed snapshots, with the implied Wed level around $59.89 to $60.32). The criterion 1 disposition depends on the exact Wed close: if final close lands at +4.3% (or ~$60), criterion 1 marginally fails the ≥5% threshold; if final close lands at +5.04% (or ~$60.30+), criterion 1 marginally clears. **Per IBM-precedent criterion-1-as-binary disposition mode: borderline — not the decisive constraint either way.** Criterion 4 is decisive irrespective of criterion 1's marginal disposition (same handling as SBUX 2026-04-29 NO-GO precedent where criterion 1 was also marginal at +4.27% intraday and criterion 4 was treated as the primary ground).

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q1 2026 print materially refuted bearish pre-print expectations on volume and organic growth: actual volume/mix -0.5% vs pre-print expected -7.5% (per Public.com pre-print preview snippet) = +700bps better than feared; actual organic net revenue +3% vs pre-print expected +0.6% (per TD Cowen post-print framing) = +240bps better. Revenue $10.08B (+3% beat vs $9.79B est); adj EPS $0.67 (+9.84% beat vs $0.61). Emerging Markets organic +6.3% with India double-digit, Brazil/Mexico solid; China softer but improving sequentially. Developed Markets "showed signs of improvement" per CEO with European Easter strong. Pre-print sentiment was elevated bearish: "increasingly bearish with revenue estimates seeing majority downward revisions over the last 30 days" (StockStory Apr 26); MDLZ trailing-30-day -1.2% vs shelf-stable food peer average +4.3%. Pre-print PT consensus $66.32 implied +15% upside from $57.57. The volume/organic-growth refutation is genuinely positive new information that contradicts the trajectory of pre-print pessimism. TD Cowen post-print: PT $65→$67 (+$2, +3%, Buy maintained), raised 2026 EPS est to $3.09 (vs $3.01 consensus). Provisional LONG thesis would argue: pre-print pessimism on cocoa-cost margin headwinds had over-priced the volume/demand-side risk; the print's volume refutation creates a 60-day mean-reversion-eligible setup toward consensus PT $66-68, with 50% gap-fill target $63 (+5% from $60 estimated mid-day Wed) plausible. Cocoa headwinds are management-described as "moderating into 2027" — a transient cyclical-input issue, not a structural-displacement issue.

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails — the V-pattern structural-overhang-persistence framing applies despite the IBM-partial-refutation features.** The cocoa cost inflation overhang that drove pre-print pessimism is ITSELF NOT REFUTED by the Q1 print — it is in fact CONFIRMED by the print's adj. EBITDA -21% miss vs $1.46B est (actual $1.15B), adj. operating income -19% constant currency, gross margin -170bps, FCF margin compressed from 8.8% to 1.5%, and the explicit guide reaffirmation rather than raise. Management's choice to "reinvest any EPS upside in the business" (per CFO Zaramella) is a signal that the cocoa-cost / margin-compression issue is durable enough that flow-through to EPS guide upside is not warranted. The Q1 print delivered (a) volume/organic-revenue better than pre-print pessimism (positive surprise) AND (b) margin/EBITDA worse than pre-print expectations (negative surprise) — these partially offset. The realized +4-5% reaction approximately reflects this offset: positive enough to beat the -1.2% trailing-30-day-into-print pessimism, but bounded by the ongoing margin pressure and reaffirmed (not raised) guide.

The structural overhang (cocoa costs) operates on multi-quarter resolution timelines per management commentary — "we expect strong 2027 EPS growth as cocoa headwinds moderate." Cocoa pricing depends on West Africa supply dynamics, weather, agronomy, and global demand patterns that operate on 1-2 year cycles. **Strategy B's 60-day window is structurally mismatched with cocoa-cycle resolution.** This is the same strategy-mechanism mismatch that fired against V (regulatory-overhang multi-quarter resolution timeline). **Decisive on the same logic as V 2026-04-29 NO-GO L4.**

(L2) **Post-print sell-side response is mild — TD Cowen +$2 / +3% PT raise is approximately appropriate-pricing of incremental information, not sentiment-suppression undershoot.** Compare to:
- INTC L1 ratification: Citi upgrade + Evercore +146% PT (extreme aggressive)
- NXPI L1: TD Cowen +24%, Needham +20%, Loop +5.5%, Citi +5.88% (multi-firm aggressive)
- STX L1: 11+ firms raising PTs Wednesday with Rosenblatt $500→$1,000 +100% (most extreme of experiment)
- SBUX L1: Guggenheim +$2 mild PT raise (+2%)
- V L1: post-print consensus PT approximately flat (~$388 vs pre-print $392)
- **MDLZ: TD Cowen +$2 (+3% PT raise) — directly comparable to SBUX/V mild post-print pattern**

The mild PT raise pattern is the smoking-gun for information-driven characterization: when sell-side raises PTs only modestly post-print, that's the empirical evidence the realized reaction approximately matches the incremental information value. Aggressive PT raises would correspond to material mispricing under information-arrival; mild raises correspond to approximately-correct pricing. MDLZ's TD Cowen +$2 puts it firmly in the SBUX/V mild-response camp.

Note: only 1 firm's post-print PT action (TD Cowen) is documented in the available sources at scan time. Other firms may have moved PTs but typically the first 24-48 hours of post-print sell-side action is documented when the moves are aggressive. The absence of multi-firm aggressive PT raises documented in initial post-print coverage is itself informative — the print was not viewed as warranting aggressive multi-firm PT shifts.

(L3) **Multi-headwind structural backdrop NOT addressed by the print:**
- *Cocoa cost inflation* — confirmed by margin metrics; multi-quarter resolution timeline
- *Middle East crisis* — explicitly cited by CFO as new cost headwind from supply chain + oil/packaging inflation; multi-quarter geopolitical resolution
- *US consumer weakness* — CEO described US consumer as "quite concerned about their financial situation"; "shopping baskets have not increased in value over three years"; multi-quarter consumer-sentiment resolution timeline
- *China softness* — partially improving but still soft; multi-quarter macro recovery timeline
- *Pricing-led growth not sustainable indefinitely* — Q1 organic +3% was driven by net pricing +3.5pp offset by volume/mix -0.5%; multi-quarter pushback risk as consumers respond to cumulative price increases

These are NOT 60-day-window-resolvable headwinds. The LONG thesis would require all of these to fade or be mitigated within 60 days — implausible. Per pre-mortem rev 7 KL note on strategy-mechanism mismatch, MDLZ's recovery thesis aligns more naturally with Strategy D long-horizon multi-year mechanism than with B's 60-day window.

(L4) **Cross-name peer-comparable evidence supports information-driven characterization.** Per StockStory pre-print preview: "Lamb Weston delivered year-on-year revenue growth of 2.9%, beating analysts' expectations by 5.2%, and McCormick reported revenues up 16.7%, topping estimates by 5.1%. Lamb Weston traded down 6.9% following the results while McCormick was also down 9.9%." Both peers BEAT on revenue but TRADED DOWN materially post-print due to margin/cost pressures (cocoa for MDLZ; potatoes/inputs for LW; spices for MKC). The shelf-stable food peer set is showing a consistent pattern of "revenue beat, margin pressure, stock disappointment" reaction. MDLZ's +4-5% reaction is actually FAVORABLE relative to LW's -6.9% and MKC's -9.9% — suggesting the market is treating MDLZ's print better than peers despite the EBITDA miss. There's no measurable sentiment-suppression at the peer-relative level; MDLZ has reacted appropriately given the mixed quality of the print.

(L5) **Pre-print PT cut pattern was structural-concerns-pricing (V-class), NOT pre-event-pessimism-priced-into-momentum (SBUX-class) — but the print does not address the structural concerns.** Pre-print "increasingly bearish revenue revisions" were driven by anticipated cocoa-cost / consumer / margin issues. The Q1 print refutes the volume side of these concerns but CONFIRMS the margin side. The structural overhang (cocoa, consumer, geopolitical) remains. This is the V-pattern: pre-print PT cuts on structural overhang + print delivers on top-line + structural overhang persists + post-print PT response mild. The IBM-pattern would require a clean transient external suppression event coincident with the print (e.g., a sector-contagion event compressing MDLZ-specific information); no such event exists for MDLZ.

LONG declined. Criterion 4 information-vs-sentiment test fails on V-pattern structural-overhang-persistence framing (L1 decisive); L2 confirms via post-print sell-side mild response; L3 confirms via multi-headwind structural backdrop with multi-quarter timelines; L4 confirms via peer-comparable evidence (LW/MKC traded down on similar margin-pressure dynamics); L5 confirms the V-pattern sub-classification.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +4-5% on a print with -21% EBITDA miss and -19% operating income decline might fade toward $57-58 over 60 days as cocoa cost pressures continue and the volume/pricing dynamic (+3.5pp pricing offset by -0.5pp volume) becomes harder to maintain.

**Why dismissed without full adversarial construction:** Shorting against a beat-and-reaffirmed-guide print with volume materially better than pre-print pessimism (-0.5% actual vs -7.5% expected) is a partial 2.20 trap. The +4-5% reaction is appropriately bounded given mixed print quality. The bearish factors (cocoa, consumer, margin) operate on multi-quarter timelines that may NOT resolve within 60 days. SHORT criterion 4 fails by the same information-vs-sentiment logic that fails LONG, but flipped: if the reaction is approximately information-driven, neither LONG nor SHORT mispricing exists. SHORT declined.

### 2.13 / 2.14 / 2.20 cross-checks

- **2.20 (textbook-rational penalty)** — MDLZ SHORT is a partial 2.20 trap (fade-the-print-with-margin-miss-on-overhang); declined above. MDLZ LONG is closer to 2.4 territory (narrative-over-fit on the "cocoa headwinds will moderate into 2027" + "volume refuted pessimism" framing as supporting undershoot).
- **2.13 (miscalibration)** — A LONG conviction call on MDLZ depends on assigning meaningful probability to "cocoa headwinds resolve favorably + Middle East geopolitical risk fades + US consumer sentiment recovers within 60 days." Multi-factor structural-question assignments are 2.13-discounted aggressively; effective probability after discount is below thesis-supporting threshold.
- **2.14 (recency bias on input data)** — MDLZ trailing-30-day was -1.2% pre-print (NOT a rallying-into-the-print pattern, unlike SBUX). 2.14 is approximately neutral on MDLZ; not a compounding factor in either direction. The volume refutation has materially shifted the trailing-30-day reading post-print to +4-5% in just one day; the trailing reading has become a partial-recency-bias-input to be weighted with the longer pre-print trajectory.

### Sector concentration check (for completeness; not cap-binding)

MDLZ = GICS Consumer Staples / Food, Beverage & Tobacco / Food Products. Strategy B currently holds IBM (IT) and HCA (Health Care). Adding MDLZ would put Consumer Staples at 1/3 — well within 3-per-sector cap. Cap is not the binding constraint; criterion 4 is.

### Effect on book

No effect. No order staged for MDLZ. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3, Health Care 1/3, Consumer Staples 0/3, others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~MDLZ B-thesis construction (watchlist promotion)~~ COMPLETE — NO-GO declined on criterion 4 (V-pattern structural-overhang-persistence on cocoa cost / consumer / Middle East / US consumer-weakness multi-headwind backdrop; print delivered volume/organic-revenue refutation but margin/EBITDA confirmation; mild TD Cowen +$2 post-print PT raise consistent with information-driven appropriate-pricing). No order staged.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook (B position).
- MA Thu 2026-04-30 BMO print — peer to V; not a deferral trigger.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow.
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at scan time.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META) — relevant for daily scan tomorrow.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session.
- GEV May 22 trailing-30-day re-screen + May 13 D long-list interim re-screen — calendar events scheduled per 2026-04-29 GEV entry.
- Other Strategy B watchlist names with windows still open: MBLY, TXN, URI, SMCI, HAS, CAR, QS, CALX, BLD, AXTI, DPZ, OGN, MRVL, OMCL. None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 textbook-rational-penalty exposure + KL note on strategy-mechanism mismatch).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; 2.6 no access to private information).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; no change from this session for MDLZ).
- Decision_Log.md 2026-04-25 IBM entry (GO format precedent; IBM clean undershoot via NOW + IGV cascade external suppression — MDLZ has IBM-pattern volume-refutation feature but lacks the transient external suppression event that distinguishes IBM's GO).
- Decision_Log.md 2026-04-25 NOW entry (NO-GO format precedent; criterion 4 failure on negative-direction move).
- Decision_Log.md 2026-04-27 HCA entry (GO with explicit lower-conviction posture; peer-corroboration via UHS/THC).
- Decision_Log.md 2026-04-27 (Sun) CHTR entry (NO-GO format precedent; cross-sectional information confirmation via CMCSA divergence).
- Decision_Log.md 2026-04-27 (Mon, post-close) INTC entry (NO-GO format precedent; positive-direction L1 sell-side immediate ratification — MDLZ is opposite of INTC pattern, mild PT response not aggressive).
- Decision_Log.md 2026-04-29 SBUX entry (NO-GO format precedent — mild post-print PT response analogue; different sub-pattern: SBUX had pre-print PT raises priced into trailing-30-day rally; MDLZ had pre-print PT cuts on structural concerns).
- **Decision_Log.md 2026-04-29 V entry (NO-GO format precedent — DIRECTLY COMPARABLE; both MDLZ and V have pre-print sell-side PT cuts on structural overhang + print delivers on top-line + structural overhang persists + post-print PT response mild. MDLZ's overhang is cocoa-cost-cycle; V's is regulatory. Both fail criterion 4 on multi-quarter-resolution-vs-60-day-window strategy-mechanism mismatch).**
- Decision_Log.md 2026-04-29 NXPI entry (NO-GO format precedent — MDLZ is opposite pattern; NXPI had aggressive sell-side PT raises, MDLZ had only mild TD Cowen +$2).
- Decision_Log.md 2026-04-29 STX entry (NO-GO format precedent — most extreme L1 instance; MDLZ is at the opposite end of the magnitude/aggression spectrum).
- MDLZ Q1 2026 8-K Ex-99 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0001103982/000162828026027915/mdlzearningsreleasecontent.htm Apr 28 2026; full Q1 financials and reaffirmed FY26 guide).
- MDLZ Q1 2026 earnings call transcript (Motley Fool / Yahoo / Investing.com Apr 28 5:00 PM ET — CEO Van de Put on emerging markets / developed markets / consumer; CFO Zaramella on Middle East cost headwinds and "reinvest EPS upside" rationale; "strong 2027 EPS growth" expectation).
- StockStory Apr 28 ("Mondelez Q1 CY2026: Beats On Revenue" — adj EBITDA -21% miss; FCF margin 1.5% from 8.8%; sell-side projects 1.6% revenue growth NTM = "underwhelming").
- StockStory Apr 26 pre-print preview ("increasingly bearish with revenue estimates seeing majority downward revisions over last 30 days"; "$57.57 vs PT $66.32 = +15% upside"; trailing-30-day -1.2% vs sector +4.3%; peer LW -6.9% / MKC -9.9% post-print analogues despite revenue beats).
- Investing.com Apr 28 (Tue AH +1.64% to $58.36; pre-AH price $57.42).
- Investing.com Apr 29 TD Cowen note (PT $65→$67 +3% raise, Buy maintained; raised 2026 EPS estimate $3.09 vs $3.01 consensus).
- QuiverQuant Apr 29 ("MDLZ is up 4.3% today").
- Motley Fool Apr 29 ("MDLZ +5.04%").
- Public.com / Marketbeat / StockAnalysis pre-print PT data (consensus $66-68).
- Daily Political pre-print summary.
- Daily.md 2026-04-29 scan ("MDLZ" candidate flagging).
- Experiment_Parameters.md (commission-disregarded-at-decision-time per 2026-04-27 protocol).

### Theater-check on this orchestrator review

Considered whether MDLZ's volume/organic-revenue refutation of pre-print expectations (-0.5% actual vs -7.5% expected, +3% organic vs +0.6% expected) constitutes IBM-style sentiment-suppression undershoot evidence. Counter-argument: the refutation is real on the volume/top-line side, but the print simultaneously CONFIRMS the margin/EBITDA-side of pre-print pessimism (adj EBITDA -21% miss; operating income -19%; gross margin -170bps). The cumulative information content is mixed, not unambiguously bullish. The +4-5% realized reaction reflects the offset between volume refutation (positive) and margin confirmation (negative). The IBM precedent specifically required the print to refute the suppression mechanism — for MDLZ, the cocoa-cost suppression mechanism is NOT refuted, it's confirmed. The volume-side information is NOT the binding suppression mechanism for MDLZ's pre-print discount.

Considered whether MDLZ's pre-print PT cuts on structural concerns + post-print mild PT response is sufficiently distinct from V's pattern to warrant separate sub-pattern classification. Counter-argument: both V and MDLZ exhibit identical pattern structure: (1) pre-print PT cuts on structural concerns; (2) print delivers on top-line beats; (3) structural overhang remains unresolved; (4) post-print PT response mild. The only differentiating feature is the SOURCE of the structural overhang (regulatory for V; cocoa-cost / consumer / geopolitical for MDLZ). Both share the same multi-quarter-resolution-vs-60-day-window strategy-mechanism mismatch. MDLZ confirms the V sub-pattern as a category of post-event setups where the structural overhang is the binding feature even when fundamental volume/revenue surprises favorable.

Considered whether the IBM-volume-refutation + V-margin-confirmation hybrid pattern deserves separate sub-pattern classification (sub-pattern 5 in the criterion 4 NO-GO taxonomy). Counter-argument: the hybrid pattern is essentially a special case of the V pattern when the print partially refutes some pre-print pessimism factors. The decisive feature for criterion 4 disposition remains whether the BINDING pre-print pessimism factor (cocoa-cost margin pressure for MDLZ) is refuted — which it is not. Adding a separate sub-pattern for "partial-refutation hybrids" would dilute the taxonomy without operational value; the taxonomy is for decision-pattern recognition, and the V-pattern logic operates correctly on MDLZ without modification.

Considered whether to defer pending tomorrow's MA / AAPL prints to gather more cross-sectional information on consumer-staples / consumer-discretionary patterns. Counter-argument: per protocol, deferral requires a trigger that resolves the binding constraint. MDLZ's binding constraint is criterion 4 multi-quarter-resolution-vs-60-day-window mismatch, which tomorrow's prints cannot resolve. MA is payments-rails (V's peer), not consumer staples. AAPL is tech-hardware. No tomorrow print would change MDLZ's structural-overhang characterization. Decision is made now without deferral.

Considered whether the criterion 1 marginality (+4-5% borderline) should be the primary NO-GO ground rather than criterion 4. Counter-argument: same logic as SBUX 2026-04-29 NO-GO theater-check — criterion 4 is structurally decisive and direction-symmetric; treating criterion 1 marginality as primary would invite re-evaluation if Wed close happens to clear +5%. Criterion 4 as primary ground holds regardless of where Wed close lands at +4.3% or +5.5%. Criterion 1 marginality is documented as compounding context.

Modulo these four considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT as a partial 2.20 trap).

### Compaction-survival note

**Strategy B MDLZ thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** MDLZ-thesis-construction COMPLETE; MDLZ-NO-GO declined on criterion 4 (V-pattern structural-overhang-persistence on cocoa-cost / Middle East / US consumer-weakness multi-headwind backdrop; print delivered volume/organic-revenue refutation of pre-print pessimism but margin/EBITDA confirmation of structural overhang; mild TD Cowen +$2 post-print PT raise consistent with information-driven appropriate-pricing); criterion 1 marginal at +4-5%. No order staged. MDLZ remains a closed name from a Strategy B perspective unless and until cocoa-cost-cycle resolution materially changes the overhang characterization (multi-quarter timeline; B's 60-day window structurally mismatched). The 10-day post-event entry window expires ~2026-05-12; no calendar event scheduled to revisit because the criterion 4 multi-quarter-resolution-mismatch is unlikely to flip from re-examining the same data.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **eighth** NO-GO of the experiment to date on criterion 4 grounds (NOW; CHTR; INTC; SBUX; V; NXPI; STX; **MDLZ**). Nine Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO, V-NO-GO, NXPI-NO-GO, STX-NO-GO, MDLZ-NO-GO = **2 GO / 8 NO-GO (20%/80%).** **All eight NO-GOs route through criterion 4 information-vs-sentiment test.** The criterion-4-NO-GO rate continues to harden; the threshold for the 30-trade-gate review has now reached 8/9 of dispositions on the same gate, suggesting a structural feature of the screen funnel.

**Sub-pattern taxonomy for criterion 4 NO-GOs (8 cases observed; MDLZ confirms V sub-pattern as a recurring category):**

1. **Negative-direction "information-confirmed-by-cross-section" pattern** (NOW, CHTR): Stock down materially after print; cross-sectional peer evidence confirms negative information is structural. LONG mean-reversion fails.

2. **Positive-direction "sell-side-immediate-ratification" pattern** (INTC, NXPI, STX as cleanest instance): Stock up materially after print; sell-side immediately and aggressively raises PTs. LONG-extension fails on L1 information-pricing. SHORT fails as 2.20 trap. STX is most extreme (Rosenblatt +100%).

3. **Positive-direction "information-priced-via-pre-print-rally" pattern** (SBUX, STX as overlay): Stock up modestly after print; pre-print sell-side raised PTs into the print and trailing momentum absorbed strong-print expectation; post-print sell-side mild PT moves confirms information-driven pricing. STX overlays with sub-pattern 2.

4. **Positive-direction "structural-overhang-persistence" pattern** (V, **MDLZ — NEW INSTANCE confirming sub-pattern as recurring category**): Stock up after print on top-line beat / volume-refutation of pre-print pessimism; pre-print sell-side CUT PTs on persistent structural overhang; print does NOT address the structural overhang; post-print PT response mild despite top-line beat; multi-quarter resolution timeline mismatched with B's 60-day window. V's overhang is regulatory (CCCA, interchange settlement, stablecoins); MDLZ's overhang is cocoa-cost / Middle East geopolitical / US consumer weakness.

The taxonomy now has a confirmed recurring V-class category (sub-pattern 4) with two distinct instances (V regulatory, MDLZ cocoa/macro). Future B thesis-construction sessions should explicitly screen for sub-pattern 4 indicators: (a) pre-print PT cuts on structural concerns; (b) print delivers top-line / volume but doesn't address the structural concerns; (c) post-print PT response mild; (d) multi-quarter resolution timeline. Any structural overhang on a multi-quarter-or-longer timeline is a sub-pattern 4 candidate regardless of overhang category (regulatory, commodity-cost, geopolitical, secular-displacement).

**Key MDLZ-specific note for future Claude:**

(a) MDLZ confirmed the V-pattern as a recurring sub-pattern by manifesting it with a different overhang source (cocoa-cost cycle vs V's regulatory). This validates the sub-pattern as structural rather than V-idiosyncratic.

(b) The "partial-refutation-hybrid" feature (pre-print pessimism partially refuted on volume but confirmed on margin) is treated as a special case of sub-pattern 4 rather than a separate sub-pattern. The decisive feature is whether the BINDING structural overhang is refuted; for MDLZ it is not.

(c) Peer-comparable LW (-6.9%) and MKC (-9.9%) post-print reactions on similar revenue-beat-margin-pressure setups CONFIRM that the shelf-stable food sector is reacting consistently to the cocoa/consumer/margin theme. MDLZ's +4-5% reaction is FAVORABLE relative to peers, suggesting the market is treating MDLZ's print better than the cohort despite the EBITDA miss. This is a cross-name evidence point that MDLZ's reaction is not undersized.

(d) Cocoa-cost cycle is structurally similar to other commodity-cost cycles (e.g., chip-shortages for autos, lumber for housing) — the resolution timeline tends to be 1-2+ years. Future B thesis-construction sessions on commodity-cost-pressured names should explicitly check whether the binding cycle is within or beyond B's 60-day window.

**Lesson for future Daily.md scans on consumer-staples / commodity-cost-pressured names:** "Mixed beat" prints (revenue beats / EBITDA misses) on names with multi-quarter commodity-cost overhangs are particularly vulnerable to criterion 4 fails because the pricing-sustainability vs cost-headwind dynamic operates on multi-quarter timelines incompatible with B's 60-day window. Future Daily.md scan flagging of MDLZ-class candidates should be read as forward-flagging-level only; thesis construction is the binding gate; the prior on these candidates clearing criterion 4 is structurally low.

**Cumulative Wed 2026-04-29 thesis-construction session summary updated:** Five B thesis constructions completed (SBUX, V, NXPI, STX, MDLZ) — all five NO-GO on criterion 4 with the four positive-direction sub-patterns now represented (NXPI+STX = sub-pattern 2 INTC; STX = sub-pattern 3 SBUX overlay; SBUX = pure sub-pattern 3; V+MDLZ = sub-pattern 4 structural-overhang-persistence). Combined with prior sessions: 2 GO / 8 NO-GO total. The framework continues to operate with high selectivity on positive-direction post-event setups, consistent with pre-mortem rev 7 KL identification of B's structural exposure to 2.20 textbook-rational-penalty.

---

## 2026-04-29 (Wed, mid-day pre-FOMC) Strategy B thesis construction outcome — OMCL (Omnicell) NO-GO (criterion 4 decisive failure on intermediate L1 hybrid sub-pattern; market cap borderline at $2.07B intraday close vs $1.96B at lower intraday levels — instrument-eligibility marginally clears at session reference but operational entry risk significant); no order staged

**Trigger:** B-thesis construction requested for OMCL (Omnicell), with explicit operator instruction "verify ≥$2B market cap before committing." OMCL was on the Strategy B watchlist (referenced in the V/NXPI/STX/MDLZ entry "Other Strategy B watchlist names" lists). The user's market-cap-verification framing flags OMCL's borderline instrument eligibility as a known concern; per protocol, Claude resolves the instrument-eligibility test honestly and applies all 5 entry criteria — the user's framing is read as an instruction to verify the threshold, not as an override directive on framework outcome.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5, instrument eligibility — market cap ≥ $2B at entry as hard floor, 30-day ADV ≥ $10M, criterion 3 closed-list rev 14, criterion 4 information-vs-sentiment test, exit rules, pre-mortem rev 7); AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; **2.6 no access to private information** — relevant for assessing buy-side persistent-pessimism source); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM and HCA both open in B; IT 1/3 and Health Care 1/3 used; **OMCL would push Health Care to 2/3 — within cap but near limit**); Decision_Log.md prior precedents — IBM 2026-04-25 GO (clean undershoot via NOW + IGV transient external suppression cascade — different from OMCL's structural buy-side persistent pessimism), HCA 2026-04-27 GO (lower-conviction with peer-corroboration); INTC 2026-04-27 NO-GO (sub-pattern 2 sell-side immediate ratification with multi-firm aggressive PT raises — OMCL is intermediate single-firm version), SBUX 2026-04-29 NO-GO (sub-pattern 3 information-priced-via-pre-print-rally with mild single-firm Guggenheim +$2 PT response — OMCL has more aggressive single-firm KeyBanc +16.7% PT raise), V 2026-04-29 NO-GO (sub-pattern 4 structural-overhang-persistence — OMCL has analogous structural NTM-EPS-shrinkage concern but pre-print sell-side stance differs), NXPI 2026-04-29 NO-GO (sub-pattern 2 multi-firm aggressive — OMCL is intermediate version), STX 2026-04-29 NO-GO (sub-pattern 2+3 cleanest L1 instance with 11+ firms PT raises and Rosenblatt $500→$1,000 — OMCL is much weaker single-firm ratification), MDLZ 2026-04-29 NO-GO (sub-pattern 4 V-pattern with cocoa-cost overhang — OMCL has analogous NTM-EPS structural concern); GEV 2026-04-29 NO-GO defer (Strategy D, not directly relevant); OMCL Q1 2026 8-K Ex-99 (SEC EDGAR Apr 28 2026 BMO; **revenue $309.88M +14.9% YoY vs $304.5M est = +1.8% beat; non-GAAP EPS $0.55 vs $0.33 est = +66% beat; non-GAAP adj EBITDA $44.65M vs $31.37M est = +42.3% beat with margin 14.4%; GAAP net income $11M ($0.25/sh) vs prior-year $7M loss = swing to profitability; non-GAAP net income $25M ($0.55/sh) up from $12M; gross profit $140.36M (+26.5%); gross margin 45.30%; Q2 adj EPS guide $0.40-$0.48 with midpoint $0.44 vs consensus $0.42 = +4.8% above midpoint; FY26 revenue guide RECONFIRMED at $1.24B midpoint (not raised); FY26 adj EBITDA guide RAISED to $153-168M; FY26 adj EPS guide RAISED to $1.80-$2.00 from $1.65-$1.85 = +8.6% midpoint raise; near-term headwinds disclosed: $12M tariff costs in 2026, cash declined to $239M from debt repayment + prior buybacks, margin/expense variability across Q2-Q3**); OMCL Q1 2026 earnings call (Yahoo / Investing.com / Daily Political Apr 28-29; CEO Randall Lipps "delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions"; growth driven by connected devices + services + SaaS + consumables; Titan XT automated dispensing system launched; OmniSphere cloud-based platform progressing; Rick Couldry hired as SVP Chief Pharmacy & Clinical Officer); FinancialContent / StockStory Apr 28 ("Beats On Revenue"; **"sell-side analysts expect revenue to grow 2.3% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds"**; "**Wall Street expects Omnicell's full-year EPS of $1.91 to shrink by 5.2%**" — NTM EPS contraction concern persists; "stock remained flat at $37.50 immediately after reporting" — no immediate Tue post-print rally); FinancialContent / StockStory Apr 27 pre-print preview ("majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings" — NEUTRAL sell-side stance, different from MDLZ's bearish revisions and SBUX's pre-print PT raises); Investing.com Apr 28 ("Following the earnings announcement, Omnicell's stock price increased by 20.65% in pre-market trading, reaching $45.40" — references Wed Apr 29 pre-market vs Mon Apr 27 close $37.63); CNN Wed Apr 29 ("price of OMCL shares has increased $7.88 since the market last closed. This is a 20.94% rise. Closed at $45.51"; AH "stock has since dropped $0.86" implying $44.65 AH); **Investing.com Apr 29 KeyBanc note** ("Omnicell price target raised to $70 from $60 at KeyBanc" — single-firm aggressive PT raise +16.7%); Daily Political Apr 29 ("Bank of America's Allen Lutz reiterated a Buy and maintained a $70 price target" — BofA reiteration only, no PT change post-print; Wells Fargo "upped their price target on Omnicell from $52.00 to $55.00" — pre-print raise Apr 23, no post-print action documented at scan time; "current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14"; "50 day moving average of $37.02 and a two-hundred day moving average of $39.40" — pre-print stock above 50-day MA, below 200-day MA); TickerNerd ("median price target of $54.00 ranging from $52.00 to $63.00; consensus Strong Buy 8.8/10; 6 Buy, 2 Hold, 0 Sell"); Investing.com forecast ("7 analysts, average $57.43, high $70, low $49"); MarketBeat (per Daily Political "consensus price target of $60.67"); Public.com ("5 analysts as of Mar 23, consensus $53.40, Buy"); Yahoo Finance Apr 29 (**"Market Cap (intraday) 1.96B"** — BELOW $2B floor at intraday lower price); Motley Fool Apr 29 (**"Market Cap $2.07B"** at $42.86 share, 45.48M shares outstanding); TradingView Apr 29 (**"market capitalization of 2.07 B, decreased by -4.99% over the last week"**); Daily Political Apr 29 (**"market cap of $2.04 billion"** at $44.78 mid-day reading); 45.48M shares outstanding × $45.51 close = **$2.070B at close** = clears $2B floor by 3.5%; 30-day avg volume 615,853 shares × ~$37 pre-print price = **~$22.8M ADV** (clears $10M floor); Daily.md 2026-04-29 scan; Experiment_Parameters.md (commission-disregarded-at-decision-time per 2026-04-27 protocol; America/Denver tz).

### Decision

**OMCL — NO-GO (DECLINE) on LONG-extension framing. SHORT-mean-reversion framing briefly considered and dismissed (canonical 2.20 textbook-rational trap on a +66% EPS beat / +42% EBITDA beat / raised FY26 EPS guide print).**

Failed Strategy B entry criterion 4 with intermediate-L1-hybrid sub-pattern characterization — the post-event reaction is partially-information-driven via single-firm aggressive sell-side ratification (KeyBanc +16.7% PT raise same-day as L1 signature) compounded by persistent structural NTM-EPS-shrinkage concern that the print does not fully address; even though stock retains atypical upside cushion to post-print PT consensus (~30% upside vs ~$60 PT consensus revised), the 60-day-window-vs-multi-quarter-recovery-thesis mismatch and incomplete multi-firm ratification produce a partial-information-pricing signature inconsistent with the clean IBM-pattern undershoot required for Strategy B GO disposition. Compounding operational risk: market-cap borderline at $2.07B at session reference close vs $1.96B at lower intraday levels — instrument-eligibility test marginally clears at the close but with thin buffer above the $2B hard floor, creating execution risk on any entry-fill below the close.

### Mechanical eligibility (criteria 1, 5, instrument rule) — instrument rule borderline-clears

- **Instrument rule borderline-clears with thin buffer:**
  - US-listed common (NASDAQ): ✓
  - Market cap at session reference close (Apr 29): **$2.070B** at $45.51 × 45.48M shares = **clears $2B floor by 3.5%**.
  - Market cap intraday at lower price levels: **$1.96B** at Yahoo intraday snapshot (lower price); $2.04B at Daily Political mid-day $44.78 reading. **Failed $2B floor at intraday low; cleared at close.**
  - Per Strategy.md "market cap ≥ $2B at entry" (hard floor): the test fires at order-fill time. If a Tue-Apr-30 limit-order is placed and fills at any level below $44.00, market cap drops below $2B floor. **Operational risk on entry: a 3.3% pullback from $45.51 close would invalidate instrument eligibility at fill.**
  - 30-day ADV: 615,853 shares × ~$37 = **~$22.8M** (post-print volume likely higher); clears $10M floor with cushion.
  - Long-or-short permitted; 2% sizing $27.77; no options.
  - **Borderline market cap is documented as a compounding NO-GO factor, not the primary ground.**
- **Criterion 5 cleared:** No A position open in OMCL.
- **Criterion 1 cleared with cushion at +20.94%** (Mon Apr 27 close $37.63 → Wed Apr 29 close $45.51; +20.94%; well above 5% threshold). Note unusual reaction timing: Tue Apr 28 (print day) saw flat reaction (StockStory "stock remained flat at $37.50 immediately after reporting"); the entire +20.94% came overnight gap + Wed regular session continuation. **The delayed-reaction pattern is itself diagnostic — appropriate-pricing of a +66% EPS beat was deferred to overnight digestion + sell-side post-print analysis (KeyBanc PT raise published Wed afternoon coincident with stock's Wed continuation).**

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Massive Q1 2026 surprise: revenue $309.88M (+14.9% YoY, +1.8% beat), non-GAAP EPS $0.55 (+66% beat vs $0.33), non-GAAP adj EBITDA $44.65M (+42.3% beat vs $31.37M, margin 14.4% +700bps vs prior year), gross margin 45.30% (+440bps), GAAP net income swing to profitability ($0.25/sh from $7M loss YoY). Management raised FY26 adj EPS guide $1.65-1.85 → $1.80-2.00 (+8.6% midpoint), FY26 adj EBITDA guide raised to $153-168M, FY26 revenue guide reconfirmed at $1.24B midpoint. Pre-print stock $37.63 vs PT consensus mean ~$54-60 (Investing.com $57.43, TickerNerd $54.00, MarketBeat $60.67, Public.com $53.40, BofA/KeyBanc $70 high) = **buy-side stock-price-implied discount of 30-50% to PT consensus** = significant pre-print suppression. Post-print stock $45.51 vs revised PT consensus ~$60 (KeyBanc $70 raised; BofA $70 reiterated; Wells Fargo $55 unchanged) = **still ~30% below post-print PT consensus** — the post-print reaction does NOT fully close the gap to PT consensus, which is atypical vs SBUX/V/MDLZ where post-print stock approached or exceeded PT consensus mean. Provisional LONG thesis would argue: pre-print buy-side persistent pessimism on NTM-EPS-shrinkage concern was disproportionate to fundamentals; the +66% Q1 EPS beat + raised FY26 guide materially refutes the buy-side pessimism; sell-side will follow KeyBanc with multi-firm PT raises over coming days/weeks; 50% gap-fill toward PT consensus = $52-53 area = **+15-16% upside in 60 days plausible**. Healthcare-tech AI / autonomous-pharmacy theme provides supporting narrative; Titan XT product launch is a 2026-2027 multi-quarter ramp catalyst.

**Adversarial counter-argument (decisive flaw on LONG side):**

(L1) **Information-vs-sentiment test fails on intermediate-L1-hybrid sub-pattern characterization.** Analysis:

*The +20.94% reaction is partially-information-driven via single-firm aggressive sell-side ratification.* KeyBanc's same-day Wed PT raise $60→$70 (+16.7%) is the L1 sub-pattern 2 signature — sell-side immediately and aggressively raised PT to ratify the print's information value. While only one firm is documented at scan time vs INTC's Citi-upgrade-plus-Evercore-+146% / NXPI's TD Cowen-+24%-plus-multi-firm-raises / STX's 11+-firms-with-Rosenblatt-+100%, the KeyBanc +16.7% PT raise IS the same mechanism class — same-day post-print sell-side aggressive ratification. The single-firm intensity is INTERMEDIATE between (a) multi-firm-aggressive sub-pattern 2 cleanest instances (INTC/NXPI/STX) and (b) single-firm-mild sub-pattern 4 instances (SBUX/V/MDLZ at +$2 / +3% PT raises). OMCL's KeyBanc +16.7% PT raise is roughly 4-5× larger than SBUX/V/MDLZ's single-firm mild raises. Until additional firms post-print actions are documented (likely by end of week), the most defensible characterization is partial sub-pattern 2 with single-firm intensity.

*Persistent structural NTM-EPS-shrinkage concern is NOT addressed by the print.* Per FinancialContent post-print: "Wall Street expects Omnicell's full-year EPS of $1.91 to shrink by 5.2%" forward 12-month basis; "sell-side analysts expect revenue to grow 2.3% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds." The Q1 print delivers a one-quarter inflection, but the multi-quarter trajectory remains structurally concerning. FY26 EPS guide raised to $1.90 midpoint covers the current fiscal year; the FY27 EPS contraction expectation per the "1.91 to shrink by 5.2%" framing is NOT addressed. Q2 guide midpoint $0.44 vs consensus $0.42 = only +4.8% above — implies beats are compressing rapidly from +66% to +5% magnitude. The structural concern (low single-digit revenue growth + EPS contraction NTM) is unrefuted by the Q1 print.

*Strategy-mechanism mismatch with B's 60-day window.* For partial gap-closure to PT consensus (~$60) within 60 days, the stock would need +30% additional rally from $45.51 → ~$60. The catalysts that could drive this in 60 days: (a) continued sell-side multi-firm PT raises following KeyBanc — possible but uncertain; (b) Q2 guidance update mid-quarter — unlikely event; (c) sympathy moves on healthcare-tech sector or AI-pharmacy-automation theme — speculative; (d) Q2 earnings beat magnitude to repeat Q1 — improbable given Q2 guide implies compressed beat. **The thesis path requires multi-quarter resolution (multi-firm sell-side rerating + structural NTM-EPS revision + sustained execution) that doesn't fit B's 60-day window.** This is the same multi-quarter-resolution-vs-60-day-window mismatch that fired against V (regulatory) and MDLZ (cocoa) — but in OMCL's case, the underlying fundamentals are stronger than V/MDLZ. The mechanism mismatch fires regardless of fundamental quality because the strategy is constructed around 60-day post-event mean-reversion, not multi-quarter accumulation.

(L2) **Single-firm aggressive PT raise is incomplete information signal — multi-firm follow-through uncertain.** KeyBanc's +16.7% PT raise IS a meaningful L1 ratification, but a single firm doesn't constitute multi-firm consensus shift. The empirical pattern in INTC/NXPI/STX was: 4-11+ firms publishing aggressive PT raises within 24-48 hours of the print. OMCL at scan time has ONLY KeyBanc explicitly raising; BofA reiterated $70 PT (no change); Wells Fargo's $55 was a pre-print raise (Apr 23). The asymmetric documentation (only KeyBanc raised, others reiterated or unchanged) creates uncertainty about whether multi-firm follow-through will materialize. Two possible explanations: (a) other firms are still digesting and will raise PTs in coming days (favorable for LONG); (b) other firms see the structural NTM-EPS-shrinkage concern as outweighing the Q1 surprise and are not raising (adverse for LONG). The empirical resolution requires ~1-2 weeks of post-print sell-side note publishing. Strategy B's 60-day window is sufficient for this resolution but at significant uncertainty cost.

(L3) **Pre-print buy-side persistent pessimism is structural, not transient — distinguishes from IBM-pattern.** IBM's pre-print suppression was driven by NOW + IGV transient external sector contagion event coincident with the print; the print refuted the suppression mechanism and IBM's stock undershot. OMCL's pre-print suppression is driven by buy-side concern about NTM-EPS-shrinkage, which is NOT a transient external event but a structural concern tied to the long-term revenue growth trajectory (sell-side projecting only 2.3% NTM revenue growth, and "underwhelming" deceleration). The Q1 print partially refutes the structural concern on the FY26 EPS dimension (raised guide +8.6%) but does NOT refute the FY27+ trajectory concern. The IBM-pattern requires the print to FULLY refute the suppression mechanism for clean undershoot characterization. OMCL's print only partially refutes — Q1 surprise + FY26 guide raise do not address the multi-quarter NTM EPS contraction concern. Therefore the post-print stock at $45.51 still below PT consensus is NOT clean IBM-pattern undershoot; it's **partial-undershoot-with-residual-structural-concern**.

(L4) **Cross-name peer-comparable evidence on healthcare-tech / medication-management names is weak in either direction.** OMCL's direct peers in medication-management automation (BD's BD/Pyxis, McKesson, Cardinal Health) are not similarly post-event candidates in the current window. Indirect peers in healthcare-tech (Veeva, Doximity, Phreesia, BrightSpring per Yahoo Finance "similar companies" list) have varied recent performance; no clean cross-sectional confirmation or refutation of OMCL's reaction is available. The peer-cohort data is insufficient to corroborate or contest the L1/L2/L3 analysis.

(L5) **Borderline market cap as compounding operational risk.** Per the inputs section, market cap is $2.070B at session reference close (clears $2B floor by 3.5%) but $1.96B at Yahoo intraday low (failed floor). A limit-order entry at any fill below $44.00 would put the position below the $2B hard floor at fill — instrument-eligibility violation. For a position that already has marginal thesis-quality (as documented in L1-L3), accepting operational entry-execution risk on top is poor risk management. **Even if criterion 4 were marginally clearing on substance, the borderline market cap would warrant cautious deferral until the cushion above $2B widens.** The $2B floor was set in Strategy.md's instrument eligibility specifically to ensure liquidity and avoid the smaller-cap names where 60-day mean-reversion theses are riskier; OMCL is right at that threshold.

LONG declined. Criterion 4 information-vs-sentiment test fails on intermediate-L1-hybrid sub-pattern characterization (L1 decisive); L2 confirms via single-firm-incomplete sell-side ratification; L3 confirms via partial-rather-than-clean undershoot on persistent structural concern; L4 confirms via insufficient peer-comparable cross-section; L5 documents compounding operational risk on borderline market cap.

### SHORT thesis briefly considered and dismissed without full adversarial construction

**Provisional affirmative thesis (SHORT / mean-reversion).** +20.94% on a print where Q2 guide implies compressed beat magnitude (+5% vs Q1's +66%) and NTM EPS expected to shrink -5.2% might fade toward $40-42 over 60 days as sell-side recognizes the Q1 was a one-quarter inflection that doesn't repeat.

**Why dismissed without full adversarial construction:** Shorting against a +66% EPS beat / +42% EBITDA beat / raised FY26 EPS guide print where stock is STILL 30% below post-print PT consensus is a canonical 2.20 textbook-rational trap. The pre-print buy-side pessimism partially refuted by the print favors continued LONG-side momentum, not SHORT-side mean-reversion. SHORT criterion 4 fails by the same logic that fails LONG, but flipped: the partial information-pricing characterization implies neither direction has clean mispricing. SHORT declined.

### 2.13 / 2.14 / 2.20 cross-checks

- **2.20 (textbook-rational penalty)** — OMCL SHORT is a canonical 2.20 trap (fade-the-beat-on-trajectory-concern); declined above.
- **2.13 (miscalibration)** — A LONG conviction call on OMCL depends on multi-firm sell-side follow-through to KeyBanc's PT raise + Q2/Q3 continued execution + healthcare-tech sentiment support. Multi-factor probability assignment is 2.13-discounted aggressively; effective probability after discount is below thesis-supporting threshold for 60-day window.
- **2.14 (recency bias on input data)** — OMCL trailing-30-day was approximately neutral pre-print (TradingView "decreased -4.99% over the last week" but longer-period returns positive). Post-print +20.94% pop creates strong recency-bias-input that the criterion 4 analysis explicitly weighted against. Not the binding factor here but a contributing consideration.
- **2.6 (no access to private information)** — Buy-side persistent pessimism source is not directly observable; the structural NTM-EPS-shrinkage concern is publicly inferable from sell-side projections, but the magnitude of buy-side discount-to-PT may reflect private-information channels that Claude cannot verify. This raises the uncertainty of the criterion 4 disposition; combined with the borderline market cap and intermediate sub-pattern fit, this argues for caution.

### Sector concentration check

OMCL = GICS Health Care / Health Care Equipment & Services / Health Care Technology / Medical Info Systems. Strategy B currently holds IBM (IT) and HCA (Health Care). Adding OMCL would put Health Care at 2/3 sector cap = within cap with 1 slot remaining. Cap is not the binding constraint; criterion 4 is. Note correlation consideration: HCA is hospital-operator (services); OMCL is healthcare-tech / medication-management automation (equipment/software). Different sub-segments; correlation likely 0.3-0.5 range. Not a structural overlap concern.

### Effect on book

No effect. No order staged for OMCL. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA). Strategy B sector concentration unchanged: IT 1/3, Health Care 1/3, Consumer Staples 0/3, others 0/3. Portfolio_Ledger.md not modified by this session.

### Pending queue updated

- ~~OMCL B-thesis construction (watchlist promotion with market-cap verification)~~ COMPLETE — NO-GO declined on criterion 4 (intermediate-L1-hybrid sub-pattern; KeyBanc same-day +16.7% PT raise + persistent NTM-EPS-shrinkage structural concern + 60-day-window-vs-multi-quarter-recovery mismatch + borderline market cap operational risk). No order staged. Market cap verification: $2.07B at close clears $2B floor by 3.5%; $1.96B intraday low at lower price levels failed floor; operational entry risk significant.
- THC Thu 2026-04-30 BMO print — HCA invalidation criterion (iii) hook (B position).
- MA Thu 2026-04-30 BMO print — peer to V; not a deferral trigger.
- AAPL Thu 2026-04-30 AMC, AMZN/CAT Thu 2026-04-30 BMO, LLY Thu 2026-04-30 BMO — routine daily scan tomorrow.
- FOMC decision Wed 2026-04-29 14:00 ET / Powell presser 14:30 ET — pending at scan time.
- Mag-7 AMC prints Wed 2026-04-29 (GOOGL, MSFT, META) — relevant for daily scan tomorrow.
- IBKR Funds-on-Hold $2,500 anomaly (per Decision_Log 2026-04-28 entry) — deferred to next routine session.
- GEV May 22 trailing-30-day re-screen + May 13 D long-list interim re-screen — calendar events scheduled per 2026-04-29 GEV entry.
- Other Strategy B watchlist names with windows still open: MBLY, TXN, URI, SMCI, HAS, CAR, QS, CALX, BLD, AXTI, DPZ, OGN, MRVL. None blocked or affected by this NO-GO.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + instrument eligibility market cap ≥ $2B + criterion 3 closed-list rev 14 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 / 2.20 / 2.6 / 2.13 / 2.14).
- AI_Trading_Foundation.md (2.13 ordinal-tier conviction; 2.14 recency bias on input data; 2.20 textbook-rational penalty; 2.4 narrative-over-fit; 2.6 no access to private information).
- Portfolio_Ledger.md (current $1,388.38 strategy B NAV at Apr 28 close; IBM and HCA open positions; Health Care 1/3 sector concentration; no change from this session).
- Decision_Log.md 2026-04-25 IBM entry (clean undershoot via NOW + IGV transient external suppression cascade — direct precedent for IBM-pattern but NOT for OMCL because OMCL lacks transient external event).
- Decision_Log.md 2026-04-27 HCA entry (lower-conviction with peer-corroboration via UHS/THC).
- Decision_Log.md 2026-04-27 INTC entry (sub-pattern 2 sell-side immediate ratification with multi-firm aggressive PT raises — OMCL is intermediate single-firm version of this pattern).
- Decision_Log.md 2026-04-29 SBUX entry (sub-pattern 3 information-priced-via-pre-print-rally with single-firm mild PT response — OMCL has analogous single-firm but more aggressive raise).
- Decision_Log.md 2026-04-29 V entry (sub-pattern 4 structural-overhang-persistence — OMCL has analogous structural NTM concern but pre-print sell-side stance differs).
- Decision_Log.md 2026-04-29 NXPI entry (sub-pattern 2 multi-firm aggressive — OMCL is intermediate version).
- Decision_Log.md 2026-04-29 STX entry (sub-pattern 2+3 cleanest L1 instance — OMCL is much weaker single-firm ratification).
- Decision_Log.md 2026-04-29 MDLZ entry (sub-pattern 4 V-pattern with cocoa-cost overhang — OMCL has analogous NTM-EPS structural concern).
- OMCL Q1 2026 8-K Ex-99 (SEC EDGAR Apr 28 2026 BMO; full Q1 financials and raised FY26 EPS guide).
- OMCL Q1 2026 earnings call (Yahoo / Investing.com / Daily Political Apr 28-29; CEO Lipps + CFO commentary).
- FinancialContent / StockStory Apr 28 ("Beats On Revenue"; NTM EPS expected -5.2% shrinkage; Tue post-print "stock remained flat at $37.50").
- FinancialContent / StockStory Apr 27 pre-print preview (NEUTRAL sell-side stance with reconfirmed estimates).
- Investing.com Apr 28 (pre-market +20.65% to $45.40).
- CNN Wed Apr 29 (closed $45.51 +20.94%; AH $44.65).
- Investing.com Apr 29 KeyBanc note (PT $60→$70 +16.7% raise).
- Daily Political Apr 29 (BofA $70 PT reiteration; Wells Fargo $55 pre-print raise; market cap $2.04B mid-day; 50-day MA $37.02; 200-day MA $39.40).
- TickerNerd, Investing.com forecast, MarketBeat (per Daily Political), Public.com (PT consensus data).
- Yahoo Finance Apr 29 (market cap intraday $1.96B).
- Motley Fool Apr 29 (market cap $2.07B at $42.86, 45.48M shares).
- TradingView Apr 29 (market cap $2.07B; -4.99% trailing 1 week).
- Daily.md 2026-04-29 scan.
- Experiment_Parameters.md (commission-disregarded-at-decision-time; America/Denver tz).

### Theater-check on this orchestrator review

Considered whether OMCL's pre-print stock-vs-PT-consensus discount of 30-50% should be characterized as buy-side persistent pessimism that the print refutes (IBM-pattern undershoot). Counter-argument: the discount source is structural NTM-EPS-shrinkage concern (sell-side projecting -5.2% NTM EPS shrinkage; "underwhelming" 2.3% NTM revenue growth deceleration), not a transient external suppression event. The print partially refutes the concern on the FY26 dimension (raised guide +8.6%) but does NOT address the FY27+ trajectory. IBM-pattern requires FULL refutation of suppression mechanism for clean undershoot characterization; OMCL has only partial refutation. The post-print stock at $45.51 still below PT consensus is a partial-undershoot-with-residual-structural-concern, not clean IBM-pattern.

Considered whether the user's "verify ≥$2B market cap before committing" framing should be read as a state-change communication that committing is the default if market cap clears. Counter-argument: per protocol, the operator does NOT direct Claude on framework outcome decisions; the framing is read as an instruction to verify the threshold (which Claude does — borderline-clears) and NOT as an override directive on the criterion-1-through-5 application. Claude resolves all decisions internally per protocol. The disposition is NO-GO on criterion 4 substance independently of the market-cap test.

Considered whether KeyBanc's +16.7% PT raise should be classified as sub-pattern 2 sell-side-immediate-ratification (failing criterion 4) or as the leading edge of a multi-firm rerating wave that hasn't fully developed yet (potential argument for delayed-decision deferral). Counter-argument: per protocol, deferral requires a trigger that resolves the binding constraint. Multi-firm sell-side follow-through is empirically observable on 1-2 week timescales but not on a specific trigger date; the 10-day post-event entry window (closes ~2026-05-12, ~13 trading days from print) provides operational space for deferral but the binding constraint (multi-quarter-recovery-vs-60-day-window mismatch) is NOT resolvable by additional sell-side data. The deferral would just delay the same NO-GO disposition. Decision is made now without deferral.

Considered whether the borderline market cap (intraday $1.96B failed floor; close $2.07B cleared) should be the primary NO-GO ground rather than criterion 4. Counter-argument: criterion 4 is the structurally decisive test that holds regardless of market-cap test resolution. If criterion 4 cleared (which it doesn't in OMCL's case), the market-cap operational risk would warrant cautious deferral but not categorical NO-GO. Treating the market-cap test as primary would invite re-evaluation if OMCL rallies further in the next few days lifting market cap above $2B more comfortably. Criterion 4 as primary ground holds regardless of where market cap lands above or below the floor; it's the binding constraint either way. Market cap is documented as compounding context.

Considered whether to treat OMCL as a NEW sub-pattern (sub-pattern 5: intermediate-L1-hybrid combining sub-pattern 2 single-firm aggressive PT raise + sub-pattern 4 persistent structural concern). Counter-argument: the sub-pattern taxonomy is for decision-pattern recognition rather than precise classification. OMCL's case is most economically described as "intermediate sub-pattern 2 with sub-pattern 4 features" rather than as a new sub-pattern. The decisive features (single-firm aggressive PT raise + multi-quarter-resolution-vs-60-day-window mismatch) are already captured by existing sub-patterns 2 and 4. If subsequent NO-GO cases appear with the same intermediate-hybrid signature, formalizing as sub-pattern 5 would warrant. For now: documented as intermediate-hybrid within existing taxonomy.

Modulo these four considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing (and dismisses SHORT as a 2.20 trap).

### Compaction-survival note

**Strategy B OMCL thesis pipeline status as of 2026-04-29 Wed mid-day pre-FOMC:** OMCL-thesis-construction COMPLETE; OMCL-NO-GO declined on criterion 4 intermediate-L1-hybrid sub-pattern (KeyBanc same-day +16.7% PT raise = single-firm aggressive sub-pattern-2 signature; persistent NTM-EPS-shrinkage structural concern = sub-pattern-4 signature; 60-day-window-vs-multi-quarter-recovery mismatch = decisive); criterion 1 cleared at +20.94% (Mon Apr 27 close $37.63 → Wed Apr 29 close $45.51); instrument-eligibility market-cap test borderline-cleared at session reference close $2.07B (45.48M shares × $45.51) but failed at intraday lows ($1.96B Yahoo). No order staged. Operational risk on entry: a 3.3% pullback from $45.51 close would invalidate market-cap eligibility at fill. The 10-day post-event entry window expires ~2026-05-12; no calendar event scheduled because criterion 4 mechanism mismatch is unlikely to flip on re-examining the same data.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **ninth** NO-GO of the experiment to date on criterion 4 grounds (NOW; CHTR; INTC; SBUX; V; NXPI; STX; MDLZ; **OMCL**). Eleven Strategy B thesis-construction opportunities to date: IBM-GO, NOW-NO-GO, HCA-GO, CHTR-NO-GO, INTC-NO-GO, SBUX-NO-GO, V-NO-GO, NXPI-NO-GO, STX-NO-GO, MDLZ-NO-GO, OMCL-NO-GO = **2 GO / 9 NO-GO (18%/82%).** **All nine NO-GOs route through criterion 4 information-vs-sentiment test.** The criterion-4-NO-GO rate continues to harden. The 30-trade-gate review topic flagged at 8/9 (MDLZ entry) now updates to 9/11 — same structural pattern persists.

**Sub-pattern taxonomy for criterion 4 NO-GOs (9 cases observed; OMCL adds intermediate-L1-hybrid case):**

1. **Negative-direction "information-confirmed-by-cross-section" pattern** (NOW, CHTR).

2. **Positive-direction "sell-side-immediate-ratification" pattern** (INTC multi-firm; NXPI multi-firm; STX cleanest 11+ firms with Rosenblatt $500→$1,000; **OMCL intermediate single-firm KeyBanc +16.7%**). OMCL is the SINGLE-FIRM intermediate variant of sub-pattern 2 — KeyBanc's aggressive same-day PT raise is the L1 mechanism but the multi-firm follow-through hasn't materialized at scan time.

3. **Positive-direction "information-priced-via-pre-print-rally" pattern** (SBUX, STX overlay).

4. **Positive-direction "structural-overhang-persistence" pattern** (V regulatory; MDLZ cocoa; **OMCL NTM-EPS-shrinkage as overlay feature**). OMCL's NTM-EPS-shrinkage concern is an overlay sub-pattern-4 feature — not the primary classification because pre-print sell-side stance was NEUTRAL (reconfirmed estimates), not bearishly revising as in V/MDLZ. But the persistent multi-quarter structural concern + 60-day-window mismatch is the decisive flaw, mirroring V/MDLZ logic.

**Key OMCL-specific note for future Claude:**

(a) OMCL is the first observed case of intermediate-L1-hybrid: single-firm aggressive PT raise (KeyBanc +16.7%) + persistent structural concern + atypical remaining-upside-cushion to PT consensus (~30% gap). Future thesis-constructions on this pattern signature should default to NO-GO unless multi-firm sell-side follow-through + clean clean-up of structural concern materialize within the 10-day post-event window.

(b) OMCL is the first observed case of borderline market-cap operational risk affecting Strategy B disposition. Names with market cap right at the $2B floor should be flagged in Daily.md scan as forward-flagging-level lower-priority; the operational risk on entry-execution is real (a few % pullback from session reference close can invalidate eligibility at fill). Future Daily.md scans should explicitly check market cap vs $2B floor before promoting watchlist names to active thesis-construction.

(c) The Tue-flat / Wed-+20.94% delayed-reaction pattern is novel for the experiment. The flat Tue reaction "immediately after reporting" suggests initial market interpretation may have been concerned about something (NTM EPS shrinkage, tariff costs, cash decline) that was overridden by overnight digestion + Wed sell-side ratification (KeyBanc). The pattern is itself diagnostic — clean inflection prints typically produce immediate Tue rally; delayed-reaction patterns may indicate hidden structural concerns the market is digesting. Future Strategy B thesis-constructions on names with delayed-reaction patterns should explicitly screen for what the initial market hesitation was and whether the print fully refutes it.

(d) The 30-50% pre-print discount to PT consensus is the largest observed in the experiment to date. Even with this large discount, the post-print +20% reaction did NOT close the gap fully — stock remains ~30% below post-print PT consensus. This atypical remaining-cushion is the strongest LONG-side feature for OMCL, but it's outweighed by the multi-quarter mechanism mismatch and single-firm-incomplete ratification. Future Strategy B thesis-constructions on names with very large pre-print PT-discount cushions should NOT auto-default to GO based on the cushion alone — the criterion 4 mechanism analysis still applies.

---

## 2026-04-29 (Wed, post-close ~14:30 MT) FOMC reaction trigger check — NO TRIGGER FIRED; FOMC reaction within tolerance

**Trigger:** Conditional post-close FOMC reaction trigger calendar event scheduled per Decision_Log.md 2026-04-29 GEV/MDLZ/OMCL session and Daily.md 2026-04-29 Recommended Actions section. Trigger conditions per Daily.md: ALL of (a) FOMC statement language unexpectedly hawkish OR Powell signals pause-extension framing change; (b) 10Y UST yield > 4.50% on the day; (c) VIX > 22 on the day; (d) SPX -1.5% or worse on the day.

**Inputs:** Web-search retrievals on FOMC statement text, Powell presser readout, closing prints for SPX, 10Y, VIX, 2Y, USD index, Brent. Sources: Federal Reserve Board press release April 29, 2026 (federalreserve.gov/newsevents/pressreleases/monetary20260429a.htm); CNBC stock market today April 29, 2026 + Fed live blog; Fox Business "Fed holds rates steady as Powell's chairmanship winds down: April FOMC"; Forex Factory FOMC press conference quotes April 29, 2026; Yahoo Finance VIX/SPX/DXY/^NYICDX closing data April 29, 2026; Trading Economics 10Y yield April 29, 2026 / DXY April 29, 2026; FXStreet "DXY peaks after Powell tilt, eases off highs into close" April 29, 2026; Cboe VIX live page; FRED VIXCLS / DGS10 series.

**Decision:** **NO ROUTER-REVIEW TRIGGER FIRED.** FOMC reaction within tolerance for criteria (b), (c), (d) by wide margins; criterion (a) marginal but moot. Standard Thu 2026-04-30 09:00 MT daily scan picks up FOMC continuity per existing calendar event.

**Reasoning:**

(a) **Statement / Powell tone — MARGINAL (does not unambiguously hold).** Statement: inflation language hardened to "elevated" from "somewhat elevated"; Middle East developments explicitly cited as "contributing to a high level of uncertainty about the economic outlook"; both-sides-risk dual-mandate framing retained; easing-bias language retained in statement (which is what three regional Fed presidents dissented against). 8-4 vote — first 4-dissent FOMC since October 1992. Miran dissented for a 25bp cut (dovish); Hammack/Kashkari/Logan dissented procedurally to remove the easing bias from the statement (hawkish-procedural, not against the hold itself). Powell tone in presser was hawkish-tilted: described decision as "a closer call than in March"; "energy price surge had not yet peaked"; signaled potential easing-bias removal "as early as the next meeting"; wants energy + tariff pressures to end before considering rate cuts; near-term inflation expectations have risen; labor demand softened; pre-print consensus framing ("hawkish hold") per Carson Group's Sonu Varghese and Kiplinger preview already incorporated this lean. Reads as marginally hawkish-tilted but largely pre-priced — surprise component small. Criterion (a) does not unambiguously hold.

(b) **10Y > 4.50% — FAIL.** 10Y closed ~4.41-4.42% (CNBC: jumped >5bps to 4.41% post-Fed; Trading Economics: rose ~7bps to 4.42%, highest in roughly a month). Well below 4.50% threshold.

(c) **VIX > 22 — FAIL.** VIX closed 18.81 (+0.98 / +5.50%) per Yahoo Finance / ycharts. Inside NORMAL band 15-25; well below 22 threshold.

(d) **SPX -1.5% or worse — FAIL.** SPX closed 7,135.95, -2.95 / -0.04% on the day per CNBC. Well above -1.5% threshold; effectively flat.

**Trigger requires ALL of (a)-(d).** With (b), (c), (d) all clearly failing by wide margins (10Y ~9bps below threshold, VIX ~3.2 points below threshold, SPX ~1.5 percentage points above threshold), trigger does not fire regardless of (a)'s marginal disposition.

**Other market-reaction context (not part of trigger evaluation but documented for downstream sessions):**
- DXY +0.40% to ~98.98 close (peaked 99.05 on Powell remarks, modest fade into close per FXStreet)
- 2Y yield +9.3bps to 3.937% (highest in ~2 years per TheStreet)
- Brent intraday peak $119.50 (4-year high since June 2022 per Yahoo / Bloomberg) — well below $130 IBM Brent invalidation trigger
- Dow -0.57% / -280pts to 48,861.81 (5th straight losing day; oil-rally drag); Nasdaq +0.04% to 24,673.24
- Powell governor-continuation announcement: Powell will remain on Board of Governors as governor for "a period of time to be determined" after his chair term ends May 15. Operationally relevant for FY26 rate path — removes assumption of automatic 7-member Board reset with 3 Trump appointees.

**Theater-check flag:** n/a (mechanical trigger evaluation, not adversarial review).

**Downstream actions:**
- Daily.md updated with FOMC outcome data points (statement language, dissent count, Powell tone, market reaction summary, governor-continuation note) for Thu 2026-04-30 09:00 MT daily scan continuity.
- No regime-state recomputation required: SPY trend, VIX, yield curve (10Y > 2Y by ~47bps), sustained-inversion flag, breadth all on same side of thresholds as Apr 27 baseline. No router-state changes triggered.
- No position-level action required: IBM (B) Brent invalidation criterion (iv) holds with $19/bbl buffer to $130 trigger; HCA (B) and RTX (D) unaffected by FOMC outcome.
- No new calendar events scheduled. Existing Thu 2026-04-30 09:00 MT daily-scan event handles FOMC outcome incorporation; existing 09:00 MT GOOGL re-screen + post-AAPL/AMZN/CAT/LLY/THC/MA print events handle Mag-7 + Thu BMO continuity.

**References:**
- Federal Reserve Board press release April 29, 2026 (https://www.federalreserve.gov/newsevents/pressreleases/monetary20260429a.htm)
- CNBC stock market today live updates (https://www.cnbc.com/2026/04/29/stock-market-today-live-updates.html); CNBC Fed meeting recap (https://www.cnbc.com/2026/04/29/fed-meeting-today-live-updates-warsh-powell.html)
- Fox Business "Fed holds rates steady as Powell's chairmanship winds down: April FOMC"
- Yahoo Finance "Stock market today: Dow, S&P 500 slip as oil surges, with Big Tech earnings on deck" April 29, 2026
- TheStreet stock market today April 29, 2026 update
- Forex Factory FOMC press conference April 29, 2026 (Powell quotes)
- FXStreet "DXY peaks after Powell tilt, eases off highs into close" April 29, 2026
- Yahoo Finance ^VIX historical data April 29, 2026
- Trading Economics United States 10-Year Government Bond Yield + United States Dollar pages April 29, 2026
- Daily.md 2026-04-29 Recommended Actions section (trigger conditions source)
- Decision_Log.md 2026-04-29 GEV / MDLZ / OMCL session entries (trigger calendar event scheduling source)
- Strategy.md regime vocabulary (router activation rules)
- Regime_State.md (current per-strategy activation states)

### Compaction-survival note

**FOMC trigger-check disposition 2026-04-29 post-close:** NO ROUTER-REVIEW TRIGGER FIRED. (b) 10Y 4.41-4.42% < 4.50% threshold; (c) VIX 18.81 < 22 threshold; (d) SPX -0.04% > -1.5% threshold; (a) Powell marginally hawkish-tilted but pre-priced. ALL-of conjunction fails on three of four criteria by wide margins. Standard Thu 2026-04-30 daily scan picks up FOMC continuity. No router-state changes; no new calendar events; no positions affected.

**FOMC outcome data for downstream sessions:**
- **Decision:** Hold federal funds rate at 3.50%-3.75% (third consecutive meeting; 100% pre-print expected hold)
- **Vote:** 8-4 (Miran dovish-cut-dissent; Hammack, Kashkari, Logan procedural dissents against retaining easing bias) — first 4-dissent FOMC since October 1992
- **Statement language change:** inflation hardened to "elevated" from "somewhat elevated"; Middle East developments cited as "contributing to a high level of uncertainty about the economic outlook"; both-sides risk framing retained; easing bias retained in statement
- **Powell tone:** "closer call than in March"; "energy price surge had not yet peaked"; signaled potential easing-bias removal "as early as the next meeting"; wants energy + tariff pressures to end before considering rate cuts; near-term inflation expectations have risen; labor demand softened
- **Market reaction (close):** SPX 7,135.95 -0.04% / Nasdaq 24,673.24 +0.04% / Dow 48,861.81 -0.57% / VIX 18.81 +5.50% / 10Y 4.41-4.42% +5-7bps / 2Y ~3.937% +9.3bps / DXY ~98.98 +0.40% / Brent intraday $119.50 (4-year high)
- **Governor-continuation:** Powell announced he will stay on Board of Governors as governor "for a period of time to be determined" after May 15 chair term end. Operationally relevant for FY26 rate path composition.

**Trigger calibration note for future post-FOMC sessions:** The 4-criterion ALL-of conjunction proved highly selective in this instance — the Apr 29 reaction was characterizable as "hawkish-tilted but contained" (notable +5.50% VIX move and +5-9bps yield move with split-decision dynamics), but the absolute thresholds (VIX > 22, 10Y > 4.50%, SPX -1.5%) were not approached. The trigger as designed correctly skips re-scans on within-band hawkish-leaning outcomes and reserves re-scans for genuine regime-shock events. No calibration adjustment indicated. Future post-FOMC trigger checks should retain the same 4-criterion ALL-of structure.

**Pre-mortem 2.13 / ordinal-tier conviction calibration update:** N/A — mechanical trigger evaluation, no conviction call in this session.

---

## 2026-04-30 (Thu, ~08:00 MT post-THC-print) Strategy B HCA invalidation criterion (iii) checkpoint — NOT TRIGGERED; HCA position holds

**Trigger:** Calendar-event-scheduled THC Q1 2026 print parse session, Wed 2026-04-30 BMO (THC press release ~07:00 ET; conference call 10:00 ET). HCA position-thesis invalidation criterion (iii) per Decision_Log 2026-04-27 (early Sun) entry: "THC reports Apr 30, 2026 with explicitly clean Q1 (no respiratory/weather flag) AND THC FY26 guide reaffirmed at midpoint or higher — would materially undercut HCA's industry-wide non-company-specific framing."

**Inputs:**
- THC Q1 2026 press release headline financials (FinancialContent / StockStory aggregation, Apr 30 07:21 EDT, sourced from THC 8-K Ex-99.1 filed BMO):
  - Revenue $5.37B vs $5.39B est (in line; +2.8% YoY)
  - Adj EPS $4.82 vs $4.17 est (+15.7% beat)
  - Adj EBITDA $1.16B vs $1.12B est (+3.7% beat; 21.6% margin)
  - **Same-store sales FLAT YoY (vs +2.9% in prior-year Q1 2025)** — material volume deceleration
  - Operating Margin 24.1% vs 18.1% YoY (driven by margin/expense management, not volume)
  - **FY26 revenue guide RECONFIRMED at $21.9B midpoint** (0.5% below sell-side $22.0B est)
  - **FY26 Adj EPS guide RAISED to $17.53 midpoint (+1.2%)**
  - **FY26 Adj EBITDA guide RECONFIRMED at $4.64B midpoint** (in line)
  - Stock reaction: −2.3% post-print to $175.99 ("investors hoping for more" per StockStory)
- Sector context already in Decision_Log: HCA Q1 same-facility equivalent admissions +1.3% (vs trailing-4Q +1.7-2.8% range; respiratory admissions −42% per management); UHS Q1 acute-care soft per Apr 27 8-K with winter-storm pre-flag from Q4 2025 call (criterion (iv) cleared); Healthcare Dive Apr 28 framing of UHS H2-loaded recovery trajectory consistent with industry-wide respiratory/weather attribution.
- Decision_Log.md 2026-04-27 (early Sun) HCA GO entry — invalidation criterion (iii) language source.
- Portfolio_Ledger.md 2026-04-28 — HCA OPEN: 0.0642 shares filled at $433.46 limit, principal $27.83 + commission $0.28 = $28.11 cost basis; convergence target $442.85 immutable; 60-day exit 2026-06-26.

**Decision:** **CRITERION (iii) NOT TRIGGERED. HCA POSITION HOLDS.** Continues to convergence at $442.85, remaining invalidation criteria (i)–(ii), or time-based exit 2026-06-26.

**Reasoning:**

Criterion (iii) is a conjunction of two conditions; both must hold to trigger.

**Condition 1 — "explicitly clean Q1 (no respiratory/weather flag)": NOT MET.**

THC Q1 2026 same-store sales came in FLAT YoY against a +2.9% prior-year-Q1 comp — a material volume deceleration of ~290bps. EBITDA and EPS beats are explained by operating-margin expansion (24.1% vs 18.1%, +6.0pp) and disciplined expense management, not by volume strength. Revenue printed in line at +2.8% YoY (acquisition + acuity / payer-mix lift) while volume itself is flat — i.e., the print is a margin/mix story, not a volume story. This is the same volume-softness signature that:
- HCA's management attributed to industry-wide respiratory weakness (−42% YoY respiratory admissions) + weather (Winter Storm Fern, FEMA DR-4898);
- UHS's Q1 disclosed (acute-care same-facility admissions −1.5%, adjusted admissions 0.0% YoY) and pre-flagged in Q4 2025 commentary as winter-storm-driven softness.

Three large hospital operators reporting the same Q1 volume softness pattern is the textbook "industry-wide non-company-specific framing" that criterion (iii) was designed to test. THC's print is the third independent corroboration of HCA's framing, not a refutation.

The criterion's "explicitly clean" standard is the inverse of this: it would have required THC to print same-facility admissions in line with (or above) its trailing-quarter range with no volume softness signal, which would have isolated HCA's Q1 weakness as company-specific. THC's flat same-store vs +2.9% comp does the opposite — it reinforces the industry-wide framing.

(Note: full conference call started 10:00 ET = ~08:00 MT, transcript not yet available at evaluation time. The press-release financial structure — same-store flat with margin-driven beat — is sufficient to fail Condition 1 regardless of management's specific call commentary, because the volume signal IS the respiratory/weather flag in numerical form. Verbal corroboration from the call would only strengthen this disposition; it cannot reverse it.)

**Condition 2 — "FY26 guide reaffirmed at midpoint or higher": MET.**

- FY26 revenue: $21.9B midpoint reconfirmed (range unchanged from Feb 11, 2026 initial guide).
- FY26 Adj EBITDA: $4.64B midpoint reconfirmed (in line with consensus).
- FY26 Adj EPS: RAISED to $17.53 midpoint (+1.2%).

This satisfies Condition 2 unambiguously.

**Conjunction disposition:** Condition 1 fails; Condition 2 holds. Conjunction fails. Criterion (iii) does not trigger.

**Position-level implication:** HCA position-thesis remains intact. Industry-wide respiratory/weather framing is now corroborated at three independent hospital operators (HCA, UHS, THC) with no single peer print contradicting the pattern. Information-vs-sentiment test (volume-only deterioration with no pricing/margin-line structural reset evidence) remains satisfied at peer level — THC also delivered margin expansion against soft volume, the same pattern HCA showed.

**Theater-check:** Considered whether criterion (iii) language strictly requires explicit verbal "respiratory" or "weather" management commentary in the press release / call rather than inferring the flag from numerical volume softness. Counter: the criterion's purpose (per its 2026-04-27 construction) is to test whether HCA's industry-wide framing is undercut. The numerical flat-vs-+2.9% same-store deceleration IS the operative signal regardless of how management verbalizes it; insisting on specific verbal flagging would let a print that financially confirms the pattern but skips verbal acknowledgment trigger the criterion. That would invert the criterion's intent. Numerical-signal-as-flag is the correct read. (Hold-side conviction would only be strengthened, not weakened, if THC's call transcript explicitly flags respiratory/weather as Q1 driver — that would move from numerical corroboration to numerical+verbal corroboration.)

Also considered whether the +1.2% FY26 EPS guide raise constitutes "higher" within Condition 2 such that a strict reading might emphasize "higher" as ratifying clean-Q1 framing. Counter: the EPS-guide raise is fully consistent with the same Q1 print pattern HCA showed — margin/expense-driven outperformance against soft volume, with management taking margin gains to the bottom line in the guide. It does not signal a "clean Q1" because the underlying volume metric is the part that fails Condition 1. The raise reinforces the structural read (sector-wide margin discipline against weather-driven Q1 volume softness) rather than rebutting it.

**Downstream actions:**

- HCA position remains open at 0.0642 shares, $28.11 cost basis, convergence target $442.85 (+2.17% gross from $433.46 actual fill), time-based exit 2026-06-26, no price-based stop.
- Remaining live invalidation criteria for HCA: (i) HCA 8-K reducing FY26 guide below reaffirmed range (revenue $76.5B / Adj EBITDA $15.55B / EPS $29.10 floors); (ii) HCA pre-announcement / negative business update materially changing Q1 narrative. Criterion (iv) UHS-checkpoint and criterion (iii) THC-checkpoint both cleared / not-triggered.
- No new calendar events scheduled this session — existing time-based exit 2026-06-26 calendar event (per HCA OPEN entry 2026-04-28) remains in force; routine daily-scan calendar events handle ongoing monitoring of (i) and (ii) at standard cadence.
- No Portfolio_Ledger update required this session (no fills, no position-state changes, no cash movements). Mark-to-market drift will reconcile at next routine IBKR-screenshot session.
- Sector-pattern persistence — three operators corroborating respiratory/weather framing is now an established peer datapoint usable for any future Strategy B post-event candidate in Health Care Facilities; recorded here for downstream session retrieval if needed.

**References:**

- THC Q1 2026 press release headline financials via FinancialContent / StockStory (https://markets.financialcontent.com/stocks/article/stockstory-2026-4-30-tenet-healthcare-nysethc-posts-q1-cy2026-sales-in-line-with-estimates), Apr 30 2026 07:21 EDT.
- THC Q1 2026 8-K Ex-99.1 (filed BMO Apr 30 2026; not directly fetched in this session — press-release aggregation is sufficient for criterion (iii) evaluation).
- Decision_Log.md 2026-04-27 (early Sun) HCA GO entry (criterion (iii) language source).
- Portfolio_Ledger.md 2026-04-28 HCA OPEN entry (position state, convergence target, exit timeline).
- HCA factbase (sections 1-11) delivered 2026-04-26 evening.
- Decision_Log.md 2026-04-27 UHS Mon-evening checkpoint (criterion (iv) cleared) and 2026-04-28 HCA fill capture entries.
- Strategy.md Strategy B criterion 3 closed-list rev 14 (convergence-target immutability) and pre-mortem rev 7.

### Compaction-survival note

**HCA invalidation criterion (iii) checkpoint disposition 2026-04-30 ~08:00 MT post-THC print:** NOT TRIGGERED. THC Q1 2026 same-store sales FLAT YoY vs +2.9% prior-year comp (margin-driven beat: Adj EPS $4.82 vs $4.17; Op margin 24.1% vs 18.1%) — Condition 1 ("explicitly clean Q1 / no respiratory-or-weather flag") FAILS because numerical volume softness IS the flag. FY26 guide reaffirmed/raised (revenue $21.9B reconfirmed; EBITDA $4.64B reconfirmed; EPS $17.53 raised +1.2%) — Condition 2 holds. Conjunction fails. HCA position holds; remaining live invalidation hooks are (i) FY26 guide cut below reaffirmed range and (ii) HCA pre-announcement/negative-business-update; (iii) and (iv) both retired. Convergence target $442.85 (+2.17% gross from $433.46 fill); time-based exit 2026-06-26. **THC print is third peer corroborating industry-wide respiratory/weather framing of Q1 volume softness (HCA + UHS + THC); information-vs-sentiment test reinforced — three operators show volume-only softness with no pricing/margin-line structural reset.**

**Reusable cross-session pattern note for Strategy B Health Care Facilities post-event candidates:** Industry-wide respiratory/weather framing of Q1 2026 volume softness now corroborated across HCA (Apr 24), UHS (Apr 27), and THC (Apr 30); all three printed soft volume with margin/mix-driven EPS performance. Any future Strategy B post-event Health Care Facilities candidate dated within Q2 2026 should weight this corroborated industry pattern when evaluating criterion 4 information-vs-sentiment characterization. The pattern is no longer "single-company narrative requiring peer validation"; it is "established sector pattern" by 2026-04-30 close.

---

## 2026-05-01 (Fri, mid/late afternoon post-META-session) Strategy B thesis construction outcome — EQIX (Equinix) NO-GO (criterion 1 mechanical eligibility failure on close-to-close magnitude; Daily.md morning-scan "-5%" label reflected after-hours initial reaction not regular-session close-to-close); no order staged

**Trigger:** B-thesis construction requested for Equinix post-event candidate flagged "secondary" / "lower priority" in Daily.md 2026-05-01 morning scan ("Equinix | -5% Apr 30 | LONG (consider) | Real Estate | Guide raise underwhelmed; data-center REIT structurally tailwinded by AI capex | Queue"). Q1 2026 earnings event date 2026-04-29 AMC. Sector cap 0/3 Real Estate available. Sequenced after META B-thesis construction (constructed earlier this session at MEDIUM conviction, GO at limit BUY 0.0454 META @ $615.00 Mon May 4 staged with pre-execution Funds-on-Hold gate).

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement ≥ 5% in either direction "measured as close-to-close move on event day"; criterion 4 information-vs-sentiment test; pre-mortem rev 7); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 ~14:30 MT IBKR snapshot; IBM + HCA open positions; META staged Mon May 4 limit-buy pending Funds-on-Hold gate; sector cap usage IT Services 1/3, Health Care Facilities 1/3, Real Estate 0/3 available; Comm Services 1/3 expected on META fill); Decision_Log.md prior precedents — META 2026-05-01 GO entry (this session, MEDIUM conviction, sequencing predecessor), 2026-04-29 batch NO-GO precedents (SBUX/V/NXPI/STX/MDLZ/OMCL all on criterion-4 information-vs-sentiment failure with criterion 1 cleared — EQIX establishes the FIRST criterion-1-mechanical-failure NO-GO pattern in the experiment); Daily.md 2026-05-01 (Equinix watchlist line and "Secondary" flag); EQIX Q1 2026 8-K Ex-99.1 (SEC EDGAR — see References); CNBC / Daily Political (MarketBeat-sourced) / GuruFocus / Yahoo Finance / Stocktitan / Seeking Alpha / TipRanks / Motley Fool / Globe and Mail / AOL Apr 29-30 coverage (Q1 print detail; FY26 guide; sell-side reset compilation; price history).

### Decision

**EQIX — NO-GO. Criterion 1 mechanical eligibility failure on close-to-close magnitude.**

Strategy B criterion 1 requires "an immediate price reaction of ≥ 5% in either direction (measured as close-to-close move on event day)". Q1 2026 earnings released Apr 29 AMC (call 5:30 PM ET). Pre-print Apr 29 close $1,089.07; post-print regular-session Apr 30 close $1,070.58 (per Daily Political / MarketBeat data: "Shares of Equinix stock traded down $18.49 on Thursday, hitting $1,070.58"). Alternative reading from Yahoo Finance shows Apr 30 close $1,082.83 −0.57% (possibly stale or differently dividend-adjusted display; flagged as source discrepancy). **Both readings yield close-to-close moves below the ≥5% threshold — Daily Political/MarketBeat reading: −1.70%; Yahoo Finance reading: −0.57%.** The Daily.md morning-scan "-5%" label corresponded to the AFTER-HOURS Apr 29 ~5:24 PM ET reaction (Seeking Alpha: "Shares were 5.24% lower at $1,032.00 during Wednesday after-market trading"), which had largely reverted by Apr 30 regular-session close. Strategy B criterion 1 is explicit on close-to-close measurement; after-hours moves do not satisfy the criterion.

LONG and SHORT directions both excluded by the same mechanical failure: a −1.70% (or −0.57%) move provides neither a long-side overreaction-to-rebound nor a short-side overreaction-to-extend setup at Strategy B's 5% magnitude threshold.

### Mechanical eligibility detail

- **Instrument rule (clears):** EQIX is US-listed common (NASDAQ:EQIX); market cap ~$105.58B post-print (Daily Political / MarketBeat — well above $2B floor); 30-day ADV ~$642M/day (~600K avg shares × ~$1,070 reference — well above $10M floor); GICS sector Real Estate / industry REIT - Specialty (data-center REIT). Long-or-short permitted by Strategy B; no options.
- **Criterion 1 — FAILS:** Event date Apr 29 AMC (post-close). Apr 29 regular-session close $1,089.07 (computed: $1,070.58 + $18.49 from Daily Political; consistent with all other observed reference prices in $1,082-$1,089 band on Apr 29 open-of-print). Apr 30 regular-session close: $1,070.58 (Daily Political / MarketBeat) — high-confidence figure given specific source attribution to MarketBeat earnings-tracking data. Yahoo Finance separately shows $1,082.83 −0.57% — discrepancy noted but immaterial to criterion-1 disposition (both readings fail). After-hours Apr 29 5:24 PM ET initial reaction was −5.24% to $1,032.00 (Seeking Alpha) but did not persist into regular-session close-to-close. **Strategy B criterion 1 binding measurement is regular-session close-to-close, per Strategy.md Strategy B entry criteria operational language; after-hours liquidity reverts at high frequency on overnight institutional repricing and pre-market rebalance flows. No operator-extension permitted on this measurement standard.**
- **Criterion 5 (clears):** No A position open in EQIX (A router DO-NOT-ACTIVATE; no A entries any name). No D position. No E leg. Criterion satisfies but does not rescue criterion 1 failure.

### Substance preserved for future re-evaluation (in case a subsequent Q-print or material follow-on event re-triggers criterion 1)

**Q1 2026 print substance** (preserved as primary-source-validated factbase for any future EQIX evaluation):

- Revenue $2.444B (+10% YoY as-reported, +8% normalized constant currency); MISSED ~$2.51B–$2.52B consensus by ~3%
- Operating income $577M (+26% YoY); operating margin expansion
- Net income $415M (+21% YoY); EPS $4.20 (+20% YoY)
- AFFO $1.065B; AFFO/share $10.79 (+12% YoY); MISSED consensus $10.89 (Zacks) / $11.04 (one street estimate) by ~1–2%
- Adj EBITDA $1.245B (record 51% margin)
- Q1 record annualized gross bookings ($378M); +$140M pre-selling; >35% YoY total sales activity growth; record cabinet backlog
- Hampton large xScale lease shifted Q1 → Q2 due to timing (full-year economics unchanged; revenue/AFFO/AFFO-per-share were "ahead of expectations adjusting for Hampton timing" per CFO commentary)
- Churn 1.7% (low)
- Fabric revenue +26% YoY; ~60% of largest Q1 deals AI-related; 46 major capacity projects (incl. 6 xScale)
- atNorth Nordic acquisition announced (~800MW capacity; immediately AFFO-accretive on close)

**FY 2026 guidance raise:**

- Revenue: $10.144–10.244B (10–11% growth) raised from prior $10.12–10.22B; ~$24M midpoint raise (incl. $21M from better-than-expected Q1 operating performance)
- Adj EBITDA: $5.165–5.245B (51% margin; +2% expansion vs prior year); ~$24M raise
- AFFO: ~$40M raise; AFFO/share $42.31–43.11 raised from $41.93–42.74 (10–12% AFFO growth as-reported; 9–11% AFFO-per-share growth)
- 2026 capex top-end ~$4.1B
- Q2 2026 revenue guide $2.571–2.611B (+6% sequential midpoint)

**Sell-side response post-print (Apr 30 — DIRECTIONALLY INVERSE of META precedent; AGGRESSIVE PT RAISES validating bull case):**

- JPMorgan: $1,100 → $1,200 (Overweight maintained)
- Citizens: $1,200 → $1,350 (raise)
- Oppenheimer: $975 → $1,200 (raise)
- Goldman Sachs: $894 → $1,015 (Neutral maintained)
- Scotiabank: $1,050 → $1,120 (raise)
- TD Cowen: $1,123 → $1,143 (raise)
- HSBC: $1,100 → $1,250 (Buy maintained — pre-print Apr 26)
- Guggenheim: $985 → $1,235 (Buy maintained — pre-print Apr 27)
- Evercore ISI: $1,060 → $1,240 (pre-print Apr 28)
- Consensus rating "Moderate Buy" with consensus PT $1,096.38 (per MarketBeat compilation pre-Q1; consensus likely repriced upward post-Q1)

**Implication for Strategy B information-vs-sentiment test (CONDITIONAL — not currently relevant given criterion 1 failure but documented for any future re-trigger):** Even if criterion 1 had been satisfied, the EQIX sell-side response pattern (aggressive PT raises validating bull case) would NOT match the META/IBM "mild/asymmetric reset" profile that successfully cleared criterion 4. The sell-side pattern is the inverse — neither aggressive ratification of the bear case (NXPI/STX/MDLZ-style information-pricing failure precedent) nor a mild reset (IBM/META mispricing-confirmation pattern) — but rather aggressive ratification of the BULL case alongside / following the (limited) selloff. Working hypothesis for any future evaluation: the Apr 30 −1.7% close-to-close move + immediate sell-side bull-case ratification suggests the market had ALREADY substantially corrected the Apr 29 after-hours overreaction within the regular session — i.e., any 60-day Strategy B mean-reversion thesis would have only ~1.7% of "drift" magnitude to claim, which is too small in absolute terms to support a Strategy B convergence target with meaningful gross-return magnitude. Mechanical failure on criterion 1 subsumes thesis-quality failure here.

### Sector concentration check

Real Estate sector remained at 0/3 usage; EQIX would have been the first entry. No cap interaction. Real Estate sector cap usage post-decision: 0/3 unchanged.

### Effect on book

No book impact. No order staged. Strategy B portfolio state unchanged from prior Decision_Log entry (META GO at MEDIUM conviction): 2 open longs (IBM 0.1198 shares cost basis $230.17; HCA 0.0642 shares cost basis $433.46), 1 staged (META Mon May 4 limit BUY 0.0454 @ $615.00 day order contingent on Mon May 4 ~09:15 MT pre-execution Funds-on-Hold gate), $1,388.38 strategy NAV per Apr 28 IBKR snapshot. Sector cap usage unchanged (IT Services 1/3, Health Care Facilities 1/3, Comm Services 0/3 staged → 1/3 expected on META fill, Real Estate 0/3).

### Pending queue updated

- ~~EQIX B-thesis construction~~ COMPLETE — NO-GO on criterion 1 mechanical failure; no order; no follow-on calendar event scheduled (no fill capture, no invalidation monitoring, no time-based exit — none applicable when no entry occurs).
- Stellantis B-long, BE B-short, Teladoc B-long, Ford B-mixed remain in Daily.md "secondary/tertiary" candidate queue per 2026-05-01 morning scan but not actioned this session — handled by next routine Daily-scan-driven thesis-construction sequencing per standard cadence. **No commitment to evaluate any of these candidates in this thesis-construction session; sequencing is left to the regular Daily-scan cadence which will re-surface eligible candidates and drop ineligible ones.**
- Existing pending items unchanged: META Mon 2026-05-04 ~09:15 MT pre-execution Funds-on-Hold gate session; META Mon 2026-05-04 ~14:30 MT fill capture session; META Mon 2026-06-01 ~10:00 MT mid-window thesis pulse-check; META Thu 2026-07-02 ~10:00 MT time-based exit checkpoint. HCA invalidation-window monitoring; HCA time-based exit Sat Jun 27 (Fri Jun 26 last trading day on/before); IBM invalidation monitoring; RTX long-horizon hold; LLY mechanical re-screen mid-June 2026; GEV mechanical re-screen May 22.

### References

- EQIX Q1 2026 8-K Ex-99.1 (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/0001101239/000110123926000089/eqix-q126xpr.htm — 2026-04-29 AMC.
- EQIX Q1 2026 press release on PRNewswire: https://www.prnewswire.com/news-releases/equinix-reports-first-quarter-results-and-raises-full-year-financial-outlook-302757572.html
- EQIX Q1 2026 earnings call transcript (Motley Fool / Yahoo Finance / Globe and Mail / AOL — 2026-04-29 5:30 PM ET start): https://finance.yahoo.com/markets/stocks/articles/equinix-eqix-q1-2026-earnings-231753996.html
- Stocktitan Q1 2026 8-K extract (recurring revenue, EBITDA, AFFO detail; FY26 guide ranges): https://www.stocktitan.net/sec-filings/EQIX/8-k-equinix-inc-reports-material-event-9c7a7bd94f79.html
- Stocktitan press-release reformat: https://www.stocktitan.net/news/EQIX/equinix-reports-first-quarter-results-and-raises-full-year-financial-q7whj685nli4.html
- TipRanks Q1 2026 earnings highlights (FY26 guide $24M EBITDA / $40M AFFO raise detail): https://www.tipranks.com/news/company-announcements/equinix-earnings-call-highlights-growth-and-tight-capacity
- GuruFocus Apr 30 2026 ($1,082.83 reference price; FY26 guide range; sell-side rating compilation; JPMorgan PT raise to $1,200): https://www.gurufocus.com/news/8834216/eqix-maintained-by-jp-morgan-price-target-raised-to-1200
- GuruFocus Apr 30 (FY26 revenue guide raise; consensus $10.19B reference): https://www.gurufocus.com/news/8828676/eqix-raises-revenue-forecast-adjusts-ffo-expectations
- GuruFocus Apr 30 Q1 miss summary (AFFO $10.79 vs $11.04 expected; revenue $2.44B vs $2.52B expected): https://www.gurufocus.com/news/8828921/equinix-eqix-reports-q1-earnings-miss-raises-2026-guidance
- Seeking Alpha Apr 29 5:24 PM ET (after-hours −5.24% to $1,032.00): https://seekingalpha.com/news/4582037-equinix-stock-plunges-as-q1-earnings-fall-short-of-expectations
- Daily Political / MarketBeat Apr 30 ($1,070.58 close, down $18.49; sell-side roundup; Q1 takeaways): https://www.dailypolitical.com/2026/04/30/equinix-nasdaqeqix-issues-earnings-results.html
- Yahoo Finance EQIX quote ($1,082.83 −0.57% Apr 30 close — source discrepancy with MarketBeat noted; both fail criterion 1): https://finance.yahoo.com/quote/EQIX/
- CNN markets EQIX (post-print sell-side PT raise compilation: Citizens $1,350; Scotiabank $1,120; Goldman $1,015; Oppenheimer $1,200; TD Cowen $1,143; Bank of America Buy maintained): https://www.cnn.com/markets/stocks/EQIX
- Daily.md 2026-05-01 morning scan (Equinix watchlist line — "-5% Apr 30 / LONG (consider) / Real Estate / Guide raise underwhelmed; data-center REIT structurally tailwinded by AI capex / Queue" — flagged as misclassification per this entry; "-5%" reflected after-hours Apr 29 reaction not regular-session close-to-close).
- Strategy.md Strategy B section (criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test; criterion 5 A-coordination; instrument rule; pre-mortem rev 7).
- Portfolio_Ledger.md (Strategy B sector cap usage, $1,388.38 NAV, staged-orders block including META).
- Decision_Log.md 2026-05-01 META GO entry (this session; sequencing predecessor; conviction calibration anchor).
- Decision_Log.md 2026-04-29 batch NO-GO precedents (SBUX/V/NXPI/STX/MDLZ/OMCL on criterion-4 information-vs-sentiment failure — establishes contrast with EQIX criterion-1 mechanical-failure pattern).

### Theater-check on this orchestrator review

(a) **Was the Daily.md "-5%" label sufficient to trigger thesis construction in good faith?** Yes — the Daily.md scan is the standard B-candidate surfacing mechanism, and the "-5%" label appeared to satisfy criterion 1 at scan-time. Primary-source verification this session correctly identified the after-hours-vs-regular-session distinction. The Daily.md scan label is corrected post-hoc by this entry; this is a minor scan-error-detection event, not a Daily.md methodology failure: Daily.md's role is to surface candidates for full thesis construction; full thesis construction is where primary-source verification occurs. The pipeline functioned as designed — the criterion-1 binding-measurement check at thesis-construction time caught the after-hours-vs-regular-session error before it could propagate to a staged order.

(b) **Should after-hours moves count toward criterion 1 in any interpretive reading?** No. Strategy.md Strategy B criterion 1 explicitly states "(measured as close-to-close move on event day)" — close-to-close is a regular-session-only measurement standard in standard market-data interpretation. After-hours liquidity is materially thinner; after-hours moves are reverted at high frequency by overnight institutional re-pricing and pre-market rebalance flows. The Strategy.md operational language is unambiguous; no operator-extension permitted on this measurement standard. (Sub-consideration: even if an interpretive reading were attempted, the after-hours -5.24% reaction at 5:24 PM ET is documented to have already substantially reverted by Apr 30 regular-session close — so even the after-hours figure does not represent a sustained 5%+ mispricing window.)

(c) **Even if the ≥5% criterion were borderline, would the sell-side response justify a closer look?** No. The sell-side response is the OPPOSITE of the mispricing-exploitation pattern Strategy B targets. Aggressive bull-case ratification by sell-side (JPM / Citizens / Oppenheimer / Goldman / Scotiabank / TD Cowen all raising PTs the day after the print) immediately after a mild selloff suggests the market had already substantially corrected any after-hours overreaction within the regular session. The MEDIUM-conviction range that Strategy B targets requires a still-mispriced setup at staging; EQIX shows the OPPOSITE — a market that already absorbed the print directionally consistent with the bull case (sell-side validation), with only a small residual close-to-close drift. This is a market-efficient print, not a mispricing.

(d) **Is the source discrepancy between Daily Political (Apr 30 close $1,070.58) and Yahoo Finance ($1,082.83) material to the disposition?** No. Both readings yield close-to-close magnitude failures (−1.70% vs −0.57%); criterion 1 disposition is identical under either reading. Source discrepancy noted for future Claude awareness; the more specific MarketBeat-attribution figure ($1,070.58 with explicit "down $18.49 on Thursday") is treated as primary, with Yahoo as secondary cross-check. If criterion 1 disposition were borderline (e.g., one source showing 5.1%, another 4.8%), this discrepancy would warrant further verification — but at -1.7% vs -0.6%, both are unambiguously sub-threshold.

### Compaction-survival note

**Strategy B EQIX thesis pipeline status as of 2026-05-01 Friday mid/late afternoon:** B-thesis construction COMPLETE for EQIX; **NO-GO on criterion 1 mechanical eligibility failure** (close-to-close move on Apr 29 → Apr 30 was −1.70% per Daily Political/MarketBeat-sourced data, or −0.57% per Yahoo Finance — both below the ≥5% threshold; Daily.md morning-scan "-5%" label reflected after-hours initial reaction not regular-session close-to-close). No order staged. No follow-on calendar event scheduled (NO-GO has no fill capture, no invalidation monitoring, no time-based exit). Substance preserved for future Claude re-evaluation if a subsequent Q-print or material follow-on event re-triggers criterion 1 — see Substance section above for Q1 2026 print detail, FY26 guide raise magnitudes, and sell-side response compilation. **Notable inverse-precedent observation:** EQIX sell-side response (aggressive PT raises validating bull case post-selloff: JPM $1,100→$1,200, Citizens $1,200→$1,350, Oppenheimer $975→$1,200, Goldman $894→$1,015, Scotiabank $1,050→$1,120) is OPPOSITE of META/IBM mild-reset pattern AND OPPOSITE of NXPI/STX/MDLZ aggressive-bear-ratification pattern; if criterion 1 ever re-triggers at a future event, criterion 4 information-vs-sentiment analysis on this dispersion pattern would be non-trivial and would warrant explicit treatment — but this is not a current concern. Strategy B sector cap usage unchanged at IT Services 1/3, Health Care Facilities 1/3, Real Estate 0/3 (Comm Services 0/3 staged → 1/3 expected on META fill).

---

## 2026-05-01 (Fri, late afternoon post-EQIX-session) Strategy B thesis construction outcome — STLA (Stellantis) NO-GO (criterion 4 decisive failure on LONG framing — Investor Day May 21 in-window binary catalyst structurally mismatched with Strategy B's mean-reversion mechanism + V/MDLZ-pattern structural-overhang-persistence overlay (lawsuits, cash flow, EV reset); criterion 1 mechanically clears at -5.45% close-to-close); no order staged

**Trigger:** B-thesis construction requested for Stellantis post-event candidate flagged "tertiary" / "lower priority" in Daily.md 2026-05-01 morning scan ("Stellantis | -5% Apr 30 | (mixed) | Cons Disc | Tariff-noise overhang; 'messy' but operating income tripled | Verify ADV given ADR; queue"). Q1 2026 earnings event date 2026-04-30 BMO (8:00 AM EDT call). Sector cap 0/3 Cons Disc available. Sequenced after META B-thesis (this session's first construction, GO MEDIUM conviction) and EQIX B-thesis (this session's second construction, NO-GO criterion 1 mechanical failure).

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 3 closed-list rev 14 — convergence target restricted to numerical price level OR strictly-enumerated event list; criterion 4 information-vs-sentiment test + "no decisive flaw"; criterion 5; pre-mortem rev 7 KL #2.20 textbook-rational penalty mechanism-embedded; pre-mortem KL #5 60-day forced exit × 2.18 trade-off; pre-mortem KL #12 long-side concurrent-position correlation gap); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.14 recency bias; 2.20 textbook-rational penalty central B risk); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 ~14:30 MT IBKR snapshot; IBM + HCA open positions; META staged Mon May 4 limit-buy pending Funds-on-Hold gate; EQIX NO-GO this session no portfolio impact; sector cap usage IT Services 1/3, Health Care Facilities 1/3, Real Estate 0/3, Cons Disc 0/3 available; Comm Services 0/3 → 1/3 expected on META fill); Decision_Log.md prior precedents — META 2026-05-01 GO entry (this session, MEDIUM conviction, sequencing predecessor; structurally CLEAN setup with no in-window company-specific binary catalyst — direct contrast for STLA); EQIX 2026-05-01 NO-GO entry (this session, criterion 1 mechanical failure); IBM 2026-04-25 GO (clean undershoot via NOW + IGV cascade), HCA 2026-04-27 GO (medium-low conviction with peer-print invalidation criteria), 2026-04-29 batch NO-GOs on criterion-4 failure (NOW/CHTR/INTC/SBUX/V/NXPI/STX/MDLZ/OMCL — V and MDLZ specifically establish "structural-overhang-persistence" sub-pattern, with multi-quarter-resolution timelines structurally mismatched with B's 60-day window — directly applicable to STLA's lawsuits + EV reset overhang); STLA Q1 2026 8-K Form 6-K (SEC EDGAR — see References); CNBC / Stellantis investor.stellantis.com / globenewswire / Stocktitan / Investing.com / Macrotrends / Yahoo Finance / MoneyCheck / Capital.com / TipRanks / Timothy Sykes / Seeking Alpha / Public.com / TickerNerd / MarketBeat / Benzinga / CNN markets Apr 29-30 coverage (Q1 print detail; FY26 guide reaffirmation; sell-side ratings; price history; Investor Day May 21 confirmation; class action lawsuits; pre-print analyst skepticism); Daily.md 2026-05-01 (Stellantis watchlist line — "tariff-noise overhang; 'messy' but operating income tripled; Verify ADV given ADR; queue").

### Decision

**STLA — NO-GO (DECLINE) on LONG framing. SHORT framing briefly considered and dismissed.**

Failed Strategy B entry criterion 4 with hybrid sub-pattern evidence — the V/MDLZ structural-overhang-persistence sub-pattern (multi-quarter-resolution overhang misaligned with B's 60-day window) PLUS a structurally novel layer not present in V/MDLZ: a known major in-window company-specific binary catalyst (Stellantis Investor Day May 21, 2026 — Auburn Hills + virtual webcast — at which management plans to unveil a new strategic plan). The in-window Investor Day combined with the unresolved V-pattern overhang (class action lawsuits over Feb 2026 €22B EV reset; persistent industrial FCF burn; tariff residual; pre-existing analyst skepticism evidenced by Apr 16 Kepler downgrade and Morgan Stanley €6.50 PT) produces a setup where Strategy B's mean-reversion mechanism cannot operate cleanly: the Q1 print's "narrative context" is structurally incomplete pending Investor Day, the market is correctly discounting both the Q1 details AND Investor Day uncertainty (information-driven characterization), and any 60-day mean-reversion thesis would implicitly require Claude to take a directional view on the Investor Day outcome (Strategy A's domain, not Strategy B's). Criterion 1 mechanically clears at -5.45% close-to-close, but criterion 4 is decisively flawed.

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** STLA = Stellantis N.V. NYSE-listed common (US-listed; Stellantis files Form 6-K as a foreign private issuer (Dutch domicile, Hoofddorp NL HQ) but trades as standard NYSE common equity, not as an ADR despite Daily.md's "ADR" framing which is colloquial — STLA shares ARE the ordinary shares listed in NYSE; companion European listings exist as STLAM Euronext Milan and STLAP Euronext Paris but US trading is on NYSE common equity at $-denominated prices); market cap ~$22.45B per TickerNerd (well above $2B floor; Yahoo confirms "large capitalization category"); 30-day ADV ~$149M+/day (20-day average shares ~20.5M × $7.28 reference per Stocktitan = ~$149M/day; well above $10M floor); long-or-short permitted; 2% sizing $27.77; no options. **Daily.md's "Verify ADV given ADR" caveat resolves cleanly: ADV is comfortably above the $10M floor with >10× cushion, and the "ADR" framing is loose terminology for foreign-issuer-NYSE-listed common rather than a structural ADR with sponsor-bank intermediation.**
- **Criterion 1 — CLEARS:** Event date 2026-04-30 BMO (Q1 results released 8:00 AM EDT pre-market; earnings call same morning). Apr 29 close $7.70 (per Stocktitan reference price "ahead of the earnings release"); Apr 30 close $7.28 (per Macrotrends "latest closing stock price for Stellantis as of April 30, 2026 is 7.28"; Timothy Sykes confirms $7.295 / -5.06% on day; MoneyCheck premarket reading -5.59% to $7.26 also consistent). **Computed close-to-close: ($7.28 - $7.70) / $7.70 = -5.45%.** Clears the ≥ 5% threshold by ~45bps. Note: Stocktitan's standalone "-2.04% Q1 2026 reaction" figure appears to measure a different interval (possibly STLAM Euronext Milan listing, premarket-to-close, or open-to-close); the regular-session close-to-close on US listing per primary-source authoritative data is -5.45%. CNBC headline "fall as much as 10%" reflects intraday low not close-to-close. **The -5.45% reading clears criterion 1; this entry differs from EQIX's parallel session in that respect.**
- **Criterion 5 cleared:** No A position open in STLA (A router DO-NOT-ACTIVATE; no A entries any name).
- **A↔B coordination per pre-mortem KL #8:** acknowledged; no A entries imminent under DO-NOT-ACTIVATE state.

### LONG thesis examined and declined

**Provisional affirmative thesis (LONG / extension).** Q1 2026 print delivered substantive fundamental turnaround vs prior 4 quarters (loss → profit; €377M net profit vs €387M loss YoY; AOI nearly tripled to €960M from €327M; AOI margin +160bps to 2.5%; net revenues +6% YoY to €38.1B; consolidated shipments +12% YoY to 1.4M units; adjusted diluted EPS €0.21 vs €0.04 prior year). North America momentum was the structural contributor: market share +80bps to 7.9%, fastest-growing automaker in a declining-industry environment (US industry -6%), Ram +20% YoY (best Q1 since 2023), Jeep refresh + new Cherokee + Grand Wagoneer driving volume mix. 2026 FY guidance REAFFIRMED (mid-single-digit revenue growth; low-single-digit AOI margin; YoY-better industrial FCF). Capital structure strengthened via €5B hybrid perpetual notes issuance (treated as equity); industrial liquidity €44.1B (28% of TTM revenues, within 25-30% target range). Tariff impact estimate REDUCED €1.6B → €1.3B (€0.4B IEEPA tariff cost adjustment recognition). Pre-print stock weakness (-16% from $8.69 Apr 20 to $7.28 Apr 30) had already heavily discounted the multi-headwind backdrop, suggesting bearish positioning was extreme into the print and creating undershoot conditions. Provisional LONG thesis would argue: pre-print pessimism on cash flow / tariff / EV reset overhang had over-priced the operational-recovery trajectory; Q1's profit turnaround + reaffirmed guide creates a 60-day mean-reversion-eligible setup. Convergence target options: 25% gap-fill from $7.28 toward $7.70 = $7.39 (+1.51% gross — too small for MEDIUM conviction); 50% gap-fill $7.49 (+2.88%); 100% gap-fill $7.70 (+5.77%).

**Adversarial counter-argument (decisive flaw on LONG side):**

The provisional LONG thesis FAILS criterion 4 on multiple compounding weights, with at least two individually decisive:

(1) **DECISIVE — Investor Day May 21, 2026 in-window binary catalyst (T+17 trading days from Mon May 4 entry, ~28% into the 60-day window).** Stellantis Investor Day on May 21 — confirmed across multiple primary sources (Stellantis press release, Investing.com, Stocktitan, Capital.com) — will see management "unveil a new strategic plan" with brand and technology sessions per Investing.com summary. This is a known scheduled COMPANY-SPECIFIC binary catalyst that falls SQUARELY inside the 60-day Strategy B window. Strategy B's mechanism — "the mispricing resolves over weeks as the market fully digests the event's narrative context" — is structurally INCOMPATIBLE with this setup: the Q1 print's narrative context is INCOMPLETE because management explicitly defers strategic plan articulation to Investor Day ("our priority is clear: to put our customers back at the center of everything we do and we look forward to sharing more on this at our Investor Day on May 21" — Filosa CEO commentary in press release). The market is therefore pricing Q1 + Investor Day risk JOINTLY; the -5.45% reaction is a partial pricing of the joint distribution, not a pure overreaction to Q1 alone. A 60-day mean-reversion thesis would implicitly require Claude to take a directional view on the Investor Day outcome (additional charges? plant closures? brand consolidation? versus credible recovery plan?), which is structurally Strategy A's mandate (entering before a known catalyst with directional thesis on the catalyst itself), not Strategy B's. **Strategy B is explicitly designed for "evaluating the quality of a realized market reaction to known public information, rather than predicting a future event's outcome" — the STLA setup forces the latter.** This factor alone is decisive even setting aside the V-pattern overhang considerations below. (Note: Strategy B exit rules permit invalidation-driven exit if Investor Day produces "new public information that changes the situation" — so worst-case loss is bounded at 2% strategy portfolio per pre-mortem rev 6 design — but the 60-day mean-reversion mechanism cannot operate cleanly when the dominant in-window directional driver is a binary catalyst, not narrative-digestion drift.)

(2) **DECISIVE — V/MDLZ-pattern structural-overhang-persistence on multi-quarter-resolution timeline.** STLA carries multiple unresolved structural overhangs that are MULTI-QUARTER (not 60-day) resolution timelines:

- **Class action lawsuits** over Feb 6, 2026 €22-22.2B EV strategic reset — multiple law firms filed (Pomerantz LLP press release Apr 30; Rosen / Faruqi / Schall / Bronstein per CNN markets news feed); class period 2025-02-26 to 2026-02-05; lead plaintiff deadline June 8, 2026. Securities class actions are multi-year resolution timelines; the Apr 30 Pomerantz press release coincided with the Q1 print, layering active legal-headline risk on top of the Q1 narrative. Per pre-mortem rev 7 KL framework, this is exactly the V/MDLZ "structural overhang persistence" feature — analogous to V's regulatory overhang and MDLZ's cocoa-cost overhang.
- **Industrial free cash flow remained NEGATIVE at -€1.9B** (improved 37% YoY but still material); FCF break-even target now 2027 not 2026; ~€2B of additional 2026 cash outflows from H2 2025 charges flagged in guide. Yahoo Finance characterization explicitly: "shares fell approximately 6% due to concerns over cash flow and tariff adjustments, overshadowing the positive profit figures" — explicit information-driven characterization from a generalist financial data source.
- **EV strategic reset trajectory unresolved** — Feb 2026 reset slashed BEV volume and profitability expectations, walked back hydrogen fuel cell efforts, impaired platforms; the "reset" is a multi-year-execution overhang, not a 60-day-resolvable framing.
- **Tariff residual €1.3B** (reduced from €1.6B but still material; sequential improvement expected H2 2026 but not within 60-day window).
- **Pre-print analyst skepticism** — Kepler Cheuvreux DOWNGRADED Buy → Hold and CUT PT €9 → €7.50 on Apr 16 (pre-print, structural-concerns-driven); Morgan Stanley PT €6.50 (low end); Stocktitan precedent "Earnings-related announcements for STLA have frequently coincided with negative price moves" (-1.13% avg over 5 prior earnings) confirming structural-overhang mechanism rather than print-quality-driven reactions; Citi raised PT €7 → €7.50 with Buy upgrade Apr 16 but framed it as "early signs of a potential shift in investor sentiment after the stock declined approximately 39% year to date" — i.e., positioning observation, not fundamental call.

The V/MDLZ sub-pattern logic applies: even when the Q1 print partially refutes some pre-print pessimism factors (volume +12%, AOI tripled, profit return), the BINDING structural overhangs (lawsuits, cash flow, EV reset, tariff) are NOT refuted by Q1 — they are merely temporarily set aside pending Investor Day articulation. The 60-day window is structurally too short to resolve these multi-quarter timelines.

(3) **Sell-side post-print response is muted/cautious, not aggressively-validating-bull-case nor aggressively-ratifying-bear-case.** No same-day Apr 30 broker upgrades or PT raises observed in primary-source compilations (CNN markets news feed shows zero Apr 30 broker-rating actions on STLA; in stark contrast to EQIX's same-day flood of PT raises from JPM/Citizens/Oppenheimer/Goldman/Scotiabank/TD Cowen). The pre-existing pre-print sell-side dispersion (Morgan Stanley €6.50 / Kepler €7.50 Hold downgrade / Citi €7.50 Buy upgrade) was already wide; Q1 didn't catalyze meaningful repricing. This is consistent with information-driven appropriate-pricing of an ambiguous print rather than aggressive bull-confirmation (which would have produced same-day PT raises) or aggressive bear-confirmation (which would have produced PT cuts). **The muted sell-side response is the inverse of the IBM/META "mild reset" pattern that successfully cleared criterion 4** — IBM/META had directional sell-side actions (downgrades + at least one notable upgrade or raise) that confirmed bull-thesis-while-acknowledging-shock; STLA sell-side simply held and waited for Investor Day, which is itself evidence that the Q1 print is INCOMPLETE narrative context.

(4) **Pre-existing extreme bear positioning argues some of the post-print decline is appropriate-pricing not overreaction.** Stock declined 16% in 10 trading days BEFORE the print ($8.69 Apr 20 → $7.28 Apr 30 close, with -5.45% of that being the print-day close-to-close, and the prior ~10.5% from pre-print sentiment shifts: Kepler downgrade Apr 16, Microsoft AI deal under-impact, Reuters reports on European plant divestitures Apr 22, securities lawsuits filings Apr 22-23). The pre-existing decline ALREADY priced significant bearishness; the question whether the additional -5.45% is over-reaction depends on whether Q1's profit turnaround should have produced enough relief to offset Investor Day uncertainty + cash flow concern + tariff residual. The market's Apr 30 verdict was NO. This isn't extreme sentiment; it's information-driven multi-factor weighting.

(5) **Pre-mortem rev 7 KL #2.20 textbook-rational-penalty.** STLA is precisely the "value-trap with binary catalyst" archetype that 2.20 punishes most severely: surface-level fundamental-improvement story (loss → profit) layered over multi-quarter structural overhangs (lawsuits, cash flow, EV reset) and a near-term binary catalyst (Investor Day). Strategy B's mechanism IS the textbook-rational instinct that "prices return to fundamental value" — but for STLA, the fundamental-value question is unresolved (depends on Investor Day outcome), so the textbook-rational instinct has nothing to anchor to.

**Information-vs-sentiment test conclusion: PREPONDERANT INFORMATION-DRIVEN.** The Q1-day -5.45% close-to-close move is appropriately-priced relative to the JOINT distribution of (a) Q1 print details + (b) Investor Day uncertainty + (c) multi-quarter structural overhangs. The provisional LONG thesis would require ALL THREE to break favorably within 60 days, which is structurally implausible given Investor Day at T+17 days and lawsuit / cash flow timelines extending past 60 days.

### SHORT thesis briefly considered and dismissed

A SHORT thesis would argue: -5.45% is UNDER-sized given the multi-headwind backdrop; further fundamental absorption + Investor Day downside surprise drives further decline. **Dismissed because:** (a) Q1 profit turnaround is genuinely positive new information and at least partially refutes the bear case on operational quality — short-side mean-reversion thesis does not have clean support from the print; (b) pre-existing 16%-in-10-days decline plus Apr 30 -5.45% means STLA is at $7.28 vs 52-week low $6.28 with a ~15% buffer; further downside has limited magnitude before structural support; (c) per pre-mortem rev 7 KL #2.20 textbook-rational-penalty, SHORT-on-already-declined-name with profit-turnaround-print is the canonical 2.20 trap (chasing the trend after the bears are already correctly positioned); (d) Strategy B short-side stop-loss at +25% from short entry would trigger on any Investor Day positive surprise (+10% to +25% Investor Day reactions are entirely plausible if Stellantis presents a credible recovery plan), capping short loss at 0.5% strategy portfolio but with high invalidation-trigger probability; (e) borrow rates may be elevated — TipRanks Apr 23 noted STLA among "Largest borrow rate increases among liquid names" — adding negative carry to the short.

The SHORT-on-STLA pattern is canonical 2.20 textbook-rational-trap territory. Not pursued.

### Sector concentration check

Cons Disc sector remained at 0/3 usage; STLA would have been the first entry. No cap interaction. Cons Disc sector cap usage post-decision: 0/3 unchanged. (Note: if STLA had cleared criteria, the Strategy B book would have moved to 4 concurrent longs (IBM IT Services + HCA Health Care Facilities + META Interactive Media & Services + STLA Cons Disc), with sum of long exposures ~8% — below the 10% leading-indicator threshold from pre-mortem KL #12, but with the pairwise-correlation metric becoming computable starting ~mid-late May 2026 once 20-trading-day windows accumulate. Not a binding constraint here, but documented for future reference if subsequent B candidates push toward 5+ concurrent longs.)

### Effect on book

No book impact. No order staged. Strategy B portfolio state unchanged from prior Decision_Log entries (META GO and EQIX NO-GO this session): 2 open longs (IBM 0.1198 shares cost basis $230.17; HCA 0.0642 shares cost basis $433.46), 1 staged (META Mon May 4 limit BUY 0.0454 @ $615.00 day order contingent on Mon May 4 ~09:15 MT pre-execution Funds-on-Hold gate), $1,388.38 strategy NAV per Apr 28 IBKR snapshot. Sector cap usage unchanged (IT Services 1/3, Health Care Facilities 1/3, Comm Services 0/3 staged → 1/3 expected on META fill, Real Estate 0/3, Cons Disc 0/3).

### Pending queue updated

- ~~STLA B-thesis construction~~ COMPLETE — NO-GO on criterion 4 decisive failure (Investor Day May 21 in-window binary catalyst + V/MDLZ structural-overhang-persistence sub-pattern); no order; no follow-on calendar event scheduled. **STLA remains a closed name from a Strategy B perspective unless and until (a) Investor Day May 21 has resolved AND (b) the structural-overhang-resolution timeline shifts to within 60-day reach** — neither condition is plausibly met within any near-term trigger horizon, so STLA is effectively closed for B purposes. The 10-day post-event entry window expires ~2026-05-14 (10 trading days from event day 2026-04-30); no calendar event scheduled to revisit because the criterion 4 failure is structural, not data-dependent.
- BE B-short, Teladoc B-long, Ford B-mixed remain in Daily.md "secondary/tertiary" candidate queue per 2026-05-01 morning scan but not actioned this session — handled by next routine Daily-scan-driven thesis-construction sequencing per standard cadence.
- Existing pending items unchanged: META Mon 2026-05-04 ~09:15 MT pre-execution Funds-on-Hold gate session; META Mon 2026-05-04 ~14:30 MT fill capture session; META Mon 2026-06-01 ~10:00 MT mid-window thesis pulse-check; META Thu 2026-07-02 ~10:00 MT time-based exit checkpoint. HCA invalidation-window monitoring; HCA time-based exit Sat Jun 27 (Fri Jun 26 last trading day on/before); IBM invalidation monitoring; RTX long-horizon hold; LLY mechanical re-screen mid-June 2026; GEV mechanical re-screen May 22.

### References

- STLA Q1 2026 8-K Form 6-K (SEC EDGAR, Stocktitan reformat): https://www.stocktitan.net/sec-filings/STLA/6-k-stellantis-n-v-current-report-foreign-issuer-d3ec08ffa656.html ; https://www.stocktitan.net/sec-filings/STLA/6-k-stellantis-n-v-current-report-foreign-issuer-1b784ba916c7.html ; https://www.stocktitan.net/sec-filings/STLA/6-k-stellantis-n-v-current-report-foreign-issuer-0d0aff70cf99.html
- Stellantis Q1 2026 press release: https://www.stellantis.com/en/news/press-releases/2026/april/first-quarter-2026-financial-results
- Stellantis Q1 2026 press release PDF: https://www.stellantis.com/content/dam/stellantis-corporate/news/press-releases/2026/april/30-04-2026/en/EN-20260430-Stellantis-Q1-2026-Financial-Results.pdf
- Stellantis Q1 2026 GlobeNewsWire release: https://www.globenewswire.com/news-release/2026/04/30/3284476/0/en/Stellantis-Reports-Q1-2026-Financial-Results.html
- Stellantis Q1 2026 Earnings Call Transcript (Seeking Alpha): https://seekingalpha.com/article/4897102-stellantis-n-v-stla-q1-2026-earnings-call-transcript
- Stocktitan Q1 2026 stock news (Apr 29 close $7.70 reference; -2.04% Q1 reaction figure noted as inconsistent with primary close-to-close): https://www.stocktitan.net/news/STLA/stellantis-reports-q1-2026-financial-3sad26k8sjy1.html
- Investing.com Q1 2026 slides analysis (Investor Day May 21 confirmed; -6.88% premarket; -5.59% premkt to $7.17 cited; tariff estimate €1.6B→€1.3B; 160bp AOI margin expansion; Investor Day May 21 strategic plan unveil): https://www.investing.com/news/company-news/stellantis-q1-2026-slides-return-to-profitability-on-north-america-gains-93CH-4649790
- CNBC Apr 30 (intraday "fall as much as 10%"; AOI €960M / $1.12B beat): https://www.cnbc.com/2026/04/30/stellantis-q1-earnings-jeep-autos.html
- Macrotrends STLA price history (Apr 30 close $7.28 confirmation): https://www.macrotrends.net/stocks/charts/STLA/stellantis/stock-price-history
- Yahoo Finance STLA (Apr 30 -6% framing tied to "concerns over cash flow and tariff adjustments, overshadowing the positive profit figures"): https://finance.yahoo.com/quote/STLA/
- Timothy Sykes Apr 30 17:03 EDT live update (-5.06% close; daily $8.69 Apr 20 → $7.295 Apr 30 16% pullback context; Kepler downgrade context; lawsuits framing): https://www.timothysykes.com/news/stellantis-nv-stla-news-2026_04_30/ ; https://www.timothysykes.com/news/stellantis-nv-stla-news-2026_04_30-2/
- MoneyCheck Apr 30 (5.59% premarket to $7.26): https://moneycheck.com/stellantis-stla-stock-slides-5-59-despite-q1-revenue-jump-and-profit-turnaround/
- Pomerantz LLP Apr 30 class-action announcement (lead plaintiff deadline June 8, 2026; class period 2025-02-26 to 2026-02-05): https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-stellantis-nv-of-class-action-lawsuit-and-upcoming-deadlines--stla-302759584.html
- Capital.com Apr 21-29 stock forecast (Citi €7→€7.50 Buy upgrade Apr 16; pre-print sentiment compilation; STLAM listing context): https://capital.com/en-int/market-updates/stellantis-price-forecast-29-04-2026
- TipRanks STLA forecast (Morgan Stanley €6.50 PT cut; Wolfe Research upgrade; mixed-consensus framing; 16-analyst breakdown 6/10/1 Buy/Hold/Sell; PT median ~$9.27): https://www.tipranks.com/stocks/stla/forecast
- TickerNerd STLA forecast (16-analyst dispersion $5.90-$15.00; median $9.45; "neutral consensus"): https://tickernerd.com/stock/stla-forecast/
- Public.com STLA forecast (5-analyst Buy consensus; PT $11.59 average): https://public.com/stocks/stla/forecast-price-target
- MarketBeat STLA (19-analyst Hold consensus; PT $11.12 average): https://www.marketbeat.com/stocks/NYSE/STLA/forecast/
- Benzinga STLA analyst ratings: https://www.benzinga.com/quote/STLA/analyst-ratings
- CNN markets STLA (Apr 30 broker-rating-actions feed showing zero same-day post-Q1 PT changes; lawsuits press release feed; "$8.06 closed" stale-data note): https://www.cnn.com/markets/stocks/STLA
- Daily.md 2026-05-01 morning scan (Stellantis watchlist line — "Stellantis | -5% Apr 30 | (mixed) | Cons Disc | Tariff-noise overhang; 'messy' but operating income tripled | Verify ADV given ADR; queue").
- Strategy.md Strategy B section (criterion 1 close-to-close magnitude requirement; criterion 3 closed-list rev 14 — convergence target restricted to numerical price level OR strictly enumerated event list of "next earnings release / next FDA decision date / next FOMC meeting / inclusion announcement in S&P 500/Russell 1000/Nasdaq 100"; criterion 4 information-vs-sentiment test + "no decisive flaw"; pre-mortem rev 7).
- Portfolio_Ledger.md (Strategy B sector cap usage, $1,388.38 NAV, staged-orders block including META, EQIX NO-GO this session noted).
- Decision_Log.md 2026-05-01 META GO entry (this session; sequencing predecessor; conviction calibration anchor; clean post-event setup with no in-window company-specific binary catalyst — direct contrast for STLA).
- Decision_Log.md 2026-05-01 EQIX NO-GO entry (this session; criterion 1 mechanical failure; sequencing predecessor for STLA).
- Decision_Log.md 2026-04-29 V/MDLZ NO-GO entries (V-pattern structural-overhang-persistence sub-pattern precedent; STLA layers Investor-Day in-window binary catalyst on top of V-pattern overhang).

### Theater-check on this orchestrator review

(a) **Was the criterion 4 disposition reachable WITHOUT the Investor Day in-window catalyst weight?** Let me imagine STLA without the May 21 Investor Day. The remaining criterion 4 weights are: V/MDLZ structural-overhang-persistence (lawsuits + cash flow + EV reset + tariff) + muted sell-side response + pre-existing 16% pre-print decline + Yahoo-explicit information-driven framing on cash flow / tariff. Even without the Investor Day, the V/MDLZ pattern alone is sufficiently strong to support criterion 4 NO-GO under the established sub-pattern precedent. The Investor Day adds an additional decisive layer but is not the SOLE decisive flaw. Disposition is robust to the counterfactual.

(b) **Does the Q1 profit turnaround (loss → profit; AOI tripled) carry enough weight to overturn the V/MDLZ classification?** Counter-argument: V's print also delivered top-line beats with structural overhang persistence; MDLZ delivered volume-refutation of pre-print pessimism. Both were classified NO-GO on V-pattern grounds when the binding pre-print-pessimism factor was NOT refuted by the print. For STLA, the binding pre-print-pessimism factor is the multi-quarter strategic-reset / lawsuit / cash-flow burden — which is NOT refuted by Q1 (Q1 doesn't resolve any of these; it merely shows operational improvement). The Q1 profit turnaround is real but operates at the operational-quality layer, not the structural-overhang layer. Same V/MDLZ disposition applies.

(c) **Is the convergence-target choice space functional for STLA?** Per criterion 3 closed-list rev 14: numerical price level OR specific event from the closed list ("next earnings release," "next FDA decision date," "next FOMC meeting," or "inclusion announcement in S&P 500/Russell 1000/Nasdaq 100"). For STLA, "next earnings release" would be H1 2026 / Q2 2026 print around July/August — outside the 60-day window. Investor Day May 21 is NOT on the closed list (introduced rev 14 to close operator-extensibility escape hatch). The only viable target is a numerical price level. 25% gap-fill ($7.39, +1.51%) is too small for MEDIUM conviction; 50%+ gap-fill ($7.49+, +2.88%+) requires bull-thesis on Investor Day outcome implicitly — which is criterion 4's structural-flaw concern. The convergence-target space itself reflects the criterion 4 problem rather than offering a clean target choice.

(d) **Is sequencing meaningful — should STLA decision wait for next-day's market reaction Friday May 1 to gather more signal?** Counter-argument: per protocol, deferral requires a specific resolution trigger and conservative-default fallback. The criterion 4 failure is STRUCTURAL (Investor Day in-window + V-pattern overhang multi-quarter timeline), not a data-resolution issue. Friday's market action would change tactical magnitudes but not the structural disposition. Decision is made now without deferral. (Note: Friday May 1 trading is happening DURING this session per Daily.md 2026-05-01 morning scan timing, but no STLA-specific Friday data has materialized to alter the criterion 4 disposition.)

(e) **Does the muted sell-side response (no same-day Apr 30 PT changes observed) constitute the "mild reset" pattern that successfully cleared criterion 4 for IBM/META?** Counter-argument: IBM and META both had AT LEAST ONE notable directional sell-side action on the print day — IBM had DZ Bank UPGRADE; META had Evercore $900→$930 RAISE plus Goldman "Buy the Fear" thesis. The directional-action signal — sell-side validating bull thesis even while acknowledging shock — was material to the IBM/META criterion 4 disposition. STLA had ZERO Apr 30 directional sell-side actions visible in primary-source compilations; this is QUALITATIVELY different from IBM/META's "mild but directional reset" pattern. STLA's silence is consistent with sell-side waiting for Investor Day before repositioning — itself evidence that the Q1 print is structurally incomplete narrative context.

Modulo these five considerations, the orchestrator review converges on the NO-GO recommendation on the LONG framing.

### Compaction-survival note

**Strategy B STLA thesis pipeline status as of 2026-05-01 Friday late afternoon:** B-thesis construction COMPLETE for STLA; **NO-GO on criterion 4 decisive failure** (Investor Day May 21 in-window binary catalyst + V/MDLZ structural-overhang-persistence sub-pattern: class action lawsuits over Feb 2026 €22B EV reset, persistent industrial FCF burn -€1.9B, tariff residual €1.3B, pre-existing analyst skepticism). Criterion 1 mechanically clears at -5.45% close-to-close (Apr 29 $7.70 → Apr 30 $7.28). No order staged. No follow-on calendar event scheduled. STLA remains effectively closed for Strategy B purposes unless and until Investor Day May 21 has resolved AND structural-overhang-resolution timeline shifts within 60-day reach — neither plausibly met within near-term trigger horizon.

**This is the FIRST Strategy B NO-GO entry where a known scheduled in-window company-specific binary catalyst (Investor Day) is the primary decisive flaw under criterion 4.** Prior criterion-4 NO-GO precedents (NOW/CHTR/INTC/SBUX/V/NXPI/STX/MDLZ/OMCL) all turned on (a) aggressive sell-side bear-ratification (NXPI/STX-pattern), (b) regulatory-overhang-persistence (V-pattern), (c) cocoa-cost / multi-headwind structural-overhang-persistence (MDLZ-pattern), or (d) borderline market-cap / instrument issues (OMCL). STLA establishes a new sub-pattern: **in-window company-specific binary catalyst** (analogous to a Strategy A entry catalyst falling inside a Strategy B post-event window), which is structurally incompatible with B's mean-reversion mechanism. This entry serves as the precedent for that pattern. Future B candidates with known scheduled major in-window catalysts (Investor Days, capital-markets days, strategic-plan-launches, regulatory ruling deadlines, FDA PDUFA dates within 60-day window, etc.) should be cross-checked against this precedent and explicitly evaluated on the in-window-catalyst dimension before construction proceeds beyond the criterion-1 mechanical screen.

**Information-vs-sentiment characterization at this NO-GO:** PREPONDERANT INFORMATION-DRIVEN. The Q1-day -5.45% close-to-close reflects appropriate-pricing of the joint distribution of (a) Q1 print details (cash flow concern, tariff residual), (b) Investor Day May 21 uncertainty, and (c) multi-quarter structural overhangs (lawsuits, EV reset, FCF break-even now 2027). This is qualitatively DIFFERENT from the V/MDLZ pure-overhang-persistence sub-pattern (which lacked an in-window binary catalyst) — STLA is a hybrid: overhang-persistence + binary-catalyst. The hybrid form intensifies criterion 4 disposition.

---

## 2026-05-01 (Fri, late afternoon post-STLA-session) Strategy B thesis construction outcome — BE (Bloom Energy) NO-GO (criterion 4 decisive failure on SHORT framing — NXPI/STX-style aggressive-sell-side-bull-ratification information-pricing failure with massive Q1 fundamental beat + Oracle Project Jupiter strategic-customer-win = canonical 2.20 textbook-rational-trap; LONG framing structurally inappropriate for Strategy B); no order staged

**Trigger:** B-thesis construction requested for Bloom Energy candidate flagged Daily.md 2026-05-01 morning scan as "BE — Strategy B short (adversarial review required; valuation-extreme momentum AI-power name; high-risk)" with explicit cautionary framing: "$79B mkt cap after 1,400% trailing-1Y move; AI-power proxy at Oracle-deal valuation extremes — classic Strategy-B overshoot setup, but adversarial: short into a momentum AI-power name with hyperscaler-deal validation is high-risk." Primary event sequence: Mon 2026-04-27 evening — Oracle announces Project Jupiter Bloom-sole-supplier 2.45–2.8GW AI data center deal; Tue 2026-04-28 AMC — Q1 2026 earnings print (revenue $751.05M / +130% YoY / 39% beat; non-GAAP EPS $0.44 / 3.4× beat; profit turnaround; FY26 revenue guide raise $3.1-3.3B → $3.4-3.8B; FY26 non-GAAP OI guide raise $425-475M → $600-750M; FY26 EPS guide raise $1.33-1.48 → $1.85-2.25). Sequenced after META B-thesis (this session GO MEDIUM), EQIX (NO-GO criterion 1), STLA (NO-GO criterion 4 in-window-catalyst).

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test + "no decisive flaw"; pre-mortem rev 7 KL #2.20 textbook-rational penalty mechanism-embedded; pre-mortem KL #7 short-side gap-up execution risk acknowledgment; short-side stop-loss at +25% from short-entry per Strategy.md exit rules; short-financing exit threshold at 10% annualized borrow rate); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk; 2.8 homogenization on commoditized AI strategies); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged Mon May 4; sector cap usage IT Services 1/3, Health Care Facilities 1/3, Comm Services 0/3 → 1/3 expected on META fill, Real Estate 0/3, Cons Disc 0/3, Industrials 0/3 available); Decision_Log.md prior precedents — META 2026-05-01 GO (this session, mild-sell-side-reset pattern that successfully cleared criterion 4 — direct contrast for BE), EQIX 2026-05-01 NO-GO (criterion 1 mechanical failure), STLA 2026-05-01 NO-GO (criterion 4 in-window-catalyst), 2026-04-29 batch NO-GOs on criterion-4 failure especially **NXPI 2026-04-29 NO-GO and STX 2026-04-29 NO-GO (positive-direction L1 with aggressive sell-side bull-ratification — direct sub-pattern match for BE)**, 2026-04-25 NOW NO-GO (positive-direction L1 with information-driven characterization), MDLZ 2026-04-29 NO-GO (V-pattern overhang); BE Q1 2026 8-K Form Ex-99.1 (SEC EDGAR / Stocktitan / TradingKey / Motley Fool transcript / Yahoo / 24-7 Wall St. coverage); JPMorgan / Susquehanna / RBC analyst PT raises (per multiple sources Apr 29); Daily.md 2026-05-01 (Bloom Energy watchlist line + adversarial-review framing); Daily.md 2026-04-30 (Apr 29 fuel-cell-erupt scan with FCEL +32% / PLUG +9% sympathy moves confirming sector-wide repricing event).

### Decision

**BE — NO-GO (DECLINE) on SHORT framing. LONG framing briefly considered and dismissed (structurally inappropriate for Strategy B mean-reversion mechanism on a positive-information re-rating event).**

Failed Strategy B entry criterion 4 with the **NXPI/STX-style aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern**, layered with multiple compounding decisive flaws (canonical pre-mortem KL #2.20 textbook-rational-trap on momentum AI-power name with hyperscaler-deal-validation; pre-mortem KL #7 short-side gap-up execution risk in active gap regime; sector-wide repricing event evidenced by FCEL +32% / PLUG +9% sympathy moves; Oracle Project Jupiter as transformative strategic-customer-win that fundamentally changes the company's profile from niche clean-energy play to mainstream AI-infrastructure provider). Criterion 1 mechanically clears with extreme cushion (Apr 29 close-to-close +13.96% on event day; Apr 27 → Apr 29 combined +27.2% on the joint Oracle-announcement + Q1-print event sequence) — but criterion 1 cushion does not rescue criterion 4 disposition.

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** BE = Bloom Energy Corporation, NYSE-listed common (US-listed); market cap ~$79B per Daily.md (well above $2B floor); 30-day ADV $multi-billion/day given the recent run + parabolic trading volume (well above $10M floor); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS with extreme cushion:** Q1 2026 print event date = Tue 2026-04-28 AMC (4:00 PM EDT release; 4:30 PM EDT call); Q1 close-to-close measured Apr 28 close $252.69 → Apr 29 close $287.97 = **+13.96%** (per Yahoo Finance "April 28 close: 252.69" + FX Leaders "shares jumped 27% to a record closing high of $287.97" — note the +27% framing measures from Apr 27 close $226.36, not Apr 28 close). The Apr 28 close itself was already +11.63% from Apr 27 close, partially incorporating Mon Apr 27 evening Oracle Project Jupiter announcement. Combined Apr 27 → Apr 29 reaction = $226.36 → $287.97 = +27.2% on the joint Oracle-deal + Q1-print event sequence. Apr 30 "held" per Daily.md (no major continuation). Both single-event-day (+13.96%) and joint-event-window (+27.2%) measurements are massively above the ≥5% criterion 1 threshold. **The magnitude of the move is itself a decisive cue for criterion 4 information-driven characterization** (single-event-day +14% is at the extreme upper tail of post-event reactions; joint-2-day +27% is exceptional and consistent only with material new information, not sentiment overreaction).
- **Criterion 5 cleared:** No A position open in BE (A router DO-NOT-ACTIVATE).

### SHORT thesis examined and declined

**Provisional adversarial-thesis (SHORT framing per Daily.md flag).** A SHORT thesis would argue: BE is at $79B market cap after a 1,400% trailing-1-year move, trading at ~163× 2026 projected EPS pre-print and now at ~130× post-print-raised-EPS guidance midpoint ($2.05 mid × 130 = ~$267 ~ recent close), with parabolic price action ($135 to $283 in weeks per Sykes). Provisional thesis: the +27% 2-day move overshoots the fundamental information content; valuation extremes mean-revert; consensus PTs ($219 average per Yahoo / TickerNerd-style aggregators) imply downside even with the post-print PT raises factored in.

**Adversarial counter-argument (decisive flaws on SHORT side — ALL decisive, multiple individually):**

(1) **DECISIVE — NXPI/STX-style aggressive sell-side bull-case ratification on the print day.** Same-day Apr 29 PT raises documented across multiple sources:

- **JPMorgan: $231 → $267 (+15.6%, Overweight maintained)** — per JPMorgan / Yahoo Finance article header "JPMorgan resets Bloom Energy stock price target"
- **Susquehanna: $173 → $293 (+69.4%, positive rating)** — per Yahoo / 24/7 Wall St
- **RBC: $335** — per Daily.md 2026-05-01 morning scan
- Pre-existing analyst sentiment was already constructive (Wells Fargo positive note pre-print on supply-constraint differentiation; Motley Fool coverage of $6B backlog growth)

This is the strongest aggressive sell-side bull-ratification pattern observed in the experiment to date. NXPI/STX precedent: aggressive same-day PT raises on a print = information-driven characterization = criterion 4 decisive failure. **BE exceeds NXPI/STX magnitudes.** The Susquehanna +69.4% PT raise alone is exceptional — sell-side analysts moved their model fundamentals dramatically based on the new information set. This is the literal definition of "the market is pricing in new information," not "the market is over-reacting." Per the criterion 4 NO-GO precedent taxonomy: SHORT-on-aggressive-bull-ratification is the canonical information-pricing-failure sub-pattern.

(2) **DECISIVE — Q1 fundamental delivery + Oracle Project Jupiter = MASSIVE NEW INFORMATION genuinely justifying re-rating.** Print fundamentals:

- Revenue $751.05M (+130.4% YoY; +39% beat vs $540M consensus) — exceptional beat magnitude
- Non-GAAP EPS $0.44 (3.4× beat vs $0.13 consensus; +242% beat surface) — exceptional beat magnitude
- GAAP operating income $72.2M (vs -$19.07M loss YoY) — profit turnaround on GAAP basis
- Operating cash flow $73.6M (vs -$110.7M outflow YoY) — cash flow turnaround
- Adjusted EBITDA $142.99M (~6× YoY)
- Service gross margin 13.3% (vs 1.3% YoY); service non-GAAP gross margin 18.0% (vs 4.8% YoY) — installed-base profitability inflection
- 30% gross margin (vs 27.2% YoY)

FY 2026 guidance raise (substantial across all metrics):
- Revenue: $3.4-3.8B (vs prior $3.1-3.3B; ~$500M midpoint raise = +15%) — implies 80% YoY growth at midpoint
- Non-GAAP OI: $600-750M (vs prior $425-475M; ~$225M midpoint raise = +50%) — operating income re-rating
- Non-GAAP EPS: $1.85-2.25 (vs prior $1.33-1.48; ~$0.65 midpoint raise = +46%)
- Gross margin outlook: 32% → 34%

Oracle Project Jupiter strategic-customer-win:
- Up to 2.45-2.8GW (depending on source) of Bloom fuel cells
- New Mexico AI data center campus
- "100% Bloom" sole-supplier — replacing planned gas turbines + diesel generators
- "One of the largest islanded microgrid power facilities in the world"
- Multi-year deployment timeline; orders convert to shipments

Brookfield Asset Management $5B AI infrastructure partnership (separate, layered)

CEO Sridhar narrative: "We at Bloom are ushering in the era of digital power for the digital age. Bloom is rapidly becoming the standard and 'go-to choice' for on-site power."

Backlog: $20B (per CEO commentary)

This is not noise; this is genuinely transformative information. The market is correctly re-rating the company from "niche clean-energy play" to "mainstream AI-infrastructure provider." Strategy B's mechanism — "prices return to fundamental value after overreaction" — does not apply because the FUNDAMENTAL VALUE has shifted upward. The +27% reaction is information-driven repricing, not sentiment overshoot.

(3) **DECISIVE — pre-mortem rev 7 KL #2.20 textbook-rational-penalty.** SHORT-on-momentum-AI-power-name with hyperscaler-deal-validation is the canonical 2.20 trap archetype. Strategy B's mechanism IS the textbook-rational instinct that "valuation extremes mean-revert" — but in regimes where the market is actively re-rating the company on new information (Oracle deal validation, Q1 mega-beat, guidance raise across all metrics), the textbook-rational instinct is wrong. 2.20 is mechanism-embedded for B (Strategy.md Strategy B Section thesis text rev 12 explicit acknowledgment); the Oracle/Q1 setup is precisely the regime where 2.20 fires hardest. Pre-mortem rev 7 has no mechanism-level mitigation for this.

(4) **DECISIVE — Sector-wide sympathy moves confirm sector-validation event, not single-name overreaction.** FCEL +32% Apr 29 / PLUG +9% Apr 29 (per 24/7 Wall St "Fuel Cell Stocks Erupt" compilation). When the same news event drives synchronized moves across an entire sector, this is by definition information-driven category-validation, not sentiment-driven single-name mispricing. Strategy B's mean-reversion mechanism operates on single-name overshoots; sector-wide repricing is a different phenomenon. **Pre-mortem rev 7 KL #2.8 (homogenization on commoditized AI strategies) further argues this is exactly the kind of crowded AI thesis where shorting against the consensus is canonical 2.8 + 2.20 compound trap territory.**

(5) **Pre-mortem KL #7 short-side gap-up execution risk in active gap regime.** Per pre-mortem rev 7 cycle 3 T1-1 surface: short-side stop-loss at +25% is approximate bounding in normal conditions but can blow through in gap-up regimes. BE has been gapping repeatedly: Apr 28 +11.63%, Apr 29 +13.96%, with the Apr 27 evening Oracle announcement triggering the multi-day gap-up sequence. This is an ACTIVE gap-up regime. Future hyperscaler announcements (other AI data center deals analogous to Oracle Project Jupiter), Brookfield deployment milestones, sector-wide AI capex revisions, or peer-validation events (e.g., FCEL/PLUG good prints) could produce additional gap-ups. The +25% short stop is structurally vulnerable — realized loss could exceed the design-bounded 0.5% strategy portfolio in gap regimes per KL #7 acknowledgment.

(6) **Borrow rate availability and cost concern.** BE has been on the high-borrow-cost side given the parabolic run-up. Strategy B short-financing exit threshold is 10% annualized; if borrow exceeds this, position must close regardless of thesis. For names in BE's profile (small-float-by-mkt-cap with extreme momentum and short interest), borrow costs commonly exceed 10% during peak-momentum periods. Even if criterion 4 cleared (which it does not), borrow-cost exit-rule trigger could produce involuntary close-out within the 60-day window before any thesis convergence. This is a tactical compounding factor; not the primary disposition driver.

(7) **Daily.md scan-level adversarial flag.** Daily.md 2026-05-01 morning scan EXPLICITLY flagged this trade as adversarial: "short into a momentum AI-power name with hyperscaler-deal validation is high-risk; Construct full thesis with caution; check whether technicals support; sector check Industrials 0/3." The scan-level flag itself surfaces the criterion 4 concern (information-driven re-rating with hyperscaler validation) as a red-flag pattern. Per protocol, the thesis-construction session is the binding gate — but the Daily.md flag pre-warned of exactly the disposition that emerged.

**Information-vs-sentiment test conclusion: PREPONDERANT INFORMATION-DRIVEN.** Every available signal points to information-driven repricing, not sentiment-driven overshoot: extreme fundamental beat magnitudes (39% revenue beat, 3.4× EPS beat), substantial guidance raises (15-50% across metrics), strategic-customer-win (Oracle 2.45GW sole-supplier deal), aggressive sell-side bull-ratification (Susquehanna +69% PT raise; JPM +16%; RBC at $335), sector-wide sympathy moves (FCEL +32%, PLUG +9%), and CEO narrative repositioning (niche-clean-energy → mainstream-AI-infrastructure). The +13.96% single-event-day or +27.2% joint-event-window move is appropriately-priced relative to the joint distribution of (a) Q1 fundamental delivery, (b) Oracle Project Jupiter strategic-customer-win, (c) FY26 guidance raise materiality, and (d) Brookfield $5B partnership. Strategy B's mean-reversion mechanism does not apply.

### LONG framing briefly considered and dismissed

A LONG framing would argue: consensus PTs ($219 average) imply ~-24% downside from $287.97; sell-side responses are aggressive but stale-aggregate consensus still shows downside; momentum continues higher. **Dismissed because:** (a) Strategy B is a MEAN-REVERSION mechanism (post-event mispricing exploitation), not momentum continuation — entering on the LONG side after a +27% 2-day re-rating is structurally inconsistent with B's design (the move is the re-rating, not an overshoot to mean-revert from); (b) the post-print PT raises (Susquehanna $293, JPM $267, RBC $335) imply consensus PT will rise toward $290+ once analysts update — the LONG thesis would essentially be "wait for stale consensus to catch up," which is timing of mechanical-data refresh rather than mispricing exploitation; (c) Strategy B criterion 3 closed-list rev 14 requires convergence target as numerical price level OR specific event from closed list — for a LONG-extension thesis, no numerical target offers meaningful gross return without taking momentum-continuation directional view (which Strategy B is not designed to take). Strategy B is not the right strategy box for BE under any framing.

### Sector concentration check

Industrials sector remained at 0/3 usage; BE would have been the first entry for Strategy B. (Note: RTX is open in Strategy D, which has its own sector cap — D sector cap usage does not interact with B sector cap usage per Strategy.md's per-strategy specification; "cap at 3 concurrent B positions per GICS sector" is B-specific.) No cap interaction. Industrials sector cap usage post-decision: 0/3 unchanged.

### Effect on book

No book impact. No order staged. Strategy B portfolio state unchanged from prior Decision_Log entries this session: 2 open longs (IBM, HCA), 1 staged (META Mon May 4 limit BUY pending Funds-on-Hold gate), $1,388.38 strategy NAV per Apr 28 IBKR snapshot. Sector cap usage unchanged across the board.

### Pending queue updated

- ~~BE B-thesis construction~~ COMPLETE — NO-GO on criterion 4 decisive failure (NXPI/STX aggressive-sell-side-bull-ratification sub-pattern + 2.20 textbook-rational-trap + sector-wide-repricing-event + gap-up-execution-risk compounding); no order; no follow-on calendar event scheduled. **BE remains effectively closed for Strategy B SHORT purposes** unless and until a regime change occurs that fundamentally repositions the AI-data-center-power thesis (e.g., a major hyperscaler deal cancellation, a regulatory action restricting fuel-cell deployments at scale, or a multi-quarter execution failure from BE) — none plausibly within near-term trigger horizon. The 10-day post-event entry window expires ~2026-05-13; no calendar event scheduled to revisit because the criterion 4 failure is structural across all sub-pattern weights, not data-resolution-dependent.
- Teladoc B-long, Ford B-mixed remain in Daily.md "secondary/tertiary" candidate queue but not actioned this session — handled by next routine Daily-scan-driven thesis-construction sequencing per standard cadence.
- Existing pending items unchanged: META Mon 2026-05-04 ~09:15 MT pre-execution Funds-on-Hold gate session; META Mon 2026-05-04 ~14:30 MT fill capture session; META Mon 2026-06-01 ~10:00 MT mid-window thesis pulse-check; META Thu 2026-07-02 ~10:00 MT time-based exit checkpoint. HCA invalidation-window monitoring; HCA time-based exit Sat Jun 27 (Fri Jun 26 last trading day on/before); IBM invalidation monitoring; RTX long-horizon hold; LLY mechanical re-screen mid-June 2026; GEV mechanical re-screen May 22.

### References

- BE Q1 2026 8-K Form Ex-99.1 (Bloom Energy investor IR materials referenced in earnings call): https://investor.bloomenergy.com/stock-information/stock-quote-and-chart/default.aspx
- BE Q1 2026 Earnings Call Transcript (Motley Fool, Apr 28 AMC call posted Apr 28 in URL stamp): https://www.fool.com/earnings/call-transcripts/2026/04/28/bloom-energy-be-q1-2026-earnings-transcript/
- BE Q1 2026 results coverage / 24-7 Wall St "Bloom Energy Fueling Transition to Critical AI Infrastructure Provider" (Q1 detail; Apr 29 +24.2% session move reference; Brookfield $5B partnership; backlog $20B): https://247wallst.com/investing/2026/04/29/bloom-energy-fueling-transition-to-critical-ai-infrastructure-provider/
- 24-7 Wall St "Fuel Cell Stocks Erupt" Apr 29 (Apr 29 mid-day +23% to $278.50; FCEL +32% / PLUG +9% sympathy moves; JPMorgan / Susquehanna PT raises): https://247wallst.com/investing/2026/04/29/fuel-cell-stocks-erupt-bloom-energy-surges-23-fuelcell-energy-rockets-32-plug-power-climbs-9/
- 24-7 Wall St "Bloom Energy Shows Why Fuel Cells - Not Nuclear - Is AI's Future Power Source" (Project Jupiter detail; Q1 print summary): https://247wallst.com/investing/2026/04/29/bloom-energy-shows-why-fuel-cells-not-nuclear-is-ais-future-power-source/
- TradingKey Apr 28 (Q1 print AMC; AH +12.2% to $253.99; non-GAAP rev $751M / +130.4% YoY beat vs $540M est; non-GAAP EPS $0.44 vs $0.12 est; gross margin 30% / non-GAAP 31.5%; FY26 guide raise materiality): https://www.tradingkey.com/analysis/stocks/us-stocks/261834375-be-orcl-oracle-interest-stock-datacenter-nasdaq-tradingkey
- Yahoo Finance "JPMorgan resets Bloom Energy stock price target" Apr 29 (JPM $231 → $267; Susquehanna $173 → $293; service gross margin inflection 13.3% from 1.3%; non-GAAP gross margin 18.0% from 4.8%; Oracle 2.8GW deployment framing; revenue +130.4% YoY): https://finance.yahoo.com/markets/stocks/articles/jpmorgan-resets-bloom-energy-stock-020300487.html
- Yahoo Finance BE Q1 2026 Earnings Call Summary (FY26 guide raise context; 80% YoY growth at midpoint; over-half non-Oracle backlog): https://finance.yahoo.com/sectors/energy/articles/bloom-energy-corporation-q1-2026-123000994.html
- Yahoo Finance BE quote (Apr 28 close $252.69 +11.63% reference; AH overnight pricing context): https://finance.yahoo.com/quote/BE/history/ ; https://finance.yahoo.com/quote/BE/
- FX Leaders Apr 30 (Apr 29 close $287.97 +27% framing; FY26 guide raise detail; CEO Sridhar narrative; service margin inflection): https://www.fxleaders.com/news/2026/04/30/bloom-energy-hits-all-time-high-as-q1-profits-surge-on-ai-data-center-demand/
- Motley Fool Apr 29 "Why Bloom Energy Stock Blew Up Today" (Apr 29 mid-morning +22.5% reference; rev $751.1M +130%; EPS $0.44 vs $0.13 est = 3.4× beat; gross margin 30%; GAAP profit $0.23 vs $0.10 loss YoY): https://www.fool.com/investing/2026/04/29/why-bloom-energy-stock-blew-up-today/
- Motley Fool Apr 27 "Is Bloom Energy Stock Set to Break Out Before Its April 28 Earnings?" (pre-print sentiment context; 1,500% trailing move from Jan 2024; 163× 2026 projected EPS; 47× 2028 projected EPS valuation context): https://www.fool.com/investing/2026/04/27/is-bloom-energy-stock-set-to-breakout-before-its-a/
- Simply Wall St Apr 30 "Bloom Energy's Record Quarter And Oracle AI Deal Reshape Growth Outlook" (Q1 net income $70.65M vs -$23.81M loss YoY; FY26 guide $3.4-3.8B; Oracle Project Jupiter): https://simplywall.st/stocks/us/capital-goods/nyse-be/bloom-energy/news/bloom-energys-record-quarter-and-oracle-ai-deal-reshape-grow
- Timothy Sykes Apr 29 (Apr 29 momentum framing; "$135 to nearly $283 within weeks"; FY26 guide raise detail; Oracle 2.45GW Project Jupiter): https://www.timothysykes.com/news/bloom-energy-corporation-be-news-2026_04_29-2/
- Meyka Apr 29 "BE Stock Today April 29: Bloom Energy Crushes Q1 Earnings" (Q1 print summary; Oracle deployment detail; AI on-site power thesis): https://meyka.com/blog/be-stock-today-april-29-bloom-energy-crushes-q1-earnings-2904-2/
- Daily.md 2026-05-01 morning scan (Bloom Energy watchlist line — adversarial-review framing; "$79B mkt cap after 1,400% trailing-1Y move; AI-power proxy at Oracle-deal valuation extremes"; "short into a momentum AI-power name with hyperscaler-deal validation is high-risk").
- Daily.md 2026-04-30 (Apr 29 fuel-cell-erupt scan with FCEL +32% / PLUG +9% sympathy moves).
- Strategy.md Strategy B section (criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test; criterion 3 closed-list rev 14; short-side stop-loss at +25%; short-financing exit at >10% annualized borrow; pre-mortem rev 7 KL #2.20, KL #7, KL #2.8 mechanism-embedded acknowledgments).
- Portfolio_Ledger.md (Strategy B sector cap usage, NAV).
- Decision_Log.md 2026-05-01 META GO entry (this session, mild-sell-side-reset pattern that successfully cleared criterion 4 — direct contrast for BE).
- Decision_Log.md 2026-05-01 EQIX NO-GO entry (this session, criterion 1 mechanical failure).
- Decision_Log.md 2026-05-01 STLA NO-GO entry (this session, criterion 4 in-window-catalyst sub-pattern).
- Decision_Log.md 2026-04-29 NXPI NO-GO entry (positive-direction L1 with aggressive sell-side bull-ratification — primary sub-pattern match for BE).
- Decision_Log.md 2026-04-29 STX NO-GO entry (positive-direction L1 with aggressive sell-side bull-ratification — primary sub-pattern match for BE; STX precedent: cleanest L1 instance to date pre-BE; **BE now establishes a new cleanest-L1 instance with magnitude exceeding STX**).

### Theater-check on this orchestrator review

(a) **Was the SHORT framing examined sufficiently before NO-GO?** Yes — provisional SHORT thesis was constructed (valuation extremes, parabolic move, trailing-1Y +1,400% positioning context, $79B mkt cap, ~163× pre-print 2026 EPS valuation) and tested against criterion 4. The criterion 4 failure on multiple decisive grounds (aggressive sell-side bull-ratification + Q1 mega-beat + Oracle Jupiter + sector-wide sympathy + 2.20 + 2.8 + KL #7 gap-up risk) is overwhelming, not marginal. Each weight individually meets the "decisive flaw" threshold; in combination, the disposition is not close.

(b) **Is the LONG framing dismissal correct?** Yes. Strategy B is a MEAN-REVERSION mechanism, not a momentum-continuation mechanism. Per Strategy.md Section thesis: "AI's narrative synthesis identifies situations where the market's immediate reaction to a public event has over- or under-shot relative to the information content of the event. The mispricing resolves over weeks as the market fully digests the event's narrative context." For BE, the +27% 2-day move is the market RE-RATING to a higher fundamental value based on new information (Q1 mega-beat, Oracle deal, guide raise) — there is no over- or under-shoot to mean-revert from. A LONG-extension thesis on momentum continuation belongs in Strategy A (which is DO-NOT-ACTIVATE) or Strategy D (long-horizon-equity, but BE doesn't fit D's thesis-category-quality criteria as a recently-IPO'd-style momentum name with binary AI-buildout dependency).

(c) **Does this NO-GO disposition create a precedent gap for future "extreme-positive-reaction-on-information-driven-re-rating" candidates?** No — NXPI 2026-04-29 NO-GO and STX 2026-04-29 NO-GO already established the positive-direction L1 sub-pattern (aggressive sell-side bull-ratification on positive Q1 print). BE strengthens this precedent at greater magnitude: +27.2% joint-event-window move (vs NXPI/STX which were ~+5-10% range moves) with even more aggressive sell-side response. Future B SHORT candidates with similar setups (mega-beat + strategic-customer-win + multi-firm aggressive PT raises + sector-wide sympathy moves) should be classified NO-GO under the BE/NXPI/STX sub-pattern without requiring full thesis-construction depth — pattern recognition at the Daily.md scan stage suffices to filter to NO-GO disposition.

(d) **Was deferral considered?** No — criterion 4 disposition is structural and data-stable. No future data within the 10-day post-event entry window (expires ~2026-05-13) would shift criterion 4 from information-driven to sentiment-driven characterization. Per protocol, deferral requires a specific resolution trigger; none applies here. Decision is made now.

(e) **Is the pre-mortem KL #7 short-side gap-up execution risk overweighted given that it's a tactical-not-strategic factor?** Counter-argument: KL #7 is a strategic acknowledgment that short-side stop-loss is approximate, not guaranteed, in gap regimes. BE is in an active gap regime (multiple recent gap-ups; sector-wide gap regime per FCEL +32% / PLUG +9% sympathy). KL #7 is genuinely binding here, not boilerplate. However, KL #7 is documented as a COMPOUNDING factor, not the primary criterion 4 disposition driver — disposition is primary on aggressive-sell-side-bull-ratification (NXPI/STX sub-pattern) and Q1-print-information-content. KL #7 strengthens the NO-GO disposition without being load-bearing.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence.

### Compaction-survival note

**Strategy B BE thesis pipeline status as of 2026-05-01 Friday late afternoon:** B-thesis construction COMPLETE for BE; **NO-GO on criterion 4 decisive failure on SHORT framing** (NXPI/STX-style aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern: JPM $231→$267 +16% PT raise, Susquehanna $173→$293 +69% PT raise, RBC PT $335; layered with massive Q1 fundamental beat (revenue +39% beat / EPS 3.4× beat / profit turnaround / FY26 guide raise 15-50% across metrics) + Oracle Project Jupiter sole-supplier 2.45-2.8GW strategic-customer-win + Brookfield $5B AI infrastructure partnership + sector-wide sympathy moves FCEL +32% / PLUG +9% confirming sector-validation-not-overshoot + canonical 2.20 textbook-rational-penalty trap + KL #7 short-side gap-up execution risk in active gap regime). LONG framing structurally inappropriate (Strategy B is mean-reversion mechanism, not momentum-continuation). Criterion 1 mechanically clears with extreme cushion at +13.96% single-event-day (Apr 28 close $252.69 → Apr 29 close $287.97) or +27.2% joint-event-window (Apr 27 close $226.36 → Apr 29 close $287.97). No order staged. No follow-on calendar event scheduled.

**This NO-GO is the cleanest information-driven-pricing-failure disposition observed in the experiment to date.** Magnitude of every criterion 4 sub-pattern weight (sell-side ratification aggressiveness, Q1 fundamental beat magnitude, strategic-customer-win materiality, sector-wide sympathy reach) exceeds prior NXPI/STX precedents. **BE establishes the new "cleanest-L1-instance" benchmark for the positive-direction-L1 sub-pattern** of Strategy B criterion 4 NO-GO taxonomy. Future B SHORT candidates with similar structural features (mega-beat + strategic-customer-win + multi-firm aggressive PT raises + sector-wide sympathy) can be efficiently filtered at Daily.md scan stage without requiring full thesis-construction depth — BE/NXPI/STX sub-pattern recognition suffices.

---

## 2026-05-01 (Fri, late afternoon post-BE-session) Strategy B thesis construction outcome — TDOC (Teladoc Health) NO-GO (instrument rule mechanical eligibility failure: market cap ~$1.07B at Apr 30 close, far below the $2B floor — Daily.md cap-borderline caveat resolves to clear failure, not borderline-clear); no order staged

**Trigger:** B-thesis construction requested for Teladoc Health candidate flagged Daily.md 2026-05-01 morning scan as "Teladoc — Strategy B long (verify mkt cap ≥$2B, healthcare cap consumed to 2/3)" with explicit cap caveat: "But Healthcare cap already 1/3 (HCA); mkt cap may be borderline ($2B+); revenue beat with EPS miss; Verify cap; if eligible, queue for full thesis; healthcare cap 2/3 if entered." Q1 2026 earnings event date 2026-04-29 AMC. Sequenced after META B-thesis (this session GO MEDIUM), EQIX (NO-GO criterion 1), STLA (NO-GO criterion 4 in-window-catalyst), BE (NO-GO criterion 4 aggressive-bull-ratification on SHORT framing).

**Inputs:** Strategy.md Strategy B section (instrument eligibility rule "Market cap ≥ $2B at entry" + "30-day average daily volume ≥ $10M" + US-listed common equity); Portfolio_Ledger.md ($1,388.38 B NAV; sector cap usage IT Services 1/3, Health Care Facilities 1/3, Real Estate 0/3, Cons Disc 0/3, Industrials 0/3, Comm Services 0/3 staged → 1/3 expected on META fill); Decision_Log.md prior precedents — **OMCL 2026-04-29 NO-GO (closest precedent: instrument-rule borderline-clears at $2.07B with criterion 4 decisive failure as primary ground; TDOC differs in that the instrument rule outright FAILS at $1.07B, materially below the $2B floor, making criterion-4 examination structurally unnecessary)**, EQIX 2026-05-01 NO-GO (criterion 1 mechanical failure precedent for handling mechanical-eligibility-failure entries with substance-preservation depth scaled to disposition certainty); TDOC Q1 2026 8-K Ex-99.1 (SEC EDGAR https://www.sec.gov/Archives/edgar/data/0001477449/000147744926000026/tdoc-20260331xexx991.htm), 2026-04-29 AMC release; CNN markets / Yahoo Finance / Benzinga / GuruFocus / Stocktitan / FinancialContent / Stifel-via-StreetInsider / TickerNerd / MarketChameleon Apr 24-30 coverage (price reference, market cap, sell-side compilation); Daily.md 2026-05-01 morning scan (Teladoc watchlist line + cap-verify caveat).

### Decision

**TDOC — NO-GO (DECLINE) on instrument-rule mechanical eligibility failure: market cap below the $2B floor.**

Strategy B instrument eligibility rule (Strategy.md line 269) requires "Market cap ≥ $2B at entry" as a hard mechanical floor. TDOC market cap is **$1.07B per GuruFocus 2026-04-30** ("Market Cap: $1.07 billion, indicating a relatively small size in the healthcare sector"; cross-confirmed by MarketChameleon 2026-04-24 reading $994.93M and CNN markets categorical placement: "A market capitalization between $300 million and $2 billion places TDOC in the small capitalization category"). At $1.07B, TDOC is approximately **53% of the $2B floor** — not borderline. Daily.md's morning-scan cap-verify caveat ("mkt cap may be borderline ($2B+)") resolves to clear failure on primary-source verification. The trade is mechanically excluded; criterion 1, criterion 4, sector concentration, and thesis-substance examination are structurally unnecessary because the eligibility gate fails upstream.

LONG and SHORT framings both excluded by the same mechanical failure: the instrument rule applies regardless of direction.

### Mechanical eligibility detail (instrument rule fails, criteria 1 and 5 separately would clear)

- **Instrument rule — FAILS on market-cap floor:** US-listed common equity (NYSE:TDOC; clears US-listing component); 30-day ADV ~$27M+/day (~5M shares × ~$5.50 reference price ≈ $27.5M/day; clears $10M floor with ~2.7× cushion); long-or-short permitted by Strategy B; 2% sizing $27.77; no options. **Market cap $1.07B per GuruFocus 2026-04-30** — approximately 53% of the $2B Strategy B floor. **Pre-print market cap was already in the $0.99-1.07B range (MarketChameleon Apr 24 reading $994.93M); the Apr 30 -9% close-to-close move per Daily.md further reduced cap below pre-print level.** Cap floor breach is not borderline (OMCL precedent at $2.07B was "borderline-clears"; TDOC at $1.07B is well below). Pre-mortem rev 7 has no operator-extension clause for instrument-rule borderline-or-below cases beyond the OMCL marginal-clear handling. TDOC is mechanically excluded.
- **Criterion 1 — would have cleared if instrument rule passed:** Event date 2026-04-29 AMC (5:00 PM ET earnings call). Pre-print Apr 29 close ~$6.00 (per Stocktitan reference price "Price: $6.00 ... ahead of the earnings release"); Apr 30 close ~$5.46 (computed from Daily.md "-9% Apr 30" close-to-close reading; consistent with Stifel Apr 30 PT cut $6→$5.50 indicating analyst expectation of price drop into $5-handle). Close-to-close move ~ -9%, mechanically clears the ≥5% threshold. (Documented for completeness; criterion 1 disposition is moot given instrument-rule failure.)
- **Criterion 5 — would have cleared if instrument rule passed:** No A position open in TDOC (A router DO-NOT-ACTIVATE). (Documented for completeness; criterion 5 disposition is moot given instrument-rule failure.)

### Substance preserved for future re-evaluation (minimal — instrument-rule failure is structural, requires ~2× cap recovery to clear)

**Q1 2026 print substance** (preserved as primary-source-validated factbase for any future TDOC evaluation if cap floor is ever crossed upward):

- Revenue $613.8M (-2% YoY); slight beat vs $610.8M consensus (~0.5% beat)
- GAAP EPS -$0.36 vs -$0.34 consensus (~4.7% miss); improved from -$0.53 prior year
- Adj EBITDA $58.17M (~flat YoY); $2M beat vs $56.17M consensus (~3.6% beat)
- Integrated Care revenue $395.4M (+2% YoY); EBITDA margin 14.2%
- BetterHelp revenue $218.4M (-9% YoY); EBITDA margin 0.9% — segment weakness
- US revenue -6%; International revenue +17%
- Free cash flow -$26.3M (worse than -$15.7M YoY)
- Q2 2026 revenue guide $611.5M (~3.2% YoY decline; ~2% below consensus)
- FY26 guide REAFFIRMED: $2.481-2.576B revenue, $267-306M adj EBITDA, net loss $0.75-1.05/share

**Sell-side response post-print:** Stifel Apr 30 PT $6.00 → $5.50 (Hold maintained); pre-print broader analyst dispersion was wide ($5-11 range; median $6.00 per TickerNerd 47-analyst aggregate); multiple PT cuts pre-print (UBS Feb 27 $9→$6, Citi Mar 3 $9→$6, Oppenheimer Mar 3 $12→$7, Goldman Feb 26 $8→$7, JPM Mar 13 $9→$7, Barclays Mar 26 $8.50→$7); offset by Deutsche upgrade Mar 10 ($7 PT, Buy) and BofA $7→$8.25 raise Mar 10. The Stifel post-print PT cut and the broader pre-print-to-post-print PT trajectory is consistent with multi-quarter overhang persistence (multi-year revenue stagnation; structural BetterHelp weakness; Pineal Capital activist pressure for cost cuts and break-up; class actions surviving motion-to-dismiss in Apr 2026).

**Working hypothesis if cap floor ever crosses upward (would require ~+87% price recovery from $5.46 base to clear $2B at ~178M shares outstanding):** Even in that case, the V/MDLZ structural-overhang-persistence sub-pattern would likely apply to any post-event setup — multi-year revenue stagnation, BetterHelp segment weakness, activist-pressure-driven uncertainty, and active class-action overhang are all multi-quarter resolution timelines structurally mismatched with B's 60-day window. **TDOC is functionally closed for Strategy B purposes regardless of cap movements** within any near-term horizon. Mechanical instrument-rule failure subsumes thesis-quality failure here.

### Sector concentration check

Health Care sector cap usage 1/3 with HCA (Health Care Facilities); TDOC would be Health Care Technology / Health Care Services within Health Care sector. Had TDOC entered, sector usage would have moved to 2/3. (Documented for completeness; sector-cap disposition is moot given instrument-rule failure.)

### Effect on book

No book impact. No order staged. Strategy B portfolio state unchanged from prior Decision_Log entries this session: 2 open longs (IBM, HCA), 1 staged (META Mon May 4 limit BUY pending Funds-on-Hold gate), $1,388.38 strategy NAV per Apr 28 IBKR snapshot. Sector cap usage unchanged across the board.

### Pending queue updated

- ~~TDOC B-thesis construction~~ COMPLETE — NO-GO on instrument-rule mechanical eligibility failure (market cap $1.07B vs $2B floor); no order; no follow-on calendar event scheduled. **TDOC remains effectively closed for Strategy B purposes** given the cap-floor breach magnitude (~2× recovery required to clear). The 10-day post-event entry window (~2026-05-13 expiry) is moot; no calendar event scheduled to revisit.
- Ford B-mixed remains in Daily.md "secondary/tertiary" candidate queue but not actioned this session — handled by next routine Daily-scan-driven thesis-construction sequencing per standard cadence.
- Existing pending items unchanged: META Mon 2026-05-04 ~09:15 MT pre-execution Funds-on-Hold gate session; META Mon 2026-05-04 ~14:30 MT fill capture session; META Mon 2026-06-01 ~10:00 MT mid-window thesis pulse-check; META Thu 2026-07-02 ~10:00 MT time-based exit checkpoint. HCA invalidation-window monitoring; HCA time-based exit Sat Jun 27 (Fri Jun 26 last trading day on/before); IBM invalidation monitoring; RTX long-horizon hold; LLY mechanical re-screen mid-June 2026; GEV mechanical re-screen May 22.

### References

- TDOC Q1 2026 8-K Ex-99.1 (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/0001477449/000147744926000026/tdoc-20260331xexx991.htm — 2026-04-29 AMC.
- TDOC Q1 2026 press release (Stocktitan reformat with Q1 detail and FY26 guide reaffirmation): https://www.stocktitan.net/news/TDOC/teladoc-health-reports-first-quarter-2026-nd5kf96n1u4r.html
- TDOC 10-Q filing (Stocktitan reformat with cash flow detail and Uplift acquisition note): https://www.stocktitan.net/sec-filings/TDOC/10-q-teladoc-health-inc-quarterly-earnings-report-fa8bad471de7.html
- TDOC 8-K guidance filing (Stocktitan reformat with FY26 reaffirmation detail): https://www.stocktitan.net/sec-filings/TDOC/8-k-teladoc-health-inc-reports-material-event-f40d8cb04c47.html
- GuruFocus Apr 30 2026 (Market Cap $1.07B confirmation; AH -5% framing; insider-selling context): https://www.gurufocus.com/news/8828815/teladoc-health-tdoc-reports-q1-earnings-miss-stock-drops-5-in-afterhours
- GuruFocus Apr 30 2026 (Market Cap $1.07B further confirmation; Q1 results coverage): https://www.gurufocus.com/news/8831104/teladoc-health-tdoc-reports-strong-q1-2026-earnings-performance
- MarketChameleon Apr 24 2026 (Market Cap $994.93M reference pre-print): https://marketchameleon.com/Overview/TDOC/Summary/
- CNN markets TDOC ("market capitalization between $300 million and $2 billion places TDOC in the small capitalization category" categorical placement; sell-side action feed): https://www.cnn.com/markets/stocks/TDOC
- Yahoo Finance TDOC (Apr 17 close $5.69; -1.58% Apr 17 reference; price history): https://finance.yahoo.com/quote/TDOC/ ; https://finance.yahoo.com/quote/TDOC/history/
- Benzinga Apr 30 2026 (Q1 print summary; -2% revenue / EPS miss; CEO commentary): https://www.benzinga.com/markets/earnings/26/04/52154608/teladoc-shares-fall-after-q1-earnings-what-investors-need-to-know
- StreetInsider Apr 30 2026 (Stifel PT $6 → $5.50 cut, Hold maintained): https://www.streetinsider.com/Analyst+Comments/Teladoc+(TDOC)+PT+Lowered+to+$5.50+at+Stifel/26401243.html
- FinancialContent / StockStory Apr 29 2026 (Q1 print summary; "Surprises With Q1 CY2026 Sales But Stock Drops"; GAAP -$0.36 vs -$0.34 expected = 4.7% miss; revenue 0.5% beat; Q2 guide 2% below): https://markets.financialcontent.com/stocks/article/stockstory-2026-4-29-teladoc-nysetdoc-surprises-with-q1-cy2026-sales-but-stock-drops
- TickerNerd TDOC forecast (47-analyst aggregate; median PT $6.00; rating dispersion): https://tickernerd.com/stock/tdoc-forecast/
- Simply Wall St Apr 30 2026 (Q1 narrative; trailing 12-month loss narrowing): https://simplywall.st/stocks/us/healthcare/nyse-tdoc/teladoc-health/news/teladoc-health-q1-loss-reduction-reinforces-bullish-margin-n
- Daily.md 2026-05-01 morning scan (Teladoc watchlist line — cap-verify caveat resolved to clear failure per this entry).
- Strategy.md Strategy B section (instrument eligibility rule "Market cap ≥ $2B at entry"; pre-mortem rev 7).
- Portfolio_Ledger.md (Strategy B sector cap usage, NAV).
- Decision_Log.md 2026-04-29 OMCL NO-GO entry (closest precedent: instrument-rule borderline-clears at $2.07B; TDOC differs in that the instrument rule outright FAILS at $1.07B, well below).
- Decision_Log.md 2026-05-01 EQIX NO-GO entry (mechanical-eligibility-failure precedent for handling format).

### Theater-check on this orchestrator review

(a) **Was the instrument-rule disposition reachable WITHOUT criterion-4 thesis examination?** Yes — instrument rule is the upstream eligibility gate; failure at the gate makes downstream thesis examination structurally unnecessary. Per Strategy.md operational language ("Market cap ≥ $2B at entry"), the floor is a hard mechanical requirement, not a soft preference. TDOC at $1.07B is unambiguously below the floor. No interpretive flexibility applies (unlike OMCL's $2.07B borderline case which did warrant additional examination).

(b) **Could TDOC market cap recover to $2B within the 10-day post-event entry window?** No — TDOC would require a ~+87% price recovery (from $5.46 Apr 30 implied close to ~$10.20 to clear $2B at ~178M shares outstanding); no plausible catalyst within 10 days could produce this magnitude of recovery, especially given Stifel's Apr 30 PT cut, multi-quarter analyst skepticism, activist-pressure overhang, and the muted post-print broader sell-side response. Cap-floor recovery scenario is implausible within entry window.

(c) **Should the substance-preservation depth match EQIX's parallel mechanical-failure entry?** EQIX's entry preserved Q1 print details and sell-side response on the rationale that future criterion-1 re-trigger remains conceivable on a subsequent print. TDOC's substance preservation should be even more minimal because instrument-rule failure is structurally less likely to flip than criterion 1 measurement (cap-floor recovery requires sustained ~2× price recovery, vs criterion 1 which can re-fire on any subsequent ≥5% post-event move). This entry's substance-preservation depth is appropriately scaled down (Q1 detail noted; sell-side detail noted; no extended pillar/adversarial analysis).

(d) **Does the Strategy B precedent taxonomy need a separate "instrument-rule-failure" sub-pattern documented alongside criterion-1 mechanical failure (EQIX) and criterion-4 sub-patterns (NXPI/STX/BE, V/MDLZ, STLA)?** Yes — but it's a low-substance entry in the taxonomy: instrument-rule failures are uncommon (Strategy B's mechanical screens (≥$2B mcap, ≥$10M ADV) are typically pre-filtered at Daily.md scan stage). TDOC is the FIRST instrument-rule market-cap mechanical failure NO-GO of the experiment (OMCL was a borderline-clears case, criterion-4 primary; TDOC is below-floor). Future B candidates flagged in Daily.md with cap-verify caveats should be cross-checked against the $2B floor as a hard binary gate before any substantive thesis construction proceeds. This entry serves as the precedent.

### Compaction-survival note

**Strategy B TDOC thesis pipeline status as of 2026-05-01 Friday late afternoon:** B-thesis construction COMPLETE for TDOC; **NO-GO on instrument-rule mechanical eligibility failure** (market cap $1.07B per GuruFocus 2026-04-30, well below the $2B Strategy B floor — approximately 53% of required floor). Daily.md morning-scan cap-verify caveat resolved to clear failure on primary-source verification. No order staged. No follow-on calendar event scheduled. TDOC remains effectively closed for Strategy B purposes given the cap-floor breach magnitude (~2× recovery required to clear).

**This is the FIRST instrument-rule market-cap-floor-failure NO-GO of the experiment.** Prior NO-GO precedents distribute as: criterion 1 mechanical failure (1 — EQIX); criterion 4 decisive failure across sub-patterns (11 — NOW, CHTR, INTC, SBUX, V, NXPI, STX, MDLZ, OMCL [criterion-4-primary with instrument-rule-borderline secondary], STLA, BE); instrument-rule failure (1 — TDOC, this entry). TDOC establishes the instrument-rule-mechanical-failure pattern: when Daily.md scan flags a cap-verify caveat, primary-source verification of market cap against the $2B floor is the binding gate, with no operator-extension clause beyond the OMCL marginal-clears handling at $2.07B.

**Total experiment Strategy B dispositions to date: 3 GO + 13 NO-GO (3 GO / 13 NO-GO = 19% / 81% hit rate).** NO-GO breakdown: 1 criterion-1, 11 criterion-4 (across 4 sub-patterns: NXPI/STX/BE aggressive-bull-ratification = 3; V/MDLZ overhang-persistence = 2; STLA in-window-binary-catalyst = 1; other = 5), 1 instrument-rule. Hit-rate skew remains consistent with pre-mortem rev 7 Section 4 indicator-1 baseline; gating threshold at 30 dispositions remains far ahead.

---

## 2026-05-01 (Fri, late afternoon post-TDOC-session) Strategy A queue acknowledgment — CAT, LLY, QCOM queued for next M1 router flip; no action this session

**Trigger:** Daily.md 2026-05-01 morning scan recommended-actions section line 190: "CAT, LLY, QCOM — queued for Strategy A at next M1 router flip; not actionable now." Closing item in the Daily.md scan candidate iteration sequence (META GO MEDIUM → EQIX NO-GO → STLA NO-GO → BE NO-GO → TDOC NO-GO → CAT/LLY/QCOM Strategy A queue acknowledgment); 5 of 5 thesis-construction-required items now evaluated this session, plus this 6th item which is queue-acknowledgment-only.

**Inputs:** Strategy.md Strategy A section (DO-NOT-ACTIVATE under current M1 router state); Daily.md 2026-05-01 morning scan (Section 1.2 scheduled events resolved — CAT/LLY/QCOM Q1 print details; Section 1.3 large single-name moves; Section 4 regime check noting SPX 50/200 SMA proximity as plausibly material for next M1 router run; Section 5 recommended actions queue line); Decision_Log.md prior precedents — **2026-04-30 LLY Strategy D NO-GO** (entry-timing failure analogous to GOOGL; trailing-30-day-too-positive after beat-and-raise + FDA approval; thesis quality intact, mechanical re-screen mid-June 2026); **2026-04-30 GOOGL Strategy D NO-GO** (entry-timing failure precedent referenced by LLY); Portfolio_Ledger.md ($1,388.38 B NAV; current Strategy state: B and D ACTIVATE, A and E DO-NOT-ACTIVATE, C HYBRID-FOMC-only with no in-window FOMC through 2026-06-15).

### Decision

**No-action queue acknowledgment for CAT, LLY, QCOM as Strategy A candidates at next M1 router flip.** Strategy A is currently DO-NOT-ACTIVATE per M1 router state; thesis construction is not appropriate this session. Each name is documented below with Q1 print substance to seed the next-M1-router-run thesis evaluation if A flips to ACTIVATE.

### Substance for next-M1-router-run thesis evaluation

**CAT (Caterpillar) — Q1 2026 BMO Apr 30 print summary:**
- Revenue $17.42B vs $16.21B consensus (+22% YoY; ~7.5% beat)
- Adj EPS $5.54 vs $4.64 prior year
- Record backlog
- Raised FY revenue outlook
- AI-data-center power-equipment demand cited as growth driver
- Apr 30 close: ~$890 (52-week high; +9.91% close-to-close)
- Strategy A queue rationale: positive Q1 beat + raised guide + sector-tailwind narrative; momentum-extension setup typical for A
- Sector: Industrials
- Source: https://www.cnbc.com/2026/04/30/caterpillar-cat-q1-earnings.html
- No prior NO-GO entry; clean candidate

**LLY (Eli Lilly) — Q1 2026 BMO Apr 30 print summary:**
- Revenue $19.8B vs $17.62B consensus (+56% YoY; 13.7% beat)
- Adj EPS $8.55 vs $6.66 consensus (25.9% beat)
- FY26 revenue guide raised $80-83B → $82-85B (~$2B midpoint raise)
- FY26 EPS guide $35.50-37
- **Foundayo (orforglipron) FDA-approved** for type-2 diabetes/incretin franchise expansion — major catalyst layered on Q1 print
- Apr 30 intraday: +~10%
- Strategy A queue rationale: Q1 mega-beat + guide raise + FDA approval = strong information-driven momentum setup
- **Cross-reference: LLY has separate Decision_Log 2026-04-30 entry establishing Strategy D NO-GO on entry-timing grounds** (trailing-30-day too positive; mechanical re-screen mid-June 2026 ~30 trading days). Strategy A queue is a separate consideration; A and D have distinct entry-timing rules. Future M1 Claude session should examine whether Strategy A's entry-timing rules are similarly violated (likely yes given the same trailing-30 dynamics).
- Sector: Health Care (Pharmaceuticals)
- Source: https://www.cnbc.com/2026/04/30/eli-lilly-lly-earnings-q1-2026.html

**QCOM (Qualcomm) — FQ2 2026 AMC Apr 29 print summary:**
- Revenue $10.6B
- Adj EPS $2.65 vs $2.55 consensus
- FQ3 guide soft (specific magnitude not captured in Daily.md scan)
- Auto >$5B annualized
- "Leading hyperscaler" custom-silicon shipments expected later 2026 (forward-narrative catalyst)
- China bottoms FQ3 (recovery framing)
- Apr 30 close: ~$179 (+~13-15% close-to-close)
- Strategy A queue rationale: hyperscaler-custom-silicon narrative + China-recovery framing + Q1 beat + auto growth = multi-vector momentum-extension setup
- Sector: Information Technology (Semiconductors)
- Source: https://www.cnbc.com/2026/04/29/qualcomm-qcom-stock-earnings-china.html
- No prior NO-GO entry; clean candidate

### Strategy A activation gate

Strategy A is currently DO-NOT-ACTIVATE per M1 router state (Daily.md 2026-05-01 line 5: "Router state: B and D ACTIVATE; A and E DO-NOT-ACTIVATE"). The next M1 router run will evaluate whether A flips to ACTIVATE based on regime indicators. Per Daily.md Section 4 regime check (line 170): "SPX 50-day < 200-day condition that produced NEUTRAL may now be on the cusp of inverting given April's magnitude. Plausibly material for next M1 router run." Aprl was the best S&P month since Nov 2020 (+10.4%), substantially shifting trend indicators; the next monthly router computation may flip A's state.

Next M1 router run is scheduled for the start of the next calendar month per standard cadence; that session will:
1. Compute fresh regime indicators (SPX 50/200 SMA, breadth, VIX regime, yield curve, oil shock proximity) per Strategy.md M1 protocol
2. If A flips to ACTIVATE, run full Strategy A thesis construction on the queued candidates (CAT, LLY, QCOM, plus any others surfaced by intervening Daily.md scans)
3. If A remains DO-NOT-ACTIVATE, candidates remain queued; this entry serves as the substance-preservation seed for the M2 thereafter

### Effect on book

No book impact this session. No order staged. Strategy B portfolio state unchanged from prior Decision_Log entries this session: 2 open longs (IBM, HCA), 1 staged (META Mon May 4 limit BUY pending Funds-on-Hold gate), $1,388.38 strategy NAV per Apr 28 IBKR snapshot. Sector cap usage unchanged across the board. Strategy A NAV / state / queue documented above.

### Pending queue updated

- ~~CAT, LLY, QCOM Strategy A queue acknowledgment~~ COMPLETE — queue documented for next M1 router run; no action this session; no follow-on calendar event scheduled (next M1 router run is on existing standard monthly cadence).
- ~~Daily.md 2026-05-01 morning scan recommended-actions iteration~~ COMPLETE — all 6 scan items evaluated this session: META (B-LONG GO MEDIUM), EQIX (B-LONG NO-GO criterion 1 mechanical), STLA (B-LONG NO-GO criterion 4 in-window-catalyst), BE (B-SHORT NO-GO criterion 4 aggressive-bull-ratification), TDOC (B-LONG NO-GO instrument-rule market-cap floor), CAT/LLY/QCOM (Strategy A queue acknowledgment).
- Existing pending items unchanged: META Mon 2026-05-04 ~09:15 MT pre-execution Funds-on-Hold gate session; META Mon 2026-05-04 ~14:30 MT fill capture session; META Mon 2026-06-01 ~10:00 MT mid-window thesis pulse-check; META Thu 2026-07-02 ~10:00 MT time-based exit checkpoint; HCA invalidation-window monitoring; HCA time-based exit Sat Jun 27 (Fri Jun 26 last trading day on/before); IBM invalidation monitoring; RTX long-horizon hold; LLY Strategy D mechanical re-screen mid-June 2026; LLY Strategy A queue position waiting on next M1 router run; CAT and QCOM Strategy A queue positions waiting on next M1 router run; GEV mechanical re-screen May 22.
- Ford Strategy B candidate (Daily.md "Lower-priority queue" tag, "(mixed)" framing) remains in secondary queue; not actioned this session — handled by next routine Daily-scan-driven sequencing per standard cadence.

### References

- Daily.md 2026-05-01 morning scan (Section 1.2 events table, Section 1.3 single-name moves, Section 3 strategy candidates, Section 4 regime check, Section 5 recommended actions line 190 — primary trigger source).
- CNBC Apr 30 CAT Q1 (https://www.cnbc.com/2026/04/30/caterpillar-cat-q1-earnings.html).
- CNBC Apr 30 LLY Q1 (https://www.cnbc.com/2026/04/30/eli-lilly-lly-earnings-q1-2026.html).
- CNBC Apr 29 QCOM FQ2 (https://www.cnbc.com/2026/04/29/qualcomm-qcom-stock-earnings-china.html).
- Strategy.md Strategy A section (DO-NOT-ACTIVATE under current router state; activation gate logic).
- Decision_Log.md 2026-04-30 LLY Strategy D NO-GO entry (entry-timing failure precedent; Strategy A entry-timing examination flagged for M1 router session).
- Decision_Log.md 2026-04-30 GOOGL Strategy D NO-GO entry (entry-timing failure precedent referenced by LLY).
- Portfolio_Ledger.md (current strategy state matrix; M1 router state).

### Theater-check on this orchestrator review

(a) **Could CAT/LLY/QCOM also be Strategy B SHORT candidates given the +9.91% / +~10% / +~13-15% close-to-close moves all clear criterion 1?** Yes mechanically; no substantively. Each is a positive Q1 beat with raised guide and (likely) aggressive sell-side bull-case ratification, fitting the NXPI/STX/BE aggressive-bull-ratification information-pricing-failure sub-pattern of Strategy B criterion 4 NO-GO precedent. A B-SHORT thesis on any of them would fail criterion 4 decisively under the BE-precedent canonical 2.20 textbook-rational-trap reasoning. Daily.md author (prior Claude session) appears to have correctly recognized this and categorized them as Strategy A queue items rather than B-SHORT candidates. No B-SHORT thesis construction warranted this session.

(b) **Should LLY's Strategy A queue position be tagged with the same entry-timing concern that produced D NO-GO?** Yes — the next M1 router session that examines LLY for A should explicitly cross-reference Decision_Log 2026-04-30 LLY D NO-GO entry-timing analysis and apply equivalent entry-timing scrutiny to A. This is documented in the LLY substance section above. The mechanical re-screen mid-June 2026 trigger applies to the D context; A-context entry-timing examination would happen at next M1 router run (sooner cadence).

(c) **Is the substance preservation depth appropriate for queue-acknowledgment-only?** Yes — full Q1 print summaries are preserved per name to seed next-M1-router-run thesis construction without requiring fresh research. Sector classifications, source URLs, and price levels are captured. Cross-references to existing Decision_Log entries (LLY D NO-GO, GOOGL D NO-GO precedent) are documented.

(d) **Does this entry need a calendar event for next M1 router run?** No — next M1 router run is on standard monthly cadence and already calendared. The Strategy A queue items will be picked up automatically by that session via Daily.md / Decision_Log scan. No additional calendar event needed.

### Compaction-survival note

**Strategy A queue status as of 2026-05-01 Friday late afternoon:** CAT, LLY, QCOM acknowledged as Strategy A queue items at next M1 router flip; substance preserved per name above. Strategy A remains DO-NOT-ACTIVATE per current M1 router state; activation depends on next M1 router run regime computation (SPX 50/200 SMA proximity is plausibly material per Daily.md regime check Section 4). No order staged. No calendar event scheduled (next M1 on standard cadence). LLY has dual queue state: Strategy D NO-GO on entry-timing (mid-June 2026 mechanical re-screen) AND Strategy A queue at next M1 flip; future Claude sessions evaluating LLY for either strategy should cross-reference both records.

**Session-end state for 2026-05-01 Strategy B thesis-construction batch (this multi-session iteration covers all 6 Daily.md morning-scan recommended-actions items):**

- META: GO MEDIUM, Limit BUY 0.0454 META @ $615.00 day order Mon 2026-05-04 staged (pending pre-execution Funds-on-Hold verification gate Mon ~09:15 MT). Convergence target $626.21. Time-based exit Thu 2026-07-02. Three invalidation criteria specified.
- EQIX: NO-GO criterion 1 mechanical failure (Apr 29→Apr 30 close-to-close was -1.70% per Daily Political/MarketBeat or -0.57% per Yahoo Finance, below ≥5% threshold; Daily.md "-5%" label reflected after-hours initial reaction not regular-session close-to-close).
- STLA: NO-GO criterion 4 decisive failure (in-window company-specific binary catalyst sub-pattern: Investor Day May 21 in-window at T+17 days from notional Mon May 4 entry; V/MDLZ structural-overhang-persistence layered: class action lawsuits over Feb 2026 €22B EV reset with lead plaintiff deadline Jun 8, persistent industrial FCF burn -€1.9B with break-even now 2027 not 2026, tariff residual €1.3B, pre-existing analyst skepticism Kepler Apr 16 downgrade Buy→Hold €9→€7.50 and Morgan Stanley €6.50). **First experiment NO-GO under in-window-binary-catalyst sub-pattern.**
- BE: NO-GO criterion 4 decisive failure on SHORT framing (NXPI/STX-style aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern: JPM $231→$267 +16% PT raise, Susquehanna $173→$293 +69% PT raise, RBC $335; layered with Q1 fundamental mega-beat (revenue +130% YoY / 39% beat / EPS 3.4× beat / profit turnaround / FY26 guide raise 15-50% across metrics), Oracle Project Jupiter sole-supplier 2.45-2.8GW strategic-customer-win, Brookfield $5B AI infrastructure partnership, sector-wide sympathy moves FCEL +32% / PLUG +9% confirming sector-validation-not-overshoot, canonical 2.20 textbook-rational-trap, pre-mortem KL #7 short-side gap-up execution risk in active gap regime). LONG framing structurally inappropriate. **BE establishes new "cleanest-L1-instance" benchmark for the positive-direction-L1 sub-pattern.**
- TDOC: NO-GO instrument-rule market-cap-floor failure (market cap $1.07B per GuruFocus 2026-04-30 vs $2B Strategy B floor, ~53% of required floor; not borderline). **First experiment NO-GO under instrument-rule market-cap-floor-failure pattern.**
- CAT, LLY, QCOM: Strategy A queue acknowledgment for next M1 router run. No-action this session.

**Total experiment Strategy B dispositions to date: 3 GO + 13 NO-GO (3 GO / 13 NO-GO = 19% / 81% hit rate).** NO-GO breakdown by criterion: criterion 1 mechanical (1 — EQIX); criterion 4 decisive (11 across 4 sub-patterns: NXPI/STX/BE aggressive-bull-ratification = 3, V/MDLZ overhang-persistence = 2, STLA in-window-binary-catalyst = 1, other = 5); instrument-rule (1 — TDOC). Hit-rate skew remains consistent with pre-mortem rev 7 Section 4 indicator-1 baseline; gating threshold at 30 dispositions remains far ahead.

---

## 2026-05-01 (Fri, late afternoon post-session-end-consolidation) Google Calendar reconciliation against current Decision_Log + Portfolio_Ledger state — 6 obsolete events deleted, 4 missing META events created, 10 pending events left in place

**Trigger:** Operator-requested calendar reconciliation. Cross-referenced Google Calendar [Claude]-tagged events against current project-source state (Decision_Log.md, Portfolio_Ledger.md, Daily.md, Strategy.md, Claude_Task_Plan.md) to (a) delete obsolete events for events that have already triggered and resolved, (b) create missing events for pending position-monitoring decisions, (c) preserve correctly-scheduled pending events. Per operator instruction: daily/weekly/monthly recurring prompts in Claude_Task_Plan.md are run automatically by the operator without calendar reminders; all other prompts (one-off, position-specific, decision-specific, quarterly-recurring) require calendar events with event-time popup reminders. Time zone: America/Denver.

**Inputs:** All trade-related Google Calendar events with "[Claude]" prefix between 2026-04-25 and 2026-12-31 (16 events total at session start); Decision_Log.md latest state (this session 2026-05-01 entries); Portfolio_Ledger.md latest state ($1,388.38 B NAV; 2 open longs IBM/HCA; META staged Mon 5/4; RTX open in D); Strategy.md (Strategy B exit rules; 60-day time-based; convergence targets); Claude_Task_Plan.md (recurring-task cadence schedule; "NO-GO records are context, not barriers" rule; standard reminder model for quarterly tasks).

### Calendar reconciliation actions taken

**DELETED (6 obsolete events; all already triggered and substantively resolved per Decision_Log entries):**

1. `i5rd51hh7a91ehvdun2tptisn8` — "[Claude] Place HCA limit buy order at open" (2026-04-28 07:25 MT) — Triggered Apr 28; HCA limit BUY 0.0642 @ $433.50 was placed and filled per Portfolio_Ledger.md HCA position record.
2. `e8gjm7njrmddken1dg262717us` — "[Claude] Screenshot IBKR — fill capture HCA" (2026-04-28 14:30 MT) — Triggered Apr 28; HCA fill captured per Portfolio_Ledger.md.
3. `a286cj6cm1fnj2lo2mr30kpesg` — "[Claude] FOMC reaction check — conditional post-close re-scan" (2026-04-29 14:30 MT) — Triggered Apr 29; FOMC outcome resolved within tolerance; no router-review trigger fired.
4. `3v8bhcgkova6ibde2kgmp0ng0c` — "[Claude] Wed: HCA invalidation check post-THC print" (2026-04-30 08:00 MT) — Triggered Apr 30; criterion (iii) NOT TRIGGERED disposition logged per Decision_Log 2026-04-30 entry "Strategy B HCA invalidation criterion (iii) checkpoint — NOT TRIGGERED" (line 3228).
5. `1dje8fvc2ou5b2o6u98vc7rm68` — "[Claude] Re-screen GOOGL — Brinkema/Q1 print check" (2026-04-30 09:00 MT) — Triggered Apr 30; NO-GO STILL ACTIVE disposition logged per Decision_Log 2026-04-30 entry "Strategy D GOOGL re-screen — NO-GO STILL ACTIVE" (line 3307).
6. `520hftph845b86smhpcv7fvjgg` — "[Claude] Re-screen LLY — post-Q1 print check" (2026-05-01 09:00 MT) — Triggered May 1 today; LLY Strategy D NO-GO formally documented per session-end consolidation entry Part 1 (line 4020+, this session); entry-timing failure on criterion 6.

**CREATED (4 missing events; all META position-specific monitoring per Decision_Log 2026-05-01 META GO MEDIUM entry; all with overrideReminders popup at minute=0 for event-time notification):**

1. `ananicr400u0s10innmnl987fk` — "[Claude] META pre-execution Funds-on-Hold gate" (Mon 2026-05-04 09:15-09:30 MT) — Pre-execution gate session for META limit BUY contingent on Funds-on-Hold $2,500 anomaly resolution. Three-branch decision logic: (a) gate clears + B-cash sufficient → place order; (b) anomaly unresolved → single-deferral fallback to Tue with NO-GO if Tue fails; (c) anomaly resolved but B-cash insufficient → NO-GO.
2. `rdiqk2rjk91qetdi71ahq05tkg` — "[Claude] META fill capture screenshot" (Mon 2026-05-04 14:30-14:45 MT) — Post-close fill capture session conditional on gate clearing earlier today. If filled: move META from staged to open positions in Portfolio_Ledger; populate position thesis details. If gate failed: skip and output no-fill summary.
3. `2i5gul5m9eiarfm7pkjf8u42u0` — "[Claude] META mid-window thesis pulse-check (Strategy B)" (Mon 2026-06-01 10:00-10:30 MT) — 30-day mid-window check. Apply convergence check ($626.21 target) + invalidation criteria check (three criteria per Decision_Log META GO entry). If exit fires: stage market sell + schedule fill-capture; if no exit: log thesis-still-intact disposition.
4. `jdki2o75a3rhrc77e5sd4h170c` — "[Claude] META 60-day time-based exit checkpoint (Strategy B)" (Thu 2026-07-02 10:00-10:30 MT) — 60-day timeline reached (day 60 = Sat 2026-07-04 over weekend + observed July 4 holiday; next trading day on/before = Thu Jul 2 since Fri Jul 3 also closed). Apply exit decision logic: convergence → exit; invalidation → exit; window-expiry default → exit. Schedule fill-capture screenshot for same day 14:30 MT in that session.

**LEFT IN PLACE (10 events; correctly scheduled per project-source state):**

- `vm3871uj0sssahho7jj7lj2rqc` — Re-screen CCJ post-Q1 print (Wed 2026-05-06 09:00 MT) — pending; trigger conditions documented in event description.
- `mv9inurbosgjh35lqdlos6stp4` — Re-screen DIS post-Q2 FY26 print (Thu 2026-05-07 09:00 MT) — pending.
- `uj4fuslc0a4u7roug9ls6hnl34` — Re-screen VST post-Q1 print (Fri 2026-05-08 09:00 MT) — pending.
- `90ja09u0qo2vj4ki326oqpkok0` — Re-screen CEG post-Q1 print (Tue 2026-05-12 09:00 MT) — pending.
- `r3ko82nat3llflevlc9k0ubqpk` — D long-list interim re-screen (Wed 2026-05-13 08:00 MT) — pending.
- `lvgdk2h2h48bspu45m4rnudces` — GEV trailing-30-day re-screen (Fri 2026-05-22 07:30 MT) — pending; D defer trigger.
- `r9i6u6mnpk9ukoj2bh15m1fr7c` — Re-screen BA trailing-30d roll-off (Mon 2026-06-01 09:00 MT) — pending; calendar-driven roll-off.
- `fpbueqccja9thjcnuj6ck9l6rs` — LLY Strategy D mechanical re-screen (Fri 2026-06-12 09:30 MT) — created earlier this session; pending.
- `vt43tmemb2u7km29p79i2dga08` — IBM time-based exit / convergence (Fri 2026-06-26 09:25 MT) — pending; 60-day mark for IBM position.
- `c9fboi05d26lplf7f6ngkh1rb4` — HCA time-based exit / convergence (Mon 2026-06-29 09:25 MT) — pending; 60-day mark for HCA position (Day 60 = Sat 2026-06-27 over weekend; next trading day = Mon Jun 29).

**PRESERVED (3 quarterly recurring events; correctly scheduled with reminders per operator instruction "quarterly and annually" recurring tasks DO need reminders):**

- `qpshtsnmi7lj8q2j02au3creh4` (recurring) — Q1 Quarterly Regime Retrospective — instances at Jul 1 + Oct 1 visible in window.
- `ecu5pu90sgoecj1dn2lvt5656s` (recurring) — Q2 Quarterly D Long-Horizon Candidates — instances at Jul 1 + Oct 1 visible in window.
- `pbacgn2esaiollpdq44ujsj9tk` (recurring) — Q3 Quarterly AI Foundation Delta — instances at Jul 1 + Oct 1 visible in window.

### Daily / weekly / monthly recurring tasks per Claude_Task_Plan.md (NO calendar events created; operator runs without reminders per protocol)

- Daily: Daily.md morning market scan (each US trading day BMO).
- Weekly: Weekly_Catalyst_Calendar.md, Weekly_Position_Deep_Dive.md, Weekly_Post_Event_Screen.md.
- Monthly: Monthly_Fundamental.md, Monthly_AI_Capabilities.md, Monthly_E_Pairs.md, Monthly_D_Position_Deep_Dive.md.

These are operator-automatic per current cadence; no calendar clutter.

### Reminder configuration verification

Calendar default reminder is `popup at minutes=0` (event-time popup); this default applies to events created without overrideReminders. The 4 newly-created META events explicitly set `overrideReminders: [{method: "popup", minutes: 0}]` to ensure event-time notification regardless of any future calendar default change. Pre-existing events (CCJ/DIS/VST/CEG/D-long-list/GEV/BA/LLY-Jun/IBM/HCA + quarterly recurring) inherit the calendar default which is also popup-at-minute-0. **All 14 [Claude]-tagged trade-related events post-reconciliation have event-time popup reminders.**

### Effect on book

No book impact from calendar reconciliation itself. Strategy B portfolio state unchanged: 2 open longs (IBM, HCA), 1 staged (META Mon 5/4), $1,388.38 NAV. Strategy D portfolio state unchanged: RTX sole position. Calendar now accurately reflects pending decisions and monitoring events.

### Theater-check

(a) **Were any deleted events still potentially-active that I missed?** Reviewed each: HCA limit buy (filled Apr 28 per ledger), HCA fill capture (captured Apr 28 per ledger), FOMC reaction check (resolved Apr 29 per Decision_Log line referenced), HCA THC invalidation check (resolved Apr 30 NOT TRIGGERED per line 3228), GOOGL re-screen (resolved Apr 30 NO-GO STILL ACTIVE per line 3307), LLY re-screen (resolved May 1 D NO-GO per session-end consolidation entry Part 1). All 6 are unambiguously past-and-resolved; no risk of missing trigger.

(b) **Were any missing events overlooked?** Cross-checked Decision_Log pending-queue lists across all this-session entries:
- META: 4 events — gate, fill, mid-window, 60-day exit. ALL CREATED.
- HCA: 1 event — 60-day exit Mon Jun 29. EXISTS.
- IBM: 1 event — 60-day exit Fri Jun 26. EXISTS.
- LLY: 1 event — mid-Jun re-screen Fri Jun 12. EXISTS (created earlier this session).
- GEV: 1 event — May 22 trailing-30 re-screen. EXISTS.
- D long-list interim: 1 event — May 13. EXISTS.
- D NO-GO re-screens (CCJ, DIS, VST, CEG, BA): 5 events. ALL EXIST.
- HCA invalidation-window monitoring: handled by ongoing Daily-scan workflow + 60-day exit event; no separate event needed.
- IBM Brent-$130-trigger monitoring: handled by Daily-scan workflow; no separate event needed.
- RTX long-horizon hold: no specific event; D-strategy monitoring via M2 monthly + interim May 13 + quarterly D candidates re-screens.
- Ford Strategy B candidate: lower-priority queue per Daily.md; will be picked up by next Daily scan; no specific event needed.
- CAT/LLY/QCOM Strategy A queue: at next M1 router run on standard monthly cadence; M1 is part of monthly recurring tasks per Claude_Task_Plan.md; no separate event needed (operator runs M1 without reminder per protocol).

All pending decisions have appropriate calendar coverage OR are handled by the recurring-task workflow.

(c) **Is there clutter remaining in the calendar?** No daily/weekly/monthly recurring [Claude] events exist (per the review of all 16 events at session start). Only quarterly recurring + one-off pending events remain. Calendar state is appropriately lean.

(d) **Any inconsistencies between calendar event descriptions and current project-source state?** The LLY mid-Jun event description references "2026-04-30 LLY Strategy D NO-GO" but the formal entry was retrospectively documented this session in the 2026-05-01 session-end consolidation entry Part 1. Future Claude reading the LLY mid-Jun event prompt will find the relevant content via grep on "LLY Strategy D NO-GO" regardless of date header; minor discrepancy not worth a separate update call. Documented for transparency.

### Compaction-survival note

**Calendar reconciliation completed 2026-05-01 late afternoon MT:** 6 obsolete events deleted (HCA buy-order, HCA fill-capture, FOMC reaction, HCA THC invalidation, GOOGL re-screen, LLY post-Q1 re-screen — all triggered and resolved); 4 missing META events created (gate Mon 5/4, fill Mon 5/4 PM, mid-window Mon 6/1, 60-day exit Thu 7/2 — all with explicit popup-at-minute-0 reminders); 10 pending events preserved (CCJ/DIS/VST/CEG/D-long-list/GEV/BA/LLY-Jun/IBM/HCA monitoring); 3 quarterly recurring events preserved (Regime/D-Candidates/AI-Foundation).

**Final calendar state (14 trade-related [Claude] events visible 2026-05-04 through 2026-10-01):** 4 META + 1 HCA + 1 IBM + 1 LLY-Jun + 1 GEV + 1 D-long-list + 1 BA + 4 D-NO-GO-re-screens (CCJ/DIS/VST/CEG) + 3 quarterly-recurring instances (Q1/Q2/Q3 in Jul + Oct).

**Daily/weekly/monthly recurring tasks operate WITHOUT calendar events** per operator-confirmed protocol — Daily.md scan, Weekly catalysts/positions/post-event, Monthly fundamental/AI-capabilities/E-pairs/D-position-deep-dive — operator runs these on internal cadence without reminders.

---

## 2026-05-02 (Sat, ~mid-day MT post-Daily-scan) Strategy B thesis construction outcome — TEAM (Atlassian) NO-GO (criterion 4 decisive failure on dual-framing test — LONG framing structurally inappropriate for B's mean-reversion mechanism on a positive-reaction event; SHORT framing fails on absent mean-reversion asymmetry given post-print sell-side mass-cut-but-ratings-maintained pattern leaves stock approximately at fair-value-per-cut-PTs); no order staged; no follow-on calendar event scheduled

**Trigger:** B-thesis construction requested for Atlassian candidate flagged Daily.md 2026-05-01 morning scan as "TEAM (Strategy B long candidate — ≥5% magnitude, large-cap eligible, IT/Software sector — flag KL aggressive-sell-side-bull-ratification sub-pattern in thesis)". Primary event: Q3 FY26 earnings print Thu 2026-04-30 5:00 PM ET. Daily.md cap-eligibility-and-magnitude noted as "clean B mechanical eligibility (>5% magnitude, >$2B cap), but check KL aggressive-sell-side-bull-ratification sub-pattern in full thesis (multiple firms raising PTs into print)" — full sell-side post-print pattern resolved this session via web search to be the OPPOSITE of bull-ratification (mass PT cuts maintaining ratings).

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test + "no decisive flaw" + structural-framing-mechanism check; criterion 3 closed-list rev 14 numerical-price-or-named-event convergence target; criterion 5 no-A-position-overlap; instrument eligibility — market cap ≥ $2B at entry, 30-day ADV ≥ $10M; pre-mortem rev 7 KL #2.20 textbook-rational-penalty mechanism-embedded; Strategy.md Section thesis "AI's narrative synthesis identifies situations where the market's immediate reaction to a public event has over- or under-shot relative to the information content of the event" — mean-reversion mechanism explicitly defined); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged Mon May 4; sector cap usage IT Services 1/3 by IBM, Health Care Facilities 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, Cons Disc 0/3, Real Estate 0/3, Industrials 0/3, Cons Staples 0/3 — TEAM would push IT sector to 2/3 if entered); Decision_Log.md prior precedents — META 2026-05-01 GO (mild-sell-side-reset cleared criterion 4), BE 2026-05-01 NO-GO (positive-direction L1 cleanest precedent — TEAM is structurally analogous in direction but with OPPOSITE sell-side response), NXPI 2026-04-29 NO-GO + STX 2026-04-29 NO-GO + INTC 2026-04-27 NO-GO (positive-direction L1 with aggressive bull-ratification — referenced for sub-pattern boundary identification); TEAM Q3 FY26 8-K Form Ex-99.1 (SEC EDGAR / Atlassian shareholder letter / Investor Relations); Atlassian Q3 FY26 Earnings Transcript (Motley Fool, Investing.com); CNBC TEAM Q3 coverage; 24/7 Wall St. Atlassian post-print analyst tracker; StocksToTrade / Tradingkey TEAM tape coverage May 1; Daily.md 2026-05-01 (TEAM watchlist line + KL flag).

### Decision

**TEAM — NO-GO (DECLINE) on dual-framing analysis. LONG framing dismissed on structural mechanism mismatch; SHORT framing dismissed on criterion 4 absent mean-reversion asymmetry per post-print sell-side mass-cut-but-ratings-maintained pattern leaving stock approximately at post-cut-PT fair value range.**

Failed Strategy B entry criterion 4 with a NEW sub-pattern variant — **"valuation-reset-but-not-narrative-reset" sub-pattern** in which post-print sell-side broadly CUTS price targets (NOT raises them, opposite of NXPI/STX/BE) but MAINTAINS bullish/Overweight ratings, signaling a sector-wide multiple-compression environment in which the company executed but the post-print stock price (post-bounce) sits AT or NEAR the cluster of cut PTs — leaving no clean mean-reversion asymmetry on either direction. Criterion 1 mechanically clears with extreme cushion at +29.58% close-to-close (Apr 30 close $68.59 → May 1 close $88.88). Instrument eligibility clears (mkt cap ~$22B, ADV multi-million-shares/day). Criterion 5 clears (no A position).

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** TEAM = Atlassian Corporation, NASDAQ-listed common (US-listed; Australian-domiciled but US-listed); market cap ~$22-23B at $88.88 close (well above $2B floor, per 24/7 Wall St); 30-day ADV multi-million shares/day (well above $10M floor on volatile post-print volume); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS with extreme cushion:** Q3 FY26 print event date = Thu 2026-04-30 5:00 PM ET (AMC); Apr 30 close $68.59 → May 1 close $88.88 = **+29.58%** close-to-close. **Magnitude is itself a cue for criterion 4 evaluation** (top-decile post-event reaction; consistent only with material new information OR substantial short-cover-on-oversold-conditions OR both — magnitude does not automatically resolve criterion 4 either direction).
- **Criterion 5 cleared:** No A position open in TEAM (A router DO-NOT-ACTIVATE; A book empty).

### Print details and entry context

- **Q3 FY26 print:** Revenue $1.787B vs $1.70B consensus (+5.1% beat, +32% YoY); Cloud revenue $1.13B vs $1.08B (+4.6% beat, +29% YoY); Data Center revenue $561M vs $515M (+8.9% beat, +44% YoY); adj EPS $1.75 vs $1.34 cons (+30.6% beat, vs $1.32-1.34 alt-cons reference); Service Collection ARR >$1B (+30%+ YoY, "key growth engine"); RPO $4B (+37%); Rovo AI credit usage growing >20% MoM. **FY26 revenue growth guide RAISED to ~24% from 22%** (Cloud ~26.5%, Data Center ~21.5%, gross margin ~88% non-GAAP, OM ~29% non-GAAP). **Q4 revenue guide $1.65-1.66B (in line, NOT a blowout)**. Q4 EPS guide also in-line (Q4 FY26 vs Q4 FY25 lapping $50M upfront-license recognition tailwind). Expanded multi-year Google Cloud partnership (Gemini models in Rovo AI / Confluence; AI Hypercomputer + GKE co-engineering). Print released 2026-04-30 5:00 PM ET; conference call same evening.
- **Pre-print context:** TEAM was DOWN ~47% YTD heading into print, trading $57-71 range over the prior weeks; Apr 30 close $68.59 (per Tradingkey "After grinding in the low-to-mid $60s through much of April, Atlassian exploded from a $68.59 close on 2026/04/30 to $85.52 on 2026/05/01"). Pre-print sentiment was decisively NEGATIVE driven by sector-wide enterprise-software multiple compression (CRM/HUBS/ADBE/WDAY/INTU/ORCL/NOW Apr 23-24 weakness — same cohort that drove the IBM-precedent IGV cascade). Prior-cycle sell-side targets had been substantially higher (Cantor $146, Oppenheimer $150, BofA $150, BTIG $140 — all PRE-cut levels).

### LONG framing dismissed (structural-mechanism check)

A LONG thesis on TEAM would argue: stock at $88.88 closed below median analyst target ~$130 with 26 Buy / 8 Hold ratings; print materially extended AI/cloud growth thesis; mean-reversion to ~$110-130 PT cluster within 60 days. **DECISIVE STRUCTURAL FLAW:** Strategy B's mechanism is mean-reversion from sentiment-overshoot relative to event-day reaction, NOT momentum-continuation after a positive-direction event. Per Strategy.md thesis section: "the market's immediate reaction to a public event has over- or under-shot relative to the information content of the event. The mispricing resolves over weeks as the market fully digests the event's narrative context." For TEAM, the event-day reaction was +29.58% UP — the mispricing-vehicle the strategy targets is the EVENT-DAY REACTION; arguing that the +29.58% UNDER-shot fundamentals (price has further to go up) is structurally a momentum-continuation thesis, which belongs in Strategy A (DO-NOT-ACTIVATE) or Strategy D (long-horizon, but TEAM at SaaS turnaround stage doesn't fit D's quarterly-stable-cash-flow thesis profile). The IBM/HCA/META precedents cleared B-LONG framing because in each case the EVENT-DAY REACTION was DOWN (sentiment overshoot DOWN; B-LONG bets on mean-reversion UP from undershoot). TEAM's positive-direction reaction inverts this structure. **LONG framing structurally inappropriate.** Same disposition logic applied to BE 2026-05-01 NO-GO (LONG dismissal) and analogous to NXPI/STX/INTC LONG-side dismissals on positive-direction events.

### SHORT framing examined and declined (criterion 4 absent mean-reversion asymmetry)

A SHORT thesis on TEAM would argue: +29.58% single-day move overshoots fundamentals (Q4 guide in-line not blowout, Data Center FY27 deceleration explicitly flagged by management, sector multiple compression broader than TEAM-specific); mean-reversion to pre-print level $68-72 over 60 days. **DECISIVE FLAW on criterion 4 information-vs-sentiment test, but with INVERTED sub-pattern relative to BE/NXPI/STX:** the post-print sell-side response is NOT bull-ratification; it is broad PT CUTS while maintaining bullish ratings — a "valuation-reset-but-not-narrative-reset" pattern indicating sector-wide multiple compression has been ratified by sell-side AT THE LOWER PT LEVEL.

Same-day Apr 30 / May 1 PT actions documented across multiple sources:

- **BofA: $150 → $84 (-44.0%, Buy maintained)** — per StocksToTrade / Timothy Sykes
- **Cantor Fitzgerald: $146 → $98 (-32.9%, Overweight maintained)** — per StocksToTrade / 24-7 Wall St.
- **Oppenheimer: $150 → $100 (-33.3%, Outperform maintained)** — per StocksToTrade / 24-7 Wall St.
- **BTIG: $140 → $110 (-21.4%, Buy maintained)** — per 24-7 Wall St.
- **KeyBanc: cut PT (specific from-to TBD)** — per 24-7 Wall St.
- **Macquarie: cut PT** May 1 — per Tradingkey
- **UBS: cut PT** — per 24-7 Wall St.
- **Piper Sandler: cut PT (Neutral maintained)** — per 24-7 Wall St.
- **Raymond James: cut PT** — per 24-7 Wall St.
- **Cantor Fitzgerald (separate analyst): cut PT** — per 24-7 Wall St.
- **Barclays: $100 → $106 (+6.0%, Overweight maintained)** — only firm raising, modest; per 24-7 Wall St.
- **Mean post-print PT cluster: ~$84-$110** (BofA $84 lowest, Cantor $98, Oppenheimer $100, BTIG $110, Barclays $106). 6-month median target was $146 PRE-CUTS; post-cuts the cluster compresses to roughly $95-105 on the ratings-maintained block.
- **Pre-existing ratings: 26 Buy / 8 Hold pre-print (per 24-7 Wall St.); rating-level changes appear to be NONE — the cuts are PT-only.**

**Why this pattern is criterion-4-DECISIVE on SHORT framing:**

(1) **Stock at $88.88 sits APPROXIMATELY AT the post-cut PT cluster.** BofA cut to $84 means $88.88 is ~6% above BofA's "fair value." Cantor at $98 means $88.88 is ~9% below "fair value." Oppenheimer $100 means ~11% below. BTIG $110 means ~19% below. **The post-bounce price is roughly bracketed by the post-cut PTs** — there is no clean asymmetric downside that a B-SHORT would harvest within 60 days.

(2) **Sell-side "PT cut + rating maintained" signal is a textbook information-driven re-rating disposition.** Translation: "the multiple compression is real (we cut targets), but TEAM's execution is real too (we kept the bullish rating)." This is sell-side explicitly classifying the rally as movement back toward (cut) fair value, not sentiment-overshoot to be mean-reverted. The information content has been priced.

(3) **The rally was largely a relief bounce from oversold conditions, not a fresh sentiment-overshoot.** TEAM was -47% YTD pre-print after sector-wide multiple compression. The +29.58% bounce takes stock from $68.59 (oversold) to $88.88 — partially closing the discount-to-(cut)-PT gap. SHORT framing's mean-reversion thesis would require stock to fall back to $68-72 — but post-cut PTs DO NOT support that level (BofA's lowest post-cut PT $84 is still above $68-72 range). No sell-side anchor for the SHORT thesis's downside target.

(4) **Q4 guide in-line and FY27 Data Center deceleration mentioned by management** are mild-bearish forward signals that COULD support a SHORT thesis on tactical grounds — but these signals are already in the cut PTs and the in-line guide reaction. They do not produce ADDITIONAL asymmetric downside vs the post-bounce price.

(5) **Information-vs-sentiment test:** the +29.58% reaction reflects (a) short-cover dynamics on a heavily-shorted name down 47% YTD (mechanical, not sentiment), (b) genuine surprise on EPS magnitude (+30.6% beat), (c) raised FY26 outlook (~22% → ~24% growth = bullish). Sell-side's MASS PT CUT signal even on a clean beat is itself the criterion-4 "smoking gun" — but inverted from BE/NXPI/STX. Where BE/NXPI/STX showed sell-side ratifying the rally direction at higher PT (criterion-4-failing-LONG-extension), TEAM shows sell-side ratifying the post-bounce price as fair (criterion-4-failing-SHORT-mean-reversion).

(6) **Pre-mortem KL #7 short-side gap-up execution risk.** TEAM showed a +29.58% single-session gap-up on May 1; even if a SHORT thesis cleared criterion 4, the gap regime makes the short-side stop-loss at +25% from entry effectively unprotected against further squeeze risk. This is COMPOUNDING context, not load-bearing — primary disposition is criterion 4 absent mean-reversion asymmetry.

### Effect on book

No effect. No order staged for TEAM. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA) and one staged order (META Mon 5/4 gated). Strategy B sector concentration unchanged: IT 1/3 (IBM IT Services); Health Care 1/3 (HCA); others 0/3 staged. Portfolio_Ledger.md not modified by this session except for the "Last updated" line.

### Pending queue updated

- ~~TEAM B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 dual-framing failure (LONG = structural-mechanism mismatch; SHORT = absent-mean-reversion-asymmetry per post-print PT-cut-but-ratings-maintained cluster).
- Sequenced sister thesis-construction sessions today (Sat 2026-05-02): TWLO and EL evaluations to follow this session in same daily-scan-driven cohort.
- 10-day post-event entry window for TEAM expires ~2026-05-14 (Thu); no calendar event scheduled to revisit because criterion 4 dual-framing failure is structural and data-stable — no future data within the entry window would shift either framing's structural defect.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 4 information-vs-sentiment test + Section thesis on mean-reversion mechanism + pre-mortem rev 7).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 META GO entry (mild-sell-side-reset cleared criterion 4 — direct contrast).
- Decision_Log.md 2026-05-01 BE NO-GO entry (positive-direction L1 cleanest precedent — TEAM is structurally-direction-analogous but with OPPOSITE sell-side response, hence NEW sub-pattern variant rather than direct sub-pattern match).
- Decision_Log.md 2026-04-29 NXPI NO-GO entry + STX NO-GO entry + INTC 2026-04-27 NO-GO entry (positive-direction L1 with aggressive bull-ratification — referenced for sub-pattern boundary).
- Daily.md 2026-05-01 (TEAM watchlist line + KL flag).
- TEAM Q3 FY26 8-K Ex-99.1 (SEC EDGAR / Atlassian Investor Relations).
- TEAM Q3 FY26 earnings call transcript (Motley Fool / Investing.com).
- 24-7 Wall St. "Atlassian Gets Mixed Calls After Q3" (post-print analyst tracker, May 1 2026).
- StocksToTrade / Tradingkey / Timothy Sykes / Quiver TEAM May 1 2026 coverage.
- CNBC "Atlassian (TEAM) Q3 2026 earnings report" May 1 2026.

### Theater-check on this orchestrator review

(a) **Was the LONG framing examined sufficiently before structural dismissal?** Yes — the LONG-extension thesis was constructed (stock below median PT $130 with 26 Buy / 8 Hold; AI/cloud/Service-Collection $1B ARR validation; mean-reversion to ~$110 cluster within 60 days). The structural dismissal is on B's mechanism: the EVENT-DAY REACTION is the mispricing-vehicle B targets, and a positive-direction reaction inverts the LONG mean-reversion structure. This is the same structural objection that disqualified BE-LONG (2026-05-01 NO-GO) and was implicit in the NXPI/STX/INTC LONG dismissals.

(b) **Was the SHORT framing examined sufficiently before criterion 4 failure?** Yes — provisional SHORT thesis was constructed (overshoot from oversold-relief-bounce, mean-revert to pre-print $68-72 range, sector multiple compression, in-line Q4 guide as bearish forward signal). The criterion 4 failure on absent-mean-reversion-asymmetry per post-cut-PT cluster (BofA $84 to Cantor $98 cluster brackets the post-bounce $88.88 price) is decisive. Each weight (cluster bracketing, "PT cut + rating maintained" signal, oversold-relief explanation, pre-mortem KL #7) is COMPOUNDING; primary criterion 4 disposition is the cluster-bracketing absence of asymmetric downside.

(c) **Does this NO-GO disposition introduce a new sub-pattern that warrants Knowledge-Library taxonomy expansion?** **YES.** The TEAM sub-pattern is meaningfully distinct from prior cataloged sub-patterns:
- vs **NXPI/STX/BE positive-direction L1 (aggressive bull-ratification)**: TEAM has the OPPOSITE post-print PT pattern (mass cuts, not raises). SHORT-framing failure mechanism is different — for NXPI/STX/BE it is "sell-side ratifies rally as new-fair-value" (information-pricing-failure); for TEAM it is "sell-side cuts targets to bracket post-bounce price as approximately-fair" (no-asymmetric-mean-reversion).
- vs **V/MDLZ structural-overhang-persistence**: TEAM has no structural-overhang per se — the company executed cleanly; the issue is sector-wide multiple compression, not company-specific structural concern.
- vs **NOW/CHTR negative-direction information-confirmed-by-cross-section**: TEAM is positive-direction, not negative.
- **NEW sub-pattern: "valuation-reset-but-not-narrative-reset" / "post-cut-PT-bracket"** — sector-wide multiple compression that produces a post-bounce price approximately at the cluster of cut PTs, leaving no asymmetric mean-reversion on either direction. **Future B candidates with similar features (clean beat + raised guide + sector-wide-multi-compression + post-print PTs broadly cut while ratings maintained + post-bounce price within or just below the cut-PT cluster) should be classified under this sub-pattern at Daily.md scan stage.**

(d) **Was deferral considered?** No — criterion 4 dual-framing failure is structural-mechanism (LONG side) and data-stable (SHORT side). No future data within the 10-day post-event entry window (expires ~2026-05-14) would shift either framing's structural defect. Per protocol, deferral requires a specific resolution trigger that resolves the binding constraint; none applies. Decision is made now.

(e) **Could TEAM's "post-cut-PT-bracket" sub-pattern be rescued by a future negative catalyst that pushes stock decisively below the cut-PT cluster, opening clean SHORT mean-reversion asymmetry?** Theoretically yes — but per protocol that would be a FRESH thesis-construction trigger (new event within new 10-trading-day window), not a re-evaluation of this session's NO-GO. Routine Daily.md scan would surface any such catalyst.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence on dual-framing analysis.

### Compaction-survival note

**Strategy B TEAM thesis pipeline status as of 2026-05-02 Saturday mid-day MT:** TEAM-thesis-construction COMPLETE; **NO-GO on criterion 4 dual-framing failure** (LONG = B's mean-reversion-mechanism structural mismatch on positive-reaction event; SHORT = absent-mean-reversion-asymmetry per post-print sell-side mass-PT-cut-but-ratings-maintained cluster ~$84-$110 bracketing post-bounce $88.88 price). Criterion 1 mechanically clears with extreme cushion at +29.58% (Apr 30 $68.59 → May 1 $88.88). No order staged. No follow-on calendar event scheduled.

**TEAM establishes the NEW "valuation-reset-but-not-narrative-reset" / "post-cut-PT-bracket" sub-pattern** for Strategy B criterion 4 NO-GO taxonomy. Distinguishing features: (i) sector-wide multiple compression environment (enterprise software cohort April compression — CRM/HUBS/ADBE/WDAY/INTU/NOW/ORCL same cohort that drove IBM-precedent IGV cascade); (ii) clean fundamental print + raised guide; (iii) mass post-print PT cuts (>5 firms cut by 20-44%); (iv) ratings broadly maintained at Buy/Overweight/Outperform (cuts are PT-only, not narrative); (v) post-bounce price approximately within cut-PT cluster, leaving no asymmetric downside for SHORT or upside for LONG. **Pattern recognition signal at Daily.md scan stage:** if a candidate exhibits a +5%+ post-print rally + raised guide + observable mass post-print PT cuts of 20%+ across multiple firms with ratings maintained, classify as TEAM-pattern NO-GO without requiring full thesis-construction depth.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **thirteenth** Strategy B NO-GO of the experiment (NOW + CHTR + INTC + SBUX + V + NXPI + STX + MDLZ + OMCL + EQIX + STLA + BE + **TEAM**). Total experiment Strategy B dispositions to date: 3 GO (IBM, HCA, META staged) + 13 NO-GO = **3 GO / 13 NO-GO (19% / 81%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (1 — EQIX); instrument-rule failure (1 — TDOC, retroactively per session sequence; counted as separate from criterion-1); criterion 4 decisive failure (11). Within criterion-4 NO-GO sub-patterns: aggressive-sell-side-bull-ratification / NXPI-STX-BE sub-pattern (3); structural-overhang-persistence / V-MDLZ sub-pattern (2); in-window-binary-catalyst / STLA sub-pattern (1); valuation-reset-but-not-narrative-reset / TEAM sub-pattern (1 — established this session); other criterion-4 patterns (4 — NOW, CHTR, INTC, SBUX, OMCL minus TEAM-only-not-yet-classified items adjusted).

**Strategy B sector cap usage unchanged** at IT 1/3 (IBM IT Services), Health Care 1/3 (HCA), Comm Services 0/3 staged → 1/3 expected on META fill, others 0/3. Total candidates evaluated this Sat 2026-05-02 session block: TEAM (this entry); pending in same session block: TWLO, EL.

---

## 2026-05-02 (Sat, ~mid-day MT post-TEAM-session) Strategy B thesis construction outcome — TWLO (Twilio) NO-GO (criterion 4 decisive failure on dual-framing test — LONG framing structurally inappropriate for B's mean-reversion mechanism on a positive-reaction event; SHORT framing fails on aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern with BofA upgrade-with-PT-raise mirroring INTC Citi-upgrade structural smoking-gun); no order staged; no follow-on calendar event scheduled

**Trigger:** B-thesis construction requested for Twilio candidate flagged Daily.md 2026-05-01 morning scan as "TWLO (Strategy B long candidate — software cohort halo + own results — verify ≥$2B mkt cap and sector-cap availability)". Primary event: Q1 2026 earnings print Thu 2026-04-30 AMC. Daily.md cap-and-sector caveat resolved this session — TWLO mkt cap ~$30.8B (well above $2B floor), GICS Information Technology / Software sector (same as IBM IT Services within IT sector — IT sector cap would push to 2/3 if entered). Sequenced after TEAM NO-GO (this session block).

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test + "no decisive flaw" + structural-framing-mechanism check; instrument eligibility — market cap ≥ $2B at entry, 30-day ADV ≥ $10M; pre-mortem rev 7 KL #2.20 textbook-rational-penalty mechanism-embedded; pre-mortem KL #7 short-side gap-up execution risk acknowledgment; short-side stop-loss at +25%; short-financing exit threshold 10%; Strategy.md Section thesis mean-reversion mechanism); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged; sector cap usage IT 1/3 by IBM, Health Care 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, Cons Disc 0/3, Real Estate 0/3, Industrials 0/3, Cons Staples 0/3 — TWLO would push IT sector to 2/3 if entered, with TEAM also evaluated this session — sector-cap is informational not binding for NO-GO disposition); Decision_Log.md prior precedents — META 2026-05-01 GO (mild-sell-side-reset cleared criterion 4 — direct contrast for TWLO), **BE 2026-05-01 NO-GO (positive-direction L1 cleanest precedent — TWLO is direct sub-pattern match)**, **NXPI 2026-04-29 NO-GO and STX 2026-04-29 NO-GO (positive-direction L1 with aggressive sell-side bull-ratification — direct sub-pattern match for TWLO)**, **INTC 2026-04-27 NO-GO (Citi upgrade-with-PT-raise structural template that BofA TWLO upgrade-with-PT-raise mirrors)**; TEAM 2026-05-02 NO-GO (this session, valuation-reset-but-not-narrative-reset sub-pattern — direct contrast for TWLO showing OPPOSITE post-print sell-side pattern); TWLO Q1 2026 8-K Ex-99 (SEC EDGAR / Twilio Investor Relations); TWLO Q1 2026 earnings call transcript (Motley Fool); 24-7 Wall St. "Wall Street Floods Twilio With Price Target Hikes" May 1 2026; CoinCentral / MEXC / Stock Observer TWLO coverage May 1 2026; Yahoo Finance / Simply Wall St Twilio valuation analysis; Twilio Q1 2026 Results press release (investors.twilio.com); Daily.md 2026-05-01 (TWLO watchlist line).

### Decision

**TWLO — NO-GO (DECLINE) on dual-framing analysis. LONG framing dismissed on structural mechanism mismatch; SHORT framing dismissed on criterion 4 aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern (NXPI/STX/BE precedent direct match, with BofA upgrade-with-PT-raise structurally identical to INTC Citi upgrade smoking-gun).**

Failed Strategy B entry criterion 4 with the **NXPI/STX/BE-style aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern** at high magnitude — TWLO is the cleanest direct match for this sub-pattern since BE itself, with multiple distinct compounding decisive flaws (canonical pre-mortem KL #2.20 textbook-rational-trap on AI-infrastructure-narrative momentum name; pre-mortem KL #7 short-side gap-up execution risk; insider selling $6.3M past 90 days adding sentiment-confirmation; trailing P/E 779.88 / 27x forward P/E premium-valuation acknowledged-by-Wells-Fargo "very little pushback to this set of results" framing). Criterion 1 mechanically clears with extreme cushion at +19.19% close-to-close (Apr 30 $148.06 → May 1 ~$176.47, alternate measurement $148.06 → $183.34 = +23.83% per Timothy Sykes 17:03 ET reading; both clear ≥5% threshold by 4-5x cushion). Instrument eligibility clears (mkt cap ~$30.8B, ADV multi-million-shares/day on volatile post-print volume).

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** TWLO = Twilio Inc., NYSE-listed common (US-listed); market cap ~$30.8B at $176 close (175M shares × $176 ≈ $30.8B, well above $2B floor — references in 24-7 Wall St., Yahoo, MarketBeat consistent with this magnitude); 30-day ADV multi-million shares/day (well above $10M floor — TWLO trades multi-million shares routinely; post-print volume elevated); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS with extreme cushion:** Q1 2026 print event date = Thu 2026-04-30 AMC. Apr 30 close $148.06 → May 1 close $176.47 (StocksToTrade close reading) = **+19.19%** close-to-close. Alternative reading: Apr 30 close $148.06 → May 1 close $183.34 (Timothy Sykes 17:03 ET reading) = +23.83%. Both measurements massively above 5% threshold. **Magnitude is itself a cue for criterion 4** (top-decile post-event reaction, fresh 52-week high $178.22 / $183.34 intraday — consistent with material new information ratified by aggressive sell-side response).
- **Criterion 5 cleared:** No A position open in TWLO (A router DO-NOT-ACTIVATE; A book empty).

### Print details and entry context

- **Q1 2026 print:** Revenue $1.41B vs $1.34B consensus (+5.0% beat, +20% YoY — "fastest revenue growth in over three years" per management); organic revenue growth 16% (vs 14% prior); Non-GAAP EPS $1.50 vs $1.27 cons (+18.1% beat, +32% YoY); GAAP EPS $0.57 (vs $0.12 PY = 4.75x improvement); Gross margin 50.0% non-GAAP; Dollar-Based Net Expansion (DBNE) climbed to 114% from 107% PY (DBNE accel is structural positive); free cash flow $256.1M; share repurchase $253M Q1 ($900M remaining authorization). **Major customer wins disclosed:** Sierra, Bland.ai, PGA of America, Scorpion, KPN Netherlands, TeleVox, Aloware, Grupo ProTG, Posh, Sella AI, Solace + a "historic professional sports league" 7-figure Verify deal. **FY26 revenue growth guide RAISED to 14-15% from 11.5-12.5%** (alternate framing 12-13% per some sources; the raise is unambiguous either way); FY26 adj operating income guide raised to $1.08-$1.10B; Q2 2026 guide $1.42-1.43B revenue + $1.27-1.32 adj EPS (BOTH ABOVE consensus). Independent third-party validation: Twilio named LEADER in 2026 IDC MarketScape AND 2026 Omdia Universe for customer engagement platforms ("scoring highest in both strategies and capabilities"). Print released 2026-04-30 AMC; conference call same evening with detailed AI-positioning narrative.
- **Pre-print context:** TWLO was UP 28.8% YTD pre-print (per FinancialContent reading) and +51% trailing-12-month per Simply Wall St ("1 year total shareholder return of 51.27%"); also +17.68% trailing-30 per Simply Wall St — fresh 52-week-high zone +50% in a few weeks per Timothy Sykes ("ripping from roughly $118 in early April 2026 to $183.34 on 2026/05/01"). Pre-print sell-side positioning was constructive-to-bullish. **Insider selling material:** CEO Khozema Shipchandler sold 15,715 shares Apr 6 @ $133.39 ($2.1M); CFO Aidan Viggiano sold 9,389 shares Apr 2 @ $127.51 ($1.2M); past-90-days total insider sales 49,588 shares ~$6.3M; insiders now hold only 0.21% of shares. Trailing P/E 779.88 (anomalous-high reflecting GAAP-low-base; forward P/E 27x).

### LONG framing dismissed (structural-mechanism check)

A LONG thesis on TWLO would argue: stock at $176 trading at ~28% upside to consensus mean PT $200 (most-recently-raised; some firms now $200-225); AI-infrastructure / customer-engagement narrative accelerating per Q1 print + IDC/Omdia leader designations + $200-225 firm cluster of post-print PTs. **DECISIVE STRUCTURAL FLAW:** Strategy B's mechanism is mean-reversion from sentiment-overshoot relative to event-day reaction, NOT momentum-continuation after a positive-direction event. TWLO's event-day reaction was +19-24% UP — arguing further upside via mean-reversion to the $200-225 PT cluster is structurally a momentum-continuation thesis (Strategy A territory if A were ACTIVATE; or Strategy D if TWLO fit D's quarterly-stable-cash-flow thesis profile — TWLO's GAAP profitability remains thin per pre-mortem KL #1 and forward P/E premium suggests A or D framing rather than B). Same disposition logic as BE-LONG dismissal (2026-05-01 NO-GO), TEAM-LONG dismissal (this session block), and analogous to NXPI/STX/INTC LONG-side dismissals on positive-direction events. **LONG framing structurally inappropriate.**

### SHORT thesis examined and declined (criterion 4 aggressive-sell-side-bull-ratification = NXPI/STX/BE direct sub-pattern match)

**Provisional adversarial-thesis (SHORT framing).** A SHORT thesis would argue: +19-24% reaction overshoots fundamentals (Q2 guide modest above-consensus but not blowout; trailing-12-mo +51% positioning extreme; trailing-30 +17.68% momentum extension; insider selling $6.3M past 90 days suggests insiders see fair value below current; trailing P/E 779.88 anomalous-high acknowledging GAAP-thin profitability); valuation-extreme-momentum-AI-name; mean-reversion to pre-print $148 or pre-momentum $118-130 range over 60 days.

**Adversarial counter-argument (decisive flaws on SHORT side — multiple individually decisive):**

(1) **DECISIVE — NXPI/STX/BE-style aggressive sell-side bull-case ratification on the print day, with INTC-style upgrade-with-PT-raise structural smoking gun.** Same-day Apr 30 / May 1 PT actions documented:

- **BofA: UPGRADED Underperform/Neutral → Buy + PT $110 → $190 (+72.7%, +$80 PT raise)** — per StocksToTrade Timothy Sykes "Bank of America flipped from Underperform/Neutral to Buy and hiked its TWLO target to $190 from $110, calling out stronger AI positioning and the potential to be a core infrastructure layer for AI." **This is structurally identical to INTC 2026-04-27 NO-GO L1 pattern (Citi upgrade) at GREATER MAGNITUDE — BofA went TWO rating notches in one move (Underperform → Buy) which is rarer than Citi's INTC upgrade and combined with a 72% PT raise.** This single event is DECISIVE on criterion 4 alone.
- **Needham: $145 → $200 (+37.9%, Buy maintained)** — per CoinCentral / MEXC
- **KeyBanc: → $200 (Buy maintained)** — per CoinCentral / MEXC
- **Morgan Stanley: → $200 (Buy maintained)** — per CoinCentral / MEXC
- **UBS: → $200 (Buy maintained)** — per CoinCentral / MEXC
- **Oppenheimer: $170 → $200 (+17.6%, Outperform maintained)** — per CoinCentral
- **Mizuho: raised PT day prior** — per FinancialContent
- **Monness Crespi & Hardt: $175 → $200 (+14.3%, Buy)** — per Stock Observer
- **Rosenblatt: $180 → $210 (+16.7%, Buy)** — per Stock Observer
- **Citi: maintained Outperform** — per Stock Observer
- **TD Cowen: maintained Buy** — per Stock Observer
- **Piper Sandler: $192 PT (Neutral maintained — modest reset to $192)** — per Stock Observer
- **Median post-print PT cluster: $200-210** with bullish targets ranging to $225 per 24-7 Wall St. ("at least six analysts to raise their Twilio stock price targets, ranging from $192 to $225"). **Pre-print 6-month median target was $146** per Quiver-style aggregators; post-print cluster has shifted +37% upward to $200 cluster. The PT-raise magnitude (+38% to +72% across multiple firms, with one upgrade-with-PT-raise) is **the cleanest direct match for the BE/NXPI/STX positive-direction L1 sub-pattern post-BE.**

**Why this is criterion-4-DECISIVE on SHORT framing:**

The sell-side post-print response is MATERIALLY identical in structure to the BE precedent (JPM $231→$267 +16%, Susquehanna $173→$293 +69%, RBC $335) and arguably CLEANER than BE because of the BofA two-notch rating upgrade combined with $80 PT raise (BofA Underperform/Neutral → Buy is an exceptional ratings move; analogous to INTC Citi upgrade structurally but with greater PT-raise magnitude). The translation per the BE-precedent reasoning: "the company executed at a fundamentally higher level than our prior model assumed; we are ratifying the new fundamentals at a substantially higher fair value." This is the smoking-gun evidence that the +19-24% reaction is INFORMATION-DRIVEN re-rating (correct pricing), NOT sentiment-overshoot (mispricing to mean-revert). B-SHORT mean-reversion thesis fails on its own terms — sell-side is NOT signaling overshoot; sell-side is signaling new-fair-value-at-elevated-price.

(2) **Compounding flaw: pre-mortem KL #2.20 textbook-rational-penalty trap on AI-infrastructure-narrative momentum name.** TWLO is positioned in management commentary and sell-side framing as "core AI infrastructure layer" — Wells Fargo cited explicitly in 24-7 Wall St. ("expects investors to feel comfortable with very little pushback to this set of results"). The dual-driver Q1 print (revenue +20% accel + DBNE 114% + AI-deal customer wins + IDC/Omdia leader designation) is the canonical mega-rerating event that 2.20 textbook-rational mean-reversion thinking is structurally wrong about. SHORT-mean-reversion belief = textbook-rational-trap.

(3) **Compounding flaw: pre-mortem KL #7 short-side gap-up execution risk in active gap regime.** TWLO showed a +19-24% single-session gap-up on May 1 plus a +50% multi-week run; even if a SHORT thesis cleared criterion 4, the gap regime makes the short-side stop-loss at +25% from entry effectively unprotected against further squeeze risk. Multi-week run is precisely the active gap regime KL #7 names.

(4) **Compounding flaw: insider selling of $6.3M past 90 days does NOT support SHORT thesis at criterion-4-level.** Counter-intuitively, the insider selling is a confirming sentiment-signal that fits the bull-ratification narrative, not the overshoot thesis. CEO/CFO sales were under 10b5-1 plans pre-arranged at $127-133 levels; that the stock subsequently mega-bounced to $176-183 reflects information-content-shift in Q1 print, not insider-confirmation-of-overshoot. Insider 0.21% holding low.

(5) **Compounding flaw: stock at fresh 52-week-high zone with PT cluster at $200-210 above current $176-183.** SHORT thesis would require stock to fall ~30% to pre-print $148 or ~35% to pre-momentum $118-130 — but the post-print PT cluster $200-210 sits ABOVE current price by 14-19%, meaning even if mean-reversion happened tactically, the sell-side anchor for "fair value" is 14-19% ABOVE current price, not below it. There is no asymmetric-downside-anchor for B-SHORT. Mirrors BE/NXPI/STX cluster-bracketing logic.

### Effect on book

No effect. No order staged for TWLO. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA) and one staged order (META Mon 5/4 gated). Strategy B sector concentration unchanged: IT 1/3 (IBM IT Services); Health Care 1/3 (HCA); Comm Services 0/3 staged → 1/3 expected on META fill; others 0/3. Portfolio_Ledger.md not modified by this session except for the "Last updated" line.

### Pending queue updated

- ~~TWLO B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 dual-framing failure (LONG = structural-mechanism mismatch; SHORT = NXPI/STX/BE direct sub-pattern match with BofA upgrade-with-PT-raise structural smoking gun + multiple compounding flaws).
- Sequenced sister thesis-construction sessions today (Sat 2026-05-02): TEAM completed; EL evaluation to follow.
- 10-day post-event entry window for TWLO expires ~2026-05-14 (Thu); no calendar event scheduled to revisit because criterion 4 sub-pattern characterization is structural and data-stable — pattern recognition for NXPI/STX/BE-direct-match is unlikely to flip from re-examining same data.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 KL #2.20 / KL #7).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 META GO entry (mild-sell-side-reset cleared criterion 4 — direct contrast for TWLO).
- Decision_Log.md 2026-05-01 BE NO-GO entry (positive-direction L1 cleanest precedent — TWLO is direct sub-pattern match; together they extend the precedent to 4 instances: NXPI / STX / BE / TWLO).
- Decision_Log.md 2026-04-29 NXPI NO-GO + STX NO-GO entries (positive-direction L1 with aggressive sell-side bull-ratification — direct sub-pattern match).
- Decision_Log.md 2026-04-27 INTC NO-GO entry (Citi upgrade-with-PT-raise structural template that BofA TWLO upgrade-with-PT-raise mirrors — TWLO is INTC-precedent-extension).
- Decision_Log.md 2026-05-02 TEAM NO-GO entry (this session block, valuation-reset-but-not-narrative-reset sub-pattern — direct contrast for TWLO showing OPPOSITE post-print sell-side pattern within same software cohort).
- Daily.md 2026-05-01 (TWLO watchlist line).
- TWLO Q1 2026 8-K Ex-99 (SEC EDGAR / Twilio Investor Relations https://investors.twilio.com/news-releases/news-release-details/twilio-announces-first-quarter-2026-results).
- TWLO Q1 2026 earnings call transcript (Motley Fool https://www.fool.com/earnings/call-transcripts/2026/04/30/twilio-twlo-q1-2026-earnings-transcript/).
- 24-7 Wall St. "Wall Street Floods Twilio With Price Target Hikes" May 1 2026.
- CoinCentral / MEXC TWLO Q1 coverage May 1 2026 (analyst PT actions detail).
- Stock Observer / FinancialContent / Simply Wall St / StocksToTrade / Timothy Sykes TWLO coverage May 1 2026.

### Theater-check on this orchestrator review

(a) **Was the SHORT framing examined sufficiently before NO-GO?** Yes — provisional SHORT thesis was constructed (valuation-extreme-momentum AI name, +50% multi-week run, insider selling, P/E 779.88, mean-reversion to $148 pre-print or $118-130 pre-momentum). Tested against criterion 4 with multiple decisive grounds (BofA upgrade-with-PT-raise, multi-firm aggressive PT raises to $200 cluster, KL #2.20 trap, KL #7 gap-up, cluster-above-current-price). Each weight individually meets "decisive flaw" threshold; in combination the disposition is overwhelming.

(b) **Is the LONG framing dismissal correct?** Yes. Strategy B is mean-reversion mechanism, not momentum continuation. The +19-24% event-day reaction is the mispricing-vehicle B targets; arguing the reaction UNDER-shot fundamentals (price has further to go up) is structurally a momentum-continuation thesis. Same dismissal logic as BE-LONG and TEAM-LONG (this session block).

(c) **Is TWLO's relationship to the BE/NXPI/STX precedent direct or analogical?** **DIRECT.** The structural features map 1:1: (i) positive-direction reaction ≥+5% on event day; (ii) clean fundamental beat-and-raise (Q1 + FY guide raised); (iii) multi-firm aggressive sell-side PT raises post-print; (iv) at least one rating-level upgrade (BofA mirrors INTC Citi); (v) post-print PT cluster ABOVE current price; (vi) AI-narrative momentum name; (vii) compounding KL #2.20 + KL #7 + insider-selling factors. **TWLO is the 4th instance of the cleanest positive-direction L1 sub-pattern (after NXPI / STX / BE).** It does NOT establish a new sub-pattern; it extends the established one.

(d) **Was deferral considered?** No — criterion 4 dual-framing failure is structural (LONG side) and sub-pattern-direct-match (SHORT side, NXPI/STX/BE precedent). No future data within the 10-day post-event entry window (expires ~2026-05-14) would shift either disposition. Decision is made now.

(e) **Could BofA's two-notch upgrade be reversed within the 10-day window, opening fresh asymmetric-downside-anchor for SHORT?** Theoretically yes — but per protocol, that would be a FRESH thesis-construction trigger (new sell-side-event), not re-evaluation of this session's NO-GO. No such reversal observable in current information set.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence on dual-framing analysis.

### Compaction-survival note

**Strategy B TWLO thesis pipeline status as of 2026-05-02 Saturday mid-day MT post-TEAM-session:** TWLO-thesis-construction COMPLETE; **NO-GO on criterion 4 dual-framing failure** (LONG = B's mean-reversion-mechanism structural mismatch on positive-reaction event; SHORT = NXPI/STX/BE direct sub-pattern match with BofA Underperform/Neutral → Buy upgrade-with-PT-raise $110→$190 mirroring INTC Citi-upgrade smoking-gun, plus 5+ firms raising PTs to $200 cluster, plus compounding KL #2.20 / KL #7 / insider-selling factors). Criterion 1 mechanically clears with extreme cushion at +19.19% close-to-close (Apr 30 $148.06 → May 1 $176.47) or +23.83% (Apr 30 $148.06 → May 1 $183.34 alt-reading). No order staged. No follow-on calendar event scheduled.

**TWLO is the 4th instance of the positive-direction L1 aggressive-sell-side-bull-ratification sub-pattern (after NXPI 2026-04-29, STX 2026-04-29, BE 2026-05-01).** The sub-pattern is now well-established with 4 instances; pattern recognition signal at Daily.md scan stage suffices to filter to NO-GO without requiring full thesis-construction depth. **Distinguishing TWLO refinement: the BofA two-notch rating upgrade (Underperform/Neutral → Buy) combined with $80 PT raise represents an even cleaner upgrade-with-PT-raise smoking gun than BE's individual aggressive PT raises** — TWLO arguably exceeds BE's "cleanest L1 instance" benchmark on the upgrade-vector specifically, though BE retains the "cleanest L1 instance" benchmark on Q1 fundamental-beat-magnitude (BE: +130% YoY revenue, +39% revenue beat, EPS 3.4× beat, profit turnaround, +15-50% guide raise) given TWLO's +20% YoY revenue and +5% revenue beat.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **fourteenth** Strategy B NO-GO of the experiment (NOW + CHTR + INTC + SBUX + V + NXPI + STX + MDLZ + OMCL + EQIX + STLA + BE + TEAM + **TWLO**). Total experiment Strategy B dispositions to date: 3 GO (IBM, HCA, META staged) + 14 NO-GO = **3 GO / 14 NO-GO (18% / 82%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (1 — EQIX); instrument-rule failure (1 — TDOC); criterion 4 decisive failure (12). Within criterion-4 NO-GO sub-patterns: aggressive-sell-side-bull-ratification / NXPI-STX-BE-TWLO sub-pattern (4 — established at 4 instances, well above 1-precedent-shadow threshold); structural-overhang-persistence / V-MDLZ sub-pattern (2); in-window-binary-catalyst / STLA sub-pattern (1); valuation-reset-but-not-narrative-reset / TEAM sub-pattern (1, established prior session-step); other criterion-4 patterns (4 — NOW, CHTR, INTC redundant-now-classified-NXPI-STX-TWLO-precedent, SBUX, OMCL).

**Strategy B sector cap usage unchanged** at IT 1/3 (IBM IT Services), Health Care 1/3 (HCA), Comm Services 0/3 staged → 1/3 expected on META fill, others 0/3. Total candidates evaluated this Sat 2026-05-02 session block so far: TEAM NO-GO, TWLO NO-GO; pending: EL.

---

## 2026-05-02 (Sat, ~mid-day MT post-TWLO-session) Strategy B thesis construction outcome — EL (Estée Lauder Companies) NO-GO (criterion 4 decisive failure on dual-framing test — LONG framing structurally inappropriate for B's mean-reversion mechanism on a positive-reaction event; SHORT framing fails on absent mean-reversion asymmetry given post-bounce price still below pre-bounce sell-side mean PT cluster, with secular-impairment headwinds substantively-confirmed by management's $100M FY26 tariff disclosure + PRGP layoff upsize 5.8-7K → 9-10K signaling demand-side fragility); no order staged; no follow-on calendar event scheduled

**Trigger:** B-thesis construction requested for Estée Lauder Companies candidate flagged Daily.md 2026-05-01 morning scan as "EL (Strategy B long candidate — staples beat+raise — clean structural setup)". Primary event: Q3 FY26 earnings print Fri 2026-05-01 BMO 8:30 AM ET — a SAME-DAY-AS-DAILY-SCAN print (the morning scan flagged the EL candidate based on the BMO release; full sell-side post-print pattern was not yet observable at scan compile time). Sequenced after TEAM NO-GO and TWLO NO-GO this session block.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test + "no decisive flaw" + structural-framing-mechanism check; instrument eligibility — market cap ≥ $2B at entry, 30-day ADV ≥ $10M; pre-mortem rev 7 mean-reversion mechanism); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk; 2.6 no access to private information; 2.14 recency bias on input data); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged; sector cap usage IT 1/3 by IBM, Health Care 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, Cons Disc 0/3, Real Estate 0/3, Industrials 0/3, **Cons Staples 0/3 — EL would push Cons Staples to 1/3 if entered** = sector cap is informational not binding for NO-GO disposition); Decision_Log.md prior precedents — META 2026-05-01 GO (mild-sell-side-reset cleared criterion 4 — direct contrast), BE 2026-05-01 NO-GO + TWLO 2026-05-02 NO-GO (positive-direction L1 with aggressive-bull-ratification — structural reference for how PT response factor in criterion 4), TEAM 2026-05-02 NO-GO (this session block, valuation-reset-but-not-narrative-reset sub-pattern with post-cut PT bracketing — closest structural sister-pattern for EL given EL's pre-print PT cuts), V 2026-04-29 NO-GO + MDLZ 2026-04-29 NO-GO (structural-overhang-persistence sub-pattern — relevant for EL's $100M tariff + PRGP upsize signaling demand fragility); EL Q3 FY26 8-K Ex-99.1 (SEC EDGAR / The Estée Lauder Companies press release elcompanies.com); EL Q3 FY26 earnings call transcript (Motley Fool / Globe and Mail / Investing.com); TipRanks / Quiver / Yahoo Finance / CNN EL post-print coverage May 1 2026; B. Riley pre-print PT raise note ($100→$105); JPM pre-print PT cut ($121→$98) + Focus List removal; HSBC pre-print Buy → Hold downgrade @$106; TD Cowen pre-print PT cut ($130→$115); Daily.md 2026-05-01 (EL watchlist line + clean structural setup framing).

### Decision

**EL — NO-GO (DECLINE) on dual-framing analysis. LONG framing dismissed on structural mechanism mismatch; SHORT framing dismissed on criterion 4 absent mean-reversion asymmetry — post-bounce price ($87.88 close-area per TipRanks) sits MEANINGFULLY BELOW pre-bounce sell-side mean PT cluster ($94.91-$112.81 range), with the +12-16% reaction representing partial recovery from oversold-into-print conditions toward (still-below) sell-side fair value, and management's $100M FY26 tariff disclosure + PRGP layoff upsize 5.8-7K → 9-10K substantively-confirming structural-overhang-persistence headwinds.**

Failed Strategy B entry criterion 4 with a HYBRID sub-pattern combining (a) TEAM-style "post-bounce price approximately at sell-side anchor leaving no asymmetric mean-reversion" structural feature, but (b) with pre-print sell-side action being CUTS-BEFORE-PRINT rather than CUTS-AFTER-PRINT — meaning the post-bounce price closes part of the discount-to-(pre-cut)-PT gap that pre-print sell-side cuts opened up. This is essentially a "pre-print-PT-cut-followed-by-relief-bounce" pattern in which the post-bounce price still sits below the pre-cut PT cluster, leaving no asymmetric SHORT downside on its own terms. Layered with V/MDLZ-style structural-overhang-persistence signals (management $100M tariff disclosure + PRGP layoff upsize signaling demand-side weakness), the disposition is decisively NO-GO. Criterion 1 mechanically clears at +12-16% close-to-close (Apr 30 $75.69 → May 1 ~$87.88 = +16.1% per TipRanks reading, alt $76.71 base = +14.6%, alt-conservative reading +6.7% intraday Quiver early-day was pre-close). All measurements clear ≥5% threshold by 1.3-3.2x cushion.

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** EL = The Estée Lauder Companies Inc. (Class A common), NYSE-listed (US-listed); market cap ~$31-32B at $87.88 close (~360M shares outstanding × $87.88; TipRanks references $39.15B at higher price levels — well above $2B floor regardless of intraday-reading-used); 30-day ADV multi-million shares/day on a $30B+ S&P 500 name (well above $10M floor); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS with cushion:** Q3 FY26 print event date = Fri 2026-05-01 BMO 8:30 AM ET. Apr 30 close $75.69 (Meyka pre-print reading) or $76.71 (Financhill alt-reading) → May 1 close $87.88 (TipRanks current-price reading post-close) = **+16.1% or +14.6%** close-to-close, depending on prior-close source. Quiver intraday +6.7% reading at 11:50 AM UTC ≈ 7:50 AM ET was pre-print premarket reading — does NOT measure regular-session close-to-close. Yahoo Finance reading "+4.2% after beating Q3 earnings estimates" was intraday at unspecified time. Daily.md scan label "+12% intraday" was midday reading. **Conservative regular-session close-to-close: +12-16% range.** Magnitude clears 5% threshold by 1.3-3.2x cushion (smaller cushion than TEAM's +29.58% or TWLO's +19-24%).
- **Criterion 5 cleared:** No A position open in EL (A router DO-NOT-ACTIVATE; A book empty).

### Print details and entry context

- **Q3 FY26 print:** Net sales $3.712B vs $3.69B consensus (+0.6% beat, +4.6% YoY from $3.550B PY); **organic sales +2%** (modest; not a blowout); operating margin "expanded significantly bolstered in part by gross margin expansion"; **adj diluted EPS $0.91 vs $0.66 cons (+37.9% beat, +40% YoY from $0.65)**; reported diluted EPS $0.24 (GAAP-low due to restructuring charges and $35M securities-class-action settlement allocation). **Q3 segment color:** Estée Lauder brand sales +double-digits (Double Wear next-gen launch); **Clinique sales DECREASED double-digits** (foundation subcategory weak); **Too Faced sales DECLINED double-digits** (retail softness + specialty-multi closures); Makeup operating results swung to LOSS (vs prior-year income) including $35M settlement allocation; Mainland China outperformed prestige beauty for 3rd consecutive quarter (share gains via La Mer / TOM FORD / Le Labo / The Ordinary); Japan share gains in Makeup (M·A·C); Korea share gains (M·A·C / Clinique); US volume share gains (every category); online +~10% YTD; new partnerships Amazon Premium Beauty / TikTok Shop / specialty multi-retailers. **FY26 outlook RAISED:** organic sales growth at high-end of prior range; adj operating margin 10.7-11.0% (raised); adj EPS $2.35-2.45 (raised from $2.03-2.23 = +16% midpoint raise); preliminary FY27 view offered. **PRGP restructuring program EXPANDED:** target gross savings range increased; **layoff target UPSIZED to 9,000-10,000 from prior 5,800-7,000** (+50-72% expansion of position-elimination scope per TipRanks). **Tariff headwind:** management explicitly disclosed **$100M FY26 profitability reduction from tariffs** (per TipRanks "Estee Lauder expects tariff headwinds to reduce FY26 profitability by $100M"). Print released 2026-05-01 8:30 AM ET BMO; conference call 9:30 AM ET.
- **Pre-print context:** EL was DOWN 27.7% YTD into print (per Meyka), trading $75.69 close Apr 30; trailing 12-month range $48.37-$121.64 per TipRanks. Pre-print sell-side stance was DEPRESSED with multiple recent CUTS:
  - **JPMorgan: $121 → $98 (-19%, Overweight maintained) + REMOVED FROM ANALYST FOCUS LIST ahead of print** — per Intellectia; cited "increased number of announced deals and potential ones reduces the visibility for Estee."
  - **HSBC: DOWNGRADED Buy → Hold @ $106** — per TipRanks
  - **TD Cowen: $130 → $115 (-11.5%, rating maintained)** — per TipRanks
  - **B. Riley: $100 → $105 (+5%, modest raise)** — per TipRanks (only firm constructive into print)
  - Pre-print 6-month median target ~$94.91-$112.81 per TipRanks/Financhill/Stock Analysis aggregations (consensus moderately bullish even on cuts; range $60-$140 high-low; 6 Buy / 13 Hold / 1 Sell ratings)
- **Insider selling material:** Jane Lauder $1.68M; Meridith Webster (EVP) $477K; Barry Sternlicht (Director) $365K; Lande Rashida (EVP/General Counsel) $151K — total ~$2.7M trailing per Quiver. Pre-print sentiment negative; insider-selling adds confirming-but-not-decisive signal.
- **Post-print sell-side response:** Limited observable detail in this session's research scope — TipRanks notes "Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Church & Dwight (CHD) and The Estée Lauder Companies (EL)" article posted day-of (May 1 11:41am ET), suggesting mixed-not-aggressive post-print response. No documented post-print PT raises analogous to TWLO ($200 cluster) observable in scope; no documented post-print PT cuts further-deepening either. **The post-print sell-side response appears MUTED relative to the magnitude of beat-and-raise** — consistent with sell-side ratifying the partial-recovery without enthusiasm.

### LONG framing dismissed (structural-mechanism check)

A LONG thesis on EL would argue: stock at $87.88 still trades at 8-29% upside to consensus mean PT ($94.91 Financhill / $97.60 Public.com / $112.81 TipRanks 3-month average); print materially de-risks turnaround narrative (38% EPS beat, FY raise $2.03-2.23 → $2.35-2.45, PRGP upsize accelerating cost takeout); mean-reversion to ~$95-100 PT cluster within 60 days. **DECISIVE STRUCTURAL FLAW:** Strategy B's mechanism is mean-reversion from sentiment-overshoot relative to event-day reaction, NOT momentum-continuation after a positive-direction event. EL's event-day reaction was +12-16% UP — the mispricing-vehicle B targets is the EVENT-DAY REACTION; arguing the reaction UNDER-shot fundamentals (further upside via mean-reversion to PT cluster) is structurally a momentum-continuation thesis. Same dismissal logic as BE-LONG / TEAM-LONG / TWLO-LONG (all dismissed in 2026-05-01 / 2026-05-02 session block). **LONG framing structurally inappropriate.**

(Note: A counter-construction of EL as B-LONG via "negative pre-print sentiment overshoot DOWN that the +12-16% only partially reverses" would require treating the event-day reaction as itself the mean-reversion-from-undershoot in progress. That logic is INTERNALLY INCONSISTENT with B's mechanism — if the mean-reversion is in progress on event day, the trade is to be ENTERED on event day at the +12-16% bounce price; B-LONG bets that event-day bounce continues another +8-29% to PT cluster within 60 days, which is the momentum-continuation thesis just dismissed. The pre-print -27.7% YTD compression was a multi-month process, not a single-event-day reaction; B's criterion 1 measures "close-to-close move on event day" which mechanically locks the framing to the +12-16% UP direction. The structural-mechanism dismissal applies regardless of the multi-month-overshoot-DOWN framing attempt.)

### SHORT framing examined and declined (criterion 4 absent mean-reversion asymmetry + structural-overhang-persistence)

**Provisional adversarial-thesis (SHORT framing).** A SHORT thesis on EL would argue: +12-16% reaction overshoots fundamentals (organic sales only +2% — modest growth; Clinique and Too Faced declining double-digits; Makeup operating loss; $35M securities-class-action settlement; $100M FY26 tariff drag; PRGP layoff upsize from 5.8-7K to 9-10K signaling deeper-than-disclosed demand weakness; FY26 EPS guide $2.35-2.45 still well below historical $5+ peak earnings power); secular-impairment-persistence (China travel-retail decline, beauty category compression); pre-print sell-side cuts (JPM Focus List removal, HSBC downgrade, TD Cowen cut) reflect persistent structural concerns; mean-reversion to pre-print $75-77 range over 60 days.

**Adversarial counter-argument (decisive flaws on SHORT side):**

(1) **DECISIVE — Post-bounce price at $87.88 sits MEANINGFULLY BELOW pre-bounce sell-side mean PT cluster ($94.91-$112.81 range).** Even after 19% pre-print PT cuts (JPM $121→$98) and 12% pre-print cuts (TD Cowen $130→$115), the cluster mean stayed at ~$95-105 with bullish PTs to $140. The +12-16% bounce takes stock from $75.69 to $87.88 — partially closing the discount-to-PT-cluster gap, but still leaving 8-19% upside to the PT cluster mean. **B-SHORT mean-reversion thesis would require stock to fall ~14% to $75-77 pre-print level — but the sell-side anchor for "fair value" is 8-19% ABOVE current price, not below.** No asymmetric-downside-anchor for B-SHORT. Mirrors TEAM-NO-GO logic (post-bounce within or below PT cluster) but with EL having even greater absolute distance below PT cluster than TEAM did, making the SHORT thesis WEAKER on this dimension.

(2) **DECISIVE — Information-driven characterization of the +12-16% reaction.** The reaction reflects (a) genuine surprise on EPS magnitude (+38% beat — substantial), (b) FY26 guide raise ($2.03-2.23 → $2.35-2.45 = +16% midpoint raise — meaningful), (c) PRGP cost-takeout acceleration (despite the demand-fragility-signal interpretation, the $1B+ annual run-rate cost structure cut is genuinely positive for FY27+ EPS power), (d) 3rd consecutive quarter Mainland China share gains (idiosyncratic-positive vs sector-wide), (e) $35M settlement allocation already absorbed in GAAP EPS — fairly priced. The bounce is approximately information-driven, taking the stock from oversold-pre-print-conditions toward (still-below) cut-PT cluster fair value. SHORT mean-reversion thesis is on the wrong side of information content.

(3) **Compounding — V/MDLZ-style structural-overhang-persistence headwinds present BUT do not generate asymmetric-downside-anchor.** The $100M FY26 tariff disclosure + PRGP layoff upsize 5.8-7K → 9-10K + Clinique/Too Faced double-digit declines + Makeup operating loss are real structural concerns and ARE present in EL — but they were ALREADY largely priced into the pre-print -27.7% YTD compression. The bounce is the partial-recovery from over-priced-headwind-pessimism, not the unwinding of justified-pessimism. SHORT framing requires NEW structural-overhang-deterioration to drive further downside; current information set provides no such fresh deterioration (the layoff upsize and tariff disclosure ARE the negative-information-confirmation already absorbed in the modest +12-16% bounce).

(4) **Compounding — Pre-mortem KL #7 short-side gap-up execution risk in active gap regime.** EL gapped up significantly ($75.69 → $84.72 open = +12% gap). KL #7 short-side stop-loss at +25% from entry would have minimal protection against further squeeze if the bounce continues; gap regime in beauty category (post-print) is plausibly active.

(5) **Compounding — Information-vs-sentiment characterization is information-driven not sentiment-driven** per the post-bounce-PT-cluster relationship (1) + magnitude-of-beat (2). SHORT-mean-reversion is the same 2.20 textbook-rational-penalty trap that disqualified other positive-direction L1 SHORT framings (BE/NXPI/STX/TWLO).

### Effect on book

No effect. No order staged for EL. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA) and one staged order (META Mon 5/4 gated). Strategy B sector concentration unchanged: IT 1/3 (IBM IT Services); Health Care 1/3 (HCA); Comm Services 0/3 staged → 1/3 expected on META fill; Cons Staples 0/3 (would have been 1/3 if EL had cleared); others 0/3. Portfolio_Ledger.md not modified by this session except for the "Last updated" line.

### Pending queue updated

- ~~EL B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 dual-framing failure (LONG = structural-mechanism mismatch; SHORT = absent-mean-reversion-asymmetry per post-bounce price below PT cluster + information-driven characterization + V/MDLZ-style structural-overhang-already-priced).
- Sequenced sister thesis-construction sessions today (Sat 2026-05-02): TEAM completed, TWLO completed, **EL completed (this entry)**. Total session block: 3 NO-GOs across TEAM/TWLO/EL.
- 10-day post-event entry window for EL expires ~2026-05-15 (Fri); no calendar event scheduled to revisit because criterion 4 dual-framing failure is structural and data-stable — no future data within the entry window would shift either disposition; routine Daily.md scan would surface any genuinely fresh catalyst.

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 4 information-vs-sentiment test + pre-mortem rev 7).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 META GO entry (mild-sell-side-reset cleared criterion 4 — direct contrast).
- Decision_Log.md 2026-05-02 TEAM NO-GO entry (this session block, valuation-reset-but-not-narrative-reset sub-pattern with post-cut PT bracketing — closest structural sister-pattern for EL).
- Decision_Log.md 2026-05-02 TWLO NO-GO entry (this session block, NXPI/STX/BE direct sub-pattern match — direct contrast for EL on post-print PT response intensity).
- Decision_Log.md 2026-05-01 BE NO-GO + 2026-04-29 NXPI NO-GO + STX NO-GO entries (positive-direction L1 sub-pattern reference for criterion 4 logic).
- Decision_Log.md 2026-04-29 V NO-GO + MDLZ NO-GO entries (structural-overhang-persistence sub-pattern — relevant for EL's $100M tariff + PRGP upsize signaling demand fragility).
- Daily.md 2026-05-01 (EL watchlist line + clean structural setup framing).
- EL Q3 FY26 8-K Ex-99.1 (SEC EDGAR / The Estée Lauder Companies press release https://www.elcompanies.com/en/news-and-media/newsroom/press-releases/2026/05-01-2026-110042145).
- EL Q3 FY26 earnings call transcript (Motley Fool https://www.fool.com/earnings/call-transcripts/2026/05/01/estee-lauder-el-q3-2026-earnings-transcript/).
- TipRanks / Quiver / Yahoo Finance / CNN / Investing.com EL post-print coverage May 1 2026.

### Theater-check on this orchestrator review

(a) **Was the SHORT framing examined sufficiently before NO-GO?** Yes — provisional SHORT thesis was constructed (V/MDLZ-style structural-overhang-persistence + +12-16% bounce as overshoot of modest organic-2% growth + secular-impairment-persistence + insider selling + Clinique/Too Faced decline + Makeup loss + $100M tariff drag). Tested against criterion 4 with multiple decisive grounds (post-bounce-below-PT-cluster, information-driven-bounce-characterization, structural-overhang-already-priced, KL #7 gap-up). The criterion 4 failure on absent-mean-reversion-asymmetry is decisive on its own; compounding factors strengthen disposition.

(b) **Is the LONG framing dismissal correct?** Yes. Same structural-mechanism logic as BE/TEAM/TWLO LONG dismissals. The +12-16% event-day reaction is the mispricing-vehicle B targets; arguing further upside is momentum-continuation thesis structurally inappropriate for B. **Note specifically considered**: a counter-construction "B-LONG bets the +12-16% only partially reverses the multi-month -27.7% YTD compression, with continued mean-reversion to PT cluster" was examined and dismissed — the multi-month compression is not a single-event-day reaction; B's criterion 1 mechanically locks framing to event-day reaction direction; the multi-month compression argument collapses into the momentum-continuation framing already dismissed.

(c) **Does this NO-GO disposition introduce a new sub-pattern, or extend an existing one?** **EXTENDS — hybrid of TEAM (post-bounce-below-PT-cluster) + V/MDLZ (structural-overhang-persistence).** EL is not a clean-single-sub-pattern instance; rather it sits at the intersection of two established sub-patterns. The hybrid is informationally clean: post-bounce-below-PT-cluster establishes absent-mean-reversion-asymmetry on SHORT; structural-overhang-already-priced establishes that the V/MDLZ-style overhang factors do NOT add fresh asymmetric-downside-anchor. **Future B candidates with similar features (deeply-oversold-into-print + clean-but-modest-beat-and-raise + post-bounce-below-pre-bounce-PT-cluster + structural-overhang-already-priced via prior compression) should be classified under this hybrid sub-pattern.**

(d) **Was deferral considered?** No — criterion 4 dual-framing failure is structural-mechanism (LONG side) and data-stable (SHORT side). The post-print sell-side PT response data was incomplete in this session's research scope, but the **directional disposition does not depend on post-print PT specifics**: even if post-print PTs were aggressively raised (TWLO-style), that would only strengthen the criterion-4-NO-GO via direct sub-pattern match; if PTs were aggressively cut (TEAM-style), that would strengthen the criterion-4-NO-GO via post-cut-PT-bracket; if PTs were unchanged-or-mildly-mixed (most likely scenario per "Analysts Have Conflicting Sentiments" framing), the absent-mean-reversion-asymmetry per pre-bounce-PT-cluster bracketing is the operative disposition driver. All three post-print PT scenarios route to NO-GO. Deferral for post-print PT clarity would not change disposition.

(e) **Could EL's "beat-and-raise + PRGP-cost-takeout" combination be characterized as a B-LONG-eligible sentiment-overshoot-DOWN candidate analogous to IBM's NOW/IGV-cascade-driven undershoot?** No, with two distinguishing features:
- **IBM event-day reaction was -9.62% (DOWN); EL event-day reaction was +12-16% (UP).** B's criterion 1 mechanically locks framing to event-day-reaction direction. EL fails the IBM-precedent template at the most basic structural level.
- **IBM's pre-print discount was driven by a TRANSIENT EXTERNAL CASCADE (NOW Q4 print + IGV sector compression) unrelated to IBM-specific fundamentals.** EL's pre-print discount is driven by COMPANY-SPECIFIC and CATEGORY-SPECIFIC concerns (Clinique/Too Faced declines, China travel-retail, makeup compression, tariff exposure) — these are the kind of structural-overhang-persistence concerns that the V/MDLZ NO-GO precedents identified as DECISIVE-FLAW signals. EL's discount is partly justified-by-fundamentals; IBM's was almost entirely sentiment-driven externally.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence on dual-framing analysis.

### Compaction-survival note

**Strategy B EL thesis pipeline status as of 2026-05-02 Saturday mid-day MT post-TWLO-session:** EL-thesis-construction COMPLETE; **NO-GO on criterion 4 dual-framing failure** (LONG = B's mean-reversion-mechanism structural mismatch on positive-reaction event; SHORT = absent-mean-reversion-asymmetry per post-bounce price $87.88 sitting 8-19% below pre-bounce sell-side PT cluster mean $94.91-$112.81, plus information-driven-bounce characterization, plus V/MDLZ-style structural-overhang-already-priced via -27.7% YTD pre-print compression). Criterion 1 mechanically clears at +12-16% close-to-close (Apr 30 $75.69 → May 1 $87.88 area). No order staged. No follow-on calendar event scheduled.

**EL establishes a hybrid sub-pattern instance** combining TEAM-style post-bounce-below-PT-cluster + V/MDLZ-style structural-overhang-persistence-but-already-priced. **Distinguishing the hybrid from clean instances:** unlike TEAM (where PT cluster bracketed post-bounce price tightly leaving no asymmetry), EL's PT cluster sits clearly ABOVE post-bounce price (8-19% above) — indicating sell-side anchor for "fair value" still has room above current. Unlike V/MDLZ (where structural-overhang-persistence was actively-deteriorating in cross-sectional peer evidence), EL's overhang signals (tariff, PRGP upsize, brand-specific declines) are largely already-priced in the pre-print compression. The hybrid yields a NO-GO on absent-asymmetric-downside-anchor for SHORT regardless of which clean precedent dominates.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **fifteenth** Strategy B NO-GO of the experiment (NOW + CHTR + INTC + SBUX + V + NXPI + STX + MDLZ + OMCL + EQIX + STLA + BE + TEAM + TWLO + **EL**). Total experiment Strategy B dispositions to date: 3 GO (IBM, HCA, META staged) + 15 NO-GO = **3 GO / 15 NO-GO (17% / 83%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (1 — EQIX); instrument-rule failure (1 — TDOC); criterion 4 decisive failure (13). Within criterion-4 NO-GO sub-patterns: aggressive-sell-side-bull-ratification / NXPI-STX-BE-TWLO sub-pattern (4 instances); structural-overhang-persistence / V-MDLZ sub-pattern (2 instances; EL adds hybrid-instance noted but classified primarily under hybrid below); in-window-binary-catalyst / STLA sub-pattern (1); valuation-reset-but-not-narrative-reset / TEAM sub-pattern (1); **TEAM+V/MDLZ-hybrid / EL sub-pattern (1, established this session-step)**; other criterion-4 patterns (4 — NOW, CHTR, SBUX, OMCL).

**Strategy B sector cap usage unchanged** at IT 1/3 (IBM IT Services), Health Care 1/3 (HCA), Comm Services 0/3 staged → 1/3 expected on META fill, Cons Staples 0/3, others 0/3.

**Total Sat 2026-05-02 session block summary:** 3 candidates evaluated (TEAM, TWLO, EL); **3 NO-GOs (0 GO, 0 deferral)**. Daily.md 2026-05-01 morning scan flagged 8 new B-evaluation candidates (TEAM, TWLO, EL, FIVN, AXSM, CBOE, CAT, plus AAPL for A); 3 of 8 evaluated this Sat 2026-05-02 session block (TEAM, TWLO, EL — the originally-prioritized triplet); 5 remaining (FIVN, AXSM, CBOE, CAT for B; AAPL for A) deferred to next routine Daily-scan-driven sequencing per standard cadence. Per the BE compaction-survival note pattern-recognition guidance, future B candidates flagged with positive-direction L1 features should be triage-filtered at Daily.md scan stage:
- **FIVN +~30%** — pending mkt-cap verification ≥$2B; likely positive-direction L1 with bull-ratification potential — apply NXPI/STX/BE/TWLO sub-pattern recognition first
- **AXSM +13%** — FDA-approval catalyst with bull-ratification PT raises (Mizuho $217 / Morgan Stanley $217 / TD Cowen $215) — likely positive-direction L1 with KL note "FDA-approval-with-bull-ratification" sub-pattern variant
- **CBOE +9% to ATH** — record print + 20% headcount cut + raised guide + ATH-extension; likely valuation-reset-style or aggressive-bull-ratification — apply hybrid recognition
- **CAT +10% Apr 30 + Morgan Stanley PT $430→$915 +485 raise + JPM PT $1,125** — direct NXPI/STX/BE/TWLO sub-pattern match, very high likelihood of NO-GO at thesis stage
- **AAPL** — Strategy A candidate, separate evaluation track if A router activates

---

## 2026-05-02 (Sat, ~mid-afternoon MT post-EL-session) Strategy B thesis construction outcome — FIVN (Five9) NO-GO (instrument rule mechanical eligibility failure: market cap ~$1.65B post-bounce — even at intraday high $22.43 mkt cap $1.72B remains below $2B floor; identical disposition path to TDOC 2026-05-01 precedent); no order staged

**Trigger:** B-thesis construction requested for Five9 candidate flagged Daily.md 2026-05-01 morning scan as "FIVN (Strategy B long candidate — verify mkt-cap ≥$2B floor)" with explicit cap-verification caveat. Primary event: Q1 2026 earnings print Thu 2026-04-30 AMC. Sequenced after TEAM/TWLO/EL session block (3 NO-GOs) per Daily-scan-driven cohort progression.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; **instrument eligibility rule — market cap ≥ $2B at entry as hard floor**, 30-day ADV ≥ $10M, US-listed common, long-or-short permitted, 2% sizing, no options); AI_Trading_Foundation.md (2.13 ordinal-tier conviction); Portfolio_Ledger.md ($1,388.38 B NAV at 2026-04-28 close; IBM + HCA open longs; META staged; sector cap usage IT 1/3 by IBM, Health Care 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, others 0/3); Decision_Log.md prior precedents — **TDOC 2026-05-01 NO-GO (instrument rule mechanical eligibility failure: market cap $1.07B at Apr 30 close, far below $2B floor — direct disposition-template match for FIVN)**, OMCL 2026-04-30 NO-GO (criterion 4 disposition with mkt-cap-borderline note that resolved by clearing $2B but failed criterion 4 separately — different disposition class than FIVN); FIVN Q1 2026 8-K Ex-99 (BusinessWire / Investor Relations); FIVN Q1 2026 earnings call transcript (Motley Fool / AOL / Seeking Alpha); Investing.com "Jefferies raises Five9 stock price target on AI revenue growth" May 1 2026; Daily Political / Ticker Report TipRanks coverage May 1 2026; Morningstar / GuruFocus / Companies Market Cap / Macrotrends FIVN market-cap-and-shares-outstanding data; Daily.md 2026-05-01 (FIVN watchlist line + cap-verification caveat).

### Decision

**FIVN — NO-GO (DECLINE) on instrument-rule mechanical eligibility failure. Market cap $1.65B at May 1 close $21.53 ($21.53 × 76.56M shares outstanding) is BELOW the $2B floor. Even at intraday high $22.43, market cap reaches only $1.72B — still below floor. Disposition resolved at instrument-rule step before criterion 1, criterion 4, and other criterion evaluation.**

The Daily.md scan flagged FIVN with explicit cap-verification caveat ("verify mkt-cap ≥$2B floor"); this session resolves the verification to clear failure, not borderline-clear. Same mechanical disposition pattern as TDOC 2026-05-01 NO-GO.

### Mechanical eligibility detail

- **Instrument rule — FAILS:** FIVN = Five9, Inc., NASDAQ-listed common (US-listed); shares outstanding 76.56M (Morningstar) / 77.528M (companiesmarketcap); pre-print close (Apr 30) $17.20 (Morningstar "previous close"); post-print close (May 1) $21.53 (per GuruFocus); intraday range $19.71-$22.43 (Morningstar). **Market cap calculations:**
  - Pre-print: $17.20 × 76.56M = **$1.32B** (well below $2B floor)
  - Post-print close: $21.53 × 76.56M = **$1.65B** (below $2B floor)
  - Post-print intraday high: $22.43 × 76.56M = **$1.72B** (still below $2B floor)
  - To clear $2B floor, FIVN would need to trade at ≥$26.10 — meaningfully above any observed price in the post-event window
- **Criterion 1 — would have cleared (moot, evaluation-not-required):** Apr 30 close $17.20 → May 1 close $21.53 = +25.2% close-to-close (Daily.md "+~30%" reading was approximately correct but uses different reference). Magnitude clears 5% threshold by ~5x cushion. **Moot because instrument-rule fails first.**
- **Criterion 5 — would have cleared (moot):** No A position open in FIVN.
- **Criterion 4 — not evaluated:** disposition resolved at instrument-rule step.

### Why instrument-rule is the binding constraint

Per Strategy.md instrument eligibility rule, the $2B market cap floor is a hard mechanical gate at entry. Per the TDOC 2026-05-01 NO-GO precedent ("Daily.md cap-borderline caveat resolves to clear failure, not borderline-clear; no order staged"), instrument-rule failures route to NO-GO without further criterion evaluation regardless of how cleanly other criteria might clear. FIVN's $1.65-1.72B post-event mkt cap range is unambiguously below the $2B floor — not borderline; the gap is approximately $300-350M (or $4.50+/share at current share count).

### Effect on book

No effect. No order staged for FIVN. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA) and one staged order (META Mon 5/4 gated). Strategy B sector concentration unchanged. Portfolio_Ledger.md not modified by this session except the "Last updated" line.

### Pending queue updated

- ~~FIVN B-thesis construction~~ COMPLETE — NO-GO declined on instrument-rule mechanical eligibility failure ($1.65-1.72B post-bounce mkt cap below $2B floor).
- 10-day post-event entry window for FIVN expires ~2026-05-14 (Thu); no calendar event scheduled to revisit because the instrument-rule failure is structural and would only be resolved by FIVN trading sustainably above $26.10 (a +21% additional move from current $21.53 close), which is unlikely within the 10-day window without new positive catalyst meriting fresh thesis-construction evaluation in any case.
- Sequenced sister thesis-construction sessions today: TEAM (NO-GO), TWLO (NO-GO), EL (NO-GO) earlier this session block; FIVN (this NO-GO); AXSM, CBOE, CAT, AAPL pending evaluation in same Sat 2026-05-02 cohort.

### References

- Strategy.md (Strategy B section + instrument eligibility rule + entry criteria 1-5).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 TDOC NO-GO entry (instrument-rule mechanical eligibility failure direct precedent — same disposition template applied).
- Decision_Log.md 2026-04-30 OMCL NO-GO entry (different instrument-rule outcome — cleared $2B floor at $4.06B then failed criterion 4 separately; provides precedent for instrument-rule mkt-cap-vs-criterion-4 routing distinction).
- Daily.md 2026-05-01 (FIVN watchlist line + cap-verification caveat).
- FIVN Q1 2026 8-K Ex-99.1 (BusinessWire / Five9 Investor Relations).
- FIVN Q1 2026 earnings call transcript (Motley Fool / AOL / Investing.com).
- Morningstar AAPL FIVN quote page (76.56M shares outstanding, Apr 30 prev close $17.20, intraday range $19.71-$22.43); GuruFocus (post-print mkt cap $1.65B at $21.53 close); CompaniesMarketCap.com (77.528M shares outstanding); Macrotrends (March 2026 mkt cap $1.31B).
- Investing.com Jefferies FIVN PT raise note May 1 2026.

### Theater-check on this orchestrator review

(a) **Were both share-count and price-point measurements verified?** Yes. Share count cross-verified across Morningstar (76.56M), companiesmarketcap (77.528M), and post-print observation. Price points cross-verified across Apr 30 close ($17.20 Morningstar / $17.03 FinancialContent April 28 reading), May 1 close ($21.53 GuruFocus), and intraday range ($19.71-$22.43 Morningstar). All combinations yield mkt cap below $2B floor.

(b) **Was the borderline-vs-clear-failure distinction examined?** Yes. The gap between FIVN's post-bounce mkt cap ($1.65B) and the $2B floor is approximately $350M, or 18% of the floor — unambiguously below, not borderline. Even at the intraday high ($22.43, mkt cap $1.72B), the gap is $280M / 14% — still clearly below. To clear $2B, FIVN would need additional +21% from current $21.53 close. Not borderline.

(c) **Could the Daily.md "+~30%" reading have referenced a higher post-bounce price that would clear the $2B floor?** No. Daily.md "+~30%" framing was approximately correct based on $17.20 × 1.30 = $22.36 (intraday high $22.43 ≈ +30.4%). At intraday high, mkt cap = $1.72B — still below $2B. The math does not support a "+30% magnitude implies cap clears" interpretation.

(d) **Was deferral considered?** No. Instrument-rule failure is a hard mechanical gate; deferral does not apply because no future data within the 10-day post-event entry window would materially shift the failure (FIVN would need to organically rally an additional +21% within 10 trading days for cap to clear, which itself would be a separate catalyst meriting fresh thesis-construction evaluation, not re-evaluation of this session's NO-GO).

Modulo these four considerations, the orchestrator review converges on NO-GO with high confidence.

### Compaction-survival note

**Strategy B FIVN thesis pipeline status as of 2026-05-02 Saturday mid-afternoon MT:** FIVN-thesis-construction COMPLETE; **NO-GO on instrument-rule mechanical eligibility failure** ($1.65-1.72B post-bounce mkt cap below $2B floor at all observed price points; TDOC precedent direct match). Criterion 1 magnitude (+25.2% close-to-close) would have cleared but is moot because instrument-rule fails first. No order staged. No follow-on calendar event scheduled.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **sixteenth** Strategy B NO-GO of the experiment (NOW + CHTR + INTC + SBUX + V + NXPI + STX + MDLZ + OMCL + EQIX + STLA + BE + TEAM + TWLO + EL + **FIVN**). Total experiment Strategy B dispositions to date: 3 GO (IBM, HCA, META staged) + 16 NO-GO = **3 GO / 16 NO-GO (16% / 84%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (1 — EQIX); **instrument-rule failure (2 — TDOC, FIVN)**; criterion 4 decisive failure (13). FIVN is the second instrument-rule failure of the experiment after TDOC; both occurred within 24 hours of each other in the Daily-scan-driven 2026-05-01-and-2026-05-02 candidate-evaluation cluster, suggesting a Daily.md scan-stage filter for mkt-cap-borderline candidates may be warranted to reduce thesis-construction overhead on instrument-rule-failure cases.

**Strategy B sector cap usage unchanged.** Total candidates evaluated this Sat 2026-05-02 session block so far: TEAM NO-GO, TWLO NO-GO, EL NO-GO, **FIVN NO-GO**; pending: AXSM, CBOE, CAT, AAPL.

---

## 2026-05-02 (Sat, ~mid-afternoon MT post-FIVN-session) Strategy B thesis construction outcome — AXSM (Axsome Therapeutics) NO-GO (criterion 1 mechanical eligibility failure on close-to-close magnitude — Daily.md scan "+13%" reading reflected May 1 premarket spike to $208 that faded to $189 close; actual event-day close-to-close measurements reach only +2.6% across both Apr 30-print-day and Apr 29-pre-event reference points; identical disposition path to EQIX 2026-05-01 precedent on premarket-vs-regular-session-close measurement); no order staged

**Trigger:** B-thesis construction requested for Axsome Therapeutics candidate flagged Daily.md 2026-05-01 morning scan as "AXSM (Strategy B long candidate — FDA approval catalyst — flag KL bull-ratification sub-pattern)" with sub-pattern flag for likely positive-direction L1 with bull-ratification PT raises (Mizuho $217 / Morgan Stanley $217 / TD Cowen $215 cited as pre-existing constructive positioning). Primary event: FDA approval of AUVELITY (AXS-05) for Alzheimer's disease agitation, announced Thu 2026-04-30 14:06 ET via GlobeNewswire (during regular trading session, NOT after-hours); investor webcast hosted Fri 2026-05-01 8:00 AM ET. PDUFA target was 2026-04-30; approval came on the target date. Sequenced after FIVN NO-GO this session block.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; **criterion 1 close-to-close magnitude requirement ≥5% on event day**; criterion 4 information-vs-sentiment test; instrument eligibility — market cap ≥ $2B at entry, 30-day ADV ≥ $10M; pre-mortem rev 7); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged; sector cap usage Health Care 1/3 by HCA — AXSM would push Health Care to 2/3 if entered, and would be Pharmaceuticals sub-industry distinct from HCA's Health Care Facilities sub-industry); Decision_Log.md prior precedents — **EQIX 2026-05-01 NO-GO (criterion 1 mechanical failure: Daily.md morning-scan "-5%" reading reflected after-hours initial reaction not regular-session close-to-close — direct disposition-template match for AXSM where Daily.md "+13%" reflected May 1 premarket spike not actual close-to-close)**, SBUX 2026-04-29 NO-GO (positive-direction L1 with information-priced-via-pre-print-rally — would have been the criterion-4 sub-pattern routing if criterion 1 had cleared, but moot since criterion 1 fails first), TDOC 2026-05-01 NO-GO + FIVN 2026-05-02 NO-GO (instrument-rule mechanical eligibility failures — different mechanical-failure category than AXSM's criterion-1 failure); AXSM FDA approval press release (GlobeNewswire 2026-04-30 14:06 ET); Axsome Therapeutics Investor Event (May 1 8:00 AM ET); StockTitan / Benzinga / SoFi / TradingView / TickerNerd / Stockopedia / Investing.com / TipRanks AXSM price-and-cap data; Daily.md 2026-05-01 (AXSM watchlist line + KL bull-ratification flag).

### Decision

**AXSM — NO-GO (DECLINE) on criterion 1 mechanical eligibility failure. Close-to-close move on event day is approximately +2.6% to -0.5% depending on event-day reference window — both measurements substantially below the ≥5% criterion 1 threshold. Disposition resolved at criterion 1 step before criterion 4 evaluation. Daily.md "+13%" framing reflected May 1 premarket spike to ~$208 that faded by regular-session open and closed at ~$189 — the +13% was not a regular-session close-to-close move.**

### Mechanical eligibility detail

- **Instrument rule — clears:** AXSM = Axsome Therapeutics, Inc., NASDAQ-listed common (US-listed); market cap ~$9.43B (per Investing.com) / $9.7B (per SoFi) at $189 area close (well above $2B floor); 30-day ADV ~$110M+ on multi-million shares/day at $185+ price level (well above $10M floor); long-or-short permitted; 2% sizing $27.77; no options. **Eligibility cap and ADV thresholds clear unambiguously — instrument-rule is NOT the binding mechanical constraint.**
- **Criterion 1 — FAILS:** FDA approval announcement timing is critical for event-day reference selection per Strategy.md criterion 1 ("close-to-close move on event day"):
  - **Announcement timestamp: 2026-04-30 14:06 ET** per GlobeNewswire — DURING regular trading session (1h54min before 4:00 PM ET close)
  - **Apr 29 close (pre-event-window)**: $185.00 (per Investing.com Apr 29 reading)
  - **Apr 30 close (announcement-day close, includes 1h54min of post-announcement trading)**: $184.00 (per StockTitan article published Apr 30 evening with embedded "Price: $184.00" reading)
  - **Apr 30 → May 1 close (next-day reference)**: May 1 close ~$188.99 (per SoFi reading "Market Price $188.99, Change +$4.80 (2.61%)") or ~$187-190 range across other sources
  - **Three plausible event-day close-to-close measurements:**
    - Apr 29 → Apr 30 (FDA-approval-during-regular-session): $185.00 → $184.00 = **-0.54%** (FAILS 5%)
    - Apr 30 → May 1 (next-day reaction): $184.00 → $188.99 = **+2.71%** (FAILS 5%)
    - Apr 29 → May 1 (combined two-day window): $185.00 → $188.99 = **+2.16%** (FAILS 5%)
  - **All three measurements substantially below 5% threshold.** Magnitude does not clear by approximately 47-66% relative shortfall (need 5%, observed max 2.71%).
  - **May 1 premarket reference point ($208 per Benzinga 9:00 AM ET reading, +13% from Apr 30 $184)** is NOT a valid criterion 1 measurement per Strategy.md spec which requires "close-to-close move on event day". Premarket prices are not closing prices. The premarket spike faded to open ($186.91 per SoFi) and closed at $188.99 — closing prices clearly do not reach +13% from any reference point.
- **Criterion 4 — NOT evaluated** (disposition resolved at criterion 1 step). For documentation completeness: had criterion 1 cleared, criterion 4 disposition would also have failed via SBUX-style "information-priced-via-pre-event-rally" sub-pattern (pre-event analyst sentiment was overwhelmingly bullish — 20 Buy / 0 Sell, consensus PT $221-228, with multiple firms raising PTs in the preceding weeks: UBS $251→$259 Apr 10, Guggenheim $205→$220 Feb 24, TD Cowen $195→$215 Feb 23; per Trefis "stock's valuation, estimated around $9 billion, appears to have largely priced in a positive outcome for this approval"; trailing-12-mo +72% per Simply Wall St; trailing-1-month +14-15% pre-FDA-decision per Stocktwits; FDA approval was the canonical "buy the rumor, sell the news" event with information already priced).

### Why criterion 1 is the binding constraint (parallel to EQIX 2026-05-01 precedent)

Per Strategy.md criterion 1, the ≥5% close-to-close threshold is a hard mechanical gate at entry. Per the EQIX 2026-05-01 NO-GO precedent ("Daily.md morning-scan '-5%' label reflected after-hours initial reaction not regular-session close-to-close"), criterion 1 measurement requires REGULAR-SESSION CLOSING PRICES, not after-hours or premarket prices. AXSM's Daily.md "+13%" framing analogously reflected May 1 premarket activity ($208 at 9:00 AM ET pre-open per Benzinga) that did not persist to regular-session close ($188.99 per SoFi closing reading). The actual close-to-close measurements across all three plausible event-day reference windows yield magnitudes 2.71%, -0.54%, and +2.16% — all materially below the 5% threshold. **Criterion 1 fails mechanically; the criterion-4 sub-pattern flag becomes moot.**

### Effect on book

No effect. No order staged for AXSM. Strategy B remains in ACTIVATE state with two open positions (IBM, HCA) and one staged order (META Mon 5/4 gated). Strategy B sector concentration unchanged: IT 1/3 (IBM IT Services); Health Care 1/3 (HCA Health Care Facilities); Comm Services 0/3 staged → 1/3 expected on META fill; Pharmaceuticals (where AXSM would have sat) 0/3; others 0/3. Portfolio_Ledger.md not modified by this session except the "Last updated" line.

### Pending queue updated

- ~~AXSM B-thesis construction~~ COMPLETE — NO-GO declined on criterion 1 mechanical eligibility failure (close-to-close max +2.71% across all plausible event-day windows, below 5% threshold; Daily.md "+13%" reflected non-binding premarket activity).
- 10-day post-event entry window for AXSM expires ~2026-05-14 (Thu, measuring from Apr 30 announcement); no calendar event scheduled to revisit because magnitude failure is structural — would require AXSM to undergo a fresh ≥5% close-to-close move within the 10-day window driven by NEW catalyst, which itself would be a separate thesis-construction trigger meriting fresh evaluation, not re-evaluation of this session's NO-GO.
- **Note: AXSM Q1 2026 earnings print is scheduled Mon 2026-05-04 BMO** (per multiple sources). If the Q1 print produces ≥5% close-to-close on Mon 5/4, that would be a SEPARATE event triggering fresh thesis-construction (not the FDA approval event evaluated here). The 2 events are sequenced 4 days apart and would be evaluated independently per Strategy B framework. **Calendar event NOT scheduled** because the routine Daily.md scan on Tue 2026-05-05 will surface any qualifying Q1-print reaction without requiring a dedicated event.
- Sequenced sister thesis-construction sessions today: TEAM, TWLO, EL, FIVN already NO-GO; AXSM (this NO-GO); CBOE, CAT, AAPL pending evaluation.

### References

- Strategy.md (Strategy B section + criterion 1 close-to-close magnitude requirement + criterion 4 information-vs-sentiment test).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 EQIX NO-GO entry (criterion 1 mechanical failure with Daily.md after-hours-vs-regular-session measurement caveat — direct precedent template for AXSM's premarket-vs-regular-session distinction).
- Decision_Log.md 2026-04-29 SBUX NO-GO entry (information-priced-via-pre-print-rally sub-pattern — would have been the criterion-4 routing for AXSM if criterion 1 had cleared, but moot here).
- Decision_Log.md 2026-05-01 TDOC NO-GO + 2026-05-02 FIVN NO-GO entries (instrument-rule mechanical failures — different mechanical-failure category than AXSM's criterion-1 failure; demonstrates distinct mechanical-gate routing).
- Daily.md 2026-05-01 (AXSM watchlist line + KL bull-ratification flag).
- AXSM FDA approval press release 2026-04-30 14:06 ET (Axsome Therapeutics / GlobeNewswire / Stocktitan).
- Axsome Therapeutics AUVELITY FDA Approval Investor Event May 1 2026 8:00 AM ET (GlobeNewswire / BioSpace / Manila Times).
- StockTitan AXSM news article published Apr 30 evening (with embedded "Price: $184.00" reading); Benzinga "AXSM Price Action: Axsome Therapeutics shares were up 0.12% at $208.00 during premarket trading" reading; SoFi AXSM quote (Market Price $188.99, Change +$4.80 (2.61%), Daily High $190.23, Daily Low $185.77, Open $186.91, mkt cap $9.7B); Investing.com AXSM data (Apr 29 close $185.00, mkt cap $9.43B); TipRanks AXSM PT history; Trefis AXSM commentary on $9B valuation pricing in approval.

### Theater-check on this orchestrator review

(a) **Was the criterion 1 measurement methodology correct?** Yes. Strategy.md criterion 1 specifies "close-to-close move on event day". Multiple plausible event-day reference windows examined (Apr 29→Apr 30, Apr 30→May 1, Apr 29→May 1) — all yield magnitudes below 5% threshold. Premarket and after-hours measurements explicitly excluded per regular-session-closing-price methodology aligned with EQIX precedent.

(b) **Was the EQIX precedent applied correctly?** Yes. EQIX 2026-05-01 NO-GO documented criterion 1 measurement as "regular-session close-to-close" with explicit rejection of after-hours initial reaction. AXSM applies the same methodology to a premarket spike — the structural distinction (premarket vs after-hours) is irrelevant; both are non-regular-session prices and excluded from criterion 1 measurement.

(c) **Was the Daily.md "+13%" reading examined for alternative interpretations?** Yes. Daily.md "+13%" was approximately consistent with $184 → $208 = +13.04% premarket reading at Daily-scan-compile time. Did not reflect any regular-session closing price reachable from any plausible event-day reference. Routine Daily.md scan-stage premarket-data caveat would have flagged this if available; documenting this case suggests a useful refinement to the Daily-scan pre-filter to distinguish premarket-vs-regular-session magnitude in event-driven candidates.

(d) **Could the criterion 4 sub-pattern flag (KL bull-ratification) have rescued the disposition if criterion 1 had been measured differently?** No. Criterion 4 cannot rescue criterion 1 failure — they are independent gates. Even if criterion 4 had been evaluated and passed (which it would not have, per the SBUX-style information-priced-via-pre-event-rally evidence), criterion 1 mechanical failure still routes to NO-GO. Hypothetical-criterion-4-pass is moot.

(e) **Was deferral considered?** No. Criterion 1 failure is a hard mechanical gate; deferral does not apply. If a fresh ≥5% close-to-close event occurs within the 10-day entry window (e.g., on Q1 earnings print Mon 5/4), that constitutes a separate event meriting fresh thesis-construction trigger, not deferral of this NO-GO.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence.

### Compaction-survival note

**Strategy B AXSM thesis pipeline status as of 2026-05-02 Saturday mid-afternoon MT post-FIVN-session:** AXSM-thesis-construction COMPLETE; **NO-GO on criterion 1 mechanical eligibility failure** (max event-day close-to-close +2.71% across all plausible reference windows — Apr 29 $185 → Apr 30 $184 = -0.54%, Apr 30 $184 → May 1 $188.99 = +2.71%, Apr 29 $185 → May 1 $188.99 = +2.16% — all below 5% threshold; Daily.md "+13%" reflected premarket spike $208 that faded by open and closed at $188.99). Criterion 4 sub-pattern flag (positive-direction L1 information-priced-via-pre-event-rally per pre-FDA-decision sentiment $9B valuation pricing in approval per Trefis) NOT evaluated because criterion 1 fails first; would have routed to SBUX-style sub-pattern NO-GO if evaluated. EQIX precedent template direct match. No order staged. No follow-on calendar event scheduled.

**EQIX precedent extension:** AXSM is the **second** instance in the experiment of the "Daily.md scan magnitude reading reflects non-regular-session-closing price (premarket OR after-hours)" measurement caveat. EQIX 2026-05-01 was the first (after-hours -5% initial reaction did not hold to regular-session close); AXSM extends this to premarket (+13% premarket spike faded by open). **Pattern recognition refinement: future Daily.md scan-stage magnitude readings should be flagged when reference is non-regular-session, with explicit note that criterion 1 evaluation requires regular-session close-to-close measurement.** This refinement reduces thesis-construction overhead on cases where Daily-scan-stage magnitude does not survive to regular-session close.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **seventeenth** Strategy B NO-GO of the experiment (... + EL + FIVN + **AXSM**). Total experiment Strategy B dispositions to date: 3 GO + 17 NO-GO = **3 GO / 17 NO-GO (15% / 85%) hit rate**. NO-GO breakdown by criterion: **criterion 1 mechanical failure (2 — EQIX, AXSM)**; instrument-rule failure (2 — TDOC, FIVN); criterion 4 decisive failure (13). The 2 criterion-1 failures both involved Daily.md scan-stage non-regular-session measurement (after-hours for EQIX; premarket for AXSM) — operationally significant pattern.

**Strategy B sector cap usage unchanged.** Total candidates evaluated this Sat 2026-05-02 session block so far: TEAM, TWLO, EL, FIVN, **AXSM** all NO-GO (5/5); pending: CBOE, CAT, AAPL.

---

## 2026-05-02 (Sat, ~mid-afternoon MT post-AXSM-session) Strategy B thesis construction outcome — CBOE (Cboe Global Markets) NO-GO (criterion 4 decisive failure on dual-framing test — LONG framing structurally inappropriate for B's mean-reversion mechanism on a positive-reaction event; SHORT framing fails on absent mean-reversion asymmetry per SBUX-style information-priced-via-pre-print-rally sub-pattern with Piper Sandler $295→$321 PT raise on Apr 15 (16 trading days pre-print) absorbing the strong-print expectation, post-bounce $319.74 close landing AT pre-raised PT $321, and modest post-print PT raise to $330 Hold confirming sell-side fair-value-shifted-up-but-not-overshoot-direction); no order staged

**Trigger:** B-thesis construction requested for Cboe Global Markets candidate flagged Daily.md 2026-05-01 morning scan as "CBOE (Strategy B long candidate — record print + cost cut — flag bull-ratification + ATH-extension risk)" with explicit cautionary framing on bull-ratification + ATH-extension. Primary event: Q1 2026 earnings print Fri 2026-05-01 BMO. Sequenced after FIVN/AXSM NO-GOs in same session block.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude requirement; criterion 4 information-vs-sentiment test + structural-framing-mechanism check; pre-mortem rev 7 KL #2.20 textbook-rational-penalty mechanism-embedded; pre-mortem KL #7 short-side gap-up execution risk acknowledgment; short-side stop-loss at +25%); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged; sector cap usage IT 1/3 by IBM, Health Care 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, **Financials 0/3** — CBOE would push Financials to 1/3 if entered (CBOE GICS Financials / Capital Markets sub-industry)); Decision_Log.md prior precedents — META 2026-05-01 GO (mild-sell-side-reset pattern that successfully cleared criterion 4 — direct contrast for CBOE), **SBUX 2026-04-29 NO-GO (positive-direction L1 with information-priced-via-pre-print-rally — direct sub-pattern match for CBOE)**, TEAM 2026-05-02 NO-GO (valuation-reset-but-not-narrative-reset sub-pattern — different sub-pattern, post-print PT cuts vs CBOE's modest post-print PT raise to Hold rating), V 2026-04-29 NO-GO + MDLZ 2026-04-29 NO-GO (structural-overhang-persistence sub-pattern — not directly applicable to CBOE which has no comparable structural overhang); CBOE Q1 2026 8-K Ex-99 (PRNewswire / SEC EDGAR / Investor Relations); CBOE Q1 2026 earnings call transcript (Alphastreet); 24-7 Wall St. / TipRanks / TradingKey / CoinCentral / StockTitan / Coinspectator CBOE post-print coverage May 1 2026; CNN AAPL CBOE PT history (Piper Sandler $295→$321 Apr 15; Morgan Stanley $246→$273 Apr 10 maintained Sell; RBC reiterated Hold Apr 16); Daily.md 2026-05-01 (CBOE watchlist line + bull-ratification + ATH-extension flag).

### Decision

**CBOE — NO-GO (DECLINE) on dual-framing analysis. LONG framing dismissed on structural mechanism mismatch; SHORT framing dismissed on criterion 4 absent mean-reversion asymmetry per SBUX-style information-priced-via-pre-print-rally sub-pattern — Piper Sandler $295→$321 PT raise on Apr 15 (16 trading days pre-print) effectively pre-priced the strong-print expectation; post-bounce stock at $319.74 lands AT Piper's pre-raised PT; modest post-print PT raise to $330 (Hold) confirms sell-side fair-value-shifted-up-but-not-bull-ratification-overshoot-direction.**

Failed Strategy B entry criterion 4 with **SBUX-style information-priced-via-pre-print-rally sub-pattern + ATH-extension overlay**. Criterion 1 mechanically clears at +6.4% to +8.5% close-to-close (Apr 30 $300.49 → May 1 $319.74 = **+6.4%** per arithmetic; 24-7 Wall St / TradingKey reports +8.33% / +8.54% per their reference points). Instrument eligibility clears (mkt cap ~$33.5B post-bounce, ADV multi-million-shares/day).

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear)

- **Instrument rule:** CBOE = Cboe Global Markets, Inc., Cboe-listed common (US-listed); shares outstanding 104.7M (per StockTitan); pre-print mkt cap $31.8B at Apr 30 close $300.49; post-print mkt cap ~$33.5B at May 1 close $319.74 (well above $2B floor); 30-day ADV multi-million-shares/day on a S&P 500 component (well above $10M floor); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS:** Q1 2026 print event date = Fri 2026-05-01 BMO (8:30 AM ET conference call). Apr 30 close $300.49 → May 1 close $319.74 = **+6.40%** close-to-close (per arithmetic from CNN-reported $25.63 increase). Alternative measurements +8.33% per TradingKey, +8.54% per CNN ($25.63/$300.49) — both higher. Conservative arithmetic-anchored reading +6.40% clears 5% threshold by 1.28x cushion (small cushion vs TWLO/CAT/BE but still clearing). May 1 intraday ATH $321.00.
- **Criterion 5 cleared:** No A position open in CBOE (A router DO-NOT-ACTIVATE).

### Print details and entry context

- **Q1 2026 print:** Net revenue $728.9M vs $688.37M cons (+5.9% beat, +29% YoY) — RECORD; Adj EPS $3.70 vs $3.25-$3.37 cons (+10-13.8% beat, +48% YoY); GAAP diluted EPS $3.66 (+54% YoY); Derivatives revenue +32%; Index options ADV 6.1M contracts (+29% YoY); 0DTE SPX options sustained growth; Global FX +38%; Data Vantage +19%; Cash and Spot Markets declined modestly. **FY26 organic net revenue growth target RAISED:** "low double-digit to mid-teens" from "mid single-digit"; Data Vantage organic growth target: "low double-digit" from "mid to high single-digit". **Adj operating expense guide CUT:** $838-$853M from $864-$879M. **Strategic realignment EXPANDED:** ~20% workforce reduction announced (~1,670 employees), $36-46M pre-tax restructuring charges Q2-Q4 2026, $40-50M targeted annualized cost savings ($100-120M total combined with prior actions), Cboe Australia + Canada divestitures to TMX Group $300M previously announced. New product pipeline: Mini-SPX prediction market June 2026 launch.
- **Pre-print context:** CBOE was UP **35.3% trailing 12-mo** per StockTitan; pre-print Apr 30 close $300.49 was at FRESH ATH territory after sustained run; trailing-30-day rallied +18-20% per intermediate sources. **Pre-print sell-side stance was MIXED but CONSTRUCTIVE-INTO-PRINT** with multiple PT raises in the weeks leading to the print:
  - **Piper Sandler: $295 → $321 (+8.8%, rating maintained) on 2026-04-15** — 16 trading days pre-print PT raise; **stock subsequently rallied +18-20% in the trailing-30 to close at $300.49 pre-print** = AT Piper's raised PT minus ~6% (room for upside); **post-print regular-session close $319.74 = essentially AT Piper's $321 PT**
  - **Morgan Stanley: $246 → $273 (+11.0%, Sell maintained) on 2026-04-10** — pre-print PT raise but maintained bearish rating
  - **Piper Sandler (separate Apr 9 entry): $? → $293 (raised earlier in same month per CNN history)**
  - **RBC Capital: maintained Hold @ $? on 2026-04-16**
  - **Pre-print 1-month PT range $265-$355 per TradingKey**
  - **Pre-print rating distribution:** 4 Strong Buy, 11 Hold, 3 Strong Sell, 0 Sell — overall HOLD consensus per Public.com Jan 26 reading; 18 analysts per Barchart Apr 11 with mean PT $295.29 (so Piper's $321 was above-consensus pre-print)
- **Post-print sell-side response:** Per TipRanks 2026-05-01 12:55 PM ET: "**The most recent analyst rating on (CBOE) stock is a Hold with a $330.00 price target**." **PT raise of +$9 from Piper's $321 = +2.8% post-print PT raise on a Hold rating — MILD, not aggressive bull-ratification.** Multiple analyst earnings-estimate upward revisions (13 per InvestingPro). 1-month PT range per TradingKey same-day: "$305.50 average, high $355, low $265".

### LONG framing dismissed (structural-mechanism check)

A LONG thesis on CBOE would argue: stock at $319.74 trading near pre-bounce PT cluster $295-$355; record print + raised guide + cost cut + expanded buyback supports continued upside; mean-reversion to top of PT cluster $355 = +11% upside potential within 60 days. **DECISIVE STRUCTURAL FLAW:** Strategy B's mechanism is mean-reversion from sentiment-overshoot relative to event-day reaction, NOT momentum-continuation after a positive-direction event. CBOE's event-day reaction was +6.4% to +8.5% UP — arguing further upside via mean-reversion to upper PT range is structurally a momentum-continuation thesis. Same dismissal logic as BE/TEAM/TWLO/EL LONG dismissals. **LONG framing structurally inappropriate.**

### SHORT thesis examined and declined (criterion 4 SBUX-style information-priced-via-pre-print-rally sub-pattern)

**Provisional adversarial-thesis (SHORT framing).** A SHORT thesis on CBOE would argue: +6-8% reaction overshoots fundamentals (record print is real but pre-print was already at fresh ATH +35% trailing-12-mo absorbing strong-print expectation; 20% workforce cut signals demand-side concerns about future revenue trajectory; Morgan Stanley maintained Sell at $273 which sits 14% below current); ATH-extension typically faces gravity over 60 days; pre-print Hold consensus with 17% Sell ratings supports modest mean-reversion thesis.

**Adversarial counter-argument (decisive flaws on SHORT side):**

(1) **DECISIVE — SBUX-style "information-priced-via-pre-print-rally" sub-pattern.** Per SBUX 2026-04-29 NO-GO precedent, the pattern is: stock rallies into the print on positive sentiment + pre-print sell-side PT raises that absorb the strong-print expectation; post-print actual print delivers; small post-print PT moves confirm information-priced-not-overshoot disposition. CBOE's pattern matches with high fidelity:
- **Pre-print rally**: +35% trailing-12-mo and ATH-zone entry-into-print
- **Pre-print PT raises**: Piper Sandler $295 → $321 on Apr 15 (16 trading days pre-print); Morgan Stanley $246 → $273 on Apr 10 (despite Sell rating); pre-existing-trajectory of analyst-conviction-building
- **Post-print stock at $319.74 ≈ Piper's pre-raised PT $321**: stock essentially landed at the price level the most-bullish-pre-print-PT-raiser had targeted — consistent with print delivering exactly as the pre-print PT raise had implied
- **Post-print modest PT raise to $330 (Hold)**: +$9 / +2.8% from Piper's $321 — mild reset on Hold rating, NOT aggressive bull-ratification (compare BE Susquehanna +69%, TWLO BofA +73%, CAT Morgan Stanley upgrade +113% for what AGGRESSIVE-bull-ratification looks like). The post-print response is structurally a "fair-value-cluster-shift-up-by-3%" not a "fair-value-step-change ratifying overshoot to new level." Translation: sell-side classifies the +6-8% bounce as appropriately-priced-information, not sentiment-overshoot to be mean-reverted.

(2) **DECISIVE — Stock at $319.74 sits APPROXIMATELY AT post-print PT cluster anchor $321-$330.** The most-recent post-print Hold @ $330 implies +3.2% upside; Piper's pre-raised $321 implies +0.4% upside; mean within $321-$330 implies ~+2% upside. **B-SHORT mean-reversion thesis would require stock to fall to $295-300 pre-print level (-7-8%) — but the post-print PT cluster mean sits ABOVE current price by 2-3%, with no PT in the cluster below $300. No asymmetric-downside-anchor for B-SHORT.** Mirrors TEAM-NO-GO bracket logic but with the TEAM-pattern's "stock-in-PT-cluster" structure rather than the BE/TWLO-pattern's "stock-far-below-aggressive-PT-cluster" structure.

(3) **Compounding flaw: pre-mortem KL #2.20 textbook-rational-penalty trap.** Record-quarter print + raised guide + cost-cut + expanded-buyback combination is the canonical mega-rerating event that 2.20 textbook-rational mean-reversion is structurally wrong about. The +6-8% reaction reflects the market re-rating to a higher fundamental-value baseline; SHORT-mean-reversion belief = textbook-rational-trap at moderate magnitude (less extreme than BE/TWLO/CAT but still applicable).

(4) **Compounding flaw: pre-mortem KL #7 short-side gap-up execution risk.** CBOE showed a +6-8% gap-up on May 1 after a sustained +35% trailing-12-mo run; gap regime is active; KL #7 short-side stop-loss at +25% from entry would have minimal protection.

(5) **Compounding flaw: insider selling reported concurrently with positive earnings news (per TradingKey "Recent insider selling, reported concurrently with positive earnings news, could signal a lack of confidence from company executives").** Specific magnitude not retrieved this session but TradingKey flags it as confirming-but-not-decisive. Direction of insider activity is neutral-to-mildly-bearish but doesn't generate asymmetric-downside-anchor by itself.

(6) **Counter-evidence considered: Morgan Stanley Sell at $273 implies -14.6% downside.** This is the most-bearish single-firm anchor in the post-print cluster. However: (a) MS rating is unchanged from pre-print (maintained Sell), so no fresh MS-driven catalyst; (b) MS PT $273 is meaningfully below the cluster mean and would represent a SOLITARY anchor for SHORT thesis if MS were the only firm with conviction; (c) the 1 firm cluster anchor is overwhelmed by the 17 other firms in the $295-$355 range, with the post-print Hold @ $330 providing the most-recent-anchor reading. Mean-reversion thesis to MS's $273 alone fails on cluster-vote-weighted basis.

### Effect on book

No effect. No order staged for CBOE. Strategy B remains in ACTIVATE state. Strategy B sector concentration unchanged: IT 1/3 (IBM); Health Care 1/3 (HCA); Comm Services 0/3 staged → 1/3 expected on META fill; Financials 0/3 (would have been 1/3 if CBOE had cleared); others 0/3.

### Pending queue updated

- ~~CBOE B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 dual-framing failure (LONG = structural-mechanism mismatch; SHORT = SBUX-style information-priced-via-pre-print-rally sub-pattern direct match with Piper Sandler $295→$321 pre-print PT raise absorbing the strong-print expectation + post-bounce $319.74 at Piper's $321 + modest post-print Hold @ $330 mild PT raise + ATH-extension overlay).
- 10-day post-event entry window for CBOE expires ~2026-05-15 (Fri); no calendar event scheduled to revisit (criterion 4 disposition data-stable).

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 KL #2.20 / KL #7).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-04-29 SBUX NO-GO entry (information-priced-via-pre-print-rally sub-pattern direct match — CBOE extends this sub-pattern to a 2nd instance).
- Decision_Log.md 2026-05-02 TEAM NO-GO entry (post-cut-PT-bracket sub-pattern — different sub-pattern, post-print mass cuts vs CBOE's modest post-print Hold @ $330; provides contrast for SBUX-vs-TEAM-pattern distinction).
- Decision_Log.md 2026-05-01 BE NO-GO + 2026-05-02 TWLO NO-GO (positive-direction L1 cleanest precedents — different sub-pattern from CBOE; CBOE's post-print PT response is materially milder than BE/TWLO aggressive-bull-ratification).
- Daily.md 2026-05-01 (CBOE watchlist line + bull-ratification + ATH-extension flag).
- CBOE Q1 2026 8-K Ex-99.1 (PRNewswire / SEC EDGAR / CBOE Investor Relations).
- CBOE Q1 2026 earnings call transcript (Alphastreet).
- TipRanks "Cboe Global Markets Announces Major Restructuring and Cost Cuts" May 1 2026 (post-print Hold @ $330 reading).
- StockTitan / 24-7 Wall St / TradingKey / CoinCentral / Coinspectator CBOE coverage May 1 2026.
- CNN CBOE PT history (Piper Sandler $295→$321 Apr 15; Morgan Stanley $246→$273 Apr 10 maintained Sell; RBC reiterated Hold Apr 16; Piper Sandler $? → $293 earlier Apr 9).

### Theater-check on this orchestrator review

(a) **Was the SBUX precedent applied correctly?** Yes. SBUX 2026-04-29 NO-GO documented information-priced-via-pre-print-rally as: pre-print sell-side PT raises into the print + trailing-30-day rally + post-print mild PT moves. CBOE matches with high fidelity: Piper $295→$321 on Apr 15 (16 trading days pre-print, parallels SBUX's BofA $450→$605 8 days pre-print); trailing-30 rally +18-20% (parallels SBUX +18.75%); post-print Hold @ $330 = +2.8% from Piper $321 (parallels SBUX's Guggenheim +$2 mild PT response).

(b) **Was the LONG framing dismissed correctly?** Yes. Same structural-mechanism logic as prior LONG dismissals (BE/TEAM/TWLO/EL).

(c) **Could MS Sell @ $273 anchor a SHORT thesis as solitary-conviction-pivot?** Considered. Counter: pre-print MS Sell was already in place and maintained post-print; no fresh MS-driven catalyst; the 17-firm cluster $295-$355 with most-recent-Hold @ $330 overwhelms the single MS anchor. SHORT thesis on a 1-firm-anchor-against-17-firm-cluster fails cluster-vote-weighted asymmetric-downside test.

(d) **Does CBOE's 20% workforce reduction signal demand-side fragility (V/MDLZ-style structural-overhang)?** Considered. Counter: the layoff is positioned as STRATEGIC REALIGNMENT (exiting non-core Australia/Canada; resource-reallocation toward derivatives/data/event-markets) rather than DEMAND WEAKNESS. Management commentary supports realignment-driven framing. Even if interpreted as demand-fragility-signal, it would only add to the V/MDLZ-style structural-overhang sub-pattern — but CBOE's pre-print compression was NOT V/MDLZ-style (CBOE was at ATH not pre-print-compressed); so structural-overhang-already-priced argument doesn't apply. Layoffs are factored into the post-print Hold @ $330 reading.

(e) **Was deferral considered?** No. Criterion 4 disposition is structural and data-stable.

Modulo these five considerations, the orchestrator review converges on NO-GO with high confidence.

### Compaction-survival note

**Strategy B CBOE thesis pipeline status as of 2026-05-02 Saturday mid-afternoon MT post-AXSM-session:** CBOE-thesis-construction COMPLETE; **NO-GO on criterion 4 dual-framing failure** (LONG = structural-mechanism mismatch; SHORT = SBUX-style information-priced-via-pre-print-rally sub-pattern with Piper Sandler $295→$321 Apr 15 pre-print PT raise + post-bounce $319.74 at Piper's $321 + modest post-print Hold @ $330 (+2.8%) + ATH-extension + KL #2.20 / KL #7 / insider-selling compounding factors). Criterion 1 mechanically clears at +6.40% close-to-close (Apr 30 $300.49 → May 1 $319.74). No order staged. No follow-on calendar event scheduled.

**CBOE is the 2nd instance of the SBUX-style information-priced-via-pre-print-rally sub-pattern (after SBUX 2026-04-29).** The sub-pattern is now established at 2 instances and forms a third major sub-pattern alongside (i) NXPI/STX/BE/TWLO positive-direction L1 aggressive-sell-side-bull-ratification (4 instances), (ii) TEAM valuation-reset-but-not-narrative-reset (1 instance), (iii) V/MDLZ structural-overhang-persistence (2 instances), (iv) STLA in-window-binary-catalyst (1 instance), (v) NOW/CHTR negative-direction information-confirmed-by-cross-section (2 instances), (vi) EL hybrid TEAM+V/MDLZ (1 instance), and now (vii) **SBUX/CBOE information-priced-via-pre-print-rally (2 instances)**. Distinguishing the SBUX/CBOE sub-pattern from BE/NXPI/TWLO/CAT: SBUX/CBOE has MILD post-print PT raises (single-digit percent), while BE/NXPI/TWLO/CAT has AGGRESSIVE post-print PT raises (often >50% on at least one firm). The structural test is whether the post-print sell-side is RATIFYING overshoot (BE/TWLO/CAT pattern) or merely RESETTING fair-value-up-by-modest-amount (SBUX/CBOE pattern).

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **eighteenth** Strategy B NO-GO (... + AXSM + **CBOE**). Total experiment Strategy B dispositions to date: 3 GO + 18 NO-GO = **3 GO / 18 NO-GO (14% / 86%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (2 — EQIX, AXSM); instrument-rule failure (2 — TDOC, FIVN); criterion 4 decisive failure (14). Within criterion-4 NO-GO sub-patterns: aggressive-sell-side-bull-ratification / NXPI-STX-BE-TWLO sub-pattern (4); structural-overhang-persistence / V-MDLZ sub-pattern (2); in-window-binary-catalyst / STLA sub-pattern (1); valuation-reset-but-not-narrative-reset / TEAM sub-pattern (1); TEAM+V/MDLZ-hybrid / EL sub-pattern (1); **information-priced-via-pre-print-rally / SBUX-CBOE sub-pattern (2 — established at 2 instances this session)**; other criterion-4 patterns (3 — NOW, CHTR, INTC re-classified-as-precedent-for-NXPI-STX-BE-TWLO).

**Strategy B sector cap usage unchanged.** Total candidates evaluated this Sat 2026-05-02 session block so far: TEAM, TWLO, EL, FIVN, AXSM, **CBOE** all NO-GO (6/6); pending: CAT, AAPL.

---

## 2026-05-02 (Sat, ~mid-afternoon MT post-CBOE-session) Strategy B thesis construction outcome — CAT (Caterpillar) NO-GO (criterion 4 decisive failure on dual-framing test — LONG framing structurally inappropriate for B's mean-reversion mechanism on a positive-reaction event; SHORT framing fails on cleanest-and-most-extreme positive-direction L1 aggressive-sell-side-bull-ratification sub-pattern observed in experiment to date — Morgan Stanley two-notch upgrade Underweight→Equal-Weight + PT $430→$915 (+113% / +$485) EXCEEDS BE Susquehanna +69% / TWLO BofA +73% / INTC Citi-upgrade in both percentage-and-dollar magnitude, plus JPM $860→$1,125 (+31%) Overweight + Baird $940→$1,165 (+24%) Buy street-high + multiple firm post-print revisions, plus extreme +184% trailing-12-mo / +56% YTD ATH context, plus $99.5M insider selling past 90 days, plus $710M Q1 tariff cost compounding tactical-skepticism); **CAT establishes new "cleanest L1 instance" benchmark for the sub-pattern, replacing BE**; no order staged

**Trigger:** B-thesis construction requested for Caterpillar candidate flagged Daily.md 2026-05-01 morning scan as "CAT (Strategy B long candidate — but very high probability of NO-GO at thesis stage on KL aggressive-sell-side-bull-ratification + extreme +90% trailing-12-month / +56% YTD / ATH context. Thesis primarily for documentation.)" with explicit user pre-flag of NO-GO disposition expectation. Primary event: Q1 2026 earnings print Thu 2026-04-30 BMO. Sequenced after FIVN/AXSM/CBOE NO-GOs in same session block.

**Inputs:** Strategy.md Strategy B section (entry criteria 1–5; criterion 1 close-to-close magnitude; criterion 4 information-vs-sentiment test + structural-framing-mechanism check; pre-mortem rev 7 KL #2.20 textbook-rational-penalty mechanism-embedded; pre-mortem KL #7 short-side gap-up execution risk; short-side stop-loss at +25%; short-financing exit threshold 10%); AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty central B risk; 2.8 homogenization on commoditized AI strategies — CAT positioned as "industrial AI play" supplying data-center-power-generation engines); Portfolio_Ledger.md ($1,388.38 B NAV; IBM + HCA open longs; META staged; sector cap usage IT 1/3 by IBM, Health Care 1/3 by HCA, Comm Services 0/3 staged → 1/3 expected on META fill, **Industrials 0/3** — CAT would push Industrials to 1/3 if entered (CAT GICS Industrials / Construction Machinery & Heavy Trucks)); Decision_Log.md prior precedents — META 2026-05-01 GO (mild-sell-side-reset cleared criterion 4 — direct contrast for CAT), **BE 2026-05-01 NO-GO (positive-direction L1 cleanest precedent pre-CAT — CAT establishes NEW cleanest-L1-instance benchmark replacing BE)**, **NXPI 2026-04-29 + STX 2026-04-29 + TWLO 2026-05-02 NO-GOs (positive-direction L1 with aggressive sell-side bull-ratification — direct sub-pattern matches; CAT extends this to 5th instance and most extreme magnitude)**, INTC 2026-04-27 NO-GO (Citi upgrade-with-PT-raise structural template that MS CAT upgrade-with-PT-raise mirrors at greater magnitude); CAT Q1 2026 Form 8-K Ex-99 (Caterpillar IR / SEC EDGAR); CAT Q1 2026 earnings call transcript (Motley Fool / Benzinga); 24-7 Wall St "Morgan Stanley Doubles Caterpillar Price Target to $915" May 1 2026; CoinCentral / Blockonomi / GuruFocus CAT post-print coverage; Investing.com Morgan Stanley CAT upgrade note May 1 2026; Yahoo Finance / TickerNerd CAT analyst data; Daily.md 2026-05-01 (CAT watchlist line + user pre-flag of NO-GO disposition expectation).

### Decision

**CAT — NO-GO (DECLINE) on dual-framing analysis. LONG framing dismissed on structural mechanism mismatch; SHORT framing dismissed on criterion 4 cleanest-and-most-extreme positive-direction L1 aggressive-sell-side-bull-ratification sub-pattern in experiment history. CAT establishes the NEW "cleanest L1 instance" benchmark for the sub-pattern, exceeding BE on both individual-PT-raise-magnitude (MS +113% vs BE Susquehanna +69%) and rating-upgrade-vector (MS two-notch vs BE no-upgrade-just-PT-raise) and ATH-context (CAT +184% trailing-12-mo vs BE +1,400% — CAT's run is structurally more sustained-and-momentum-driven, BE's was concentrated event-driven).**

Failed Strategy B entry criterion 4 with the **NXPI/STX/BE/TWLO-style aggressive-sell-side-bull-ratification information-pricing-failure sub-pattern at maximum-magnitude observed in experiment to date**, layered with multiple compounding decisive flaws (canonical pre-mortem KL #2.20 textbook-rational-trap on momentum industrial-AI name with hyperscaler-capex-tailwind-validation; pre-mortem KL #7 short-side gap-up execution risk in active gap regime; record-magnitude $99.5M insider selling past 3 months; 44x P/E ratio extreme-premium valuation; $710M Q1 tariff cost adding tactical-but-not-strategic concern; $63B record backlog providing 5-year revenue visibility eliminating "cyclical-mean-reversion-from-overshoot" thesis; long-term sales growth target raised to 6-9% through 2030 from 5-7% structurally re-rating the entire forward earnings curve). Criterion 1 mechanically clears with very large cushion at approximately +9-10% single-event-day reaction. Instrument eligibility clears massively (mkt cap ~$410-414B post-bounce — S&P 500 mega-cap component).

### Mechanical eligibility detail (criteria 1, 5, instrument rule — all clear with extreme cushion)

- **Instrument rule:** CAT = Caterpillar, Inc., NYSE-listed common (US-listed); shares outstanding ~466M; pre-print mkt cap (Apr 29) ~$378-380B at $810-820 area; post-print mkt cap ~$410-414B at $890.11 close (massively above $2B floor); 30-day ADV multi-billion-dollars/day (massively above $10M floor); long-or-short permitted; 2% sizing $27.77; no options.
- **Criterion 1 — CLEARS with extreme cushion:** Q1 2026 print event date = Thu 2026-04-30 BMO. Pre-event Apr 29 close ~$815-820 → Apr 30 close $890.11 (per Yahoo) = approximately **+8.5-9.2%** close-to-close (Coincentral reports "nearly 10% surge to over $890 establishing unprecedented record"; Blockonomi "stock experienced a remarkable Thursday surge of nearly 10%"). Conservative arithmetic +8.5%; reported +9-10% per multiple sources. May 1 close $890.11 area, slight +0.65% per Yahoo from prior close. **Magnitude clears 5% threshold by 1.7-2x cushion.**
- **Criterion 5 cleared:** No A position open in CAT (A router DO-NOT-ACTIVATE).

### Print details and entry context

- **Q1 2026 print (Apr 30 BMO):** Revenue $17.41B vs $16.49B cons (+5.6% beat, +22% YoY); Adj EPS $5.54 vs $4.64 cons (+19.4% beat); Construction Industries revenue +38% YoY; **Power Generation revenue +41% YoY (data center demand)** — driver of bull narrative; Resource Industries margin fell 700bps to 10% on tariff costs (-500bps from tariffs alone); $710M Q1 tariff cost vs $400M PY = +$310M YoY tariff burden. **Record backlog $63B (+80% YoY)** — extraordinary visibility metric. **FY26 sales growth guide RAISED:** "low double-digit" from "5-7%" (original FY26 guide). **Long-term sales growth guide RAISED:** "6-9% through 2030" from prior "5-7% through 2030" — structural raise extending the entire forward earnings curve. Power generation capacity expansion ahead of plan; large reciprocating engines incremental capacity announced; gas turbines for hyperscale data centers.
- **Pre-print context:** CAT was UP **184% trailing-12-mo** (per Blockonomi) and **+55-56% YTD** (per Blockonomi/Yahoo); pre-print Apr 29 close ~$815-820 was at FRESH ATH territory; trailing-30-day in active gap regime per multiple gap-ups during the rally. **Pre-print sell-side stance was MIXED — CAT was a CONTRARIAN-BEARISH name pre-print** with multiple firms holding bearish positioning into the print:
  - Morgan Stanley UNDERWEIGHT @ $430 (pre-upgrade — the most-bearish single-firm anchor)
  - Pre-print median PT $689 per TickerNerd; range $380-$850 with 15 Buy / 12 Hold / 2 Sell ratings (per TickerNerd reading from before MS upgrade)
  - JP Morgan Overweight @ $860 (per pre-print update; later raised to $1,125 post-print)
  - Yahoo Finance pre-print analyst target table: "430.00 Low, 772.18 Average, 890.11 Current, 960.00" — the Yahoo reading shows current price ABOVE the average target, which is an unusual configuration suggesting either (a) PT raises hadn't fully caught up, or (b) the market was bidding ahead of consensus via momentum/AI-narrative factors

**Insider selling material:** "$99.5 million worth of shares" sold past 3 months per GuruFocus — **the largest insider-sell magnitude observed in any candidate evaluated in the experiment to date** (vs TWLO $6.3M, BE $not-disclosed, STX $46.9M previously the largest). Insider activity suggests insider-perceived-fair-value below current $890 price.

### Post-print sell-side response — CANONICAL CLEANEST-L1-INSTANCE BULL-RATIFICATION

(Multiple decisive same-day Apr 30 / May 1 PT actions documented, in descending order of magnitude:)

1. **MORGAN STANLEY: UPGRADED Underweight → Equal-Weight + PT $430 → $915 (+113.0%, +$485 PT raise)** — per multiple sources (24-7 Wall St; GuruFocus; Investing.com; Blockonomi). Analyst Angel Castillo cited "ongoing strong market execution, robust backlog, demand growth," replaced valuation methodology from "20 times 2026 estimated EPS" to "multi-growth stage discounted cash flow valuation methodology" — i.e., MS replaced its entire valuation framework, not just bumped a multiple. **This is structurally identical to the INTC 2026-04-27 NO-GO Citi-upgrade L1 template at ~3x greater magnitude on PT-raise dollar amount and ~1.6x on percentage. The $485 absolute PT raise is the LARGEST single-firm PT raise observed in the experiment to date by a substantial margin (vs prior largest BE Susquehanna $173→$293 = $120 absolute / +69%; TWLO BofA $110→$190 = $80 absolute / +73%).**

2. **JPMORGAN: $860 → $1,125 (+30.8%, Overweight maintained)** — per 24-7 Wall St "JPMorgan Chase went further, lifting its target on Caterpillar to $1,125 from $860 and reiterating an Overweight rating after calling Q1 2026 a 'resounding' beat." JPM also stated "Caterpillar's earnings should more than double by 2030" with management's margin outlook "conservative" leaving "high-growth valuation here to stay" framing.

3. **BAIRD: $940 → $1,165 (+23.9%, Buy maintained, "Fresh Pick" tag)** — per CoinCentral. **Street-high PT** at $1,165. Analyst Mig Dobre called the power generation opportunity "early innings" with "another 30% upside from current levels." Tagged Q1 as "highest order intake quarter for CAT's Resource Industries" — operational-superlative framing.

4. **9 analysts revised earnings estimates upward** per Investing.com / InvestingPro post-print.

5. **Per Blockonomi: "the consensus analyst price target currently stands near $860, remaining beneath current trading levels. This average has climbed approximately $80 since the earnings announcement."** — cluster mean shifted +$80 (+10.3%) post-print, with the high-end firms ($1,125 JPM / $1,165 Baird) driving the upper bound substantially higher.

**Why this is criterion-4-DECISIVE on SHORT framing:**

The Morgan Stanley two-notch rating upgrade (Underweight → Equal-Weight) combined with $485 PT raise is **the cleanest information-pricing-failure smoking-gun observed in the experiment to date**. Translation per the BE/NXPI/STX/TWLO precedent reasoning: "the company executed at a fundamentally higher level than our prior model assumed; we are abandoning our prior valuation methodology and ratifying a new fundamentals baseline at substantially higher fair value." The MS upgrade is structurally EVEN MORE EXTREME than BE's individual aggressive PT raises (which had no rating-upgrade component) and TWLO's BofA upgrade (which was magnitude $80 PT raise + 2-notch rating upgrade — CAT MS is $485 PT raise + 2-notch rating upgrade, so identical rating-vector but ~6x greater PT-raise magnitude).

The post-print PT cluster $915-$1,165 sits ABOVE current $890.11 by 3-31% — **no asymmetric-downside-anchor for B-SHORT**. Morgan Stanley's pre-print Underweight @ $430 (which would have been the bearish-anchor for SHORT) was abandoned with the same-day upgrade — there is now ZERO bearish anchor in the post-print PT cluster. (Compare: CBOE has Morgan Stanley Sell @ $273 still in place post-print as a bearish anchor; CAT has no equivalent. The absence-of-bearish-anchor distinguishes CAT as MORE-DECISIVE than CBOE.)

### LONG framing dismissed (structural-mechanism check)

A LONG thesis on CAT would argue: stock at $890.11 trades at $35-275 upside to post-print PT cluster $915-$1,165; record backlog + raised long-term guide + power-generation tailwind + AI-infrastructure narrative supports continued upside; mean-reversion to ~$1,000 mid-cluster within 60 days. **DECISIVE STRUCTURAL FLAW:** Strategy B's mechanism is mean-reversion from sentiment-overshoot relative to event-day reaction, NOT momentum-continuation after a positive-direction event. Same dismissal logic as BE/TEAM/TWLO/EL/CBOE LONG dismissals.

### Compounding flaw stack

(1) **DECISIVE — multi-firm aggressive sell-side bull-ratification + 2-notch rating upgrade (above).**

(2) **Compounding — pre-mortem KL #2.20 textbook-rational-penalty trap on industrial-AI momentum name.** CAT is positioned as "industrial AI play" supplying data-center-power-generation engines + critical-minerals-mining equipment. The dual-driver Q1 print (revenue +22% + record backlog +80% YoY + raised long-term guide + power-generation +41% + Construction +38%) is canonical mega-rerating that 2.20 textbook-rational mean-reversion is structurally wrong about.

(3) **Compounding — pre-mortem KL #7 short-side gap-up execution risk in active gap regime.** CAT showed +9-10% single-session gap-up on Apr 30 print after sustained +184% trailing-12-mo run; gap regime active; KL #7 short-side stop-loss at +25% from entry would have minimal protection.

(4) **Compounding — extreme P/E premium valuation (44.45x P/E per GuruFocus).** Premium-valuation factor compounds 2.20 textbook-rational-penalty trap.

(5) **Compounding — $99.5M insider selling past 3 months** (largest in experiment). Insider activity is confirming-but-not-decisive negative signal; indicates insider-perceived-fair-value below current $890.

(6) **Compounding — 2.8 homogenization on commoditized AI strategies.** "Industrial AI" thesis is widely disseminated (24-7 Wall St "Caterpillar increasingly looks like an 'industrial AI' play"); the SHORT-mean-reversion framework against the AI-narrative is the canonical 2.8 homogenization trap.

(7) **Counter-evidence considered: $710M Q1 tariff cost is a TACTICAL bearish factor.** Resource Industries margin fell 700bps to 10% on tariff costs alone. Could this support a SHORT thesis on tactical-tariff-deterioration grounds? Counter: management explicitly guided through the tariff cost in raising the FY26 sales-growth target to "low double-digit" from "5-7%" — i.e., the tariff cost was already in the post-print guide raise. Sell-side responded with MS +113% PT raise + JPM +31% + Baird +24% INCLUDING the tariff disclosure. The tariff is NOT a fresh negative-information-driver for SHORT thesis post-print.

(8) **Counter-evidence considered: stock at fresh ATH after +184% trailing-12-mo run.** Could mean-reversion-from-extreme-momentum support SHORT? Counter: same logic as BE/TWLO precedent — the +184% trailing-12-mo run is itself information-driven (record backlog growth, structural data-center-tailwind ratification, hyperscaler capex acceleration). SHORT-mean-reversion against momentum-driven-by-information-content is the canonical 2.20 trap. The ATH-context is COMPOUNDING the criterion-4-NO-GO disposition, not generating asymmetric-downside-anchor for SHORT.

### Effect on book

No effect. No order staged for CAT. Strategy B remains in ACTIVATE state. Strategy B sector concentration unchanged: IT 1/3 (IBM); Health Care 1/3 (HCA); Comm Services 0/3 staged → 1/3 expected on META fill; Industrials 0/3 (would have been 1/3 if CAT had cleared); others 0/3.

### Pending queue updated

- ~~CAT B-thesis construction~~ COMPLETE — NO-GO declined on criterion 4 dual-framing failure (LONG = structural-mechanism mismatch; SHORT = NXPI/STX/BE/TWLO direct sub-pattern match at MAXIMUM MAGNITUDE — MS two-notch upgrade + $485 PT raise is the cleanest-and-most-extreme L1 instance in experiment history; CAT establishes new benchmark replacing BE).
- 10-day post-event entry window for CAT expires ~2026-05-14 (Thu); no calendar event scheduled to revisit (criterion 4 disposition data-stable; sub-pattern-recognition-at-scan-stage is sufficient for future filtering).

### References

- Strategy.md (Strategy B section + entry criteria 1-5 + criterion 4 information-vs-sentiment test + pre-mortem rev 7 KL #2.20 / KL #7).
- AI_Trading_Foundation.md (2.4 narrative-over-fit; 2.13 ordinal-tier conviction; 2.20 textbook-rational penalty; 2.8 homogenization on commoditized AI strategies).
- Portfolio_Ledger.md (Strategy B sector cap usage; current NAV).
- Decision_Log.md 2026-05-01 BE NO-GO entry (positive-direction L1 prior-cleanest-instance — CAT supersedes BE as new cleanest-L1-benchmark).
- Decision_Log.md 2026-04-29 NXPI NO-GO + STX NO-GO + 2026-05-02 TWLO NO-GO entries (positive-direction L1 with aggressive sell-side bull-ratification — direct sub-pattern matches; CAT extends to 5th instance and most extreme magnitude).
- Decision_Log.md 2026-04-27 INTC NO-GO entry (Citi upgrade-with-PT-raise structural template that MS CAT upgrade-with-PT-raise mirrors at greater magnitude).
- Daily.md 2026-05-01 (CAT watchlist line + user pre-flag of NO-GO expectation).
- CAT Q1 2026 8-K Ex-99 (Caterpillar IR / SEC EDGAR).
- CAT Q1 2026 earnings call transcript (Motley Fool / Benzinga).
- 24-7 Wall St "Morgan Stanley Doubles Caterpillar Price Target to $915" May 1 2026.
- CoinCentral "Caterpillar (CAT) Stock Hits All-Time High After Blowout Earnings and Morgan Stanley Upgrade" May 1 2026.
- Blockonomi "Caterpillar Stock Soars to Record $890" May 1 2026.
- GuruFocus "CAT Upgraded by Morgan Stanley" May 1 2026 + "Caterpillar (CAT) Upgraded by Morgan Stanley After Strong Earnings Performance" + insider-selling magnitude $99.5M.
- Investing.com "Morgan Stanley upgrades Caterpillar stock rating on strong results" May 1 2026.
- Yahoo Finance CAT analyst target table.
- TickerNerd CAT analyst-PT history.

### Theater-check on this orchestrator review

(a) **Was the "cleanest L1 instance" claim verified against BE precedent?** Yes. BE 2026-05-01 NO-GO documented "**cleanest information-driven-pricing-failure disposition observed in the experiment to date**" with magnitude factors: JPM +16% PT raise / Susquehanna +69% PT raise / RBC PT $335 / multi-pattern overlay. CAT exceeds on multiple dimensions: MS +113% PT raise + 2-notch rating upgrade is GREATER than any single BE PT raise on magnitude (+113% vs +69% Susquehanna); MS upgrade-with-PT-raise structural template (which BE did not have); JPM +31% / Baird +24% multi-firm aggressive raises in addition to MS; absence-of-bearish-anchor post-print (Underweight abandoned) where BE did not have analogous "all-bearish-anchors-removed" event; record backlog $63B + raised long-term guide structural-multi-year-rerating that BE's quarterly-event-driven dynamics did not match. **CAT establishes new "cleanest L1 instance" benchmark; BE retains "first major instance of strategic-customer-win + Q1-mega-beat overlay" benchmark for that specific feature.**

(b) **Was the user's "+90% trailing-12-mo" framing reconciled?** Yes. The user's "+90% trailing-12-mo" was inconsistent with the actual data (+184% per Blockonomi / +190.92% per Yahoo). The actual trailing-12-mo magnitude is approximately 2x the user's pre-flag estimate, making the disposition direction (NO-GO) MORE decisive than the user pre-flagged, not less. User pre-flag and actual disposition converge.

(c) **Was the absence-of-bearish-anchor structural feature examined?** Yes. Post-print PT cluster has no bearish-rating anchor (MS abandoned Underweight + raised PT to $915; remaining cluster is $915-$1,165 with mean ~$960; no firm in cluster below $915). Compare: CBOE has MS Sell @ $273 still active post-print; BE retained some pre-existing-Underweight-positioning per available data; CAT is the cleanest "all-bearish-anchors-removed" event, distinguishing it as MORE-DECISIVE-than-prior-precedents.

(d) **Was deferral considered?** No. Criterion 4 disposition is structural and data-stable.

(e) **Could the $710M Q1 tariff cost rescue a SHORT thesis on tactical-tariff-deterioration grounds?** Considered. Counter: tariff cost was already factored into the post-print guide raise + sell-side PT cluster shift. No fresh tariff-driven asymmetric-downside-anchor.

Modulo these five considerations, the orchestrator review converges on NO-GO with maximum confidence — this is the cleanest-and-most-extreme positive-direction L1 NO-GO disposition observed in the experiment to date.

### Compaction-survival note

**Strategy B CAT thesis pipeline status as of 2026-05-02 Saturday mid-afternoon MT post-CBOE-session:** CAT-thesis-construction COMPLETE; **NO-GO on criterion 4 cleanest-and-most-extreme positive-direction L1 sub-pattern in experiment history** (MS Underweight → Equal-Weight upgrade + PT $430→$915 = +113%/+$485 raise EXCEEDS BE Susquehanna +69% / TWLO BofA +73% on both percent and dollar magnitude; +$485 is the largest single-firm PT raise in experiment to date; JPM $860→$1,125 +31% Overweight + Baird $940→$1,165 +24% Buy street-high; absence-of-bearish-anchor post-print; +184% trailing-12-mo / +56% YTD ATH context; $99.5M insider selling 3-mo; 44x P/E premium valuation; canonical KL #2.20 + KL #7 + 2.8 trap configurations). Criterion 1 mechanically clears with very large cushion at +9-10% close-to-close (Apr 29 ~$815 → Apr 30 $890.11). No order staged. No follow-on calendar event scheduled.

**CAT establishes the NEW "cleanest L1 instance" benchmark for the positive-direction L1 aggressive-sell-side-bull-ratification sub-pattern, replacing BE.** The sub-pattern is now well-established at 5 instances (NXPI, STX, BE, TWLO, **CAT**); **future B SHORT candidates with similar structural features (multi-firm aggressive PT raises with at least one rating-level upgrade or PT raise >+30% / >+$50, ATH-zone entry-into-print, fundamental record-backlog or record-guide raise, absence-of-or-removal-of-bearish-anchors) should be classified NO-GO under the CAT/BE/NXPI/STX/TWLO sub-pattern via Daily.md scan-stage pattern recognition without requiring full thesis-construction depth.** Future candidates with PARTIAL features (e.g., PT raise <+30% on a single firm, ATH but no record-backlog, etc.) merit hybrid-pattern evaluation via SBUX/CBOE-style milder sub-pattern.

**Pre-mortem 2.20 / textbook-rational-penalty calibration update:** This NO-GO is the **nineteenth** Strategy B NO-GO (... + CBOE + **CAT**). Total experiment Strategy B dispositions to date: 3 GO + 19 NO-GO = **3 GO / 19 NO-GO (14% / 86%) hit rate**. NO-GO breakdown by criterion: criterion 1 mechanical failure (2 — EQIX, AXSM); instrument-rule failure (2 — TDOC, FIVN); criterion 4 decisive failure (15). Within criterion-4 NO-GO sub-patterns: **aggressive-sell-side-bull-ratification / NXPI-STX-BE-TWLO-CAT sub-pattern (5 instances — established at 5 instances, well above 1-precedent-shadow threshold; CAT is new cleanest)**; structural-overhang-persistence / V-MDLZ sub-pattern (2); in-window-binary-catalyst / STLA sub-pattern (1); valuation-reset-but-not-narrative-reset / TEAM sub-pattern (1); TEAM+V/MDLZ-hybrid / EL sub-pattern (1); information-priced-via-pre-print-rally / SBUX-CBOE sub-pattern (2); other criterion-4 patterns (3 — NOW, CHTR, INTC re-classified-as-precedent-for-NXPI-STX-BE-TWLO-CAT — INTC was the structural-template instance, predating the 4 subsequent instances).

**Strategy B sector cap usage unchanged.** Total candidates evaluated this Sat 2026-05-02 session block so far: TEAM, TWLO, EL, FIVN, AXSM, CBOE, **CAT** all NO-GO (7/7); pending: AAPL.

---

## 2026-05-02 (Sat, ~late afternoon MT post-AAPL-session) Session-end consolidation for the Sat 2026-05-02 thesis-construction cohort — full Daily.md 2026-05-01 candidate cohort evaluated (8 of 8 NO-GO across TEAM/TWLO/EL/FIVN/AXSM/CBOE/CAT/AAPL); zero orders staged; zero portfolio-state changes; sub-pattern taxonomy refined with 3 new sub-patterns established this session block (TEAM valuation-reset-but-not-narrative-reset; EL TEAM+V/MDLZ-hybrid; CAT new cleanest-L1-instance benchmark replacing BE; CBOE 2nd instance of SBUX-style information-priced-via-pre-print-rally); experiment Strategy B totals advance to 3 GO / 19 NO-GO (14% / 86%); Strategy A first router-gate-failure precedent established with AAPL

**Trigger:** Session-end consolidation for the Sat 2026-05-02 Strategy B (and Strategy A AAPL secondary) thesis-construction cohort, aggregating 8 candidate dispositions across two sequential session blocks (block 1: TEAM/TWLO/EL completed earlier in day; block 2: FIVN/AXSM/CBOE/CAT/AAPL completed in this latter half). Standard session-bookend cadence per BE 2026-05-01 + EQIX/STLA/META 2026-05-01 + 2026-04-29 batch consolidation precedents.

**Aggregate session-block dispositions:**

| Candidate | Strategy | Disposition | Mechanical-failure category | Sub-pattern (if criterion 4) |
|-----------|----------|-------------|----------------------------|------------------------------|
| TEAM | B | NO-GO | criterion 4 dual-framing | Valuation-reset-but-not-narrative-reset (NEW; 1st instance) |
| TWLO | B | NO-GO | criterion 4 dual-framing | NXPI-STX-BE-TWLO positive-direction L1 aggressive bull-ratification (4th instance) |
| EL | B | NO-GO | criterion 4 dual-framing | TEAM+V/MDLZ-hybrid (NEW; 1st instance) |
| FIVN | B | NO-GO | instrument-rule mkt-cap (TDOC precedent; 2nd instance) | N/A |
| AXSM | B | NO-GO | criterion 1 close-to-close (EQIX precedent; 2nd instance — premarket-vs-regular-session) | N/A |
| CBOE | B | NO-GO | criterion 4 dual-framing | SBUX-style information-priced-via-pre-print-rally (2nd instance) |
| CAT | B | NO-GO | criterion 4 dual-framing | NXPI-STX-BE-TWLO-CAT positive-direction L1 aggressive bull-ratification (5th instance; **NEW cleanest-L1-instance benchmark replacing BE**) |
| AAPL | A | NO-GO | router-gate (Strategy A DO-NOT-ACTIVATE; 1st instance) | N/A |

**Aggregate metrics this session block (2026-05-02):**
- 8 candidates evaluated (full Daily.md 2026-05-01 cohort)
- 8 NO-GOs / 0 GOs / 0 deferrals
- Criterion 4 NO-GO sub-pattern distribution: 5 instances (TEAM 1, TWLO 1, EL 1, CBOE 1, CAT 1)
- Mechanical-failure NO-GO distribution: 3 instances (FIVN instrument-rule, AXSM criterion 1, AAPL A router-gate)
- 3 NEW sub-patterns established or refined (TEAM, EL hybrid, CAT new cleanest-benchmark)
- 1 sub-pattern advanced from 1 → 2 instances (SBUX-CBOE)
- 1 sub-pattern advanced from 4 → 5 instances (NXPI-STX-BE-TWLO-CAT)
- 1 first-instance precedent (AAPL Strategy A router-gate)
- Zero orders staged; zero Portfolio_Ledger state changes; zero new calendar events

**Cumulative experiment Strategy B totals (post-session-block):**
- 3 GO (IBM 2026-04-25, HCA 2026-04-27, META 2026-05-01-staged-Mon-5/4)
- 19 NO-GO (NOW + CHTR + INTC + SBUX + V + NXPI + STX + MDLZ + OMCL + EQIX + STLA + BE + TDOC + TEAM + TWLO + EL + FIVN + AXSM + CBOE + CAT)

Wait, that's 20 not 19. Let me recount... NOW (1) + CHTR (2) + INTC (3) + SBUX (4) + V (5) + NXPI (6) + STX (7) + MDLZ (8) + OMCL (9) + EQIX (10) + STLA (11) + BE (12) + TDOC (13) + TEAM (14) + TWLO (15) + EL (16) + FIVN (17) + AXSM (18) + CBOE (19) + CAT (20). **20 NO-GO**. Total: 3 GO + 20 NO-GO = 23 dispositions; rate **3 GO / 20 NO-GO (13% / 87%)**. Earlier compaction-survival notes incorrectly counted; this session-end consolidation provides the corrected count.

- Cumulative experiment Strategy A totals: 0 GO / 1 router-gate-NO-GO (AAPL); A book empty
- Cumulative experiment Strategy C totals: HYBRID-FOMC-only state, no current FOMC catalyst in 60-day window
- Cumulative experiment Strategy D totals: 1 GO (RTX), N NO-GOs across LLY/GOOGL/GEV/etc per prior Decision_Log
- Cumulative experiment Strategy E totals: DO-NOT-ACTIVATE; book empty

**Sub-pattern taxonomy as of session-end 2026-05-02:**

(Strategy B criterion 4 NO-GO sub-patterns; total 15 instances across 7 distinct sub-patterns; total criterion-4 NO-GOs 16 — small discrepancy due to multi-pattern overlay cases counted under primary pattern):

1. **Aggressive-sell-side-bull-ratification / NXPI-STX-BE-TWLO-CAT** (5 instances; **CAT is new cleanest-L1-benchmark**): NXPI 2026-04-29, STX 2026-04-29, BE 2026-05-01, TWLO 2026-05-02, CAT 2026-05-02
2. **Structural-overhang-persistence / V-MDLZ** (2 instances): V 2026-04-29, MDLZ 2026-04-29
3. **Information-priced-via-pre-print-rally / SBUX-CBOE** (2 instances; established at 2 this session block): SBUX 2026-04-29, CBOE 2026-05-02
4. **Negative-direction information-confirmed-by-cross-section / NOW-CHTR** (2 instances): NOW 2026-04-25, CHTR 2026-04-27
5. **In-window-binary-catalyst / STLA** (1 instance): STLA 2026-05-01
6. **Valuation-reset-but-not-narrative-reset / TEAM** (NEW; 1 instance): TEAM 2026-05-02
7. **TEAM+V/MDLZ-hybrid / EL** (NEW; 1 instance): EL 2026-05-02
8. Other (3 instances — INTC re-classified-as-precedent-for-NXPI-STX-BE-TWLO-CAT; OMCL miscellaneous; unclear residuals)

(Strategy B mechanical-failure NO-GO categories):

1. **Criterion 1 mechanical failure** (2 instances): EQIX 2026-05-01 (after-hours-not-regular-session reading), AXSM 2026-05-02 (premarket-not-regular-session reading)
2. **Instrument-rule mkt-cap failure** (2 instances): TDOC 2026-05-01 ($1.07B mkt cap), FIVN 2026-05-02 ($1.65-1.72B mkt cap)
3. (Strategy A) **Router-gate failure** (1 instance): AAPL 2026-05-02 (Strategy A DO-NOT-ACTIVATE; first instance of A router-gate disposition)

### Pending queue updated (post-session-end-consolidation)

- ~~Sat 2026-05-02 thesis-construction cohort~~ COMPLETE (8/8 evaluated, all NO-GO).
- Strategy A watchlist (queued for next M1 router flip): CAT, LLY, QCOM, **AAPL** (4 names — AAPL added this session per pattern; queue purpose is re-evaluation when A router activates with then-current upcoming-catalyst).
- Strategy B open positions: IBM (entry 2026-04-27 @ $230.17, target $245, time-exit 2026-06-26), HCA (entry 2026-04-28 @ $433.46, target $442.85, time-exit 2026-06-27), META staged Mon 2026-05-04 (limit BUY 0.0454 @ $615.00 day order, gated on 09:15 MT Funds-on-Hold verification).
- Strategy D open positions: RTX (entry 2026-04-27 @ $175.12, no time-exit, LTCG date 2027-04-28).
- IBKR Funds-on-Hold $2,500 anomaly remains DEFERRED pending next routine session screenshot check (per Decision_Log 2026-04-28 entry); conservative branch did not engage this session block as no order staging was attempted.
- HCA invalidation-window checkpoint late June (per Decision_Log 2026-04-27 HCA staging entry; criteria (iii) THC and (iv) UHS already cleared/not-triggered per Decision_Log 2026-04-30 + 2026-04-27 entries; remaining live invalidation hooks are (i) HCA 8-K reducing FY26 guide and (ii) HCA pre-announcement/negative-business-update — both monitored via routine Daily.md scan cadence).
- AXSM Q1 earnings print scheduled Mon 2026-05-04 BMO — separate event from FDA approval evaluated this session; routine Daily.md scan Tue 2026-05-05 will surface any qualifying ≥5% reaction without dedicated calendar event.
- HCA time-based exit 2026-06-27 (entry + 60 days from Apr 28).
- IBM time-based exit 2026-06-26 (entry + 60 days from Apr 27).

### References

- Decision_Log.md 2026-05-02 entries: TEAM NO-GO, TWLO NO-GO, EL NO-GO, FIVN NO-GO, AXSM NO-GO, CBOE NO-GO, CAT NO-GO, AAPL NO-GO (this session block, 8 entries).
- Decision_Log.md 2026-05-01 entries: META GO, EQIX NO-GO, STLA NO-GO, BE NO-GO, TDOC NO-GO, CAT-LLY-QCOM Strategy A acknowledgment, session-end consolidation, Calendar reconciliation (precedent-context for this session block).
- Decision_Log.md 2026-04-29 entries: SBUX NO-GO, V NO-GO, NXPI NO-GO, STX NO-GO, MDLZ NO-GO, OMCL NO-GO (sub-pattern precedents for criterion 4 routing in this session block).
- Decision_Log.md 2026-04-27 entries: IBM GO, HCA GO, INTC NO-GO (sub-pattern templates).
- Decision_Log.md 2026-04-25 entries: IBM thesis construction, NOW NO-GO (initial precedents).
- Strategy.md (entry criteria reference for all dispositions).
- Regime_State.md (router state reference for AAPL Strategy A disposition).
- Daily.md 2026-05-01 (full candidate cohort source).

### Theater-check on session-end consolidation

(a) **Were all 8 candidates from Daily.md 2026-05-01 cohort evaluated?** Yes. 8 of 8: TEAM, TWLO, EL (block 1 morning); FIVN, AXSM, CBOE, CAT, AAPL (block 2 afternoon).

(b) **Are the sub-pattern taxonomy refinements internally consistent?** Yes. Each criterion-4 NO-GO is classified under a primary sub-pattern with secondary-overlay notes where applicable. The aggregate-vs-cumulative-counts reconciled in this consolidation entry (correcting earlier session-step compaction notes).

(c) **Were the GO-rate trends documented?** Yes. Strategy B advances from 3 GO / 12 NO-GO (20%/80%) at start of 2026-05-02 to 3 GO / 20 NO-GO (13%/87%) at end of session block. **8 sequential NO-GOs in a single session block is the largest such streak in experiment history.** This is consistent with the Strategy B pre-mortem rev 7 KL #1 framing that "B's mechanism IS the textbook-rational instinct" (2.20 textbook-rational-penalty central exposure) — the funnel surfaces more information-driven-repricing setups than sentiment-overshoot setups in the current regime, which is the structural design feature that produces high NO-GO rates.

(d) **Were any sub-pattern recognition refinements added to support future Daily.md scan-stage filtering?** Yes:
- **Premarket-vs-regular-session magnitude flag** (AXSM precedent): future Daily.md scan-stage magnitude readings should be flagged when reference is non-regular-session, with explicit note that criterion 1 evaluation requires regular-session close-to-close measurement.
- **Mkt-cap-borderline pre-filter** (TDOC + FIVN precedent): Daily.md scan-stage should pre-verify mkt cap ≥$2B before flagging as B candidate.
- **Aggressive-bull-ratification 30%-PT-raise threshold** (NXPI/STX/BE/TWLO/CAT pattern): post-print PT raise of >30% on any single firm with rating-level upgrade or rating-maintained-aggressive PT raise is a high-signal indicator of NXPI-STX-BE-TWLO-CAT sub-pattern; can route to NO-GO at scan stage without full thesis-construction depth.

(e) **Was the 30-trade-gate review topic re-flagged?** Per BE 2026-05-01 + STX 2026-04-29 compaction-survival notes, the 30-trade-gate review was flagged at criterion-4-NO-GO-rate-persistence threshold. Current state: 16 criterion-4-NO-GO instances across 23 total Strategy B dispositions = 70% rate routing through criterion 4. **The 30-trade gate has not been triggered yet (need 30 closed positions, current 0 closed)** — the criterion-4 disposition rate observation remains as ongoing-monitoring-flag for when the 30-trade gate fires (well in the future given current trade frequency).

### Compaction-survival note

**Sat 2026-05-02 session block status as of late afternoon MT:** Full Daily.md 2026-05-01 candidate cohort thesis-construction COMPLETE (8/8 NO-GO across TEAM/TWLO/EL/FIVN/AXSM/CBOE/CAT/AAPL); zero orders staged; zero portfolio-state changes. **3 sub-patterns refined or established this block (TEAM new "valuation-reset-but-not-narrative-reset"; EL new "TEAM+V/MDLZ-hybrid"; CAT new cleanest-L1-instance replacing BE).** **2 mechanical-failure precedents extended (FIVN 2nd instrument-rule failure after TDOC; AXSM 2nd criterion-1 failure after EQIX).** **1 first-instance precedent (AAPL Strategy A router-gate).** **1 sub-pattern advanced 1→2 instances (SBUX-CBOE information-priced-via-pre-print-rally).** **1 sub-pattern advanced 4→5 instances (NXPI-STX-BE-TWLO-CAT aggressive-bull-ratification, with CAT exceeding BE on cleanest-L1-instance benchmark).**

**Cumulative experiment-state post-session:**
- Strategy A: 0 GO / 1 router-gate-NO-GO; book empty; A-watchlist 4 names (CAT, LLY, QCOM, AAPL).
- Strategy B: 3 GO / 20 NO-GO (13% / 87%); book has IBM + HCA open; META staged Mon 5/4 gated. Sector cap usage IT 1/3, Health Care 1/3, Comm Services 0/3 staged → 1/3 expected on META fill, others 0/3.
- Strategy C: HYBRID-FOMC-only; no current FOMC catalyst in 60-day window.
- Strategy D: 1 GO (RTX) + multiple NO-GOs per prior Decision_Log; no new D activity this session block.
- Strategy E: DO-NOT-ACTIVATE; book empty.
- Funds-on-Hold $2,500 anomaly remains DEFERRED to next routine session screenshot check.
- 14 trade-related [Claude] calendar events visible 2026-05-04 through 2026-10-01 (per 2026-05-01 calendar reconciliation entry; unchanged this session block).

**Future Daily-scan-driven thesis-construction cadence:** Routine Daily.md scan continues at standard cadence (typically morning post-market-open, processing prior-day prints + overnight news + same-morning prints). The next Daily scan covering Mon 2026-05-04 trading session would surface (a) META staged-order execution + fill capture, (b) AXSM Q1 earnings print (separate event from this session's FDA approval evaluation), (c) any other Mon prints meeting Daily-scan candidate filters (CHTR Q1 expected within 1-2 weeks per Daily.md 2026-05-01 watchlist note; BRK annual meeting Sat 2026-05-02 commentary potentially moving BRK-correlated sectors Mon open). No specific calendar events scheduled for these — handled via routine Daily.md cadence per operator-confirmed protocol.

---

## 2026-05-02 (Sat, ~late afternoon MT post-session-end-consolidation) Calendar reconciliation against current Decision_Log + Portfolio_Ledger state — zero deletions, zero updates, zero creations (calendar already aligned with current state per 2026-05-01 reconciliation execution); 20 trade-related [Claude] events confirmed current Mon 2026-05-04 through Thu 2026-10-01

**Trigger:** D2 Calendar Hygiene prompt per Claude_Task_Plan.md following session-end consolidation. Reconcile Google Calendar against current Decision_Log + Portfolio_Ledger + Strategy.md state. Per Claude_Task_Plan.md line 3 + line 71 policy: only quarterly and annual recurring events get calendar reminders for Claude_Task_Plan.md prompts (D1, D2, W1-W3, M1-M4 cadence prompts execute automatically without reminders); all event-specific prompts (fill captures, position checkpoints, re-screens, etc.) get calendar reminders.

**Inputs:** /mnt/project/Claude_Task_Plan.md (cadence policy + D2 calendar hygiene prompt); /mnt/project/Strategy.md (entry criteria + activation rules); /mnt/project/Regime_State.md (router state); /mnt/project/Portfolio_Ledger.md (open positions + staged orders); /mnt/project/Decision_Log.md (this session's 8 NO-GO entries + session-end consolidation + prior calendar reconciliation entry 2026-05-01); Google Calendar list_events query Sat 2026-05-02 → end-2026 (20 events returned).

### Decision

**Calendar reconciliation outcome: ZERO changes needed.** All 20 [Claude] trade-related events visible in calendar Mon 2026-05-04 through Thu 2026-10-01 are current, correctly-timed, and correctly-configured (fire-at-event-time popup notifications). Today's session-block dispositions (8 NO-GOs) produced ZERO new calendar event needs: criterion-4 dispositions are data-stable; mechanical-failure dispositions (instrument-rule for FIVN, criterion-1 for AXSM) require no follow-up; AAPL Strategy A router-gate disposition routes to watchlist queue (handled via Daily-scan-driven router-state-transition surfacing, not a dedicated calendar event); no current calendar events resolved or invalidated by today's session.

### Calendar inventory verified current

**Strategy B / META workflow (4 events, all correct popup-at-0):**
1. Mon 2026-05-04 09:15 MT — META pre-execution Funds-on-Hold gate
2. Mon 2026-05-04 14:30 MT — META fill capture screenshot
3. Mon 2026-06-01 10:00 MT — META mid-window thesis pulse-check (also encompasses META criterion (i) capex-trigger monitoring per Daily.md 2026-05-01 data-gap flag)
4. Thu 2026-07-02 10:00 MT — META 60-day time-based exit checkpoint

**Strategy D re-screens (8 events, all calendar-default popup-at-0):**
5. Wed 2026-05-06 09:00 MT — CCJ post-Q1 print check (May 5 print)
6. Thu 2026-05-07 09:00 MT — DIS post-Q2 FY26 print check (May 6 print)
7. Fri 2026-05-08 09:00 MT — VST post-Q1 print check (May 7 print)
8. Tue 2026-05-12 09:00 MT — CEG post-Q1 print check (May 11 print)
9. Wed 2026-05-13 08:00 MT — D long-list interim re-screen (24-candidate broaden-emphasis)
10. Fri 2026-05-22 07:30 MT — GEV trailing-30-day re-screen
11. Mon 2026-06-01 09:00 MT — BA roll-off check
12. Fri 2026-06-12 09:30 MT — LLY mechanical re-screen

**Strategy B IBM/HCA exits (2 events, all calendar-default popup-at-0):**
13. Fri 2026-06-26 09:25 MT — IBM 60-day exit / convergence
14. Mon 2026-06-29 09:25 MT — HCA 60-day exit / convergence (also encompasses HCA invalidation-window late-June monitoring per Decision_Log 2026-04-30 entry — criteria (iii) THC and (iv) UHS already cleared/not-triggered; remaining live hooks (i) FY26 guide and (ii) pre-announcement monitored via routine Daily.md scan cadence)

**Quarterly recurring (6 instances visible, 3 prompts × Q3 + Q4 instances, all calendar-default popup-at-0):**
15. Wed 2026-07-01 09:00 MT — Q1 Quarterly Regime Retrospective (Jul 1 instance)
16. Wed 2026-07-01 10:30 MT — Q2 Quarterly D Long-Horizon Candidates (Jul 1 instance)
17. Wed 2026-07-01 12:00 MT — Q3 Quarterly AI Foundation Delta (Jul 1 instance)
18. Thu 2026-10-01 09:00 MT — Q1 Quarterly Regime Retrospective (Oct 1 instance)
19. Thu 2026-10-01 10:30 MT — Q2 Quarterly D Long-Horizon Candidates (Oct 1 instance)
20. Thu 2026-10-01 12:00 MT — Q3 Quarterly AI Foundation Delta (Oct 1 instance)

**Notification configuration verified:** Calendar default reminders are `[{"method":"popup","minutes":0}]` (popup at minute 0 = event-time). Events with explicit `overrideReminders` (META 4-event series) explicitly set `[{"method":"popup","minutes":0}]`. Events without overrideReminders inherit the calendar default — also popup-at-minute-0. **All 20 events fire popup-at-event-time per Claude_Task_Plan.md D2 specification.**

### What was NOT created (and why)

This session's 8 NO-GO dispositions produced ZERO new event needs. Documenting rationale per disposition:

- **TEAM/TWLO/EL/CBOE/CAT NO-GO (criterion 4 dual-framing failures):** Data-stable dispositions; sub-pattern recognition at Daily.md scan stage handles future similar candidates without per-name follow-up events. Decision_Log compaction-survival notes provide future-Claude triage hints.
- **FIVN NO-GO (instrument-rule mechanical eligibility failure):** Mkt cap $1.65-1.72B below $2B floor — would require sustained organic rally above $26.10 (+21% from current) for re-evaluation; that itself would be a separate fresh-catalyst trigger surfaced via routine Daily.md scan, not a scheduled event.
- **AXSM NO-GO (criterion 1 mechanical eligibility failure on premarket-vs-regular-session distinction):** Magnitude failure structural; future fresh ≥5% close-to-close move within 10-day window (e.g., Q1 print Mon 2026-05-04 BMO) would be SEPARATE event triggering fresh thesis-construction, not deferred re-evaluation. Routine Daily.md scan Tue 2026-05-05 surfaces any qualifying Q1 reaction.
- **AAPL NO-GO (Strategy A router-gate failure):** A router state DO-NOT-ACTIVATE per Regime_State.md; Strategy A entries blocked at gate. AAPL added to A-watchlist queue (CAT, LLY, QCOM, AAPL = 4 names). Watchlist re-evaluation triggered by router state transition surfaced via Daily.md scan + M1 monthly review cadence — neither requires a dedicated calendar event.

### Daily.md 2026-05-01 data-gap items absorbed into existing event coverage

- **Funds-on-Hold $2,500 anomaly verification:** absorbed into Mon 2026-05-04 09:15 MT META pre-execution gate event (event #1).
- **Exact May 1 closing prices (IBM/HCA/RTX) precision verification:** handled via routine Daily.md scan cadence (D1 prompt; auto-execution, no event needed).
- **May 1 SPDR-sector ETF closes:** handled via routine Daily.md scan cadence.
- **FIVN exact mkt-cap relative to $2B floor:** RESOLVED this session ($1.65B post-close, $1.72B intraday-high; both below floor; NO-GO confirmed).
- **META Q2'26 capex/expense actuals (criterion (i) capex top-of-range $145B trigger boundary):** absorbed into Mon 2026-06-01 10:00 MT META mid-window pulse-check event (event #3) which explicitly re-verifies invalidation criteria.
- **CHTR Q1'26 print date (within 1-2 weeks):** handled via routine Daily.md scan cadence; CHTR is "no-change watchlist" per Daily.md 2026-05-01 RECOMMENDED ACTIONS — no event needed.
- **BRK annual meeting Saturday May 2 commentary risk for Monday open:** absorbed into Mon 2026-05-04 09:15 MT META pre-execution gate session (which would naturally absorb any market-moving overnight commentary affecting Funds-on-Hold or open-position behavior) AND routine Daily.md scan post-Mon-close (D1 auto-execution).

### Theater-check on this calendar reconciliation

(a) **Were any potentially-active events missed?** Reviewed all 20 events: all future-dated, all reference Decision_Log entries that remain active, all align with current Portfolio_Ledger position state. Per-event verification against current Decision_Log entries confirms each event's trigger condition remains potentially-active (no resolved-and-not-yet-deleted obsolete events).

(b) **Is the "zero new events" outcome correct given today's 8 NO-GO dispositions?** Yes. Per protocol in compaction-survival notes for each disposition, criterion-4 dispositions are data-stable (no per-name follow-up events warranted; sub-pattern recognition at scan stage handles future similar candidates), and mechanical-failure dispositions (FIVN instrument-rule, AXSM criterion-1) route to NO-GO without follow-up event needs. AAPL A-router-gate routes to watchlist queue handled via Daily-scan transition-surfacing.

(c) **Is the notification configuration correctly fire-at-event-time?** Yes. Calendar default `[{"method":"popup","minutes":0}]` + META 4-event explicit override `[{"method":"popup","minutes":0}]` both produce popup-at-minute-0 (event-time). All 20 events configured correctly per Claude_Task_Plan.md D2 specification.

(d) **Are quarterly + annual recurring Claude_Task_Plan.md prompts on calendar (per policy)?** Yes — Q1 (Regime Retrospective), Q2 (D Candidates), Q3 (AI Foundation Delta) are present as recurring events with Jul 1 and Oct 1 instances visible. A1 (AI Foundation Annual Re-Derivation) and A2 (Per-Strategy Constraint Audit) are annual cadence — first scheduled instance would be in 2027 (annual cadence not yet triggered in this experiment year). No need to create A1/A2 events yet; will be created when their first scheduled instance approaches.

(e) **Are daily/weekly/monthly recurring Claude_Task_Plan.md prompts NOT on calendar (per operator-automatic execution)?** Yes — D1 (Daily Market Development Scan), D2 (Calendar Hygiene), W1 (Catalyst Calendar), W2 (Post-Event Screen), W3 (Open-Position Deep-Dive), M1 (Fundamental and Macro), M3 (E Pair Divergence Screen), M4 (D Position Deep-Dive) all execute on operator-automatic cadence without calendar events. Verified: no daily/weekly/monthly recurring [Claude] events present in calendar.

Modulo these five considerations, the orchestrator review converges on zero calendar changes with high confidence.

### Compaction-survival note

**Calendar state as of 2026-05-02 Saturday late afternoon MT (post-session-end-consolidation):** 20 trade-related [Claude] events visible Mon 2026-05-04 through Thu 2026-10-01; ZERO calendar changes this session-block reconciliation; calendar already aligned with current state per 2026-05-01 reconciliation execution + this session's 8 NO-GOs producing no new event needs. All 20 events configured popup-at-minute-0 (event-time) per Claude_Task_Plan.md D2 specification.

**Calendar coverage by category (post-reconciliation):**
- Strategy B META workflow: 4 events (gate Mon 5/4, fill Mon 5/4, mid-window Mon 6/1, exit Thu 7/2)
- Strategy B IBM/HCA exits: 2 events (IBM Fri 6/26, HCA Mon 6/29)
- Strategy D re-screens: 8 events (CCJ Wed 5/6, DIS Thu 5/7, VST Fri 5/8, CEG Tue 5/12, D-long-list Wed 5/13, GEV Fri 5/22, BA Mon 6/1, LLY Fri 6/12)
- Quarterly recurring: 6 events (Q1/Q2/Q3 × Jul 1 + Oct 1 instances)
- Daily/Weekly/Monthly cadence Claude_Task_Plan.md prompts: NOT on calendar (auto-execution per operator-confirmed protocol)
- Annual A1/A2 prompts: NOT yet scheduled (annual cadence first triggers in 2027)

---

## 2026-05-03 (Sun, ~late afternoon MT, follow-on) Decision-log lifecycle architecture decision — Claude_Task_Plan.md modified to add file-conventions/read-access-scope section, W4 Decision Log Hygiene weekly prompt, and per-prompt scope-bounds language; Decision_Log.md/Archive/Sub-Pattern-Taxonomy three-tier structure designed; first archive cut deferred to first scheduled W4 run

**Trigger:** Operator question about whether Decision_Log.md grows indefinitely surfaced an unaddressed scaling concern. Decision_Log.md currently 5,495 lines / ~999KB after this session's prior weekend-scan + HCA exit-date-correction entries. No cap, rotation, or compaction mechanism existed in any project source. Operator directed: "design a lifecycle-based archive policy with the sub-pattern extraction… Monthly or longer recurring prompts can read everything that's fine. You probably need to modify Claude_Task_Plan.md to ensure the archive is triggered at the right time and not accessed at the wrong times."

**Inputs:** Claude_Task_Plan.md full read (4 daily/weekly prompts D1/D2/W1/W2/W3, 3 monthly M1/M3/M4 with M2 retired, 3 quarterly Q1/Q2/Q3, 2 annual A1/A2); Decision_Log.md current state (5,495 lines, ~23 NO-GO entries with scattered sub-pattern classifications, ~3 open-position entries that must remain live, multiple protocol-shift revisions, calendar-reconciliation entries); Portfolio_Ledger.md (4 open/staged positions, sector-cap state); Strategy.md (immutability lock — cannot modify); Experiment_Parameters.md (immutability lock — cannot modify); operator constraint that daily/weekly prompts execute auto-cadence without calendar reminders, only quarterly+ get reminders.

### Decision

**Three-tier file structure adopted for decision-log lifecycle management:**

1. **`Decision_Log.md` (LIVE)** — read by all sessions; contains entries that are still operationally relevant per the lifecycle rules. Pruned weekly by new W4 prompt.

2. **`Decision_Log_Archive_<YYYY>_<QN>.md` (per-quarter ARCHIVE)** — one file per calendar quarter; appended-to throughout the quarter as W4 archives matured entries; closed at quarter-end. Read only by monthly+ cadence prompts.

3. **`B_Sub_Pattern_Taxonomy.md` (FACTBASE)** — canonical reference for Strategy B criterion-4 NO-GO sub-patterns, extracted from individual Decision_Log NO-GO entries by W4. Read by all cadences (it is a factbase, not an archive). Eliminates the "scattered sub-pattern data across NO-GO entries" pattern that has accumulated to 23 NO-GO instances across 7+ sub-pattern categories.

**Lifecycle rules (entry STAYS in live if ANY of (a)-(f) is true):**
- (a) Entry-record / fill-capture / mid-window / exit-checkpoint for any open position currently in Portfolio_Ledger.md
- (b) Active unresolved deferral
- (c) Most-recent revision of any protocol-shift series (older revisions can archive)
- (d) Created within last 30 calendar days
- (e) Closed-position entry within 30 calendar days of position-exit date
- (f) Calendar-reconciliation or session-end-consolidation entry within last 7 calendar days

If ALL (a)-(f) are false → archive. Live file retains a single-line pointer "# [archived] <date> <title> → Decision_Log_Archive_<YYYY>_<QN>.md" replacing the moved-out section.

**Read-access scope by cadence:**
- Daily / Weekly (D1, D2, W1, W2, W3, W4): Live `Decision_Log.md` only. Do NOT read or act on archive files. Read factbases per prompt direction.
- Monthly (M1, M3, M4): May read live + all archive files. In practice mostly operates on current open-book state.
- Quarterly (Q1, Q2, Q3): Read live + all archive files. Q1 has explicit dependencies on prior-quarter archive content for router history.
- Annual (A1, A2): Read everything. A2 traces full citation graphs across history.

### Claude_Task_Plan.md modifications applied this session

**1. New "FILE CONVENTIONS AND READ-ACCESS SCOPE" section inserted after the header.** Documents the three-tier structure, lifecycle, pointer convention, and per-cadence read-access rules. Lives at the top of the file so it's the first thing future Claude reads.

**2. New W4 prompt added in WEEKLY section** (after W3, before MONTHLY). Mechanical lifecycle bookkeeping prompt — not deep research. Specifies:
- Lifecycle rules (a)-(f) with concrete language
- Archival actions (move to current-quarter archive file; create file if doesn't exist; replace live section with pointer line)
- Sub-pattern extraction rules — for each NO-GO being archived, extract sub-pattern instance to B_Sub_Pattern_Taxonomy.md with detail sufficient that future thesis-construction sessions don't need to read the archived NO-GO entry
- Quarter-rollover handling (close prior quarter's archive, start new one)
- Output format (3 four-backtick blocks: pruned live, current-quarter archive, taxonomy)
- "No entries matured" early-exit
- Brief Decision_Log entry appended documenting the W4 cycle outcome
- Mechanical-failure NO-GOs (criterion-1 mechanical, instrument-rule, router-gate failures): no sub-pattern extraction; pure archive move

**3. Per-prompt "Read access scope" line added to all 14 prompts** (D1, D2, W1, W2, W3, W4, M1, M3, M4, Q1, Q2, Q3, A1, A2). Each prompt carries its scope-bounds explicitly so a future Claude session pasting the prompt into a fresh conversation reads the scope line and bounds retrieval accordingly.

### What was NOT done this session

**First archive cut and bootstrap of B_Sub_Pattern_Taxonomy.md were deferred to the first scheduled W4 run.** Rationale:

- The first W4 run will be more involved than steady-state runs because ~23 NO-GO entries need sub-pattern extraction and the archive file needs initial creation. Steady-state runs handle 0-3 newly-archived entries per week.
- Per the protocol "Claude resolves all decisions internally" + the operator's directive "modify Claude_Task_Plan.md", the design + plan modification was the in-scope deliverable this session. The first archive cut is the natural job of the first cadence-triggered W4 execution.
- W4 is weekly-recurring; per the "no calendar reminder for daily/weekly/monthly recurring prompts" policy, no calendar event is created. The operator triggers W4 on natural Sun/Mon weekly cadence whenever they're ready.

**Strategy.md and Experiment_Parameters.md were NOT modified.** Both are under immutability locks per Experiment_Parameters.md. The lifecycle policy lives entirely in Claude_Task_Plan.md, which is under the operational-document modification authority that the project's framework permits.

**No calendar event scheduled for the first W4 run.** Per the operator's policy, weekly recurring prompts execute auto-cadence without reminders. The first time the operator runs W4 (next Sunday or Monday), it will be the bootstrap cycle.

### Effect on book

No book impact. Open positions IBM/HCA/RTX/META-staged unchanged. No order. The change is purely operational-infrastructure.

**Effect on file-system state next session:**
- Decision_Log.md unchanged structure for now (W4 hasn't run yet). Will be pruned at first W4 execution.
- New file Claude_Task_Plan.md (modified) replaces existing. 737 lines vs 599 prior (138 new lines: ~50 for File Conventions header section, ~80 for W4 prompt, ~14 for per-prompt scope lines).

### Pending queue updated

- **NEW (no calendar event by policy — auto-cadence weekly):** First W4 Decision Log Hygiene run on next Sun/Mon. Bootstrap will:
  (i) Create `Decision_Log_Archive_2026_Q2.md` (we are in 2026-Q2; quarter end 2026-06-30)
  (ii) Walk through all current Decision_Log.md entries; archive those where (a)-(f) all fail
  (iii) Bootstrap `B_Sub_Pattern_Taxonomy.md` with all 7+ existing sub-pattern categories and their NO-GO instances (NXPI/STX/BE/TWLO/CAT aggressive-bull-ratification; V/MDLZ structural-overhang-persistence; SBUX/CBOE information-priced-via-pre-print-rally; NOW/CHTR negative-direction-cross-section; STLA in-window-binary-catalyst; TEAM valuation-reset-but-not-narrative-reset; EL TEAM+V/MDLZ-hybrid)
  (iv) Replace archived sections in live with pointer lines
  (v) Append a brief Decision_Log entry documenting the bootstrap cycle outcome
- All other pending items unchanged (Mon 5/4 META gate session, fill-capture, IBM/HCA/RTX monitoring, Strategy D re-screens on existing calendar, etc.)

### References

- /mnt/project/Claude_Task_Plan.md (pre-modification baseline; 599 lines).
- /mnt/user-data/outputs/Claude_Task_Plan.md (post-modification; 737 lines).
- /mnt/project/Strategy.md (immutability lock — referenced but not modified).
- /mnt/project/Experiment_Parameters.md (immutability lock — referenced but not modified).
- Decision_Log entries with sub-pattern classifications targeted for first-W4 extraction: 2026-04-25 NOW; 2026-04-27 IBM-GO/HCA-GO/INTC; 2026-04-29 SBUX/V/NXPI/STX/MDLZ/OMCL; 2026-05-01 META-GO/EQIX/STLA/BE/TDOC/CAT-LLY-QCOM-A-queue; 2026-05-02 TEAM/TWLO/EL/FIVN/AXSM/CBOE/CAT/AAPL.
- Operator directive (this session, prior turn): "design a lifecycle-based archive policy with the sub-pattern extraction… Monthly or longer recurring prompts can read everything that's fine. You probably need to modify Claude_Task_Plan.md to ensure the archive is triggered at the right now and not accessed at the wrong times."

### Compaction-survival note

(a) **The first W4 run is structurally different from steady-state runs.** It bootstraps two new files (current-quarter archive, sub-pattern taxonomy) and processes a 5,500-line backlog. Steady-state runs process maybe 5-20 entries per week. The W4 prompt as written handles both cases (file-existence check; "if doesn't exist, create") but the first run will produce the largest file outputs of any W4 cycle.

(b) **B_Sub_Pattern_Taxonomy.md design intent: thesis-construction sessions read it INSTEAD of scanning NO-GO entries.** Each sub-pattern instance entry must contain enough decisive-flaw / evidence / comparable-name detail that a new B-candidate thesis-construction session can route the candidate against the sub-pattern without reading the archived NO-GO entry. If first-W4 execution finds extraction targets where this is hard, that's a signal to enrich the per-instance template — flag for design-revisit at next operator-directed session.

(c) **Read-access scope discipline is operational, not technically enforced.** project_knowledge_search returns content from any file regardless of "scope". The "Read access scope" line in each prompt is an instruction to the future Claude session to ignore archive content if it surfaces. If the operator notices a session reading archives when scope says not to, that's a prompt-discipline failure to flag.

(d) **The cleavage between "open-position entry stays live" + "Portfolio_Ledger duplicates invalidation criteria" creates redundancy.** Both files contain the position's invalidation criteria. This is intentional: Decision_Log entry has the full thesis-construction context (adversarial review, conviction calibration, sector contagion analysis); Portfolio_Ledger has the operational-execution version. Daily Daily.md scans use Portfolio_Ledger for criterion lookup; thesis-construction sessions reference back to Decision_Log entry for conviction-calibration ladder. Both are needed. Don't try to deduplicate.

(e) **Lifecycle rule (c) "most-recent revision of any protocol-shift series" requires care during bootstrap.** Older revisions of the Human Operator Interaction Protocol (originally introduced 2026-04-27 Sun late, with subsequent refinements) and the commission-disregarded protocol (also 2026-04-27) might exist in non-most-recent forms. First W4 run should identify the canonical-current-revision entry per series and keep only that in live; older revisions archive normally.

(f) **Calendar-event scheduling for first W4 run.** None. Per policy. Operator runs W4 at natural weekly cadence whenever convenient. If operator wants a one-time calendar reminder for the bootstrap (since it's first-of-its-kind), that's an opt-in operator decision; default is no reminder.

(g) **Future operator-directed extensions:** if Strategy A, C, D, or E accumulates enough sub-pattern data to warrant per-strategy taxonomy extraction (analogous to B_Sub_Pattern_Taxonomy.md), a new factbase file can be created by the W4 prompt. The W4 prompt as written is B-specific in its sub-pattern extraction mechanics; extending to other strategies would be a future Claude_Task_Plan.md modification, not in scope this session.

---

## 2026-05-03 (Sun, evening MT, follow-on) Watchlist.md and Operating_Protocols.md factbases added; W4 PRE-ARCHIVAL MIRRORING step inserted; rule (c) simplified; Claude_Task_Plan.md modified

**Trigger:** Operator-directed "fix as you see fit with best decisions" follow-on to the prior Decision_Log lifecycle/archive policy session, after operator probed gaps via questions about (a) whether Decision_Log grows indefinitely, (b) whether NO-GOs are permanent. Probing surfaced two latent gaps in the prior policy that the open-ended fix instruction authorized addressing.

**Inputs:** Claude_Task_Plan.md post-Part-3 state (737 lines, with FILE CONVENTIONS section + W4 prompt + per-prompt read-access-scope lines added in prior session); /mnt/project/Decision_Log.md latest state (5,600 lines after Part 3 entry); Portfolio_Ledger.md current state (4 open/staged positions); operator-stated framework philosophy "NO-GO records are context, not barriers" + "fresh evaluation always allowed" — used to constrain in-scope vs out-of-scope additions; prior-session search results identifying scattered watchlist/protocol context as the operational gaps.

### Gaps identified (probed by operator via prior turns)

**Gap 1 — Strategy A queue persistence.** Strategy A queue (CAT/LLY/QCOM/AAPL) loses its consolidated representation when session-end consolidation entries archive at 30 days. Individual router-gate NO-GO entries (e.g., AAPL 2026-05-02) also archive at 30 days under rule (d). After ~2026-06-02, "what names are queued for next M1 router ACTIVATE flip?" requires archive reads to reconstruct. M1 has archive read access per the new policy, but would need to actively search archive files for queue-membership references — fragile and easy to miss names. **Real failure mode** when the experiment runs long enough.

**Gap 2 — Rule (c) "most-recent revision of any protocol-shift series" is fragile.** W4 hygiene prompt would have to read entry text and infer protocol-series membership across multiple entries. Currently only 2 protocols (Human Operator Interaction Protocol, commission-disregarded protocol), each single-revision — manageable. As protocols accumulate revisions over the experiment's life, the inference grows brittle: W4 would need to identify "is this a new protocol or a revision of an existing one?" and "is this the canonical-current revision or a superseded one?" from natural-language entry text. Mechanical hygiene prompts should not depend on natural-language inference.

### Decisions

**Two new factbase files added** to the file-conventions taxonomy:

1. **`Watchlist.md`** — factbase tracking names queued for re-evaluation under specific conditions. Living document; read by all cadences. Sections per strategy. Currently the only structurally-needed section is **Strategy A queue** (names awaiting router-activation re-evaluation). Strategy D pending re-screens NOT in Watchlist.md (calendar events are canonical source); Strategy B prior-NO-GOs NOT in Watchlist.md (B operates on event-flow with fresh-evaluation discipline; sub-pattern factbase preserves the durable signal). Sections may be added as other strategies surface persistent queue needs.

2. **`Operating_Protocols.md`** — canonical reference for active operational protocols (Human Operator Interaction Protocol, commission-disregarded protocol, "NO-GO records are context, not barriers" rule, conviction-calibration ladder, deferral-chaining rules, file-conventions/read-access-scope policy, decision-log lifecycle policy, etc.). Living document; read by all cadences. Each protocol section: title + current canonical text + revision-history pointer list (date + Decision_Log entry pointer + brief change description per revision). When a protocol is revised, new revision text replaces canonical section and prior canonical appended to revision history.

**Rule (c) simplified.** Old form: "Entry is the most-recent revision of a protocol-shift series." New form: "Entry contains canonical-current protocol text NOT YET reflected in `Operating_Protocols.md`." Once W4's PRE-ARCHIVAL MIRRORING step has copied the canonical-current text from a protocol-shift entry to Operating_Protocols.md (with revision-history pointer back to the entry), the entry can archive normally under standard 30-day rule (d). This eliminates the natural-language inference burden — W4 just checks whether the entry's canonical content is reflected in the factbase.

**W4 PRE-ARCHIVAL MIRRORING step inserted.** Before applying lifecycle rules, W4 walks current Decision_Log.md entries and mirrors durable signal into factbases:
- Mirror to Watchlist.md: for any entry that adds a name to a strategy queue, ensure the name appears in Watchlist.md under appropriate strategy section. For any entry that resolves a queue item, ensure resolved name is removed.
- Mirror to Operating_Protocols.md: for any entry that introduces or revises an operational protocol, ensure canonical-current text is reflected.
- After mirroring, contributing entries are eligible for archival under updated rule (c).
- Bootstrap creation handled the same way as Decision_Log_Archive_<YYYY>_<QN>.md and B_Sub_Pattern_Taxonomy.md: file created on first need, first lines specified.

**M1 prompt updated to drain Watchlist.md A-queue when router flips ACTIVATE.** Read scope language explicitly states: "M1 maintains Watchlist.md when router-activation calls flip Strategy A from DO-NOT-ACTIVATE to ACTIVATE: trigger fresh thesis-construction sessions for queued names, then remove processed names from Watchlist.md (or hand off to W4 to remove if M1 doesn't process all queued names same-session)." This closes the loop on queue lifecycle.

**Read scopes updated** for D1, W1, W2, M1 to explicitly include the new factbases. Daily/Weekly cadence keeps "live + factbases only" discipline; factbases ARE in scope.

### Explicitly NOT added

- **Closed_Names.md** (would gate fresh evaluation, conflicts with framework's "NO-GO records are context, not barriers" philosophy and "fresh evaluation always allowed" stance). The cost of occasional wasted thesis-construction work on structurally-closed names (e.g., TDOC re-flagged on a fresh ≥5% reaction in 6 months) is accepted; the benefit of preserving framework integrity is paramount.
- **Strategy_B_Watchlist.md** (B's universe is event-flow, not a static queue; sub-pattern factbase preserves durable signal; prior-NO-GO list of 23 names would clutter without operational value).
- **Strategy_D_Watchlist.md** (calendar events are canonical source for D pending re-screens; duplicating to a watchlist file would create consistency-maintenance burden without benefit).
- **Generalizing B_Sub_Pattern_Taxonomy.md to other strategies.** D entry-timing-defer NO-GOs are mechanical (rally-roll-off triggers), not pattern-based. A router-gate NO-GOs are regime-conditional, not pattern-based. The B sub-patterns ARE genuine pattern recognition (criterion 4 decisive-flaw types). Asymmetry reflects mechanism asymmetry — don't generalize unnecessarily.

### Claude_Task_Plan.md modifications applied this session

- **FILE CONVENTIONS section expanded** (after the prior session's Decision_Log archive policy paragraph) with full descriptions of Watchlist.md and Operating_Protocols.md factbases, including what NOT to put in each.
- **Rule (c) text replaced** in W4 prompt with the canonical-mirroring formulation.
- **PRE-ARCHIVAL MIRRORING step inserted** in W4 prompt before the lifecycle rules — sub-bullets for Watchlist.md mirroring and Operating_Protocols.md mirroring with explicit do/don't lists.
- **W4 OUTPUT FORMAT updated** to include 5 fenced blocks (Decision_Log, Archive, B_Sub_Pattern_Taxonomy, Watchlist, Operating_Protocols) with "if changes; else state no changes" early-exit per file.
- **W4 read scope updated** to include reading the two new factbase files.
- **D1, W1, W2 read scopes updated** to explicitly mention the new factbases.
- **W1 scope adds emphasis line** "Strategy A queue is in Watchlist.md — relevant for Strategy A shortlisting" because W1 is the natural place this matters operationally.
- **M1 read scope updated** with explicit Watchlist.md drainage role on router activation.

### Effect on book

No book impact. No order. Open positions IBM/HCA/RTX/META-staged unchanged.

**Effect on file-system state:**
- Claude_Task_Plan.md grows from 737 lines (post-Part-3) to 760 lines (+23 net for the factbase additions and W4 mirroring step).
- No factbase files created this session (deferred to first W4 run as bootstrap).
- Decision_Log.md grows by this entry (~125 lines).

### Pending queue updated

- **Bootstrap action expanded** for first W4 run. In addition to bootstrapping `Decision_Log_Archive_2026_Q2.md` and `B_Sub_Pattern_Taxonomy.md` per prior-session plan, first W4 run also bootstraps `Watchlist.md` (initial Strategy A queue: CAT/LLY/QCOM/AAPL extracted from current Decision_Log entries) and `Operating_Protocols.md` (initial canonical text for Human Operator Interaction Protocol + commission-disregarded protocol + "NO-GO records are context, not barriers" rule + file-conventions/read-access-scope policy + decision-log lifecycle policy, all extracted from current Decision_Log entries).
- All other pending items unchanged (Mon 5/4 META gate session, fill-capture, IBM/HCA/RTX monitoring, Strategy D re-screens on existing calendar, etc.)

### References

- /mnt/user-data/outputs/Claude_Task_Plan.md (post-Part-5; 760 lines; this session's deliverable).
- /mnt/project/Claude_Task_Plan.md (pre-Part-5 baseline; 737 lines; same as Part-3 output).
- Decision_Log.md 2026-05-03 prior entry "Decision-log lifecycle architecture decision" (Part 3) — established the three-tier structure that Part 5 extends with two more factbases.
- Operator turns this session: "do we we have any measure to cap the length of decision log?"; "so do we use decision log for any analysis or execution later or purely as a analysis after strategy is done?"; "okay. I just don't want the file that's actively read weekly or daily to grow indefinitely…"; "so the archive is on a 30 day rolling basis?"; "do we have anything where no-go are not perma no-gos and get removed accordingly?"; "okay fix as you see fit with best decisions" — the operator's probing-question pattern surfaced the gaps that this session addresses.

### Compaction-survival note

(a) **Two-factbase addition does NOT change the basic three-tier structure** (Decision_Log live / Decision_Log_Archive / B_Sub_Pattern_Taxonomy) — it adds two more factbases that ride the same lifecycle pattern: written by W4 maintenance, read by all cadences, contain durable signal extracted from Decision_Log entries that would otherwise be lost on archival.

(b) **Operating_Protocols.md is the more architecturally significant addition.** It moves the framework from "protocols live in Decision_Log entries with W4 inferring revision lineage" to "protocols live in their own document with explicit revision history". Future protocol revisions (e.g., revised conviction-calibration ladder, modified deferral-chaining rules) become cleaner: revise the Operating_Protocols.md section, append revision history entry, write a Decision_Log entry summarizing the change, let the Decision_Log entry archive normally at 30 days. No "find the most-recent revision among scattered entries" inference required.

(c) **Watchlist.md is the more operationally significant addition.** Without it, the Strategy A queue (CAT/LLY/QCOM/AAPL) is genuinely at risk of being lost when session-end consolidation entries archive ~2026-06-02. With it, the queue is a stable factbase that all Daily/Weekly/Monthly sessions can read, and M1 has explicit drainage responsibility when router flips ACTIVATE.

(d) **First W4 run is now further expanded.** Per prior compaction-survival notes, first W4 run already had to bootstrap Decision_Log_Archive_2026_Q2.md and B_Sub_Pattern_Taxonomy.md from current Decision_Log entries. With Part 5, it also bootstraps Watchlist.md (extracting current A-queue) and Operating_Protocols.md (extracting current canonical protocols). Bootstrap workload is concentrated in the first run; steady-state runs are much lighter.

(e) **The "fix as you see fit" instruction is not standing authorization for unilateral framework changes.** This session's Part 5 changes were narrowly scoped to closing two specific gaps that operator-probing had surfaced. Future open-ended "fix" instructions should similarly be interpreted in the context of explicitly-surfaced gaps rather than as broad design discretion. Strategy.md and Experiment_Parameters.md immutability locks remain in force; Claude_Task_Plan.md modifications are the only operational-document edits in scope.

(f) **Operator communication-style observation:** The operator's question pattern ("do we have X?", "is it Y?", "do we have anything for Z?") consistently probes for gaps without prescribing solutions. The pattern is "surface the gap, then authorize the fix." Future sessions should expect operator probing to converge on a "fix as you see fit" turn after 2-4 question turns — and should use the question turns to map gap dimensions accurately so the eventual fix is well-targeted.

(g) **Open-position book at 2026-05-03 Sunday evening** (unchanged from earlier this session): IBM (B, entry 2026-04-27 @ $230.17, target $245, time-exit Fri 2026-06-26); HCA (B, entry 2026-04-28 @ $433.46, target $442.85, time-exit Fri 2026-06-26 [corrected this session]); RTX (D, entry 2026-04-27 @ $175.12, no time-exit, LTCG date 2027-04-28); META (B, STAGED Mon 2026-05-04 limit BUY 0.0454 @ $615.00 day, gated on 09:15 MT Funds-on-Hold $2,500 anomaly resolution; if filled, target $626.21, time-exit Thu 2026-07-02). Mon 2026-05-04 09:15 MT META pre-execution gate session is the next operational checkpoint.
